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Abstract 
Hyponatremia is a potentially dangerous serum electrolyte disorder, and is associated 
with increased morbidity and mortality. Older adults are frequently prescribed 
psychotropic drugs, and may be at an increased risk of hyponatremia. Currently, there is 
limited information about this risk in real-world practice, leading to poor consensus and 
inconsistent messaging in pharmaceutical reference manuals and clinical practice 
guidelines. 
This thesis used linked health administrative records from Ontario, Canada to 
examine the association between hospitalization with hyponatremia and psychotropic 
drug use within 30 days of drug initiation. Specifically, four population-based, 
retrospective cohort studies were conducted with a focus on: i) antidepressants (study 1), 
(ii) antipsychotics (study 2), and iii) antiepileptics (studies 3 and 4). In each study, a 
group of eligible drug users was propensity score matched to non-users with similar 
indicators of baseline health. Hospitalization with hyponatremia was assessed using a 
hospital diagnosis code and when possible, laboratory measurements (serum sodium 
concentration ≤132 mmol/L). Conditional logistic regression analysis was used to 
estimate odds ratios (approximated as relative risks (RR)) and 95% confidence intervals 
(CI)).  
Second-generation antidepressant use was associated with a higher 30-day risk of 
hospitalization with hyponatremia compared to non-use (RR 5.46 [95% CI 4.32 to 6.91]). 
This association was consistent in a subpopulation with available laboratory 
measurements (RR 4.23 [95% CI 2.50 to 7.19]; absolute risk increase 1.31% [95% CI 
0.87% to 1.75%]).  
Atypical antipsychotic use was associated with a slightly higher 30-day risk of 
hospitalization with hyponatremia compared to non-use (RR 1.62 [95% CI 1.15 to 2.29]).  
Antiepileptic use was associated with a higher 30-day risk of hospitalization with 
hyponatremia compared to non-use (carbamazepine use, RR 8.20 [95% CI 5.40 to 
12.46]); valproic acid (V), phenytoin (P), and topiramate (T) use, RR 2.62 [95% CI 1.57 
to 4.36]). The association with carbamazepine use was consistent in a subpopulation with 
available laboratory measurements (RR 4.50 [95% CI 1.60 to 12.64]; absolute risk 
increase 1.03% [95% CI 0.14% to 1.90%]).  
  
ii 
 
Results of this thesis can be used to increase physician awareness and inform safer 
prescribing to minimize hyponatremia from psychotropic drugs in a vulnerable segment 
of the population. 
 
Keywords: hyponatremia, low serum sodium, psychotropic drugs, antidepressant drugs, 
antipsychotic drugs, antiepileptic drugs. 
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CHAPTER 1: Introduction 
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1.1 Background and Overview 
Older adults represent a rapidly growing segment of the population around the world, 
including Canada. With an increase in the number of Canadians over the age of 65, the 
number of prescription drugs has also risen. Between 1997 and 2006, the Ontario 
population over 65 years of age increased by 18% while their prescription drug claims 
increased by 214%.1 Psychotropic drugs are a category of medications that are widely 
used to manage symptoms of mental and neurological disorders.2 In Canada, more than 
7% of the general population is taking a psychotropic drug, with the highest use 
occurring among older adults.3 According to the Canadian Community Health Survey: 
Mental Health and Well-Being (CCHS 1.2), the prevalence of psychotropic drug use was 
11.8% in older adults.3 Some of the most frequently prescribed classes of psychotropic 
drugs in the CCHS were antidepressants, antipsychotics, and antiepileptics.  
Antidepressant drugs are indicated for the treatment of mood and anxiety disorders, 
with over 8% of Canadians over the age of 65 living with such a condition.4 Second-
generation antidepressant drugs are preferred medications as they have fewer 
anticholinergic and cardiovascular side effects than older antidepressant agents, such as 
tricyclics.5 Among community-dwelling older adults in Ontario, the prevalence of 
antidepressant drug use increased from 5.6% in 1993 to 10.9% in 2002.6 This large spike 
seen over the nine-year period was largely attributable to the greater availability of 
second-generation antidepressants, particularly selective serotonin reuptake inhibitors 
(SSRIs). Some of the most frequently prescribed second-generation antidepressants in 
Ontario include: fluoxetine, paroxetine, sertraline, citalopram, escitalopram, fluvoxamine 
(SSRIs), venlafaxine, duloxetine (selective norepinephrine reuptake inhibitors; SNRIs), 
and mirtazapine (noradrenergic and specific serotonergic antidepressant; NaSSA).6–8 
These drugs are indicated for similar uses, of which major depression is the most 
common.9 Of these second-generation antidepressants, SSRIs are the oldest and most 
commonly used in routine care; however SNRIs and NaSSAs have been growing in 
popularity.  
Second-generation antipsychotics (more commonly referred to as atypical 
antipsychotics) are indicated for use in patients with schizophrenia, bipolar and unipolar 
mood disorders.10 Despite being an unapproved indication, most use occurs in patients 
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with dementia.11 In 2008, an estimated 400,000 older Canadians were living with 
dementia, and this number is projected to double by 2038.12 Atypical antipsychotics have 
a similar efficacy profile as typical (first-generation) antipsychotics but are preferred as 
they have fewer adverse effects, particularly extra-pyramidal symptoms.13 From 1993 to 
2002, the prevalence of antipsychotic drug use among community-dwelling older adults 
in Ontario increased from 2.2% to 3.0%, respectively, with a significant shift towards use 
of atypical antipsychotic drugs (82.5% of all antipsychotics dispensed).14 In a study of 
307 community-dwelling older adults with dementia, olanzapine (7.9%), risperidone 
(6.7%), and quetiapine (3.3%) were the most commonly used antipsychotic drugs.15 
Similarly, these three atypical antipsychotic drugs are among the most commonly 
prescribed antipsychotics in Ontario. 
Antiepileptic drugs are mainly used to treat epilepsy, but are also often used to treat 
conditions such as pain and psychiatric disorders. The prevalence and incidence of 
epilepsy are both increasing in older adults.16 According to the CCHS, over 16,000 
(0.4%) older adult Canadians had epilepsy in the year 2010.17 While no studies have been 
conducted in Ontario, a Manitoba study noted an increase in the prevalence of 
antiepileptic use from 0.08% to 2.3% from 1999 to 2013.18 Carbamazepine, phenytoin, 
and valproic acid were amongst the most commonly prescribed drugs for the treatment of 
epilepsy, while carbamazepine and valproic acid were also frequently prescribed for non-
epileptic conditions.18 These antiepileptics are older drugs that are still widely used in 
routine care. As well, several newer antiepileptic drugs became popular over the last 15 
years; one such drug is topiramate.18 These four drugs have all been indicated for initial 
use as monotherapy, and do not have major differences in their ability to control 
seizures.19 
Even though these drugs have been deemed safe in clinical trials, adverse drug 
events can still occur. An adverse drug event (ADE) is defined as, “an injury resulting 
from the use of a drug.”20 Older adults are especially susceptible to ADEs due to age-
related changes in pharmacokinetics (i.e. absorption, distribution, metabolism, and 
excretion) and pharmacodynamics (the physiologic effects of the drug).21 Additionally, 
older adults tend to have multiple comorbidities, and are usually prescribed a greater 
number of drugs, increasing the likelihood of an ADE.5,22–24 A recent report from the 
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Canadian Institute for Health Information noted that close to two-thirds of older adults 
are prescribed at least five drugs at a time, and more than one-quarter are prescribed 10 or 
more drugs.25 Among older adults, ADEs are a common cause of hospital admission, and 
a significant cause of morbidity and mortality.24 For example, adults over the age of 70 
are 3.5 times more likely to be admitted to hospital due to an ADE associated with 
psychotropic drug use compared to younger individuals.26 ADEs also pose a significant 
financial burden on the healthcare system, with each hospitalization in Ontario costing an 
average of $7,500.27 Yet, approximately 30% of all ADEs in the outpatient setting are 
potentially preventable.28  
Hyponatremia (a low serum sodium concentration) is a common electrolyte 
disturbance encountered within various clinical settings and populations. It is also a type 
of ADE that has been observed in patients taking a range of antidepressants, 
antipsychotics, and antiepileptics. In general, hyponatremia is present in 1% to 15% of 
hospital admissions, and is especially prevalent in older adults.29–33 It is recognized that 
patients with hyponatremia may experience dramatic consequences such as confusion, 
falls, fractures, seizures, and death.31,34–36 Causes of hyponatremia are multifactorial, with 
complex pathophysiologies, but when it occurs with frequently prescribed drugs, their 
propensity for causing hospitalization and death is of particular significance. Drug-
induced hyponatremia is often avoidable yet it still occurs in routine practice. As seen in 
small studies and case reports, many psychotropic drugs can induce hyponatremia by 
affecting water homeostasis. Currently, the evidence available regarding the risk of 
hyponatremia from popular psychotropic drugs in older adults is limited. Existing studies 
focus on hospitalized patients (who tend to be very ill) or are lacking in data quality 
(limitations summarized in Chapter 2). Furthermore, it is of interest to determine if the 
potential risk of hyponatremia is influenced by certain factors, such as chronic kidney 
disease, congestive heart failure, and diuretic use as hyponatremia occurs commonly in 
these settings. 
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1.2 Objectives and Hypotheses 
This thesis was undertaken to improve the current knowledge around the risk of 
hyponatremia from common psychotropic drugs in non-hospitalized older adults in 
routine care. Currently, there are more than 5.5 million Canadians over the age of 65. 
With a rapidly aging population and increased use of psychotropic drugs, prevention of 
ADEs such as hyponatremia is becoming crucial. Addressing the specific objectives of 
this thesis will inform key stakeholders of the potential risk, which will inform strategies 
to mitigate hospitalizations with hyponatremia.  
The objectives of this thesis were addressed in four population-based, retrospective 
cohort studies of older adults in Ontario, Canada with a focus on select i) second-
generation antidepressant, ii) atypical antipsychotic, and iii) antiepileptic drugs 
(collectively referred to as “psychotropic drugs” throughout this thesis). See Table 1-1 for 
the specific drugs examined in each study. These drugs were selected based on two main 
factors: evidence from pre-existing literature (i.e. case reports and observational studies) 
and prevalence of use in an outpatient setting within a Canadian context. 
Table 1-1. Psychotropic drugs examined in each study 
Study 
 
Psychotropic drug class 
 
Drug names 
1 Antidepressant drugs 
 
Paroxetine, Fluoxetine, Citalopram, Escitalopram, 
Fluvoxamine, Sertraline, Mirtazapine, Duloxetine, Venlafaxine 
2 Antipsychotic drugs Risperidone, Olanzapine, Quetiapine 
3 
 
4 
Antiepileptic drugs 
Carbamazepine (examined alone)  
 
Valproic Acid, Phenytoin, Topiramate 
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1.2.1 Primary Objective 
Within each study: 
Objective 1: To estimate the 30-day risk of hospitalization with hyponatremia in new 
users of a psychotropic drug compared to non-users. This will be assessed using:  
i. A hospital diagnosis code 
ii. Serum sodium laboratory measurements (only available for a subpopulation) 
Hypothesis: There will be a higher 30-day risk of hospitalization with 
hyponatremia in new users of a psychotropic drug compared to non-users.  
1.2.2 Secondary Objectives 
Within each study: 
Objective 2: To determine if the association between new use of a psychotropic drug and 
hospitalization with hyponatremia is modified by the following factors: 
i. Drug type (within each class) 
ii. Drug dose (higher vs. normal dose) 
iii. Chronic kidney disease (present vs. absent) 
iv. Congestive heart failure (present vs. absent) 
v. Diuretic use (use vs. non-use) 
Hypotheses:  
i. The relative association between psychotropic drug use and hospitalization 
with hyponatremia will not be modified by psychotropic drug typea (i.e. 
the association will not differ across the drugs within the class).  
aWith the exception of carbamazepine (antiepileptic drug), which will be 
examined separately from the other antiepileptic drugs. 
ii. The relative association between psychotropic drug use and hospitalization 
with hyponatremia will be modified by psychotropic drug dose (i.e. the 
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association will be greater in patients prescribed a higher dose compared 
to those prescribed a normal dose).  
iii. The relative association between psychotropic drug use and hospitalization 
with hyponatremia will be modified by chronic kidney disease (i.e. the 
association will be greater in patients with chronic kidney disease 
compared to those without chronic kidney disease). 
iv. The relative association between psychotropic drug use and hospitalization 
with hyponatremia will be modified by congestive heart failure (i.e. the 
association will be greater in patients with congestive heart failure 
compared to those without congestive heart failure). 
v. The relative association between psychotropic drug use and hospitalization 
with hyponatremia will be modified by diuretic use (i.e. the association 
will be greater in patients prescribed diuretics compared to those not 
prescribed diuretics). 
In studies where there are an adequate number of events: 
Objective 3: To estimate the 30-day risk of hospitalization with both hyponatremia and 
delirium in new users of a psychotropic drug compared to non-users.  
Hypothesis: There will be a greater 30-day risk of hospitalization with both 
hyponatremia and delirium in new users of a psychotropic drug compared to 
non-users. 
Within each study: 
Objective 4: To determine the risk factors associated with hospitalization with 
hyponatremia in psychotropic drug users and in non-users (to provide context). 
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1.3 Thesis Organization 
An integrated manuscript style will be used to present the work of this thesis in a series of 
three manuscripts. This dissertation is presented in an integrated-article format, organized 
into seven chapters. Chapter 2 provides an examination of the current literature on 
psychotropic drugs and hyponatremia, and presents the conceptual model. Chapter 3 
presents an overview of the methodology used in this thesis. Chapters 4 to 6 contain the 
articles that comprise the main results and discussion of the thesis: Chapter 4 has been 
accepted for publication at the American Journal of Kidney Diseases; Chapter 5 has been 
published at the Canadian Journal of Kidney Health and Disease; and Chapter 6 has been 
accepted for publication at Epilepsia. Chapter 7 provides an integrated discussion of 
Chapters 4 through 6. Specifically, this chapter summarizes the major findings of this 
thesis and links all chapters together. Information on clinical importance, implications for 
clinical practice, strengths and limitations, future directions, and conclusions are also 
discussed. 
 Several appendices are included to supplement each of the chapters within this 
thesis. Specifically, Appendix A contains supporting information corresponding to 
Chapter 2; Appendix B contains supplementary information and results corresponding to 
Chapter 4; Appendix C contains supplementary information and results corresponding to 
Chapter 5; and Appendix D contains supplementary information and results 
corresponding to Chapter 6; Appendix E contains the validation study that was completed 
in preparation for this thesis; and Appendix F contains the ethics approval forms for 
Chapters 4 to 6.   
 
 
 
9 
 
 
 
Reference List 
1.  Kwan D, Farrell B. Polypharmacy: Optimizing medication use in elderly patients. 
CGS J C. 2014;4(1):21-27. 
2.  Voyer P, Cohen D, Lauzon S, Collin J. Factors associated with psychotropic drug 
use among community-dwelling older persons: A review of empirical studies. 
BMC Nurs. 2004;3:3. 
3.  Beck CA, Williams JV, Wang JL, et al. Psychotropic medication use in Canada. 
Can J Psychiatry. 2005;50(10):605-613. 
4.  Informing the future: Mental health indicators for Canada. Mental Health 
Commission of Canada. 
http://www.mentalhealthcommission.ca/English/system/files/private/document/Inf
orming the Future - Mental Health Indicators for Canada.pdf. Published 2015. 
Accessed August 20, 2015. 
5.  Brooks JO, Hoblyn JC. Neurocognitive costs and benefits of psychotropic 
medications in older adults. J Geriatr Psychiatry Neurol. 2007;20(4):199-214. 
6.  Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Mental health-
related drug utilization among older adults: Prevalence, trends, and costs. Am J 
Geriatr Psychiatry. 2005;13(10):892-900. 
7.  Mamdani MM, Parikh S, Austin PC, Upshur RE. Use of antidepressants among 
elderly subjects: Trends and contributing factors. Am J Psychiatry. 
2000;157(3):360-367. 
8.  Mamdani M, Herrmann N, Austin P. Prevalence of antidepressant use among older 
people: Population-based observations. J Am Geriatr Soc. 1999;47(11):1350-1353. 
9.  Thorpe L, Whitney DK, Kutcher SP, Kennedy SH, CANMAT Depression Work 
Group. Clinical guidelines for the treatment of depressive disorders. VI. Special 
populations. Can J Psychiatry. 2001;46 Suppl 1:63S-76S. 
10.  Horn M, Procyshyn RM, Warburton WP, et al. Prescribing second-generation 
antipsychotic medications: Practice guidelines for general practitioners. B C Med 
J. 2012;54(2):75-82. 
11.  Maglione M, Bagley S, Suttorp M, et al. Efficacy and comparative effectiveness of 
atypical antipsychotic medications for off-label uses in adults: A systematic review 
and meta-analysis. J Am Med Assoc. 2011;306(12):1359-1369. 
12.  Butler-Jones D. Report on the state of Canada public health in Canada 2010, 
growing older - Adding life to years. http://www.phac-aspc.gc.ca/cphorsphc-
respcacsp/2010/fr-rc/pdf/cpho_report_2010_e.pdf. Published 2010. Accessed 
10 
 
 
 
December 11, 2014. 
13.  Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical 
antipsychotics in the treatment of early psychosis: Meta-analysis. Br J Psychiatry. 
2010;196(6):434-439. 
14.  Rapoport M, Mamdani M, Shulman KI, Herrmann N, Rochon PA. Antipsychotic 
use in the elderly: Shifting trends and increasing costs. Int J Geriatr Psychiatry. 
2005;20(8):749-753. 
15.  Rhee Y, Csernansky JG, Emanuel LL, Chang C-G, Shega JW. Psychotropic 
Medication Burden and Factors Associated with Antipsychotic Use: An Analysis 
of a Population-Based Sample of Community-Dwelling Older Persons with 
Dementia. J Am Geriatr Soc. 2011;59(11):2100-2107. 
16.  Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000;355(9213):1441-
1446. 
17.  Neurological conditions, by age group and sex, household population aged 0 and 
over, 2010/2011. Statistics Canada. 
http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=1051300. Published 2010. 
Accessed April 4, 2015. 
18.  Leong C, Muhammad M, Gomes T, Juurlink DN, Macdonald EM, Yogendran M. 
Antiepileptic use for epilepsy and nonepilepsy disorders. Neurology. 2016;86:939-
946. 
19.  Leppik IE. Treatment of epilepsy in the elderly. Curr Treat Options Neurol. 
2008;10(4):239-245. 
20.  Nebeker JR, Barach P, Samore MH. Improving patient care clarifying adverse 
drug events: A clinician’s guide to terminology, documentation, and reporting. 
Ann Intern Med. 2004;140(10):795-802. 
21.  Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and 
pharmacodynamics: Basic principles and practical applications. Br J Clin 
Pharmacol. 2004;57(1):6-14. 
22.  Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse 
drug events in older adults. Am Fam Physician. 2013;87(5):331-336. 
23.  Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalization 
for adverse drug events in older Americans. Surv Anesthesiol. 2012;56(2):65-66. 
24.  Routledge P, O’Mahony M, Woodhouse K. Adverse drug reactions in elderly 
patients. Br J Clin Pharmacol. 2004;57(2):121-126. 
25.  Drug use among seniors on public drug programs in Canada, 2012. Canadian 
11 
 
 
 
Institute for Health Information. 
https://secure.cihi.ca/free_products/Drug_Use_in_Seniors_on_Public_Drug_Progr
ams_EN_web_Oct.pdf. Published 2014. Accessed September 4, 2015. 
26.  Lindsey PL. Psychotropic medication use among older adults: What all nurses 
need to know. J Gerontol Nurs. 2011;35(9):28-38. 
27.  Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug 
reactions among elderly patients in Ontario emergency departments: A 
retrospective study. Drug Saf. 2012;35(9):769-781. 
28.  Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse 
drug events among older persons in the ambulatory setting. JAMA. 
2003;289(9):1107-1116. 
29.  Anderson RJ. Hospital-associated hyponatremia. Kidney Int. 1986;29(6):1237-
1247. 
30.  Asadollahi K, Beeching N, Gill G. Hyponatraemia as a risk factor for hospital 
mortality. Q J Med. 2006;99(12):877-880. 
31.  Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, 
moderate, and severe hyponatremia. Am J Med. 2009;122(9):857-865. 
32.  Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and 
economic outcomes of admission hyponatremia among hospitalized patients. Curr 
Med Res Opin. 2008;24(6):1601-1608. 
33.  Tierney WM, Martin DK, Greenlee MC, Zerbe RL, McDonald CJ. The prognosis 
of hyponatremia at hospital admission. J Gen Intern Med. 1986;1(6):380-385. 
34.  Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic 
hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J 
Med. 2006;119(1):1-8. 
35.  Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia 
and risk of fracture in the ambulatory elderly. Q J Med. 2008;101(7):583-588. 
36.  Hoorn EJ, Zietse R. Hyponatremia and mortality: Moving beyond associations. Am 
J Kidney Dis. 2013;62(1):139-149. 
 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: Literature Review 
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
2.1 Introduction 
This chapter provides an overview of hyponatremia and psychotropic drugs, and 
examines the current state of knowledge related to the study objectives for this research. 
The following databases were used to locate articles: PubMed, Ovid MEDLINE, 
EMBASE, and Google Scholar. 
2.2 Hyponatremia 
2.2.1 Physiology  
The concentration of sodium in the blood is normally maintained within a safe range 
between 135 and 145 millimoles per litre (mmol/L).1 The kidneys are responsible for 
maintaining serum osmolarity by regulating total body water and sodium content. Fluid 
balance is controlled by the hypothalamic production of antidiuretic hormone (ADH), 
which promotes thirst and water retention by binding to vasopressin receptors on the 
kidneys, aiding in the reabsorption of water and sodium ions in the distal tubule. In the 
presence of non-osmotic stimuli, homeostatic conditions may be disrupted, resulting in 
hyponatremia.2 Hyponatremia occurs when the sodium concentration drops below 135 
mmol/L.3 It denotes an excess of total water relative to sodium content in the body. 
Hyponatremia can be broadly classified as dilutional or depletional. The most 
common type is dilutional (hypotonic) hyponatremia. Based on a patient’s medical 
history, volume status, urine osmolality, and serum sodium concentration, hypotonic 
hyponatremia can be classified into one of three categories: i) hypervolemia (increase in 
total body sodium with greater increase in total body water), ii) hypovolemia (decrease in 
total body water with a greater deficit in sodium), or iii) euvolemia (normal body sodium 
with increase in total body water). These hyponatremic states occur in the presence of 
certain comorbidities, medications, and lifestyle factors. Euvolemic hyponatremia is the 
most common type, and has several etiologies, with the syndrome of inappropriate 
antidiuretic hormone (SIADH) accounting for nearly 60%.4 Figure 2-1 describes the 
different states of hypotonic hyponatremia and provides an overview of common 
causes.4–6 Overall, the causes of hyponatremia are multifactorial, with complex 
pathophysiologies. 
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Figure 2-1. Classifications of hyponatremia 
Abbreviations: SIADH=syndrome of inappropriate antidiuretic hormone secretion; CNS=central nervous 
system; *Only common causes of SIADH are listed 
2.2.2 The Clinical Picture  
Clinical manifestations of hyponatremia are primarily neurologic and correlate with 
severity and rapidity of changes in serum sodium.4,7 Acute onset hyponatremia 
(developing within 24 to 48 hours) tends to be more severe (serum sodium concentration 
≤125 mmol/L), resulting in more dramatic outcomes compared to chronic hyponatremia. 
Typical symptoms of mild acute hyponatremia include nausea, headache, and fatigue. As 
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hyponatremia becomes more severe, patients may experience confusion, seizures, coma, 
respiratory arrest, permanent brain damage, and even death.6 A summary of the possible 
clinical manifestations of varying degrees of hyponatremia can be found in Table 2-1. 
The neurologic sequelae seen with severe hyponatremia largely occur as a result of 
changes in brain cell volume driven by high intracellular osmolality, which causes 
swelling (cerebral edema).8 However, the brain has the unique ability to protect against or 
minimize cellular swelling in chronic hyponatremia. Therefore, symptoms of 
hyponatremia can vary by patient, and not all patients with low serum sodium present 
with clinical symptoms or adverse sequelae. Many patients with chronic hyponatremia 
are often able to adapt to changes in sodium, resulting in fewer symptoms.9  
Table 2-1. Symptoms associated with varying degrees of hyponatremia4 
Classification Clinical Manifestations 
Mild hyponatremia 
(≤132 mmol/L) 
Headache, nausea, vomiting, fatigue, confusion, anorexia, muscle cramps, 
depressed reflexes; may be asymptomatic 
Moderate hyponatremia 
(≤128 mmol/L) 
Malaise, unsteadiness, headache, nausea, vomiting, fatigue, confusion, 
anorexia, muscle cramps, depressed reflexes; may be asymptomatic 
Severe hyponatremia 
(≤125 mmol/L) 
Delirium, headache, restlessness, lethargy, seizures, brainstem herniation, 
respiratory arrest, coma, death 
2.3 Epidemiology of Hyponatremia in Older Adults 
Hyponatremia is the most common type of electrolyte disorder encountered in clinical 
practice.10 The reported incidence and prevalence of hyponatremia varies depending on 
the definition used and the patient population studied. In a study by Hawkins et al., the 
prevalence of hyponatremia was assessed in 120,137 patients (of all ages) in Singapore. 
Between 4% and 7% of patients living in the community (i.e. those who presented to a 
primary care clinic) were noted to have a serum sodium concentration <136 mmol/L.11 In 
older adults, this estimate is higher, with nearly 7% to 11% of community-based older 
adults and over 18% of long-term care residents with hyponatremia (serum sodium 
concentrations <137, <136, <135 mmol/L).10–14 In hospitalized and critically ill patients, 
hyponatremia is more prevalent and severe with a wide range of estimates cited.11,15–19  
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Hyponatremia occurs more frequently in the elderly population, as they have a 
higher number of comorbid conditions and use several medications known to cause 
hyponatremia, and also because of age-related physiological changes that may affect 
electrolyte balance. This imbalance can occur in a number of ways, including decreases 
in total body water, an impaired ability to dilute urine, and diminished renal blood flow 
and glomerular filtration.5,20 Older adults can lose up to 25% of their original kidney 
mass simply due to the aging process.21 As well, analysis of serum sodium concentrations 
in a healthy population has shown an age-related decline of approximately 1 mmol/L per 
decade.22 In the study by Hawkins et al., the risk of hyponatremia increased with age 
when defined by a serum sodium concentration of <136 mmol/L (age 61 to 70 years: OR 
1.06 [95% CI 1.01 to 1.12]; age 71 to 80 years: OR 1.39 [95% CI 1.32 to 1.37]; and age 
>81 years: OR 1.89 [95% CI 1.78 to 2.01]).11 Each of these relationships became more 
pronounced with lower levels of serum sodium.  
Also, it has been suggested that there are differences in sodium metabolism, 
transport, and intracellular concentration that make women more susceptible to 
hyponatremia.23 In a cohort study of 4123 older patients (mean age, 77 years) by Terzian 
et al., women had a greater prevalence of hyponatremia than men (4.6% vs. 2.6%).24 In 
addition, Movig et al. found that female sex was a significant risk factor for 
hyponatremia (serum sodium concentration, ≤125 mmol/L) (OR 1.19 [95% CI 1.09 to 
1.30]).25  
Both symptomatic and asymptomatic hyponatremia are associated with poor patient 
outcomes. Some of the most commonly cited reasons for hospital admission among older 
adults with symptomatic hyponatremia include nausea/vomiting, tiredness/weakness, and 
encephalopathy.26 Acute hyponatremic encephalopathy is a serious medical emergency 
with a morbidity and mortality rate of 42%.3 Traditionally, mild hyponatremia was 
considered asymptomatic. However, recent evidence has demonstrated that even mild 
chronic hyponatremia is associated with adverse events in older adults, such as impaired 
gait, attention deficits, bone loss, falls, and fractures (serum sodium concentration, <135 
mmol/L).27–32 For example, a case-control study by Renneboog et al. examined the 
frequency of falls in patients (mean age, 72 years) with chronic hyponatremia admitted to 
an emergency department. Among these patients with hyponatremia, 21% were admitted 
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with a fall compared with 5% of matched controls (adjusted odds ratio (OR) 67 [95% 
confidence interval (CI) 7.5 to 607]; p <0.001).31 The authors also showed that 
‘asymptomatic’ hyponatremia (mean serum sodium concentration, 128 mmol/L) was 
associated with gait disturbances and attention deficits. In another case-control study by 
Gankem Kenge et al., 513 older adults with bone fractures after a fall were age- and sex-
matched to 513 older adults with no history of bone fractures.27 A serum sodium 
concentration <135 mmol/L was present in 13% of cases vs. 4% of controls, and was 
associated with a greater risk of bone fracture in cases compared to controls (adjusted OR 
4.2 [95% CI 5.54 to 12.86]). Hyponatremia is also associated with significant 
mortality.1,15,33,24,34–38 For example, Terzian et al. found that hyponatremia (serum sodium 
concentration, <130 mmol/L) at hospital admission was a significant predictor of 
mortality.24 They reported that in-hospital mortality was 16.0% among patients admitted 
with hyponatremia vs. 8.0% among those admitted without this condition. In a study by 
Tierney et al., patients (mean age, 61 years) with hyponatremia (serum sodium 
concentration, <130 mmol/L) at hospital admission were seven times as likely to die in 
hospital and twice as likely to die post-discharge compared to patients with normal serum 
sodium levels.33 In a large population-based study by Chawla et al., mild hyponatremia 
(serum sodium concentration, <135 mmol/L) was associated with significant mortality 
compared to those with normal serum sodium levels (6.1% vs. 2.3%). A meta-analysis by 
Corona et al. examined data from 81 studies and found an increased risk of overall 
mortality (relative risk (RR) 2.60 [95% CI 2.31 to 2.93]) among patients with 
hyponatremia.38 In many of these studies, hyponatremia was independently associated 
with mortality; however an increased death rate is not always attributed to hyponatremia 
itself and often occurs due to the presence of other underlying factors (discussed below). 
Besides contributing to poor patient outcomes, hyponatremia also poses a 
significant burden on the healthcare system. In the United States, hyponatremia is 
recorded as a principal or secondary discharge diagnosis in approximately 1 million 
hospitalizations every year. In addition, an estimated 105,000 to 120,000 emergency 
room visits and 1.4 to 3.4 million outpatient visits for hyponatremia occur each year.39 
Hyponatremia has been linked to longer lengths of hospital stay, a greater need for 
hospital resources, and increased costs.34–36,39–41 For example, Wald et al. found that 
18 
 
 
 
hyponatremia at hospital admission was associated with a 14% longer length of stay 
compared to those without hyponatremia;36 Zilberberg et al. found that a greater number 
of patients with hyponatremia were admitted to the intensive care unit compared to those 
without hyponatremia (17.3% vs. 10.9%, p <0.001);35 and Boscoe et al. determined that 
the annual cost of hyponatremia ranged from $1.6 billion to $3.6 billion.39 Cost estimates 
were derived under a variety of scenarios (e.g. treatment setting, low vs. high prevalence, 
symptomatic vs. asymptomatic hyponatremia, etc.). In a study of older adults admitted to 
the emergency department, Turgutalp et al. found that morbidity, mortality, and hospital 
costs increased in parallel to decreasing serum sodium levels and increasing age.26  
2.3.1 Hyponatremia with Specific Conditions, Drugs, and Settings 
Hyponatremia can occur in a number of different situations. As seen in Figure 2-1, there 
are number of ways hyponatremia can occur. Congestive heart failure, chronic kidney 
disease, and diuretic use are of particular interest to this thesis, as they are clinically 
important causes of hyponatremia, and affect a large proportion of the population. Other 
common factors related to hyponatremia are also discussed. 
Congestive Heart Failure: Hyponatremia is a very common finding in patients with 
congestive heart failure (CHF). CHF affects nearly 600,000 Canadians, with the highest 
prevalence in older adults.42,43 It occurs as a result of low cardiac output and/or 
pulmonary or systemic congestion.44 The low cardiac output triggers a compensatory 
response by the body that activates neurohumoral systems, and particularly ADH release. 
ADH increases free-water reabsorption in the renal collecting ducts, increasing blood 
volume and diluting plasma sodium concentrations.45 Hyponatremia is strongly correlated 
with poor patient outcomes in both inpatients and outpatients with CHF.46 In a large 
study of over 47,000 patients, nearly 20% admitted to hospital with CHF were reported to 
have a serum sodium concentration <135 mmol/L and was associated with a 75% 
increase in 60- to 90-day mortality compared to patients with normal serum sodium 
levels.47 A number of other studies noted similar estimates in patients with varying 
degrees of CHF.48–50  
Chronic kidney disease: Approximately 35% of older adult Canadians are living with 
chronic kidney disease (CKD).51 CKD is a condition characterized by a gradual loss of 
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kidney function or presence of kidney damage, and can be categorized into six stages 
(stages 1, 2, 3a, 3b, 4, and 5; from least to most severe).52 As mentioned previously, 
kidney function can decline substantially in older adults simply due to the aging process. 
As kidney function declines, patients have a greater tendency to develop hyponatremia 
due to a diminished ability to regulate water homeostasis.53 In a study examining 655,493 
US veterans with non-dialysis-dependent CKD, the prevalence of hyponatremia (serum 
sodium concentration, ≤135 mmol/L) was 13.5%, with nearly 26% of all patients 
developing hyponatremia during the mean follow-up of 5 years.54 Patients with CKD 
may also develop nephrotic syndrome (kidney disease with proteinuria, 
hypoalbuminemia, and edema) which is a very rare cause of hyponatremia.4 
Diuretics: Diuretics are among the most commonly prescribed medications and are used 
as first-line antihypertensive treatment in the elderly.55 Hyponatremia is a well-known 
complication of diuretic use, including community-acquired hyponatremia.56 All diuretics 
can cause hyponatremia to some extent, however thiazide diuretics are most frequently 
implicated.7 These diuretics inhibit sodium chloride reabsorption in the distal convoluted 
tubule of the kidney, which leads to direct inhibition of urinary diluting capacity.57 In a 
study of 2613 adult outpatients newly treated for hypertension, thiazide diuretic use was 
associated with a higher risk of hyponatremia compared to use of other antihypertensive 
medications (incidence rate ratio, 1.61 [95% CI, 1.15 to 2.25]).58 In the study by Liamis 
et al., both thiazide diuretics and potassium-sparing diuretics were significant risk factors 
for community-acquired hyponatremia (OR 1.66 [95% CI 1.18 to 2.33] and OR 3.64 
[95% CI 1.94 to 6.82], respectively).10 
Cirrhosis: Cirrhosis is characterized by heavy scarring of the liver, reduced blood flow 
through the liver, and a reduced ability to regenerate.59 The prevalence of cirrhosis in 
Canada is less than 1% but is increasing in older adults.60 Cirrhosis results in increased 
primary systemic arterial vasodilation, which subsequently triggers the neurohumoral 
systems and leads to hyponatremia as seen in CHF. Hyponatremia in cirrhotic patients is 
also a strong predictor of poor outcomes.61,62 In a study of approximately 1000 inpatients 
and outpatients with cirrhosis and ascites, the prevalence of hyponatremia was 57% and 
40%, respectively (serum sodium concentration, ≤135 mmol/L).63  
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Diabetes Mellitus: Nearly 50% of individuals with type II diabetes mellitus (DM) are 
over the age of 65.64 DM occurs as a result of defects in insulin secretion and/or action, 
and is characterized by the chronic elevation of blood glucose levels.65 A number of 
pathophysiological mechanisms may lead to hyponatremia in diabetic patients. Mainly, 
elevated blood glucose concentrations (hyperglycemia) can induce the movement of 
water from intracellular to extracellular space, resulting in extracellular dilution of 
sodium.66 Hyponatremia can also occur due to increased thirst and water intake and 
increased ADH release in DM.66 In a study by Liamis et al., DM was a significant 
predictor of hyponatremia (serum sodium concentration, ≤135 mmol/L) in 5179 
community-based adults over the age of 55 (OR 1.98 [95% CI 1.47-2.68]).10  
Cancer: Thousands of older adults are diagnosed with various types of cancer each 
year.67 Hyponatremia has been observed with various malignancies, but occurs most 
frequently in small-cell lung cancer.20 Hyponatremia usually occurs through SIADH, 
specifically from ectopic production of ADH by the tumor tissue.68 In a prospective study 
of 106 patients admitted to a cancer hospital with various types of cancer, the incidence 
of hyponatremia was nearly 4% (serum sodium concentration, ≤130 mmol/L).69 Other 
factors may also lead to hyponatremia, such as diarrhea and vomiting caused by cancer 
therapy. 
Hypothyroidism: Hypothyroidism is one of the most prevalent endocrine disorders. It is a 
condition in which the thyroid gland produces insufficient thyroid hormone.70 The 
proposed mechanisms by which hyponatremia occurs include alterations in renal 
perfusion and a reduced glomerular filtration rate (GFR) from thyroid hormone 
deficiency.71,72 Compared to other conditions, hyponatremia is less commonly found in 
patients with hypothyroidism and is mostly seen in older patients when the disorder is 
severe.73 As such, estimates of hyponatremia are not well-established.74 In a small study 
(188 patients) by Baajafer et al., the prevalence of hyponatremia (serum sodium 
concentration, <135 mmol/L) among patients diagnosed with hypothyroidism was 4%.75 
Pneumonia: Pneumonia is a very common infection, with an estimated 5.6 million cases 
occurring each year.76 The mechanism of hyponatremia in pneumonia is unclear, but 
increased ADH secretion and resetting of the osmostat for ADH secretion have both been 
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implicated. In a retrospective study of 340 patients hospitalized with community-acquired 
pneumonia (mean age, 74 years), hyponatremia (serum sodium concentration, ≤135 
mmol/L) was present in 28% of patients with pneumonia at hospital admission, and was 
influenced by severity of pneumonia. In another large retrospective cohort study using 
health administrative databases (7965 patients), hyponatremia (serum sodium 
concentration, <135 mmol/L on at least 2 measurements within 24 hours of admission) 
was present in 8% of patients hospitalized with pneumonia.77 
Central nervous system disorders: Hyponatremia is known to occur in patients with 
various CNS disorders, such as vascular injury, head trauma, lesions, infection, and 
psychosis.78 CNS disorders can cause dysfunction of the hypothalamic system involved 
in the normal regulation of ADH secretion, resulting in increased ADH levels.79 In the 
study by Miller et al., hyponatremia occurred in 54% of nursing home patients with a 
CNS disorder.14 Sherlock et al. conducted a retrospective cohort study of 1698 
neurosurgical patients and found that hyponatremia (serum sodium concentration, <130 
mmol/L) developed in 11% of patients, and was present in 6.3% of patients with pituitary 
disorders, 20% with subarachnoid hemorrhage, and 9.6% with brain trauma.80 
Antineoplastic drugs: Various anticancer drugs have been linked to the development of 
hyponatremia through SIADH.7,81 Some of the common types of medications include 
vinca alkaloids, platinum compounds, and alkylating agents.82–89 In a retrospective study 
of adverse event reports, hyponatremia or SIADH was reported in 1.3/100,000 patients 
treated with vincristine (a vinca alkaloid).90 Patients on cyclophosphamide therapy may 
also develop hyponatremia due increased ingestion of fluids for the prevention of 
chemical cystitis.7  
Antidiabetic drugs: Antidiabetic drugs are frequently used to achieve normoglycemia 
and relieve symptoms of diabetes. Medications such as chlorpropamide, tolbutamide, and 
insulin have all been associated with hyponatremia.91 These drugs can cause 
hyponatremia through various mechanisms, but usually it occurs through potentiation of 
ADH effect on the kidneys. In a study of 176 chlorpropamide-treated patients, 11 (6.3%) 
exhibited hyponatremia (serum sodium concentration, <130 mmol/L) during a mean 
follow-up period of 7.4 years.92 
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Pre-existing hyponatremia/low baseline sodium: Patients who have had lower serum 
sodium levels (either symptomatic or asymptomatic hyponatremia) tend to be at a greater 
risk of future or worsening hyponatremia. In a study by Bissram et al., pre-existing 
hyponatremia upon hospital admission (mean serum sodium concentration, <134 
mmol/L) was significantly associated with a subsequent hospitalization with 
hyponatremia (p < 0.05).93 Of these patients, 66% had altered mental status, which 
improved after treatment of the hyponatremia. 
Residential Status: Compared to community-based older adults, residents of long-term 
care facilities or nursing homes are more susceptible to hyponatremia.13,14 This may be 
attributed to increased administration of hypotonic fluids, lower sodium diets, and tube 
feeding in this patient population.14,18 Additionally, patients living in long-term care 
facilities tend to have a larger number of and more severe comorbidities and take more 
medications, which may predispose them to hyponatremia. 
Psychotropic drugs: Several psychotropic drugs have been implicated in the 
development of hyponatremia and will be described further in the following section. 
2.4 Hyponatremia from Psychotropic Drugs 
Medications are one of the most frequent causes of hyponatremia. Certain 
antidepressants, antipsychotics, and antiepileptics (psychotropic drugs), are important 
causes of hyponatremia. As with most drugs, psychotropic drug-induced hyponatremia 
most commonly occurs through SIADH. Although the exact mechanism by which these 
drugs can induce SIADH is not clear, it is speculated that they interfere with the normal 
secretion of ADH by stimulating its release from the hypothalamus, by potentiating its 
effect (or acting directly) in the distal convoluted tubules of the kidneys, or by resetting 
the osmostat (threshold for ADH secretion is reset downward).94 The mechanisms of 
hyponatremia for the psychotropic drugs of interest are summarized in Table 2-2.  
Hyponatremia risk from these drugs is poorly characterized. This can be owing to 
the fact that hyponatremia is a very complex condition to understand, particularly in 
patients with mental health disorders. In these patients, hyponatremia is frequently under-
diagnosed as its symptoms can often be mistaken for symptoms associated with the 
23 
 
 
 
underlying illness or for common side effects of the psychotropic drugs, such as 
confusion.95 Additionally, patients with psychiatric disorders can also experience 
psychogenic polydipsia, a condition characterized by excessive fluid consumption.96 It is 
estimated that nearly 20% of inpatients with chronic psychiatric disorders experience 
polydipsia.97 Although rare, hyponatremia may result if the kidneys are unable to excrete 
the excess fluid. The mechanism of hyponatremia in these patients likely occurs from a 
defect in thirst regulation or from increased secretion or renal action of ADH.98 These 
factors make the timely diagnosis and treatment of hyponatremia very challenging.  
 
Table 2-2. Mechanisms of psychotropic drug-induced hyponatremia 
Syndrome of Inappropriate Antidiuretic Hormone 
Increased hypothalamic production 
of ADH 
Potentiation of ADH effect Reset Osmostat 
Second-generation antidepressants 
Atypical antipsychotics 
Carbamazepine, Valproic acid 
Carbamazepine Venlafaxine 
Carbamazepine 
 
2.4.1 Data from Epidemiological Studies   
A review of the scientific literature for evidence of hyponatremia from select second-
generation antidepressant, atypical antipsychotic, and antiepileptic drugs was performed. 
Relevant case reports, case series, systematic reviews of case reports, cohort and case-
control studies were included in this review. To inform the primary objective of this 
thesis, methodological quality was assessed for those studies examining the risk of 
hyponatremia using a modified version of the Downs and Black checklist for 
nonrandomized studies, which assesses the completeness and clarity of reporting, bias, 
and external validity (Appendix A Table A-1).99 
2.4.1.1 Antidepressant Drugs and Hyponatremia 
Two years after the introduction of the first SSRI, hyponatremia was initially reported 
following fluoxetine use in 1989.100 Since then, a number of case reports and descriptive 
studies have surfaced, describing the relationship between second-generation 
antidepressants and hyponatremia (case reports summarized in Appendix A Table A-2). 
Twelve descriptive/clinical studies of hyponatremia from second-generation 
antidepressants were identified. The results of these studies and their limitations are 
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summarized in Table 2-3. None of these studies included a control group, most were 
based on case notes or chart reviews, and reported only crude estimates of incidence. The 
incidence of hyponatremia from SSRIs was variable, ranging from less than 1% to 40%, 
with most events occurring in older adults.101–113 Estimates of incidence from SNRIs 
were even wider, ranging from less than 1% to 71%.107,108,111,114,115 The incidence with 
mirtazapine (NaSSA) is not as well-established with an estimate of less than 0.01%.108,115 
The population-based study (surveillance program of over 260,000 psychiatric inpatients) 
by Letmaier et al. resulted in more modest incidence estimates (less than 1% for all drugs 
considered).108 The large variability in incidence reflects the heterogeneity of the 
populations studied (inpatients, outpatients, specific psychiatric populations), and the 
definitions used (serum sodium <135 or <130 mmol/L). Seven of these studies were 
based on inpatients,102,104,106,108,112,116,117 while three looked at a combination of in and 
outpatients.103,109,114 None of these studies focused on community-based older adults. 
About half of these studies defined hyponatremia using a serum sodium threshold of 
<135 mmol/L,101,102,104,106,116,117 while three of the studies used a threshold of <130 
mmol/L.108,114,117 Hyponatremia tended to occur within the first four weeks following 
initiation of an antidepressant drug.108–110,112 In the study by Liu et al. of 736 spontaneous 
reports of patients who developed hyponatremia while taking an SSRI, fluoxetine was 
implicated in 75% of the cases, paroxetine in 12%, sertraline in 12% and fluvoxamine in 
1%, with a majority of the cases (83%) occurring in the elderly. While this study 
certainly generates potential hypotheses, it was based on voluntary reports of spontaneous 
adverse events, which is subject to reporting bias (typically under-reporting).110 
Five observational studies reported effect measures for the association between 
hyponatremia and the second-generation antidepressants of interest. The results of these 
studies, their limitations and data quality scores are summarized in Table 2-4. These 
studies had variable methodological quality, with study methods’ quality scores ranging 
from 12 to 17 (with higher quality studies receiving a higher score, range 0 to 21). The 
mean age of patients included in these studies were all greater than 60 years of age. This 
is consistent with literature in that hyponatremia commonly affects older adults. All these 
studies found a significant risk of hyponatremia following use of a second-generation 
antidepressant. However, the majority of these risk estimates were based on small sample 
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sizes of psychiatric inpatients with the exception of the population-based study conducted 
by Coupland et al., which reported the lowest risk of hyponatremia. In this population-
based retrospective cohort study of over 60,000 community-based older adults, a 
significant risk of hyponatremia was observed with several SSRIs, but not with 
mirtazapine or venlafaxine (grouped together) (hazard ratio (HR) 1.52 [95% CI 1.33 to 
1.75]).107 Given the size of the study, differences between the individual SSRIs was 
possible to elucidate. The authors found that fluoxetine, citalopram, and escitalopram 
were associated with significantly higher risks of hyponatremia but interestingly, 
paroxetine and sertraline were not. A possible explanation for the null findings with these 
specific drugs is that patients were followed-up for an average of 5 years (SD 3.3 years), 
during a time at which a risk of hyponatremia might not be present. As hyponatremia 
occurs within the first few weeks of initiating a second-generation antidepressant, it is 
possible that a null association with paroxetine, sertraline, and mirtazapine/venlafaxine 
was observed due to the longer follow-up period. The largest risk of hyponatremia was 
reported in a small case-control study (64 cases, 192 controls) by Siegler et al., who 
found that fluoxetine use was associated with a 21-fold increased risk of hyponatremia in 
psychiatric inpatients (95% CI 5.3 to 86.9).118 In one case-control study by Movig et al., a 
risk of hyponatremia was highest in older patients (OR 6.3 [95% CI 1.0 to 41.0]) in 
subgroup analysis (29 cases, 78 controls).119 However, in both of these studies, the 
confidence intervals were very wide, indicating that there is a large potential for random 
error. As well, the Seigler study was based only on a single center and a single SSRI; the 
Movig study combined inpatients and outpatients who tend to be different from each 
other. Four of these five studies did not consider other commonly used second-generation 
antidepressants including duloxetine, citalopram, escitalopram, and mirtazapine, which 
makes it challenging to generalize the results across other commonly used second-
generation antidepressants.111,118–120 The large disparities observed across these measures 
of effect can be attributed to the differences in the populations studied, the types of study 
designs, the definitions of hyponatremia, and sample sizes. 
There is inconclusive evidence regarding potential differences between individual 
second-generation antidepressants in their propensity for causing hyponatremia, and for 
the relationship between second-generation antidepressant dose and hyponatremia. This 
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is owing to the small sample sizes in most of these studies, which precludes meaningful 
stratified analysis. The drug-specific findings in the study by Coupland et al. are novel, 
and need to be replicated in other settings to confirm the findings. One small study of 14 
inpatients with dementia found that citalopram dose was significantly correlated with 
lower serum sodium levels.121 However, in the review of spontaneously reported cases of 
SSRI-induced hyponatremia by Liu et al., no dose-response relationship was apparent.110 
Concomitant diuretic use is a well-established risk factor for hyponatremia in patients 
taking second-generation antidepressants. Using data from a multidrug surveillance 
program, Letmaier et al. found that hyponatremia occurred more frequently when an 
SSRI was used in combination with a diuretic compared to when the SSRI was used 
alone (0.14% vs. 0.02%, p <0.001); a similar result was observed with venlafaxine (0% 
vs. 0.51%, p <0.001).108 Kirby et al. investigated concomitant diuretic use as an effect 
measure modifier in their assessment of SSRI and venlafaxine use and hyponatremia in 
psychiatric inpatients. The association was significantly modified by concomitant 
thiazide diuretic use (diuretic use: OR 11.2 [95% CI 2.2 to 58.1] vs. diuretic non-use: OR 
2.5 [95% CI 1.1 to 5.4]).111 A similar finding was observed in the study of psychiatric 
patients by Movig et al. (concomitant diuretic use: OR 13.5 [95% CI 1.8 to 101]).119 
Studies to date have not investigated whether antidepressant drug-induced hyponatremia 
is influenced by the presence of kidney disease and heart failure, which are two clinically 
important groups of patients.  
In these studies, several important risk factors for hyponatremia among older adults 
taking second-generation antidepressants were identified. In the prospective study of 
older psychiatric inpatients taking SSRIs and venlafaxine, Kirby et al., found that renal 
disease, cancer, a group of ‘other’ comorbidities which included diabetes, 
hypoaldosteronism, and hypothyroidism, and severity of medical illness were all 
significantly associated with hyponatremia.111 Siegler et al. found the following risk 
factors to be significantly associated with hyponatremia: female sex, systolic blood 
pressure, elevated serum creatinine levels, abnormal serum potassium levels, diabetes 
mellitus, hypertension, chronic obstructive pulmonary disease, diuretics, tricyclic 
antidepressants, and calcium channel blockers.118 Movig et al. found that loop diuretics, 
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thiazide diuretics, peptic ulcer drugs, proton pump inhibitors, heart failure, and 
hypothyroidism were significant risk factors for hospitalization for hyponatremia.120 
In summary, most of the observed associations were based on case reports and 
descriptive studies that lack control groups, providing only a crude estimate of incidence 
of hyponatremia. The risk of hyponatremia from second-generation antidepressant drug 
use was quite variable (HR of 1.52; ORs of 3.5 to 21.4). Only the study by Coupland et 
al. was of good quality,107 while the remaining studies were of moderate quality.113,118–120 
Most of these estimates were based on inpatients or combined in- and outpatients in their 
analyses. Inpatients are fundamentally different from the outpatient population, as they 
tend to be older and sicker, which means the results are not necessarily generalizable to 
populations living the community or long-term care facilities. Due to the small sample 
sizes in four of these studies, adequate control for confounding was not possible. There 
are a number of demographic factors, concomitant drugs, comorbidities, and healthcare 
system use factors that were not or could not be accounted for. In many of these studies, 
follow-up time was variable or not indicated, and often included periods where the risk of 
hyponatremia was negligible. Lastly, all the studies were conducted outside of Canada, 
where prescribing practices differ from other parts of the world. Given the limitations of 
the current literature, there is a need to conduct further studies that address the limitations 
of previous research.  
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Table 2-3. Descriptive and clinical studies of hyponatremia from second-generation antidepressant drugs 
Study/ 
Country 
Study 
Type 
Outcome 
definition 
Sample Size/ 
Population 
Studied 
Relevant drugs 
studied 
Time to 
Hyponatremia 
Results 
Significant 
Risk Factors 
Limitations 
Letmaier et 
al. 
(2012)108 
 
Germany, 
Austria, 
Switzer-
land 
Retro-
spective  
Serum 
sodium 
<130 
mmol/L 
263 864 
psychiatric 
inpatients  
Citalopram 
Escitalopram 
Paroxetine 
Sertraline 
Duloxetine 
Venlafaxine 
Mirtazapine 
-Not reported -Incidences: 
0.078% Citalopram 
0.085% 
Escitalopram 
0.033% Paroxetine 
0.053% Sertraline 
0.106% Duloxetine 
0.077% Venlafaxine 
0.004% Mirtazapine 
-Not assessed -Reporting bias 
(Under-reporting 
likely) 
-No control group 
 
Roxanas et 
al. 
(2007)114 
 
Australia  
 
Pro-
spective  
Serum 
sodium 
<130 
mmol/L 
58 outpatients 
and inpatients 
>65 years of 
age  
 
Mean age: 76 y 
Venlafaxine -Median time 
to onset: 4 
days (range 3 
to 5 days) 
-10 pts developed 
HN (17.2%) within 3 
to 5 days 
-Not assessed -No control group  
-Small N 
Fabian et 
al. 
(2004)101 
 
United 
States of 
America 
Pro-
spective 
(longitud-
inal study) 
Serum 
sodium 
<135 
mmol/L 
75 outpatients 
(63-90 years 
old) diagnosed 
with major 
depressive 
episode 
 
Mean age: 75 y 
Paroxetine -Mean time to 
onset: 9.3 
days 
-9/75 pts developed 
HN (12%) 
 
-Low BMI OR 
0.74 (95% CI 
0.56 to 0.99), p 
<0.04 
 
-Low baseline 
sodium OR 0.40 
(95% CI 0.22 to 
0.73), p <0.003  
-No control  
-Small N 
 
Wee and 
Lim 
(2004)106 
 
Australia 
Retro-
spective 
(chart 
view) 
Serum 
sodium 
<135 
mmol/L 
116 inpatients  
 
Mean age: 79 y 
SSRIs (did not 
specify 
individual drugs) 
-Not reported -7/40 pts who 
started on an SSRI 
developed HN 
(17.5%) 
-16/63 pts who are 
already on an SSRI 
developed HN 
(25.4%) 
-Diuretic use 
p<0.025 
-No control group  
-Small N 
-Single center 
Fabian et 
al. 
(2003)116 
 
Pro-
spective 
(pilot 
study)  
Serum 
Sodium 
<135 
mmol/L 
15 inpatients 
who were 
diagnosed with 
major 
Paroxetine  
 
-HN developed 
after 2 weeks 
of treatment 
-6/15 pts developed 
HN (40%)  
-Not assessed -No control group  
-Very small N 
(pilot) 
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United 
States of 
America 
depression  
 
Mean age: 76 y 
Jung et al. 
(2011)115 
 
Korea 
Retro-
spective  
Serum 
sodium 
<135 
mmol/L 
249 inpatients 
with depression 
 
Mean age: 51 y 
Paroxetine 
Sertraline 
Escitalopram 
Fluoxetine 
Venlafaxine 
Mirtazapine 
-Not reported -11/240 pts 
developed HN 
 
SSRIs: 8/93 (8.6%) 
Venlafaxine: 3/71 
(4.2%) 
Mirtazapine: 0 
 
-Not assessed -No control group 
-Small N 
Wilkinson 
et al. 
(1999)109 
 
New 
Zealand 
Retro-
spective 
‘Definite’ or 
‘probable’ 
hyponatre
mia using 
likelihood 
criteria 
845 inpatient 
and outpatient 
elderly pts >65 
years old 
 
Mean age: not 
specified 
Paroxetine 
Fluoxetine 
-Median time 
to onset: 13 
days (range 3 
to 120 days) 
-14 HN cases   
-Matched with 56 
controls (no HN) 
-All taking 
paroxetine or 
fluoxetine 
-Incidence: 0.47% 
people treated/year 
-Low body 
weight OR 0.92 
(95% CI 0.86 to 
0.99), p<0.04 
 
-No control group 
-Single center 
Bouman et 
al. 
(1998)102 
 
United 
States of 
America 
Retro-
spective 
(chart 
review) 
Serum 
sodium 
<135 
mmol/L 
32 psychiatric 
inpatients  
 
Mean age: 79 y 
SSRI -Not reported -8/32 patients (25%) 
developed HN 
-Not assessed -No control group  
-Small N 
Critchlow 
(1998)117  
 
Ireland 
Retro-
spective 
(chart 
review) 
Serum 
sodium 
<135 
mmol/L 
and <130 
mmol/L 
1010 psychiatric 
inpatients >65 
years old on 
various 
medications  
 
Mean age: not 
specified  
Not specified -Not reported -11/51 (22%) 
developed HN while 
taking SSRIs 
-Not assessed -All psychiatric 
inpatients 
-No control group  
-Pts on several 
medications which 
may also cause 
HN 
Strachan 
and 
Shephard 
(1998)112 
 
Australia 
 
Retro-
spective 
(chart 
review) 
Serum 
Sodium 
<134 
mmol/L 
53 inpatients  
 
Mean age: 74 y 
Paroxetine 
Fluoxetine  
-Not reported -13 pts developed 
HN (24.5%) 
-Not assessed -Incomplete data 
-Small N 
-No control group 
-Single center 
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Liu et al 
(1996)110 
 
Un-
specified 
location 
Retro-
spective 
(case 
review) 
Terms 
"water-
electrolyte 
imbalance"
, "HN", and 
"inappro-
priate ADH 
syndrome"  
A review of 736 
reports of HN 
 
Mean age: not 
specified 
 
-Most (83%) of 
the published 
cases involved 
pts 65 years of 
age or more 
Fluoxetine 
Paroxetine 
Sertraline 
Fluvoxamine 
-Median time 
to onset: 13 
days (range 3 
to 120 days)  
 
Of 736 cases,  
 
75.3% Fluoxetine 
12.4% paroxetine 
11.7% sertraline  
1.5% fluvoxamine  
-Not assessed -All case reports 
of SSRIs 
-No control group  
-Reporting bias 
(voluntary 
reporting, true 
incidence 
underestimated) 
-Quality of reports 
can vary greatly 
-Incidence cannot 
be determined   
 
Pillans et 
al. 
(1994)103 
 
New 
Zealand 
 
Retro-
spective 
(case 
review)  
Not 
specified 
376 in and 
outpatients >65 
years old  
 
Mean age: not 
specified (>65 y) 
Fluoxetine -Not reported -7 women 
developed HN  
-Incidence rate of 
fluoxetine-
associated reports 
of HN was 5.4 for 
1000 patients 
(0.54%) 
-Not assessed -No control group  
-Reporting bias 
(voluntary 
reporting, true 
incidence 
underestimated) 
-All documented 
cases were 
female 
Abbreviations: y=year; SIADH=syndrome of inappropriate antidiuretic hormone secretion; OR=odds ratio; CI=confidence interval; BMI=body mass index; 
SSRI=selective serotonin reuptake inhibitor; pt=patient; HN=hyponatremia 
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Table 2-4. Studies reporting a measure of association for the risk of hyponatremia from second-generation antidepressant drugs 
Study/ 
Country 
Design 
Outcome 
definition 
Sample Size/ 
Population 
Studied 
Relevant 
drugs 
studied 
Follow-up 
window 
Results 
Significant Risk 
Factors 
Limitations 
Quality 
Score 
Coupland 
et al. 
(2011)107 
 
United 
Kingdom 
Retro-
spective 
Cohort 
(population
-based) 
Read 
Codes 
(diagnoses 
made in 
primary 
and 
secondary 
care)  
 
60 746 
outpatients (≥65 
y) diagnosed as 
having a new 
episode of 
depression  
 
Mean age: 75 y 
Citalopram 
Escitalopram 
Fluoxetine 
Paroxetine  
Sertraline 
Mirtazapine 
Venlafaxine 
-Not pre-
defined 
-Mean 
follow up of 
5 years 
Incidence:  
 
-SSRIs: 
Adjusted HR 
1.52  
(95% CI 1.3- 
1.75) 
-SNRI/NaSSA: 
Adjusted HR 
1.28 (0.98-1.67) 
-Not assessed -Residual 
confounding 
-Confounding by 
indication 
-Average 5-year 
follow-up 
-Read codes 
used 
(performance 
characteristics 
unknown) 
 
17 
Kirby et al. 
(2002)111 
 
Australia 
Retro-
spective 
Cohort  
Serum 
sodium 
<135 
mmol/L 
199 psychiatric 
inpatients  
 
Mean age: 74 y 
Fluoxetine 
Sertraline 
Paroxetine 
Fluvoxamine 
Venlafaxine 
-Not 
reported 
-29/74 exposed 
pts developed 
HN (39%) 
-13/125 
unexposed pts 
developed HN 
(10%) 
 
Fluoxetine: 3/5 
(60%) 
Sertraline: 8/28 
(29%) 
Fluvoxamine: 0 
Venlafaxine: 
10/14 pts (71%) 
 
-Adjusted OR 
3.5 
(95% CI 1.4-8.9) 
  
 
-Renal diease 
p=0.005 
-Cancer p=0.01 
-Other (diabetes, 
hypoaldo-
steronism, hypo-
thyroidism, and 
severity of 
medical illness) 
p=0.02 
-Small sample 
size 
-All psychiatric 
inpatients 
-Single center 
13 
Movig et 
al. 
(2002)119 
Matched 
Case-
control 
Serum 
sodium 
≤130 
107 psychiatric 
in- and out-
patients  
SSRIs 
(did not 
specify 
-Not 
reported 
-General 
population: 
Adjusted OR 3.9  
-Abnormal 
potassium level 
(>5.0 mmol/l) OR 
-Small sample 
size 
-Did not 
16 
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The 
Nether-
lands 
mmol/L (29 cases, 
hyponatremia; 
78 controls, no 
hyponatremia) 
(all ages) 
 
Mean age: 68 y 
individual 
drugs) 
(95% CI 1.2-
13.1) 
-Over 65 y: 
Adjusted OR 6.3  
(95% CI 1.0-
41.0) 
24 (95% CI 2.0-
283) 
-Older age (>65 
years) OR 6.3 
(95% CI 1.0-41) 
 
consider milder 
levels of 
hyponatremia  
-In-patients may 
differ from 
outpatients  
-Two centers 
-Not exclusively 
elderly 
population (19 
cases, 30 
controls ≥65 
years); very 
wide CI in age 
≥65 
-Could not 
determine 
incidence 
Movig et 
al. 
(2002)120 
 
The 
Nether-
lands 
Matched 
Case-
control 
Primary or 
secondary 
diagnosis 
of hypo-
natremia 
(ICD-10 
code 
276.1) or 
SIADH 
(ICD-10 
code 
253.6)  
811 outpatients 
(203 cases, 
hyponatremia; 
608 controls, no 
hyponatremia) 
(all ages) 
 
Mean age: 71 y 
Fluoxetine 
Fluvoxamine  
Paroxetine 
Sertraline 
Venlafaxine  
 
-Median 
time to 
onset: 10 
days 
(range 1 to 
108 days) 
-Adjusted OR 
3.96  
(95% CI 1.33- 
11.83) 
 
-Thiazide diuretics 
use OR 3.21 (95% 
CI 1.68-6.15) 
-Heart failure OR 
3.28 (95% CI 
1.68-6.41)  
-Hypo-thyroidism 
OR 18.29 (95% CI 
1.96-171) 
-Small sample 
size 
-Diagnostic 
codes used 
(limited 
sensitivity) 
-Unknown risk in 
elderly 
population 
-Could not 
determine 
incidence  
 
15 
Siegler et 
al. 
(1995)118 
 
USA  
Case-
control 
Serum 
sodium 
≤130 
mmol/L 
256 psychiatric 
inpatients (64 
cases, 
hyponatremia; 
192 controls, no 
hyponatremia) 
 
Mean age: 62 y 
Fluoxetine -Not 
reported 
-Adjusted OR 
21.4 (95% CI 
5.3-86.9) 
 
-Female sex OR 
4.0 (95% CI 1.2-
13.3)  
-Systolic blood 
pressure OR 1.02 
(95% CI 1.0-1.04)  
-Elevated serum 
creatinine levels 
OR 2.1 (95% CI 
1.3-3.6) 
-Small sample 
size 
-Single center 
-All psychiatric 
inpatients 
-Single drug 
studied 
12 
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-Abnormal serum 
potassium levels 
OR 19.1 (95% CI 
4.2-87.7) 
-Diabetes mellitus 
OR 4.4 (95% CI 
1.1-18.4) 
-Hyper-tension 
OR 5.7 (95% CI 
2.1-15.2) 
-Chronic 
obstructive 
pulmonary 
disease OR 90.6 
(95% CI 5.6-1453) 
-Diuretics OR 8.2 
(95% CI 2.2-30.8) 
-Tricyclic anti-
depressants OR 
4.9 (95% CI 1.6-
15.2) 
-Calcium channel 
blockers OR 4.0 
(95% CI 1.1-14.2) 
Abbreviations: y=year; ICD-10=International Classification of Diseases, 10th revision; SIADH=syndrome of inappropriate antidiuretic hormone secretion; 
OR=odds ratio; HR=hazard ratio; CI=confidence interval; SSRI=selective serotonin reuptake inhibitor; SNRI=selective norepinephrine reuptake inhibitor; 
pt=patient; HN=hyponatremia 
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2.4.1.2 Antipsychotic Drugs and Hyponatremia 
Hyponatremia from atypical antipsychotic drugs is far less understood compared to 
antidepressant drugs. Hyponatremia occurs in about 4% of patients with schizophrenia 
and to a lesser extent with other conditions.95 Older antipsychotic agents such as 
haloperidol and phenothiazines have been implicated in the development of 
hyponatremia, but similar information for atypical antipsychotics is lacking.122,123 Most 
observations of hyponatremia from atypical antipsychotic drugs are limited to case 
reports (summarized in Appendix A Table A-1).  
The incidence of hyponatremia from atypical antipsychotics is not well-established, 
with only the one drug surveillance study by Letmaier et al. reporting an incidence of less 
than 0.01% for risperidone.108 A systematic review conducted by Meulendijks et al. 
identified 120 cases of hyponatremia from 1978 to 2008 from any type of antipsychotic 
drugs.95 The authors reported that hyponatremia developed at a median of 19 days after 
commencing treatment. Even though this number is based on combined information from 
both typical and atypical antipsychotics, a risk window of three to four weeks for atypical 
antipsychotics is biologically plausible. The results and limitations of these two studies 
are summarized in Table 2-5. 
To date, only one case-control study has evaluated the association between atypical 
antipsychotic use and hyponatremia, which was of moderate quality (quality score of 14). 
The results and limitations of this study are summarized in Table 2-6. The reporting of 
hyponatremia was significantly associated with the use of atypical antipsychotics 
compared to use of other drugs (adjusted reporting odds ratio (ROR) 1.58 [95% CI 1.46 
to 1.70]).124 In subgroup analysis, risperidone and olanzapine were both significantly 
associated with hyponatremia, but quetiapine was not. This study was based on 
spontaneous reports available from a World Health Organization (WHO) database of 
adverse drug reactions, which is subject to under-reporting and misclassification, leading 
to biased estimates of association.125 In this study, estimates were adjusted only for age, 
sex, and concomitant medication use, which means residual confounding may be present. 
As well, there is potential for confounding by indication, as hyponatremia may have 
occurred due to the psychogenic polydipsia. In addition, follow-up time for the 
development of hyponatremia was not clear. Nonetheless, these findings do highlight a 
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potential signal of hyponatremia following atypical antipsychotic drug treatment, which 
needs to be replicated in additional studies.  
The systematic review by Meulendijks et al. was also based on spontaneous 
reports, and only examined the effect of dose on the development of hyponatremia. A 
non-significant negative correlation between the defined daily dose and serum sodium 
levels was observed for atypical antipsychotics (r = -0.16).95 However, the authors 
concluded that further investigations are warranted to confirm this finding. Whether the 
risk of hyponatremia is higher in patients with kidney disease, heart failure or in those 
taking diuretics is currently unknown, but is worth investigating from a clinical 
standpoint. As well, there are no studies that have looked at the risk factors of 
hyponatremia among patients taking atypical antipsychotics. 
In summary, there is insufficient evidence in the literature demonstrating a risk of 
hyponatremia from atypical antipsychotic use. The majority of the evidence comes from 
single case reports or case series. The studies that do exist also stem from case reports, 
which are severely impacted by reporting bias and potential misclassification. In addition, 
the individuals that these studies are based on may not necessarily be representative of 
individuals in non-hospitalized settings. Only one study of spontaneous case reports has 
been conducted to date, and highlights a potential signal. This warrants further 
exploration through carefully designed epidemiological studies, better control for 
confounding, with a pre-defined follow-up window.  
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Table 2-5. Descriptive and clinical studies of hyponatremia from atypical antipsychotic drugs 
Study / 
Country 
Design 
Outcome 
definition 
Sample Size/ 
Population 
Studied 
Relevant 
drugs studied 
Time to 
Hyponatremia 
Results 
Significant Risk 
Factors 
Limitations 
Letmaier et 
al. (2012)108 
 
Germany, 
Austria, 
Switzerland 
Retro-
spective  
Serum sodium 
<130 mmol/L 
263 864 
psychiatric 
inpatients  
 
Mean age: 49 y 
Risperidone -Not reported -Incidence: 
0.004% 
-Not assessed -Reporting bias 
(under-reporting 
likely) 
-No control 
group 
 
Meulendijks 
et al. 
(2010)95 
 
English, 
Dutch, 
German,  
French and 
Spanish 
articles 
Retro-
spective 
(System-
atic 
Review) 
‘hypo-
natremia’, 
‘inappropriate 
ADH 
syndrome’, 
‘sodium blood 
level’, ‘sodium 
deficiency’, 
‘sodium 
depletion’, 
‘water-
electrolyte 
balance’, and 
‘polydipsia’ 
123 reports of 
hyponatremia 
  
Mean age: 46 y 
Antipsychotics 
(typical and 
atypical) 
-Median time 
to onset: 19 
days 
-23/123 – probable  
-99/123 – possible 
-1/123 – unlikely 
-atypical 
antipsychotics:  
48/123 reports 
 
 
-Not assessed -Based primarily 
on case reports 
-Could not 
estimate risks 
-Reporting bias 
-Publication 
bias 
Abbreviations: y=year; ADH=antidiuretic hormone 
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Table 2-6. Studies reporting a measure of association for the risk of hyponatremia from atypical antipsychotic drugs 
Study / 
Country 
Design 
Outcome 
definition 
Sample Size/ 
Population 
Studied 
Relevant 
drugs 
studied 
Follow-up 
window 
Results 
Significant 
Risk Factors 
Limitations 
Quality 
Score 
Mannesse 
et al. 
(2010)124 
 
90 
countries 
(WHO 
Vigibase 
database 
of adverse 
drug 
reactions) 
Matched 
Case-
control  
WHO 
preferred term 
Hyponatremia 
/ SIADH (as 
documented in 
case reports) 
145 253 case 
reports (15 728 
cases, 
hyponatremia;  
129 252 
controls, other 
adverse events) 
 
Mean age: 59 y 
(cases 67 y; 
controls 52 y) 
Risperidone 
Olanzapine 
 
(other 
atypical and 
typical anti-
psychotics) 
-Not 
reported 
-ROR 1.58 
(95% CI 1.46-
1.70)  
-Risperidone: 
ROR 1.52 (95% 
CI 1.3-1.77) 
-Olanzapine: ROR 
1.45 (95% CI 
1.23-1.71) 
-Quetiapine: ROR 
1.34  
(95% CI 0.94-
1.91) 
-Not assessed -Reporting bias 
(spontaneous 
reports) 
-Selection bias 
 
14 
Abbreviations: y=year; WHO=World Health Organization; SIADH=syndrome of inappropriate antidiuretic hormone secretion; ROR=reporting odds ratio; 
CI=confidence interval
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2.4.1.3 Antiepileptic Drugs and Hyponatremia 
The literature describing hyponatremia from antiepileptics varies by drug. 
Carbamazepine was the first antiepileptic drug to be implicated in the development 
hyponatremia in 1966.126 Since then, a number of cases reports describing hyponatremia 
with carbamazepine have been conducted (summarized in Appendix A Table A-1).  
Fourteen descriptive/clinical studies and one randomized controlled trial describing 
the relationship between carbamazepine and hyponatremia were identified. The results of 
these studies and their limitations are summarized in Table 2-7. Hyponatremia was 
observed in patients of all ages (mean ages ranging from 30 to 72 years of age). Eight of 
these studies did not use a control group in their assessments.108,127–133 In three controlled 
studies, patients exposed to carbamazepine had a significantly greater frequency of 
hyponatremia than those who were no exposed.134–136 The incidence of carbamazepine-
induced hyponatremia ranged widely from less than 1% to 42%.128–130,132–135,137–139 
Similar to antidepressants, the broad range of incidences observed reflect the patient 
populations studied and the range of definitions used for hyponatremia. Eleven of these 
studies defined hyponatremia using a serum sodium threshold of <135 mmol/L127–
129,131,133,134,136–140 while the remaining studies used stricter definitions of hyponatremia 
(<132 mmol/L and <130 mmol/L)108,132,135 or did not specify a definition.130 Most of 
these estimates were based on small studies of unique populations, primarily inpatients 
with intellectual disabilities or affective disorders making them underpowered to detect 
significant changes in serum sodium. Except for the surveillance program study by 
Letmaier et al., all sample sizes were small (<700 patients). In one of the larger studies, 
Kalff et al. studied 674 in- and outpatients with epilepsy and found that hyponatremia 
developed in 1.8% of patients taking carbamazepine alone and in 5.7% of patients taking 
carbamazepine with other antiepileptics (mostly valproic acid and barbiturates).140 No 
hyponatremia developed in those who were taking antiepileptics other than 
carbamazepine (control group). However, no statistical tests were used in this study to 
compare the three groups. Both acute and chronic hyponatremia have been associated 
with carbamazepine use, and occurred up to three months following treatment.131,140,141 
Despite being a well-understood problem, no studies characterized the risk of 
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hyponatremia from carbamazepine. It would be of clinical significance to quantify this 
risk for neurologists and other physicians.  
In a cross-sectional study by Dong et al., 451 patients taking carbamazepine were 
evaluated, and age and dose were significant risk factors for the development of 
hyponatremia, but not sex.127 In the study by O’Hare et al., age was also significantly 
associated with development of hyponatremia (p = 0.01). In a self-controlled study by 
Udhe et al., hyponatremia correlated with a high daily dose of carbamazepine (r = 0.62, p 
<0.05).138 Some additional studies support this dose correlation,133,134,137 while others do 
not.132,139 Additionally, Udhe et al. found that patients with lower baseline serum sodium 
levels had the greatest decrements in serum sodium following carbamazepine use (r = 
0.69, p <0.02).138 Hyponatremic effects are greater in patients who simultaneously use 
diuretics and other drugs known to cause hyponatremia.142,143 It is not clear from the 
literature if patients taking carbamazepine who have kidney disease or congestive heart 
failure are at greater risk of developing hyponatremia than those without such conditions. 
There is less information in the literature about hyponatremia associated with 
valproic acid (case reports summarized in Appendix A Table A-1). Only one case-control 
study examining the association between valproic acid and hyponatremia was found, 
which was of moderate quality (quality score of 15). Results and limitations of this study 
are summarized in Table 2-8. In this study, spontaneous reports of all types of adverse 
drug reactions made to the WHO were evaluated (22 606 reports in total). Of these, four 
females (>57 years of age) developed hyponatremia following the initiation of valproic. 
A modest increased risk of hyponatremia from valproic acid was found (adjusted ROR 
1.83 [95% CI 1.61 to 2.08]).144 The cases used in this assessment were considered 
‘strongly’ suggestive of a causal relationship with hyponatremia. The time to develop 
hyponatremia from valproic acid remains unclear due the limited available evidence. It is 
possible that a dose effect exists, although this needs to be confirmed in other studies.144–
146  
The relationship between hyponatremia and topiramate or phenytoin is not clear. In 
the product information sheet for topiramate, hyponatremia is described as a rare adverse 
event.147 However, topiramate is a newer antiepileptic, and limited experience with this 
drug may explain why no case reports or studies were found in the literature. As for 
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phenytoin, there is conflicting information about its effect on hyponatremia. Some studies 
demonstrated a reversal of hyponatremia by phenytoin. In a few cases, phenytoin was 
successfully used in patients taking carbamazepine or with SIADH to reverse antidiuretic 
effects.148–150 However, this finding was not consistent in a prospective study that 
examined the role of phenytoin in patients with SIADH.151 This may be because the 
“reversal” of hyponatremia by phenytoin was actually caused by a reduction in serum 
carbamazepine levels during combined therapy.152  
In summary, the majority of the evidence describing hyponatremia from 
carbamazepine is based on small clinical studies in select groups of patients of a variety 
of ages, with only one study focusing on patients over the age of 65. It is apparent from 
these studies that carbamazepine leads to a decrease in serum sodium levels. However, it 
is not clear whether these results are generalizable non-hospitalized older adults, who are 
healthier than the unique populations examined in these studies. Only one study reported 
the time to onset of hyponatremia of one to three months, which makes it challenging to 
understand the risk window associated with this drug. Furthermore, the risk of 
hyponatremia following carbamazepine in non-hospitalized older adults has yet to be 
quantified. Evidence for valproic acid and hyponatremia is based mostly on case reports. 
One study characterized a reporting odds ratio of hyponatremia from valproic acid, but 
this was based on spontaneous cases, which is hampered by limitations such as reporting 
bias. Furthermore, adequate control for confounding was not possible. The available 
evidence regarding potential association with hyponatremia and phenytoin and 
topiramate is limited and conflicting. Population-based epidemiological studies with a 
well-defined control group, adequate control for confounding, and pre-defined follow-up 
are needed to better understand the potential risk of hyponatremia with these drugs in a 
Canadian context. 
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Table 2-7. Descriptive and clinical studies of hyponatremia from carbamazepine (antiepileptic drug) 
Study / 
Country 
Design 
Outcome 
definition 
Sample Size / 
Population 
Studied 
Relevant drugs 
studied 
Time to 
Hyponatremia 
Results 
Significant 
Risk Factors 
Limitations 
Letmaier et 
al. (2012)108 
 
Germany, 
Austria, 
Switzerland 
Retro-
spective  
Serum 
sodium 
<130 
mmol/L 
263 864 
psychiatric 
inpatients  
 
Mean age: 49 y 
Carbamazepine -Not reported -Incidence: 0.103% -Not assessed -Reporting bias 
(Under-reporting 
likely) 
-No control group 
(no measure of 
association) 
-No adjustment for 
confounders 
Rowan et al. 
(2005)135 
 
United 
States of 
America 
Random-
ized, 
Double-
blind, 
Double 
Dummy, 
Parallel 
Study 
(efficacy 
study) 
Serum 
sodium 
<130 
mmol/L 
-18 Veterans 
Affairs Medical 
Centers  
-593 elderly pts 
with newly 
diagnosed 
seizures 
-197 pts on 
carbamazepine 
-395 pts on other 
AEDs 
 
Mean age: 72 y 
Carbamazepine -Not reported -19/171 pts 
(remaining in study) 
developed HN 
(11.1%) 
-Not assessed -Study population 
was predominantly 
men 
-Efficacy study (did 
not examine risk of 
hyponatremia) 
Dong et al. 
(2005)127 
United 
States of 
America 
 
Cross-
sectional 
Study 
Serum 
sodium 
<135 
mmol/L 
-Patients were 
≥15 years old 
from MINCEP 
Epilepsy Care 
patient database 
-451 
carbamazepine 
treated pts 
 
Mean age: 38 y 
Carbamazepine -Not reported -Prevalence of HN 
was 13.5% 
-Advanced 
age p<0.0001 
-Dose 
P<0.0001 
-Small N 
-No control group 
(no measure of 
association) 
-Patients of all ages 
-Exposure time 
unknown 
-Could not estimate 
incidence 
Kelly and 
Hillery 
(2001)134 
 
Ireland 
Retro-
spective 
(chart 
review)  
Serum 
sodium 
<135 
mmol/L 
-117 individuals 
from a 
residential center 
with an 
intellectual 
Carbamazepine -Not reported -Exposed: 22/53 
(41.5%) developed 
HN 
-Control: 6/64 
(9.4%) developed 
-Not assessed -Small N 
-All patients with 
intellectual disability 
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disability 
 
Mean age: 42 y 
HN 
Critchlow 
(1998)117  
 
Ireland 
Retro-
spective 
(chart 
review) 
Serum 
sodium 
<135 
mmol/L 
 
1010 psychiatric 
inpatients >65 
years old on 
various 
medications  
 
Mean age: not 
specified  
 
Carbamazepine -Not reported -1/51 (2%) 
developed HN while 
taking 
carbamazepine 
-Not assessed -All psychiatric 
inpatients 
-No control group 
(no measure of 
association) 
-Patients on several 
medications which 
may also cause HN 
Abdul-
Hussain and 
White 
(1996)129 
 
United 
Kingdom 
Retro-
spective 
(chart 
review) 
Serum 
sodium 
<135 
mmol/L 
-67 pts from 
learning 
disability 
hospitals; 146 
serum assays 
examined 
(uncontrolled) 
 
Mean age: not 
specified 
Carbamazepine -Not reported -Prevalence 32/60 
(48%) 
-Not assessed -Small N 
-No control group 
(no measure of 
association) 
 
 
Seymour 
(1993)130 
 
Australia 
Retro-
spective  
Not 
specified 
-Retrospective 
review of 
pharmacology 
records at 2 
teaching 
hospitals where 
33 cases of 
carbamazepine 
overdose (≥100 
umol/L) were 
identified  
 
Mean age: 30 y 
Carbamazepine -Not reported -4/33 developed HN 
(12%) 
-Not assessed -Small N 
-No control group 
(no measure of 
association) 
-Study of overdose 
 
 
Kastner et 
al. (1992)136 
 
Unspecified 
location 
Pro-
spective  
Serum 
sodium 
<135 
mmol/L 
- Mentally 
retarded pts 
-Exposed: 40 pts 
on 
carbamazepine 
-Control: 40 age, 
Carbamazepine -Not reported -2/40 developed HN 
(5%) 
-Statistical, but not 
clinically significant 
decrease in sodium 
levels  
-Not assessed -All mentally 
retarded patients 
-Small N 
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sex-matched pts, 
other AEDs  
 
Mean age: not 
specified 
 
Yassa et al. 
(1988)131 
Canada 
 
Pro-
spective  
Serum 
sodium 
<135 
mmol/L 
-20 pts with 
bipolar and 
unipolar 
disorders 
following 
carbamazepine 
treatment  
 
Mean age: 61 y 
Carbamazepine -Within 1 to 3 
months 
-5/20 developed HN 
(25%) within 1-3 
months 
-Not assessed -Small N 
-No control group 
(no measure of 
association) 
 
Lahr 
(1985)139 
 
United 
States of 
America 
Pro-
spective  
Serum 
sodium 
<135 
mmol/L 
-Mentally 
retarded pts 
-Group 1: 60 pts 
on 
carbamazepine 
-Group 2: age-
matched 
controls, 31 pts 
on other AEDs 
-Group 3: age-
matched controls 
with no history of 
epilepsy 
 
Mean age: not 
specified 
Carbamazepine -Not reported -13/60 pts 
developed HN 
(21.7%) 
-Increased age 
p = 0.005 
-CBZ level  
>6 ug/ml, 
p<0.001 
-Small N 
-Single center 
Kalff et al. 
(1984)140 
 
Netherlands 
Retro-
spective  
Serum 
sodium 
<135 
mmol/L 
-674 in and out-
patient epileptics 
-Group 1: 113 on 
carbamazepine 
monotherapy 
-Group 2: 460 on 
carbamazepine 
and other AEDs 
-Group 3: 
Control, on other 
AEDs (no 
Carbamazepine -Not reported -Group 1: 2/113 
developed HN 
(1.8%) 
-Group 2: 26/460 
developed HN 
(5.7%) 
-Group 3: 0 
developed HN 
 
-Not assessed -Two centers only 
-No characterization 
of significance 
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carbamazepine) 
 
Mean age: not 
specified 
Uhde and 
Post 
(1983)138 
 
United 
States of 
America 
Pro-
spective  
Serum 
sodium 
<135 
mmol/L 
-Mentally ill pts 
on placebo first, 
followed by 
carbamazepine 
for bipolar, 
schizoaffective, 
unipolar 
disorders  
-ages: 22 to 66 
 
Mean age: not 
specified 
Carbamazepine -Not reported -4/12 pts developed 
HN (33.3%) with 
carbamazepine use 
-No pts developed 
HN when on 
placebo 
-Low baseline levels 
resulted in greater 
sodium decrements 
(r = 0.69, p < 0.02) 
-Not assessed -Small N 
-Single center 
O’Hare et al. 
(1980)132 
 
Ireland 
Pro-
spective  
Serum 
sodium 
<132 
mmol/L 
-55 pts on 
carbamazepine 
for epilepsy (52) 
and trigeminal 
neuralgia (2) 
(uncontrolled) 
 
Mean age: 28 y 
Carbamazepine -Not reported -7/55 developed HN 
(12.7%) 
-range 117-132 
mmol/L 
-Age (p=0.01) -Small N 
-No control group 
Perucca 
(1978)137 
 
United 
Kingdom 
Pro-
spective  
Serum 
sodium 
<135 
mmol/L 
-Epileptic pts 
-Exposed: 80 pts 
on 
carbamazepine 
or 
carbamazepine 
combination 
-Control: 50 
patients on other 
AEDs 
 
Mean age: 33 
yrs 
Carbamazepine 
or 
carbamazepine 
combination 
-Not reported -5/80 developed HN 
(6.3%) 
-Not assessed -Small N 
 
Henry et al. 
(1977)133 
 
United 
Pro-
spective  
Serum 
sodium 
<135 
mmol/L  
-16 pts on 
carbamazepine 
for epilepsy (14) 
and trigeminal 
Carbamazepine -Not reported -5/16 developed HN 
(31.3%) 
-Not assessed -Small N 
-No control group 
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Kingdom neuralgia (2)  
 
Mean age: 37 y 
Abbreviations: y=year; CI=confidence interval; pt=patient; HN=hyponatremia; AED=antiepileptic drug 
 
 
Table 2-8. Studies reporting a measure of association for the risk of hyponatremia from valproic acid (antiepileptic drug) 
Study / 
Country 
Design 
Outcome 
definition 
Sample Size / 
Population 
Studied 
Relevant 
drugs studied 
Follow-up 
window 
Results 
Significant 
Risk Factors 
Limitations 
Quality 
Score 
Beers et al. 
(2010)144 
 
The 
Netherlands 
Case-
control 
Study 
Not 
specified 
-Study of reports 
submitted to the 
Netherlands 
Pharmaco-
vigilance Centre 
-22 606 reports of 
ADRs with 
valproic acid 
-Cases: reports of 
HN in valproic 
acid users 
-Controls: all other 
reports 
 
Mean age: not 
specified 
Valproic acid -Not 
reported 
-HN suspected 
in 238/22 606 
reports (1.05%) 
-Adjusted ROR 
1.83 (95% CI 
1.61, 2.08) 
-Not assessed -Spontaneous 
reporting 
system 
-Possibility of 
duplicate 
reports 
-Selection bias 
 
15 
Abbreviations: ROR=reporting odds ratio; CI=confidence interval; pt=patient; HN=hyponatremia; ADR=adverse drug reaction 
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2.5 Factors Affecting Psychotropic Drug Use 
There are a number of factors related to psychotropic drug use, and are further 
described below. 
Age: Several studies have shown that older adults are more likely to use 
psychotropic drugs compared to younger age groups.153–157 Older adults tend to 
have more mental health and neurological problems which can explain the higher 
prevalence of psychotropic drug use among this age group.158 In a population-
based study by Alonso et al., adults over the age of 65 were three times more 
likely to use a psychotropic drug compared to adults 18 to 24 years of age (OR 
3.1 [95% CI 2.4 to 4.0]).156 Mamdani et al., studied patients over the age of 65, 
and found that antidepressant use increased linearly with age until about 85 to 89 
years (p <0.001).159  
Sex: In a review examining psychotropic drug use by gender, 28 studies from 
various countries consistently showed that women used more psychotropic drugs 
then men.160 According to the CCHS, the prevalence of psychotropic drug use 
was 9.5% in women and 5.0% in men.161 Several reasons have been postulated for 
this finding. This could be because women are more likely to perceive illness, 
visit their physicians, share their problems with their physician, be more open 
about the use of psychotropic drugs, or directly request a prescription.162,163 
Another suggestion is a longer life expectancy among women can result in more 
effects of aging, losses and health problems, which increases their likelihood of 
using a psychotropic drug.162  
Residential Status: A number of studies have reported increased psychotropic 
drug use among older adults residing in long-term care facilities in Canada and 
around the world.164–170 In a study conducted in Ontario, up to 55% of older adults 
residing in a long-term care facility were prescribed at least one psychotropic 
drug.170 In a study of older Swedish adults, those living in a long-term care 
facility were more likely to use antidepressant and antipsychotic drugs than those 
not living in such facilities (antidepressant drugs, OR 3.82 [95% CI 1.60 to 9.10]; 
antipsychotic drugs, OR 2.72 [95% CI 1.29 to 5.74]).171 In another large Swedish 
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study, antiepileptic drugs were more commonly used among institutionalized 
residents compared to community-dwelling older adults (OR 3.98 [95% CI 3.86 
to 4.10]).172 This is attributed to the increased prevalence of dementia, depression, 
anxiety, epilepsy, and other psychiatric disorders observed in these types of 
facilities. 
Physician visits: The number of annual visits to a physician increases the 
likelihood that an older adult will be prescribed a psychotropic drug.162,173,174 This 
relationship is quite apparent, as a visit to a physician is required in order to 
obtain a prescription. Nearly 75% of visits to a physician result in at least one 
prescription of any kind.175 In a study by Gustafsson et al., community-dwelling 
older adults who had visited a physician within the previous three months were 
more likely to use a psychotropic drug then those who had not visited a physician 
(52% versus 22%, p < 0.001).  
Mental health and neurological disorders: Psychotropic drugs such as 
antidepressants, antipsychotics, and antiepileptics are frequently used in the 
treatment of mental health and neurological disorders. Naturally, presence of 
these disorders is correlated with use of specific types of psychotropic drugs. For 
example, in a study examining psychotropic drug use among nursing home 
residents, depression was a significant predictor of psychotropic drug use (OR 
3.5, p < 0.01).176 In another study of older adults, compared to non-users, 
psychotropic drug users had higher mean (standard deviation [SD]) scores for 
anxiety (1.4 (0.5) vs. 1.7 (0.6), p < 0.001) and depression (13.1 (9.1) vs. 18.9 
(11.3), p < 0.001).177 Paterniti et al. found that psychotropic drug users were four 
times more likely to report symptoms of anxiety and depression than non-users 
(OR 4.0 [95% CI 2.5 to 6.5]).178 In a study by Kamble et al., long-term care 
residents with schizophrenia or bipolar disorder were more likely to use 
antipsychotic drugs compared to residents without these conditions (OR 11.15 
[95% CI 7.84 to 15.87]; p < 0.05 and OR 3.97 [95% CI 2.52 to 6.24]; p < 0.05, 
respectively).179 
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Other Comorbidities: The presence of comorbidities (related or unrelated to 
hyponatremia), have been associated with psychotropic drug use.162 Since older 
adults suffer from more diseases than younger individuals, they tend to use more 
psychotropic and non-psychotropic drugs. A possible reason for this is that the 
presence of multiple comorbidities can worsen an individual’s mental health 
status, which may result in the need for a psychotropic drug.180 It is also possible 
that adults with other comorbidities are more conscious of their health, making 
them more likely to visit their physician and receive medications to treat their 
medical problems. 
2.6 Conceptual Model 
Based on the review of the literature, a conceptual model was developed to depict 
the hypothesized relationship between psychotropic drug use and hyponatremia 
(Figure 2-2).  
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Healthcare System 
Usage 
Physician Visits 
Procedures/Tests 
Prescription Drug Use 
 
Outcome 
Hospitalization with 
HYPONATREMIA 
Exposure 
Psychotropic Drugs 
 
ANTIDEPRESSANTS 
ANTIPSYCHOTICS 
ANTIEPILEPTICS 
Mental Health and 
Neurological Disorders 
Mood Disorders 
Anxiety Disorders 
Bipolar/Unipolar Disorders 
Dementia 
Schizophrenia 
Epilepsy  
Pain Disorders 
Delirium 
 
Demographic 
Characteristics 
Age 
Sex 
Residential Status  
 
Comorbidities 
Heart Failure 
Kidney Diseases 
Liver Diseases 
Malignancies 
Pulmonary 
Disorders 
Endocrine Disorders 
CNS Disorders 
Pneumonia 
  
Concomitant Drugs 
Diuretics 
Antineoplastics 
Antidiabetics 
NSAIDs 
Antibiotics 
Antihypertensive Agents 
 
Other Characteristics 
Low Baseline Sodium Levels  
History of Hyponatremia 
 
Figure 2-2. Conceptual model of the hypothesized relationship between psychotropic drug use and hyponatremia 
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2.7 The Need for Research 
2.7.1 Summary of Limitations of the Current Literature 
A thorough review of the literature has identified several gaps and limitations with 
existing research: i) most observed associations were based on case reports and 
descriptive studies that lack control groups, providing only a crude estimate of prevalence 
or incidence of hyponatremia; ii) studies assessing the risk of hyponatremia from one of 
the three psychotropic drug classes of interest were generally of moderate methodological 
quality, iii) many of the studies were older, based on small sample sizes, were conducted 
in a single center, and studied highly specific patient populations, making it challenging 
to generalize results to the contemporary outpatient/community setting; iv) follow-up 
time was variable, and often included periods where the risk of hyponatremia was 
negligible; v) all studies were conducted outside of Canada where the healthcare system, 
prescription drug coverage, and prescribing practices may differ; and vi) many studies 
did not or could not (due to limited power) consider several potentially confounding 
variables. Additionally, it is unclear whether the risk of hyponatremia from psychotropic 
drugs is higher in certain high-risk groups such as those with heart failure and kidney 
disease, or in those simultaneously taking diuretics. As well, there is limited information 
regarding the existence of a dose-dependent risk of hyponatremia among psychotropic 
drug users.  
2.7.2 Gaps in Prescribing Reference Manuals 
The weak evidence available regarding these risks has led to poor consensus and 
inconsistent messaging in pharmaceutical reference manuals, online sources and clinical 
practice guidelines (current warnings and recommendations are summarized in Appendix 
A Table A-2). For example, the Compendium of Pharmaceuticals and Specialties (CPS) 
and UptoDate® are pharmaceutical references frequently used by physicians and nurse 
practitioners.181,182 In both of these references, hyponatremia is listed as an adverse event 
for all of the study antidepressants, risperidone, and carbamazepine, while for olanzapine 
and quetiapine similar information is only available in UptoDate®. Recommendations for 
the management of low serum sodium levels in these patients are unclear. Carbamazepine 
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is the only drug for which both the CPS and UptoDate® suggest to monitor serum 
sodium, but the strategies differ. For antidepressants and antipsychotics, UptoDate® 
suggests monitoring serum sodium concentration closely when initiating or adjusting the 
dose in older adults, but no such suggestions are made in the CPS.  
2.8 Conclusion 
Hyponatremia is a clinically important adverse drug event that is a significant cause of 
morbidity and mortality, even when mild. As the number of adults over the age of 65 
continues to grow, the economic burden that drug-induced adverse events place on the 
healthcare system will increase. The available evidence surrounding psychotropic drug-
induced hyponatremia is limited, with many questions remaining unanswered. This 
research has the potential to overcome the limitations of prior research, and can provide a 
better understanding of the risk of hyponatremia with psychotropic drugs commonly used 
in routine care, and will contribute to emerging knowledge regarding the safety of their 
use in older adults. Associations between the psychotropic drugs of interest and 
hyponatremia can be better understood at the population-level by taking advantage of 
Canada’s universal health care system and large healthcare databases in Ontario. 
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3.1 Introduction 
Pharmacoepidemiology is an evolving discipline that studies, “the frequency and 
distribution of health and disease in populations, as a result of the use and effects 
(beneficial or adverse) of drugs.”1 Although randomized controlled trials are considered 
the “gold standard” study design, they have an inability to examine rare events and 
usually do not represent the entire clinical picture. Observational pharmacoepidemiologic 
studies are ideal for investigating drug-outcome relationships in real world practice as 
they typically use large comprehensive datasets, such as health administrative data. 
However, as with any observational study, pharmacoepidemiologic studies are subject to 
biases and confounding. In order to minimize these effects, special consideration must be 
given to the methodology. The purpose of this chapter is to provide an overview of the 
data sources and the data analytic methods used in this thesis. 
3.2 Health Administrative Data Sources 
The Institute for Clinical Evaluative Sciences houses a number of linked health 
administrative databases, nine of which were used in this thesis. Using a unique 
identifier, the ICES Key Number (IKN), is common to all datasets and is used to link 
them. A description of each of the datasets is provided below.  
Registered Persons Database: The Ontario Registered Persons Database (RPDB) is a 
population-based registry that contains demographic information on all individuals who 
have been issued an Ontario health card number. Information on date of birth, date of 
death, gender, income (categorized into quintiles of average neighbourhood income), and 
location of residence (rural or urban) was obtained from the RPDB.  
Ontario Drug Benefits: The Ontario Drug Benefit (ODB) is a province-wide program 
that provides coverage for more than 4,400 drug products to adults over the age of 65 and 
other special populations.2 This database contains information from 1997 onward on 
prescription drug claims for outpatients and long-term care residents. For this thesis, the 
ODB was used to identify exposure to psychotropic drugs, as well as other important 
concomitant medications. Prescription claims are accurately recorded in the database 
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with an error rate of 0.7% (95% CI 0.5% to 0.9%).3 This database was also used to 
determine residential status (community-dwelling or long-term care). 
Canadian Institutes for Health Information Discharge Abstract Database: The 
Canadian Institutes for Health Information Discharge Abstract Database (CIHI-DAD) 
contains patient-level data for acute, chronic, rehab, and day surgery institutions in 
Ontario. Inpatient information is available from 1988 onward. This database was used to 
ascertain baseline comorbidities and outcome information, including the primary 
outcome of hospitalization with hyponatremia. After a patient is discharged from 
hospital, a medical records coder draws up an abstract from the chart, compiling 
administrative and clinical data on that particular stay.4 CIHI-DAD provides the ability to 
record up to 25 diagnoses, each with a corresponding diagnosis type. Since 2002, 
diagnoses have been coded with International Classification of Diseases, 10th revision 
(ICD-10) codes. Prior to this, ICD-9 codes were used. Similarly, procedures were coded 
using the Canadian Classification of Procedures (CCP) until 2002 after which the 
Canadian Classification of Interventions (CCI) system was adopted. 
Canadian Institutes for Health Information National Ambulatory Care Reporting 
System: The Canadian Institutes for Health Information National Ambulatory Care 
Reporting System (CIHI-NACRS) includes information on patient visits to hospital and 
community-based ambulatory care facilities. Specifically, information on day surgery, 
outpatient clinic visits, renal dialysis visits, and emergency department visits are 
captured. In NACRS, up to 10 diagnoses can be recorded, each with a corresponding 
diagnosis type. Information is abstracted and coded in the same way as in the DAD. In 
this thesis, information from emergency department visits was used for baseline 
assessments of comorbidities and as a measure of health care utilization.   
Ontario Mental Health Reporting System (OMHRS): OMHRS collects data on adult 
patients who are admitted to an inpatient mental health bed. This includes beds in 
general, provincial psychiatric, and specialty psychiatric facilities. Collection of data in 
OMHRS began in October 2005. Prior to this, information was captured in the CIHI 
DAD. Therefore, in this thesis both datasets were used to identify patients with a mental 
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health disorder. In the CIHI-DAD, specific diagnoses were identified using ICD-10 
codes, while OMHRS contains Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition (DSM-IV) codes. Appropriate codes were compiled based on expert opinion. 
Ontario Health Insurance Plan: The Ontario Health Insurance Plan (OHIP) database 
includes claims made by physicians and other health care providers for insured services 
provided to all residents of Ontario. Most Ontario physicians are paid on a fee-for-service 
basis and submit claims to OHIP for reimbursement. Records contain several important 
pieces of information such as the type of service provided, service provider, diagnostic 
information, the date that it occurred, and the associated fee code. The OHIP database 
was used to obtain baseline information on important baseline comorbidities and 
measures of health care usage.  
ICES Physician database: The ICES Physician database contains information related to 
practicing physicians in Ontario, such as age, gender, specialty, and year of graduation. 
This database was used to abstract the specialty of the prescriber physician for the 
exposure of interest.   
Cerner: Cerner is an electronic medical record system used by 12 hospitals in 
southwestern Ontario. This system stores laboratory information for inpatients, 
outpatients, and emergency room visits in one repository and is available since June 
2003. For this thesis, the Cerner data holdings were linked to the other ICES healthcare 
databases. Data were available for a subpopulation residing in or near the hospital 
catchment area.5 Among this subpopulation, serum sodium laboratory data were used to 
define outcomes and to ascertain baseline serum sodium levels.   
Gamma-Dynacare: Gamma-Dynacare is a medical laboratory provider that contains 
outpatient laboratory data for the province since 2002. For this thesis, serum sodium data 
were used define outcomes and to ascertain baseline serum sodium levels.   
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3.3 Data Analytic Techniques 
3.3.1 Overview 
In pharmacoepidemiologic studies, exposure to a specific treatment is influenced by a 
number of patient, physician, and health care system factors.6 Consequently, the baseline 
characteristics between exposed and unexposed patients may differ systematically, and 
may ultimately influence the estimated treatment effect. Propensity score methods are 
often used to reduce the impact of this treatment selection bias. Propensity score methods 
mimic aspects of a randomized study by “balancing” observed baseline characteristics or 
covariates between exposed and unexposed subjects.7 The propensity score is the 
predicted probability of exposure to treatment conditional on observed covariates. This 
means that among subjects with the same propensity score, the distribution of baseline 
covariates are similar between exposed and unexposed groups.8 Four types of propensity 
score methods exist: matching on the propensity score, stratification on the propensity 
score, inverse probability of treatment weighting using the propensity score, or covariate 
adjustment using the propensity score.7  
3.3.2 Estimating the Propensity Score Model 
In each study comprising this thesis, the method of propensity score matching was 
selected. Given that a much larger number of unexposed subjects (compared to exposed 
subjects) were available for matching, this method was deemed suitable for each of the 
studies. Specifically, greedy nearest neighbor matching without replacement using a 
caliper width of ±0.2 of the standard deviation of the logit of the propensity score was 
selected as the matching technique. In this method, a randomly selected exposed subject 
is matched to an unexposed subject that has the closest propensity score within the 
specified caliper width (i.e. the difference in propensity scores between matched subjects 
differs by a maximum of ±0.2 of the standard deviation of the logit of the propensity 
score). The matching process is repeated until exposed subjects have been matched to 
eligible unexposed subjects. If an eligible match cannot be found, the exposed subject is 
excluded from the matching process.  
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The propensity score was derived for psychotropic drug treatment using a logistic 
regression model. This model included psychotropic drug exposure (dependent variable) 
and an extensive list of covariates (independent variables) related to either the treatment 
and/or outcome (potential confounders), as well as other covariates to ensure that both 
exposed and unexposed groups were as similar as possible on a wide range of baseline 
characteristics.7 Factors that were considered potential confounders for the relationship 
between psychotropic drug use and hyponatremia are broadly outlined in the Literature 
Review (section 2.5). Exposed and unexposed patients were then matched (using the 
desired matching ratio) on the logit of the propensity score within a caliper of ±0.2 
standard deviations. As well, other relevant factors that were considered important 
confounders or were of interest for subgroup analyses were directly matched on.  
3.3.2.1 Matching Factors 
In each of the studies comprising this thesis, exposed and unexposed subjects were 
matched on age, sex, residential status, index date, chronic kidney disease, congestive 
heart failure, diuretic use, or constituency in the catchment area with linked lab data. 
Within each study, the major labeled indications for which the drugs were likely 
prescribed for were also directly matched on (second-generation antidepressants study: 
mood and/or anxiety disorder; atypical antipsychotics study: dementia, schizophrenia, 
bipolar disorder, unipolar depression/anxiety, and/or Parkinson’s disease; antiepileptics 
study: epilepsy/seizure) 
Age, sex, and residential status are important confounders for the relationship 
between psychotropic drug use and hyponatremia. It is well-documented that older 
adults, women, and long-term care residents tend to experience hyponatremia and be 
prescribed more psychotropic drugs, compared to younger individuals, women, and 
patients living in the community.9–22 Since hyponatremia is known to occur in the 
presence of chronic kidney disease, congestive heart failure, and diuretic use, and since 
they all affect a large proportion of the population, they were of interest to subgroup 
analyses. As such, these factors were directly matched on to retain matched pairs. 
Similarly, analyses by sodium lab data was of interest but was only available for a 
subpopulation so an indicator variable for the constituency in the catchment area with 
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linked lab data was directly matched on to retain matched pairs for analysis of lab values. 
Lastly, the indications for which the drugs are typically prescribed were also matched on 
directly to remove the effects of confounding by indication.  
3.3.2.2 Strengths of Propensity Score Matching 
For each of the studies contained within this thesis, propensity score matching using a 
caliper width of ±0.2 standard deviations was the ideal method for several reasons. In 
empirical and simulation studies, propensity score matching was found to remove a 
greater degree of the systematic differences in observed covariates between exposed and 
unexposed groups.30 Since exposed and unexposed patients are, by definition, inherently 
different from each other, there is greater potential for treatment selection bias to 
influence the results. In addition, a sample that is matched on the propensity score is 
similar on all the covariates that are included in the propensity score.31 Thus, for each 
study, a large number of covariates (>100) were included in the propensity score models 
(see Appendix B, C, and D for the list of variables included in each study). This 
technique allowed for balance on a wide range of prognostically important variables. As 
well, a caliper width of ±0.2 standard deviations has been shown to eliminate nearly 98% 
to 99% of the bias due to observed covariates in many studies.32 
3.3.2.3 Limitations of Propensity Score Matching 
A key limitation of the propensity score matching approach is that a large number of 
exposed and unexposed patients are lost due to incomplete matching, resulting in reduced 
generalizability of the results to these subjects. However, upon examination, these 
patients tended to be sicker and older, which puts them at a greater risk of the outcome.  
3.3.3 Assessing Balance in Measured Covariates 
In order to ensure similarity between exposed and unexposed groups, baseline 
characteristics were examined before and after matching. Standardized differences were 
used to compare the two groups. Unlike t-tests or Wilcoxon rank-sum tests, standardized 
differences are independent of sample size, and their use is recommended in propensity-
score matched studies.33 This metric describes differences between group means relative 
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to the pooled standard deviation. The standardized differences for continuous and 
categorical baseline variables are calculated as follows: 
(1) Continuous baseline variable 
d =
(𝑥1̅̅̅ − 𝑥2̅̅ ̅)
√𝑠1
2 +  𝑠2
2
2
 
Where: 
𝑥1̅̅ ̅ and 𝑥2̅̅ ̅ denote the sample mean in exposed and unexposed groups, respectively; 
𝑠1
2 and 𝑠2
2 denote the sample variance in exposed and unexposed groups, respectively. 
(2) Categorical baseline variable  
d =
(𝑝1̂ − 𝑝2̂)
√[𝑝1̂(1 − 𝑝1̂) + 𝑝2̂(1 − 𝑝2̂)]
2
 
Where: 
𝑝1̂ and 𝑝2̂ denote the proportion in exposed and unexposed groups, respectively 
A standard difference that is less than 10% has been widely accepted as indicative of 
negligible imbalance in a baseline covariate between treatment groups.34 
3.3.4 Outcomes 
To answer the primary objective of this thesis, hyponatremia was assessed using an ICD-
10 code and using serum sodium laboratory values. When a patient presents to hospital 
with hyponatremia, they may be confused or delirious, which is indicative of the severity 
of hyponatremia. Generally, the lower serum sodium levels are, the more severe the 
symptoms of hyponatremia will be (as described in the literature review, section 2.2.2). 
Therefore, to understand if the observed hyponatremia was symptomatic, a combined 
outcome of hyponatremia and delirium was assessed in a secondary objective. Often, 
patients with mild hyponatremia do not display overt signs or symptoms, which may not 
be of clinical significance to health care professionals. As the sensitivity of this combined 
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outcome was very low, it was only feasible to evaluate this if there were an adequate 
number of events (i.e. >5 events).  
3.3.5 Analysis 
For all binary outcomes, conditional logistic regression was used to estimate odds ratios, 
and the Wald method to estimate 95% confidence intervals. This method was selected to 
account for the correlation within matched sets. This was done using the SAS procedure 
PROC LOGISTIC with a STRATA statement, which specifies the stratification 
variable(s) and requests the appropriate conditional logistic model.35 To calculate 95% 
confidence intervals for risk differences, a repeated measures model with PROC 
GENMOD was used.36 This method adjusts for the correlation within matched sets. 
Multivariable logistic regression models were used to determine the risk factors 
associated with the primary outcome in psychotropic drug users and non-users. This was 
adjusted for known risk factors of the outcome. 
3.3.5.1 Effect measure modification 
Separate interaction terms for potential effect measure modifiers (pre-specified) were 
included in the primary outcome main effects model to assess effect measure 
modification. Interaction p-values based on the Wald test for homogeneity were used to 
determine if the primary association differed significantly by levels of a third variable. 
3.3.5.2 Sensitivity Analyses 
Despite the measures taken to control for confounding through the design and analysis of 
these studies, residual confounding or other sources of error could have potentially 
influenced the results. As such, a number of sensitivity analyses were conducted (when 
possible) to ensure that confounding did not influence the primary results. 
In each study, a separate analysis was conducted using a negative control or tracer 
outcome. This is an outcome that is not expected to be associated with the exposure, and 
a null association with this outcome reassures us that the primary result is not a spurious 
finding.37 More specifically, if an association between two variables A-B is considered 
implausible and is used as a negative control for an association X-Y, then presence of an 
association between A and B will suggest bias in the association X-Y.37 
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In two of the studies, the primary outcome was re-assessed using a new time zero in 
retained matched pairs. The presence of a null association at that time would enhance 
causal inference in the primary analysis. Specifically, a new cohort entry date occurring 
in the 90 days prior to the original cohort entry date was selected - a time when both 
groups were not exposed to any study psychotropic drugs. Exclusion criteria were re-
applied to both groups at this new time zero.  
In study 1, as the magnitude of the effect was quite large, a quantitative bias 
analysis was conducted to ensure hidden bias wasn’t meaningfully influencing the results. 
Although conditioning on the propensity score allows for an unbiased estimation of the 
treatment effect, this is under the assumption that all variables affecting treatment 
assigned were measured.35 This means that two subjects with the same observed 
covariates may nonetheless differ in terms of unobserved covariates (i.e. unmeasured 
confounders). Hidden bias exists when these unobserved covariates cannot be accounted 
for in the anlaysis.38,39 This analysis helped to determine the potential impact that 
unmeasured confounding had on the findings. Specifically, it quantified the magnitude of 
bias that would need to be present to alter the conclusions of the study.39 
3.3.6 Missing Values 
The datasets were mostly complete for all variables included in the studies. There were 
three variables for which information was missing. These included location of residence, 
income quintile, and prescriber information. Only location of residence and income 
quintile were included in the propensity score models. Prescriber information was 
examined only out of interest. Location of residence was missing in less than 1% of each 
cohort. These patients were included in the urban category. Similarly, income 
information was missing in less than 0.1% of each cohort. These patients were included 
in the third income quintile (average income category). Prescriber information was 
missing in less than 15% of each cohort.  
 
 
76 
 
 
 
Reference List 
1.  Salas M, Stricker B. Research Methods for Pharmacoepidemiology Studies. In: 
Essentials of Clinical Research. Dordrecht: Springer Netherlands; 2008:201-216. 
2.  Drugs funded by Ontario Drug Benefit (ODB) program. Ontario Ministry of 
Health and Long-term Care. 
http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_mn.aspx. Published 
2016. Accessed April 30, 2016. 
3.  Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of 
administrative drug claims in the Ontario Drug Benefit database. Can J Clin 
Pharmacol. 2003;10(2):67-71. 
4.  Canadian Coding Standards for Version 2012: ICD-10-CA and CCI. Canadian 
Institutes for Health Information. 
https://secure.cihi.ca/free_products/canadian_coding_standards_2012_e.pdf. 
Accessed March 14, 2012. 
5.  Gandhi S, Shariff SZ, Beyea MM, et al. Identifying geographical regions serviced 
by hospitals to assess laboratory-based outcomes. BMJ Open. 2013;3(1):1-6. 
6.  Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding 
control in healthcare database research: Challenges and potential approaches. Med 
Care. 2010;48(6 Suppl):S114-S120. 
7.  Austin PC. An introduction to propensity score methods for reducing the effects of 
confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-
424. 
8.  Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in 
Observational Studies for Causal Effects. Biometrika. 1983;70(1):41-55. 
9.  Hoorn EJ, Rivadeneira F, Van Meurs JBJ, et al. Mild hyponatremia as a risk factor 
for fractures: The rotterdam study. J Bone Miner Res. 2011;26(8):1822-1828. 
10.  Liamis G, Milionis HJ, Elisaf M. Endocrine disorders: causes of hyponatremia not 
to neglect. Ann Med. 2011;43(3):179-187. 
11.  Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. 
Clin Chim Acta. 2003;337(1-2):169-172. 
12.  Parry HJ, Ph D. Use of psychotropic drugs by U.S. adults. Public Heal Rep. 
1968;83(10):799-810. 
13.  Ohayon MM, Lader MH. Use of psychotropic medication in the general 
77 
 
 
 
population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry. 
2002;63(9):817-825. 
14.  Nielsen MW, Hansen EH, Rasmussen NK. Patterns of psychotropic medicine use 
and related diseases across educational groups: National cross-sectional survey. 
Eur J Clin Pharmacol. 2004;60(3):199-204. 
15.  Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in 
Europe: Results from the European Study of the Epidemiology of Mental 
Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;109(420):55-64. 
16.  Carrasco-Garrido P, Jimenez-Garcia R, Astasio-Arbiza P, Ortega-Molina P, Gil de 
Miguel A. Psychotropic use in the Spanish elderly: Predictors and evolution 
between years 1993 and 2003. Pharmacoepidemiol Drug Saf. 2007;16:449-457. 
17.  Snowdon J, Vaughan R, Miller R, Burgess E, Tremlett P. Psychotropic drug use in 
Sydney nursing homes. Med J Aust. 1995;163(2):70-72. 
18.  Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population. 
J Am Geriatr Soc. 1995;43(12):1410-1413. 
19.  Miller M, Hecker MS, Friedlander DA, Carter JM. Apparent idiopathic 
hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc. 
1996;44(4):404-408. 
20.  Harrington C, Tompkins C, Curtis M, Grant L. Psychotropic drug use in long-term 
care facilities: A review of the literature. Gerontologist. 1992;32(6):822-833. 
21.  Wancata J, Benda N, Meise U, Müller C. Psychotropic drug intake in residents 
newly admitted to nursing homes. Psychopharmacology (Berl). 1997;134(2):115-
120. 
22.  Lasser RA, Sunderland T. Newer psychotropic medication use in nursing home 
residents. J Am Geriatr Soc. 1998;46(2):202-207. 
23.  Grikiniene J, Volbekas V, Stakisaitis D. Gender differences of sodium metabolism 
and hyponatremia as an adverse drug effect. Medicina (Kaunas). 2004;40(10):935-
942. 
24.  Movig KLL, Leufkens HGM, Lenderink AW, Egberts ACG. Validity of hospital 
discharge International Classification of Diseases (ICD) codes for identifying 
patients with hyponatremia. J Clin Epidemiol. 2003;56(6):530-535. 
25.  Morabia A, Fabre J, Dunand J. The influence of patient and physician gender on 
prescription of psychotropic drugs. J Clin Epidemiol. 1992;45(2):111-116. 
26.  Beck CA, Williams JV, Wang JL, et al. Psychotropic medication use in Canada. 
78 
 
 
 
Can J Psychiatry. 2005;50(10):605-613. 
27.  Voyer P, Cohen D, Lauzon S, Collin J. Factors associated with psychotropic drug 
use among community-dwelling older persons: A review of empirical studies. 
BMC Nurs. 2004;3:3. 
28.  Cafferata GL, Meyers SM. Pathways to psychotropic drugs. Understanding the 
basis of gender differences. Med Care. 1990;28(4):285-300. 
29.  Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. 
Am J Med. 2006;119(7 SUPPL. 1):30-35. 
30.  Austin PC. The Relative Ability of Different Propensity Score Methods to Balance 
Measured Covariates Between Treated and Untreated Subjects in Observational 
Studies. 2009;(416):661-677. 
31.  Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using 
Greedy Matching Techniques. Proc Twenty-Sixth Annu SAS Users Pap. 2001:214-
226. 
32.  Austin PC. Optimal caliper widths for propensity-score matching when estimating 
differences in means and differences in proportions in observational studies. 
Pharm Stat. 2011;10(2):150-161. 
33.  Yang D, Dalton J. A Unified Approach to Measuring the Effect Size between Two 
Groups Using SAS®.; 2012. 
34.  Austin PC. Using the standardized difference to compare the prevalence of a 
binary variable between two groups in observational research. Commun Stat - 
Simul Comput. 2009;38(6):1228-1234. 
35.  Faries DE, Obenchain R, Haro JM, Leon AC. Analysis of Observational Health 
Care Data Using SAS. SAS Institute; 2010. 
36.  SAS. Estimating the risk (proportion) difference for matched pairs data with binary 
response. http://support.sas.com/kb/46/997.html#note. 
37.  Lipsitch M, Tchetgen ET, Cohen T. Negative controls: A tool for detecting 
confounding and bias in observational studies. Epidemiology. 2010;21(3):383-388. 
38.  Rosenbaum PR. Observational Studies. Second Edi. New York, NY: Springer 
New York; 2002. 
39.  Hsu JY, Small DS. Calibrating sensitivity analyses to observed covariates in 
observational studies. Biometrics. 2013;69(4):803-811. 
 
79 
 
*A version of this chapter has been accepted for publication as: Gandhi S, Shariff SZ, Al-
Jaishi A, Reiss JP, Mamdani MM, Hackam DG, Li L, McArthur E, Weir MA, Garg AX. 
Antidepressants and hyponatremia risk: A population-based cohort study of older adults. 
Am J Kid Dis. 2016. 
 
 
 
 
 
 
 
 
CHAPTER 4: Second-generation Antidepressants and 
Hyponatremia Risk: A Population-based Cohort Study of 
Older Adults* 
 
 
 
 
 
 
 
 
 
80 
 
 
4.1 Introduction 
Mood and anxiety disorders are common and affect approximately 1 in 8 older adults.1–3 
Second-generation antidepressants are frequently recommended in the treatment of these 
disorders, with over 180 million prescriptions dispensed in the United States in 2013.4–7 
While generally well tolerated, a potentially dangerous side effect of these medications is 
hyponatremia. Hyponatremia can lead to adverse sequelae such as confusion, seizures, 
and even death.8 The accepted mechanism of hyponatremia with antidepressants occurs 
through the syndrome of inappropriate antidiuretic hormone.9,10  
Most prior studies of antidepressant-induced hyponatremia are descriptive with 
variable definitions of hyponatremia and lengths of follow-up. Reported estimates of 
incidence range widely from less than 1% to 40% for selective serotonin reuptake 
inhibitors (SSRIs) and up to 70% for venlafaxine, with most events observed in older 
adults within four weeks of antidepressant initiation.11–18 In three small retrospective 
studies of risk (maximum sample size 812 patients), older antidepressant users were up to 
six times more likely to develop hyponatremia compared to non-users.19–21  
Whether the results of prior studies generalize to the contemporary North American 
non-hospitalized setting remains uncertain since most studies consisted of small samples 
of patients, did not investigate newer second-generation antidepressants used in practice 
today, and were limited to patients admitted to psychiatric hospitals or long-term care 
facilities where patient health and monitoring differs from the community. Thus, using a 
population-based cohort, we aimed to investigate the 30-day risk of hospitalization with 
hyponatremia in older adults who were newly dispensed a second-generation 
antidepressant in the non-hospitalized setting. 
4.2 Methods 
4.2.1 Study Design and Setting 
We conducted a retrospective, population-based, cohort study of older adults from 1 June 
2003 through 1 March 2012 using linked health care databases in Ontario, Canada. 
Ontario has approximately 2.2 million residents over the age of 65 who are eligible to 
receive universal access to hospital care, physician services and prescription drug 
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coverage.22 These datasets were linked using unique encoded identifiers and were 
analyzed at the Institute for Clinical Evaluative Sciences (ICES). We conducted this 
study according to a pre-specified protocol that was approved by the institutional review 
board at Sunnybrook Health Sciences Centre, Toronto, Canada. Participant informed 
consent was not required for this study. We followed the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines for the reporting of our study 
(Appendix B Table B-1).23 
4.2.2 Data Sources 
We used records from nine linked databases to identify patient characteristics, drug use, 
covariate information, and outcome data. We used the Ontario Registered Persons 
Database to obtain vital statistics. This database contains demographic information on all 
residents who have been issued a provincial health card. We identified drug information 
using the Ontario Drug Benefit program database. This database documents all outpatient 
prescriptions dispensed to patients aged 65 and older, with an error rate less than one 
percent (1%).24 We used the Canadian Institute for Health Information (CIHI) Discharge 
Abstract Database to obtain diagnostic and procedural information on all hospital 
admissions. Similarly, we used the CIHI National Ambulatory Care Reporting System 
database to identify information relating to emergency department visits. We also used 
the Ontario Mental Health Reporting System database to identify diagnostic information 
on admissions to mental health facilities. We obtained covariate information from the 
Ontario Health Insurance Plan database, which includes health claims for inpatient and 
outpatient physicians’ services. We also used the ICES Physician Database to ascertain 
study antidepressant prescriber information. We obtained hospital-based serum sodium 
measurements from Cerner (a medical laboratory service provider) for a subpopulation in 
southwestern Ontario, residing in the catchment area of 12 hospitals where linked 
laboratory data were available (this catchment area has been previously defined).25 We 
also identified outpatient serum sodium measurements using Gamma-Dynacare Medical 
Laboratories (an outpatient laboratory service provider in Ontario). We have previously 
used these databases to research adverse drug events and health outcomes in several 
studies (including outcomes of hyponatremia and health services).26–30 
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We used International Classification of Diseases, 9th revision (ICD-9; pre-2002) 
and 10th revision (ICD-10; post-2002) codes to assess baseline comorbidities in the 5 
years prior to cohort entry. Only ICD-10 codes were used to identify outcomes as these 
events were ascertained following the implementation of this coding system. Codes used 
to ascertain baseline comorbidities and outcomes are detailed in Appendix B Table B-2. 
The databases were complete for all variables used in this study, with the exception of 
income quintile, rural residence, and prescriber information, which were missing in less 
than 0.5%, 0.1%, and 12% of older adults, respectively. 
4.2.3 Patients 
We established a cohort of older adults who had evidence of a hospital diagnosis or 
physician claim for a mood or anxiety disorder in the five years prior to a new 
prescription for one of nine second-generation study antidepressants: citalopram, 
escitalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, mirtazapine 
or sertraline (referred to as the ‘users’ group). We defined new use as no prescriptions for 
any type of antidepressant drug in the prior six months. The date of the eligible 
prescription served as the index date (cohort entry date) for users. We restricted the 
cohort to those who had a prescription for only one type of study second-generation 
antidepressant on their index date in order to compare mutually exclusive groups in 
subgroup analyses. We also established a control group from the Ontario population who 
were not prescribed any antidepressants (referred to as the ‘non-users’ group), and 
randomly assigned them an index date based on the distribution of index dates among 
users.28,31 
We excluded the following patients from both groups: (1) those who were 
discharged from a hospital in the two days prior to their index date to ensure (in the case 
of the users) that the drug was not initiated in a hospital setting (as patients continuing 
antidepressant drug treatment would have their oral outpatient prescription dispensed the 
day of or the day after hospital discharge) and (2) those with evidence of end-stage renal 
disease prior to their index date since in these patients sodium blood levels are regulated 
through dialysis. Among non-users, we excluded those who did not have at least one 
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outpatient medication dispensed in the 90 days prior to their index date to ensure active 
usage of the Ontario Drug Benefits program. 
A propensity score for the predicted probability of receiving a new second-
generation antidepressant drug was derived from a logistic regression model in which 
treatment status was regressed on over 100 variables that were potentially associated with 
the exposure or outcome (Appendix B Table B-3).32 We used greedy matching to match 
each user to a non-user (1:1) based on the following characteristics: the logit of the 
propensity score (within a caliper of ±0.2 standard deviations); age (within two years); 
sex; index date (within one year); residential status (community-dwelling or long-term 
care); evidence of a mood or anxiety disorder, chronic kidney disease, congestive heart 
failure; diuretic use; and constituency in the catchment area where linked laboratory data 
were available. We matched on these characteristics to ensure good balance of 
prognostically important characteristics and to facilitate subgroup analyses (to keep 
matched pairs intact).32 We applied matching without replacement where users and non-
users could only be selected once for inclusion in the study. Greedy matching without 
replacement within specified caliper widths has been shown to produce less biased 
estimates compared to other matching algorithms.33  
4.2.4 Outcomes 
We assessed outcomes within 30 days of the second-generation antidepressant 
prescription as most cases of hyponatremia have the greatest potential to occur during 
this period.13,34 As well, we expected fewer crossovers between the two groups during the 
first 30 days. 
4.2.4.1 Primary Outcome 
We defined the primary outcome of hospitalization with hyponatremia as any hospital 
admission with evidence of ICD-10 code E87.1 (hypo-osmolality or hyponatremia) in 
any of the 25 diagnostic fields in the CIHI Discharge Abstract Database. Based on an 
Ontario validation study assessing hospital admission with hyponatremia, the presence of 
code E87.1 identifies older patients with a median serum sodium value of 125 mmol/L 
(interquartile range [IQR] 120 to 130 mmol/L), whereas its absence identifies a median 
value of 137 mmol/L (IQR 135 to 139 mmol/L).35 Although the specificity of the hospital 
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diagnosis code is greater than 99%, the sensitivity is limited particularly for milder forms 
of hyponatremia (sensitivity of 11% for serum sodium ≤132 mmol/L). As such, we 
examined a subpopulation with linked hospital laboratory values. The full study is 
included in Appendix E. 
4.2.4.2 Secondary Outcome 
We assessed a secondary outcome of hospitalization with both hyponatremia and 
delirium using diagnostic codes. We expected the specificity of this combination of 
diagnosis codes to be high, but the sensitivity to be low, with an underestimation of the 
true incidence of the event. 
4.2.5 Statistical Analyses 
We compared baseline characteristics between second-generation antidepressant users 
and non-users using standardized differences. This metric describes differences between 
group means relative to the pooled standard deviation, and a difference is considered 
meaningful if greater than 10%.36 We expressed risk in both relative and absolute terms.  
To account for correlation within pairs, we used conditional logistic regression to 
estimate odds ratios and associated 95% confidence intervals (CIs) and a generalized 
linear model to estimate absolute risk differences and associated 95% CIs. Using 
statistical tests for interactions, we analyzed the primary outcome in five pre-specified 
subgroups: 1) second-generation antidepressant type, 2) second-generation antidepressant 
dose (higher dose vs. normal dose; higher dose defined by a higher than median starting 
daily dose for the study cohort), 3) evidence of chronic kidney disease, 4) evidence of 
congestive heart failure, and 5) baseline use of a diuretic. Chronic kidney disease and 
congestive heart failure were identified using separate algorithms of hospital diagnosis 
codes validated for adults in our study region.37,38 Matched pairs were retained in all 
subgroups. We conducted several additional analyses to support our primary findings. 
All odds ratios were approximated as relative risks (appropriate given the 
incidences observed). We performed all analyses using SAS version 9.4 (SAS Institute, 
Cary, North Carolina). Detailed methods are provided in Chapter 3. 
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4.2.5.1 Additional Analyses 
First, given the limited sensitivity of the hospital diagnosis code for hyponatremia, we 
examined the association between second-generation antidepressant use and 
hospitalization with a serum sodium concentration ≤132 mmol/L among the 
subpopulation with linked laboratory data.  
Second, we examined the association between second-generation antidepressant use 
and an outpatient serum sodium concentration ≤132 mmol/L among a subgroup for which 
information on outpatient serum sodium levels was available.  
Third, to test the specificity of our findings, we examined whether the 30-day risk 
of hospitalization with bowel obstruction differed in second-generation antidepressant 
users vs. non-users. Since there is no plausible reason why second-generation 
antidepressant use would increase the risk of bowel obstruction, we reasoned that a null 
association with this outcome would enhance causal inference in our hyponatremia 
analyses.39  
Fourth, to assess the temporality of our findings, we re-examined the primary 
outcome in our cohort at a date that preceded the index date by 90 days (i.e. 90 days prior 
to the original index date), and followed retained matched pairs to assess the 30-day risk 
of hospitalization with hyponatremia (exclusion criteria were re-applied at the new index 
date). We reasoned that a null association in this analysis would provide reassurance that 
the two groups were similar in their baseline risk for hospitalization with hyponatremia in 
the absence of second-generation antidepressant use.  
Fifth, to assess whether hidden bias could meaningfully influence the results, we 
conducted a sensitivity analysis to determine the magnitude of bias that would need to be 
present from unmeasured confounder(s) to alter the conclusions of the study.40,41 In this 
analysis, we examined the association between second-generation antidepressant use and 
hyponatremia under different scenarios by varying the strength of association between 
antidepressant use and the unmeasured confounder(s) as well as hyponatremia and the 
unmeasured confounder(s).  
Finally, we investigated the characteristics associated with hospitalization with 
hyponatremia separately in users and non-users. These characteristics included age (per 
year); sex; evidence of chronic kidney disease, congestive heart failure, diabetes, liver 
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disease, cancer, hypothyroidism, previous hyponatremia; and receipt of a diuretic, 
antiepileptic, antipsychotic, or antineoplastic medication.  
4.3 Results 
4.3.1 Baseline Characteristics 
Cohort selection is presented in Figure 4-1. We identified 172 552 second-generation 
antidepressant users and 297 501 non-users who were eligible for our study. 
Antidepressant users were more likely to be women (68% vs. 59%), and were more likely 
to reside in a long-term care facility (9% vs. 4%), have higher comorbidity scores, be 
prescribed a greater number of medications, and had more baseline health care service 
use than non-users. After matching, 138 246 patients remained in each group. Matched 
second-generation antidepressant users and non-users were nearly identical on all 
measured characteristics (standardized differences <10%) (Table 4-1; full table presented 
in Appendix B Table B-4). The mean age was 76 years and 68% were women. Among 
users, the most frequently prescribed second-generation antidepressant was citalopram 
(46%) and family physicians were the most frequent prescribers (78%). Amongst those 
with baseline values, the mean (standard deviation) serum sodium concentration was no 
different in second-generation antidepressant users (140.4 (3.3)) and non-users (140.5 
(3.2)).
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464 384 Without at least one 
outpatient medication dispensed in 
the 90 days prior to the index date 
  
10 579 Discharged from a hospital or 
emergency room in the two days prior 
to the index date 
 
4 859 Evidence of end-stage renal 
disease prior to the index date 
 
697 592 No evidence of a mood or 
anxiety disorder in the five years prior 
to the index date 
 
289 274 Ontario residents >65 years of age 
who were dispensed a new oral outpatient 
prescription for one of the following second-
generation antidepressant drugs prior to the 
index date: citalopram, escitalopram, 
paroxetine, fluoxetine, fluvoxamine, venlafaxine, 
duloxetine, mirtazapine or sertraline (from June 
2003 to March 2012). 
1 474 915 Ontario residents >65 years of age 
who were not dispensed an oral outpatient 
prescription for any antidepressant drug in the 
six months prior to the randomly assigned index 
date (from June 2003 to March 2012). 
 
19 832 Discharged from a hospital or 
emergency room in the two days prior 
to the index date  
 
2 331 Evidence of end-stage renal 
disease prior to the index date 
 
94 559 No evidence of a mood or 
anxiety disorder in the five years prior 
to the index date 
 
172 552 
 
297 501 
 
138 246 antidepressant 
users 
138 246 antidepressant 
non-users 
Matched 
(1:1) 
 
Remaining 
 
Excluded 
 
Figure 4-1. Cohort selection 
88 
 
 
Table 4-1. Baseline characteristics of second-generation antidepressant users and non-users* 
Characteristic Unmatched Matched 
 Antidepressant 
users 
(n=172 552) 
Antidepressant  
non-users 
(n=297 501) 
Standardized 
Differencea 
Antidepressant 
users 
(n=138 246) 
Antidepressant  
non-users 
(n=138 246) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 76 (7.5) 75 (7.2) 5.9% 76 (7.3) 76 (7.2) 0.3% 
Women 116 830 (67.7%) 177 662 (59.2%) 16.7% 93 303 (67.5%) 93 303 (67.5%) 0 
Income quintileb       
1  (low) 35 747 (20.7%) 59 184 (19.9%) 2.0% 28 057 (20.3%) 28 574 (20.7%) 0.9% 
2 35 935 (20.8%) 61 849 (20.8%) 0.1% 28 853 (20.9%) 28 954 (20.9%) 0.2% 
3 (medium) 33 863 (19.6%) 58 284 (19.6%) 0.1% 27 166 (19.7%) 27 279 (19.7%) 0.2% 
4 33 049 (19.2%) 58 377 (19.6%) 1.2% 26 684 (19.3%) 26 504 (19.2%) 0.3% 
5 (high) 33 958 (19.7%) 59 807 (20.1%) 1.1% 27 486 (19.9%) 26 935 (19.5%) 1.0% 
Rural residence 21 796 (12.6%) 34 381 (11.6%) 3.3% 17 660 (12.8%)  17 015 (12.3%) 1.4% 
Long-term care 14 989 (8.7%) 10 812 (3.6%) 21.1% 6859 (5.0%) 6859 (5.0%) 0 
Comorbid conditionsc       
Charlson comorbidity index, mean (SD) 0.8 (1.5) 0.6 (1.3) 14.0% 0.6 (1.3) 0.6 (1.4) 3.0% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.5 (3.8) 12.5 (3.7) 25.0% 13.0 (3.8) 13.1 (3.7) 0.8% 
Mood disorder 44 363 (25.7%) 34 484 (11.6%) 0.4% 24 207 (17.5%) 24 207 (17.5%) 0 
Anxiety disorderd 159 901 (92.7%) 282 632 (95.0%) 10.0% 129 861 (93.9%) 129 861 (93.9%) 0 
Congestive heart failure 25 766 (14.9%) 35 778 (12.0%) 8.5% 16 735 (12.1%) 16 735 (12.1%) 0 
Chronic kidney disease 10 798 (6.3%)  17 931 (6.0%) 1.0% 6094 (4.4%) 6094 (4.4%) 0 
Hypertension 129 149 (74.8%) 226 854 (76.3%) 3.3% 102 983 (74.5%) 101 948 (73.7%) 1.7% 
Chronic liver disease 6608 (3.8%) 10 759 (3.6%) 1.1% 5152 (3.7%) 4966 (3.6%) 0.7% 
Hypothyroidism 20 098 (11.7%) 32 199 (10.8%) 2.6% 15 723 (11.4%) 15 472 (11.2%) 0.6% 
Cancere 26 002 (15.1%) 43 459 (14.6%) 1.3% 19 741 (14.3%) 20 943 (15.1%)  2.5% 
Diabetes mellitus 14 371 (8.3%) 26 405 (8.9%) 2.0% 11 298 (8.2%) 11 234 (8.1%) 0.2% 
Pneumonia 9350 (5.4%) 10 796 (3.6%) 8.6% 5681 (4.1%) 5775 (4.2%) 0.3% 
Coronary artery diseasef 54 319 (31.5%) 89 377 (30.0%) 3.1% 40 738 (29.5%) 41 051 (29.7%) 0.5% 
Angina 40 486 (23.5%) 62 974 (21.2%) 5.5% 30 250 (21.9%) 30 287 (21.9%) 0.1% 
Previous hyponatremia 3889 (2.3%) 3941 (1.3%) 7.0% 2353 (1.7%) 2257 (1.6%) 0.5% 
Lung disease 53 458 (31.0%) 78 087 (26.3%) 10.5% 40 129 (29.0%) 40 321 (29.2%) 0.3% 
Epilepsy/seizure 1763 (1.0%) 2056 (0.7%) 3.6% 1053 (0.8%) 1092 (0.8%) 0.3% 
Acute kidney injury 3745 (2.2%) 4689 (1.6%) 4.4% 1964 (1.4%) 2009 (1.5%) 0.3% 
Delirium 4015 (2.3%) 3640 (1.2%) 8.4% 2104 (1.5%) 2103 (1.5%) 0 
Peripheral vascular disease 2974 (1.7%) 3973 (1.3%) 3.2% 1923 (1.4%) 1999 (1.4%) 0.5% 
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Concurrent medication useg       
Number of unique drug products, mean 
(SD) 
11.47 (7.4) 9.42 (6.1) 31.0% 10.47 (6.6) 10.41 (6.5) 0.9% 
Antiepileptics 16 212 (9.4%) 15 602 (5.2%) 16.0% 10 901 (7.9%) 10 499 (7.6%) 1.1% 
Antipsychotics 13 052 (7.6%) 11 759 (4.0%) 15.5% 7609 (5.5%) 7659 (5.5%) 0.2% 
Antidiabetics 27 160 (15.7%) 50 240 (16.9%) 3.1% 20 847 (15.1%) 21 461 (15.5%) 1.2% 
Antineoplastics 6848 (4.0%) 11 287 (3.8%) 0.9% 5199 (3.8%) 5636 (4.1%) 2.0% 
Thyroxine 29 654 (17.2%) 48 974 (16.5%) 1.9% 23 403 (16.9%) 23 457 (17.0%) 0.1% 
Potassium sparing diuretics 6498 (3.8%) 10 213 (3.4%) 1.8% 4827 (3.5%) 5020 (3.6%) 0.8% 
Non-potassium sparing diuretics  51 687 (30.0%) 86 612 (29.1%) 1.8% 38 879 (28.1%) 38 550 (27.9%) 0.5% 
ACE inhibitors and/or ARBs 79 341 (46.0%) 149 937 (50.4%) 8.9% 63 863 (46.2%) 63 390 (45.9%) 0.7% 
NSAIDs (excl. ASA) 34 309 (19.9%) 53 241 (17.9%) 5.1% 26 986 (19.5%) 27 803 (20.1%) 1.5% 
Calcium channel blockers 44 345 (25.7%) 80 594 (27.1%) 3.2% 35 214 (25.5%) 35 342 (25.6%) 0.2% 
Beta-adrenergic agonists 48 093 (27.9%) 88 616 (29.8%) 4.2% 37 652 (27.2%) 37 995 (27.5%) 0.6% 
Statins 64 831 (37.6%) 128 405 (43.2%) 11.4% 53 052 (38.4%) 52 777 (38.2%) 0.4% 
Benzodiazepines 67 701 (39.2%) 61 887 (20.8%) 41.1% 48 049 (34.8%) 46 320 (33.5%) 2.6% 
Healthcare contacts, mean (SD)h       
Hospitalizations 0.4 (0.8) 0.2 (0.5) 25.4% 0.3 (0.6) 0.3 (0.7) 1.7% 
Emergency department visits 1.0 (1.8) 0.6 (1.3) 27.1% 0.8 (1.5) 0.8 (1.5) 3.4% 
Family physician visits 19.3 (19.9)  14.8 (14.0) 26.8% 16.9 (16.4) 16.5 (15.3) 2.1% 
Geriatrician visits 0.4 (2.9) 0.2 (1.5) 13.3% 0.2 (1.6) 0.2 (1.6) 3.2% 
Psychiatrist visits 0.6 (3.9) 0.2 (2.0) 13.4% 0.3 (2.3) 0.2 (2.3) 4.0% 
Healthcare usei       
Previous sodium tests 108 033 (62.6%) 172 302 (57.9%) 9.6% 83 879 (60.7%) 80 886 (58.5%) 4.4% 
Carotid ultrasound 10 937 (6.3%) 14 166 (4.8%) 6.9% 7816 (5.7%) 7996 (5.8%) 0.6% 
Cardiac catheterization 3293 (1.9%) 4401 (1.5%) 3.3% 2327 (1.7%) 2311 (1.7%) 0.1% 
Echocardiography 31 184 (18.1%) 47 863 (16.1%) 5.3% 23 425 (16.9%) 23 657 (17.1%) 0.4% 
Holter monitoring 13 196 (7.6%) 18 248 (6.1%) 6.0% 9913 (7.2%) 9844 (7.1%) 0.2% 
Colorectal cancer screening 35 246 (20.4%) 63 516 (21.3%) 2.3% 28 856 (20.9%) 27 638 (20.0%) 2.2% 
Cervical cancer screening 12 870 (7.5%) 22 600 (7.6%) 0.5% 11 054 (8.0%) 11 111 (8.0%) 0.2% 
Thyroid stimulating hormone 103 460 (60.0%) 162 166 (54.5%) 11.0% 81 060 (58.6%) 80 776 (58.4%) 0.4% 
Bone mineral density test 23 220 (13.5%) 40 668 (13.7%) 0.6% 19 452 (14.1%) 19 433 (14.1%) 0 
Hearing test 10 395 (6.0%) 15 668 (5.3%) 3.3% 8086 (5.8%) 7967 (5.8%) 0.4% 
Computed tomography of the head 28 544 (16.5%) 22 761 (7.7%) 27.5% 17 175 (12.4%) 16 389 (11.9%) 1.7% 
Chest x-ray 74 792 (43.3%) 97 878 (32.9%) 21.6% 54 158 (39.2%) 54 782 (39.6%) 0.9% 
Pulmonary function test 17 023 (9.9%) 25 317 (8.5%) 4.7% 12 975 (9.4%) 13 134 (9.5%) 0.4% 
Laboratory measurementsj       
Evidence of baseline serum sodium 
measurement, N (%) 
31 228 (18.1%) 51 076 (17.2%) 2.4% 22 280 (16.1%) 22 280 (16.1%) 0 
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Most recent serum sodium, mean (SD) 140.2 (3.4) 140.6 (3.1) 12.3% 140.4 (3.3) 140.5 (3.2) 3.1% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive depression” was included into the anxiety disorder category 
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.  
g Concurrent medication use in the six months preceding the index date were considered. 
h Healthcare contacts in the year preceding the index date were considered. 
i Healthcare use in the year preceding the index date was considered. 
j Serum sodium measurements were obtained at a mean (SD) of 140 (102) days in users and 149 (101) days in non-users (matched groups), prior to the index 
date
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4.3.2 Primary Outcome 
Results using the hospital diagnosis code to define hyponatremia are presented in Table 
4-2. Second-generation antidepressant use vs. non-use was associated with a higher 30-
day risk of hospitalization with hyponatremia (450/138 246 [0.33%] vs. 84/138 246 
[0.06%]; relative risk 5.46 [95% CI 4.32 to 6.91]).  
Results from subgroup analyses are presented in Figure 4-2. The relative 
association between second-generation antidepressant use and hospitalization with 
hyponatremia was consistent in all five subgroup analyses (all p-values for interaction > 
0.05). The absolute increase in the incidence of hyponatremia associated with second-
generation antidepressant use vs. non-use was greater in patients with congestive heart 
failure than in those without heart failure (absolute risk increase 0.55% [95% CI 0.42% to 
0.68%] vs. 0.22% [95% CI 0.19% to 0.26%]) and in those using a diuretic vs. those not 
using a diuretic (absolute risk increase 0.48% [95% CI 0.40% to 0.56%] vs. 0.18% [95% 
CI 0.14% to 0.21%]).  
4.3.3 Secondary Outcome 
Results for the outcome of hospitalization with hyponatremia and delirium are also 
presented in Table 4-2. Second-generation antidepressant use vs. non-use was associated 
with a higher 30-day risk of hospitalization with concomittant hyponatremia and delirium 
(relative risk 4.00 [95% CI 1.74 to 9.16]). 
 
Table 4-2. 30-day outcomes (defined by hospital diagnosis codes) in second-generation 
antidepressant users and non-users 
 Events, No. (%)a 
Relative Risk 
(95% CI) 
Absolute Risk 
Increase (95% CI), % 
Antidepressant 
users 
(n=138 246) 
Antidepressant 
non-usersd 
(n=138 246) 
Primary Outcome 
Hospitalization with 
hyponatremiab 
450 (0.33) 84 (0.06) 5.46 (4.32 to 6.91) 0.27 (0.23 to 0.30) 
Secondary Outcome 
Hospitalization with 
hyponatremia and 
deliriumc 
28 (0.02) 7 (0.005) 4.00 (1.74 to 9.16) 0.02 (0.01 to 0.02) 
CI=confidence interval 
a The event rates and absolute risk differences are underestimated as the hospital-based diagnosis codes 
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used to define the outcomes have high speciﬁcity but low sensitivity.  
b The sensitivity and specificity of the code for hyponatremia is 11% and 99%, respectively.34  
c We expected the specificity of this combination of diagnosis codes to be high, but the sensitivity to be 
low, with an underestimation of the true incidence of the event. 
d An antidepressant non-user group was the referent.
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Events/At Risk, n/N (%)a 
  
 Antidepressant 
user  
(n=138 246) 
Antidepressant 
non-user  
(n=138 246) 
 
Relative Risk 
(95% CI) 
P-value for 
Interaction 
     
Antidepressant Drug Typeb 
   Citalopram 231/63 352 (0.36) 41/63 352 (0.06) 5.75 (4.11 to 8.04) 
4.77 (2.62 to 8.67) 
3.17 (1.27 to 7.93) 
8.00 (3.65 to 17.55) 
7.29 (3.31 to 16.05) 
0.08 
   Escitalopram 62/15 584 (0.40) 13/15 584 (0.08) 
   Mirtazapine 19/11 748 (0.16) 6/11 748 (0.05) 
   Paroxetine 57/20 886 (0.28) 8/20 866 (0.04) 
   Sertraline 51/15 013 (0.34) 7/15 013 (0.05) 
    
 
Antidepressant Drug Dosec 
   Higher Dose 29/14 763 (0.20) 8/14 763 (0.05) 3.63 (1.66 to 7.93) 
5.68 (4.42 to 7.30) 
0.28 
   Normal Dose 411/118 892 (0.35) 74/118 892 (0.06) 
    
 
Chronic Kidney Diseased 
   Yes 16/6094 (0.26) 6/6094 (0.10) 2.67 (1.04 to 6.82) 
5.68 (4.45 to 7.25) 
0.13 
   No 434/132 152 (0.33) 78/132 152 (0.06) 
    
 
Congestive Heart Failuree 
   Yes 105/16 735 (0.63) 14/16 735 (0.08) 7.50 (4.30 to 13.10) 
5.04 (3.89 to 6.54) 
0.22 
   No 345/121 511 (0.28) 70/121 511 (0.06) 
    
 
Diuretic Usef 
   Yes 237/40 413 (0.59) 43/40 413 (0.11) 5.62 (4.05 to 7.80) 
5.30 (3.78 to 7.43) 
0.81 
   No 213/97 833 (0.22) 41/97 833 (0.04) 
. 
 
Figure 4-2. The association between second-generation antidepressant use and hospitalization with hyponatremia assessed in five 
subgroups* 
 
Risk higher 
with medication use 
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CI=confidence interval.  
* Antidepressant medication type, antidepressant medication dose, chronic kidney disease, congestive heart failure and use of a diuretic. Sets of medication users 
and non-users were matched on presence of chronic kidney disease, congestive heart failure, and baseline diuretic use. For antidepressant medication type and 
dose, matched sets were categorized according to this characteristic in medication users. Data marker size is proportional to the inverse of the source variance. 
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is 
underestimated for some outcomes because the code for hyponatremia has high speciﬁcity but low sensitivity.  
b Fluoxetine, fluvoxamine, duloxetine, and venlafaxine were included in the tests for interactions but were removed from presentation as there were too few 
events for meaningful analysis. This was also done to comply with privacy regulations, to prevent the risk of re-identification when the size of the numerator is 
small (less than or equal to 5).  
c Higher dose was defined as a higher than median daily dose. See Appendix B Table B-2 for definitions. Fluoxetine was not considered in the assessment of 
higher vs. normal dose as a higher than median daily dose could not be accurately defined.  
d Chronic kidney disease was identiﬁed by using an algorithm of hospital diagnosis codes validated for older adults in the study region.37 The algorithm 
identiﬁed patients with a median estimated glomerular ﬁltration rate of 38 mL/min/1.73m2 (interquartile range, 27–52 mL/min/1.73m2), whereas its absence 
identiﬁed patients with a median estimated glomerular ﬁltration rate of 69 mL/min/1.73m2 (interquartile range, 56–82 mL/min/1.73m2). 
e Congestive heart failure has a sensitivity, specificity and positive predictive value of 84.3, 85.4, and 35.8%, respectively.38  
f Diuretic use includes potassium sparing and non-potassium sparing medications.  
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4.3.4 Additional Analyses 
Among the subpopulation with linked laboratory data, baseline characteristics were 
similar between second-generation antidepressant users and non-users (Appendix B 
Table B-5, 4186 matched pairs of users and non-users). Amongst those with baseline 
values, the mean (standard deviation) serum sodium concentration was no different in 
users (139.3 (3.6)) and non-users (139.6 (3.5)). Second-generation antidepressant use vs. 
non-use was associated with a higher 30-day risk of hospitalization with hyponatremia 
(73/4186 [1.74%] vs. 18/4186 [0.43%]; relative risk 4.23 [95% CI 2.50 to 7.19]; absolute 
risk increase 1.31% [95% CI 0.87% to 1.75%]).  
In patients who had serum sodium measurements available from an outpatient 
laboratory, second-generation antidepressant use remained associated with an increased 
30-day risk of hyponatremia compared to non-use (170/22 280 [0.76%] vs. 68/22 280 
[0.31%]; relative risk 2.50 [95% CI 1.89 to 3.31]; absolute risk increase 0.45% [95% CI 
0.32% to 0.60%]).  
In our test of specificity, we did not observe an association between second-
generation antidepressant use vs. non-use in the 30-day risk of hospitalization with bowel 
obstruction (94/138 246 [0.07%] vs. 94/138 246 [0.07%]; relative risk 1.00 [95% CI 0.75 
to 1.33]). 
When we re-examined the primary outcome in the 90 days prior to the original 
index date, baseline characteristics were similar between the two groups (Appendix B 
Table B-6; 90 195 matched pairs of drug users and non-users). We did not observe any 
significant differences between second-generation antidepressant use and non-use in the 
baseline 30-day risk of hospitalization with hyponatremia (relative risk 1.29 [95% CI 
0.86 to 1.92]).  
In our sensitivity analysis of hidden bias, we demonstrated that it would be very 
unlikely that unmeasured confounding was influencing the results (Appendix B Figure B-
1). To make the observed association non-significant, the unmeasured confounder(s) 
would need to produce an eight-fold increase in the odds of second-generation 
antidepressant use and a ten-fold increase in the odds of hyponatremia. 
When we looked at the characteristics that predict hospitalization with 
hyponatremia in second-generation antidepressant users, older age, female sex, liver 
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disease, previous hyponatremia, and diuretic use were associated with a higher 30-day 
risk of hospitalization with hyponatremia (Table 4-3).  
 
Table 4-3. Risk factors for hyponatremia in second-generation antidepressant users and 
non-users* 
CI=confidence interval 
* Separate multivariable logistic regression models created for antidepressant drug users and non-users 
4.4 Discussion 
In this large population-based cohort study consisting of older adults prescribed common 
second-generation antidepressant drugs in a non-hospitalized setting, we found a robust 
association between second-generation antidepressant use and hospitalization with 
hyponatremia. However, the absolute 30-day risk remained low (below 2%). It also 
appeared that some of the hyponatremia was symptomatic as evidenced by hospital 
admission with hyponatremia and delirium. 
Certain groups of patients, such as those with chronic kidney disease, congestive 
heart failure, and those receiving diuretics, are usually at a higher risk for 
hyponatremia.18,42,43 However, when examined in subgroup analyses, none of these 
characteristics modified the relative association between second-generation 
antidepressant use and hyponatremia. The absolute risk increases were greatest in patients 
with congestive heart failure and in those using diuretics. In second-generation 
antidepressant users, characteristics that associated with a higher risk of hospitalization 
 Antidepressant users 
(n=138 246) 
Antidepressant non-users 
(n=138 246) 
Hospitalization with hyponatremia Relative risk (95% CI) Relative risk (95% CI) 
Older age (per year) 1.08 (1.07 to 1.10) 1.05 (1.02 to 1.08) 
Women (vs. men) 1.50 (1.19 to 1.90) 1.43 (0.85 to 2.39) 
Chronic kidney disease (yes vs. no) 0.49 (0.29 to 0.81) 1.14 (0.49 to 2.67) 
Congestive heart failure (yes vs. no) 1.05 (0.83 to 1.34) 0.69 (0.37 to 1.28) 
Diabetes (yes vs. no) 0.74 (0.50 to 1.10) 1.48 (0.76 to 2.87) 
Liver disease (yes vs. no) 1.84 (1.23 to 2.73) 1.50 (0.60 to 3.75) 
Cancer (yes vs. no) 1.08 (0.82 to 1.43) 1.90 (1.12 to 3.21) 
Hypothyroidism (yes vs. no) 0.97 (0.73 to 1.27) 1.05 (0.55 to 1.98) 
Previous hyponatremia (yes vs. no) 8.44 (6.53 to 10.90) 7.92 (4.27 to 14.68) 
Diuretic use (yes vs. no) 2.03 (1.67 to 2.48) 2.14 (1.36 to 3.37) 
Antiepileptic use (yes vs. no) 0.95 (0.67 to 1.35) 1.37 (0.68 to 2.75) 
Antipsychotic use (yes vs. no)  0.60 (0.90 to 0.93) 1.14 (0.52 to 2.50) 
Antineoplastic use (yes vs. no) 0.87 (0.52 to 1.47) 1.03 (0.40 to 2.65) 
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with hyponatremia included older age, female sex, liver disease, a history of 
hyponatremia, and diuretic use.  
We observed a similar strength of association between second-generation 
antidepressant use and hospitalization with hyponatremia across each of the drug types 
including mirtazapine (a noradrenergic and specific serotonergic antidepressant). In a 
population-based cohort study by Coupland et al. (published after the initiation of our 
study), there was an increased risk of hyponatremia following use of a selective serotonin 
reuptake inhibitor (SSRI) (hazards ratio 1.52 [95% CI 1.33 to 1.75]), but not with use of 
mirtazapine/venlafaxine (non-SSRIs) when compared to non-use.44 This combined 
estimate was based on a mean follow-up time of 5 years after antidepressant initiation. In 
another study by Jung et al., no patients developed hyponatremia while taking 
mirtazapine (76 patients), whereas 8% of those taking SSRIs developed the condition.45 
Mirtazapine is chemically different from SSRIs and may confer a lower risk of 
hyponatremia compared to them. Given the findings of the past and present studies, 
future studies should focus on better understanding the risk of mirtazapine-induced 
hyponatremia. 
The results of this population-based study raise awareness about hyponatremia 
from second-generation antidepressants. Although we are reporting observational data, 
our findings should be considered when defining practice standards for the prescription of 
second-generation antidepressants. Our primary results proved robust in a number of 
additional analyses. Overall, our findings are consistent with four other retrospective 
studies19–21,44 and are biologically plausible given the current understanding of how this 
class of medications induces hyponatremia.9,10 Although an absolute risk increase of 
1.3% for hospitalization with hyponatremia may appear small, in the context of the 
prevalence of antidepressant use it translates into thousands of events each year. 
Therefore, we suggest that guidance be developed on the utility of baseline or post-
administration monitoring of serum sodium concentrations in new users of all second-
generation antidepressant medications. Currently, in the Compendium of Pharmaceuticals 
and Specialties, which is the standard for drug monographs, there are no such guidelines 
for measurement of serum sodium in this setting (additional details are provided in 
Appendix A Table A-2).  
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Our study has several strengths. It was a population-based cohort study that allowed 
us to estimate an uncommon but important adverse drug event with good precision in a 
large sample of older adults who were initiated on a second-generation antidepressant in 
routine care. This information is complementary to the data provided in smaller, 
regulated randomized trials with eligibility criteria that preclude many older individuals 
from being studied.46–48 In this study, the association between second-generation 
antidepressant use and hyponatremia proved robust in multiple additional analyses.   
Our study does have limitations. First, as with all observational studies, we may 
have failed to account for important unmeasured confounding variables. However, we 
used a propensity-matched design, which has been widely used in observational studies 
of drug safety to minimize sources of confounding.32,49 We also matched on factors that 
are known risk factors for hyponatremia, and baseline indicators of health in our second-
generation antidepressant user and non-user groups were almost identical after the 
matching technique was applied. Furthermore, our quantitative bias analysis suggests the 
observed association is unlikely to be altered by unmeasured confounding variables. 
Second, to minimize effects of confounding and to ensure the comparability of our 
matched second-generation antidepressant user and non-user groups, we studied patients 
with prior evidence of a mood or anxiety disorder. However, we would expect the risk to 
be similar in all patients taking these drugs. Third, the code used to assess hospitalization 
with hyponatremia had limited sensitivity and can underestimate the true incidence of 
hyponatremia by eight-fold. For this reason, we supplemented our primary outcome 
findings by observing a subpopulation with serum sodium values and showed a similar 
relative risk of hyponatremia with second-generation antidepressant use. In this 
subpopulation we could also more accurately estimate the true 30-day incidence of 
hospitalization with hyponatremia after starting a second-generation antidepressant in our 
region. Fourth, we could not investigate the long-term risk of hyponatremia, as the 
median duration of follow-up for second-generation antidepressant use was only 82 (IQR 
30 to 286) days. Several factors might have influenced the short duration observed in our 
study, such as a switch to an alternate antidepressant or lack of adherence.50 Fifth, we did 
not include the second-generation antidepressant bupropion or older classes of 
antidepressants such as tricyclic antidepressants or monoamine oxidase inhibitors in our 
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assessment of hyponatremia. In our region, bupropion is prescribed primarily for 
smoking cessation purposes so we excluded this drug from consideration. In prior 
publications, bupropion was less commonly implicated in the development of 
hyponatremia;51 future investigations could consider a comparative effectiveness design 
to compare the risk of hyponatremia between bupropion and other second-generation 
antidepressants. Although older antidepressant drugs are still used in routine care, their 
use has been declining, as second-generation antidepressants are generally safer. Sixth, 
with our data sources we could not tell how symptomatic patients were from their 
hyponatremia. Rather, all we could determine was that second-generation antidepressant 
use compared to non-use was associated with a higher risk of a combined outcome of 
hospitalization with hyponatremia and delirium (where delirium was assessed with 
database codes that lack sensitivity and with a limited number of events). Finally, given 
our data sources we could only study older adults. Younger patients are often healthier 
and may not be as susceptible to hyponatremia from second-generation antidepressants. 
4.5 Conclusion 
In conclusion, initiation of a second-generation antidepressant in routine care in the non-
hospitalized setting is associated with an approximate five-fold relative increase in the 
30-day risk of hospitalization with hyponatremia. However, the absolute increase in the 
30-day incidence is low.  
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5.1 Introduction 
Hyponatremia is one of the most frequently encountered electrolyte disorders in clinical 
practice, and occurs in about 7% to 11% of community dwelling older adults.1 Older 
adults are particularly susceptible to developing hyponatremia with age-related changes 
in homeostatic mechanisms, and an increased number of comorbidities and concomitant 
medications known to cause hyponatremia.2 As the sodium concentration falls below 135 
mmol/L, there is a greater potential for clinical consequences such as confusion, seizures, 
respiratory arrest, fractures, or even death.3–6  
Atypical antipsychotic drugs are routinely prescribed for the treatment of 
psychiatric disorders such as schizophrenia as well as behavioral and psychological 
symptoms of dementia. The use of atypical antipsychotics has been rising, with nearly 15 
million prescriptions dispensed in Canada in 2012.7,8 Frequently prescribed atypical 
antipsychotics include risperidone, olanzapine, and quetiapine. A number of case reports 
have suggested a possible association between atypical antipsychotics and 
hyponatremia.9–14 Hyponatremia from older typical antipsychotics has also been 
observed, but their use has been declining in routine care, primarily due to their adverse 
side effect profile.7,15,16 Like other psychotropic drugs, it is suspected that atypical 
antipsychotics can induce hyponatremia by either stimulating antidiuretic hormone 
release from the brain or enhancing antidiuretic hormone activity in the kidneys.13  
Currently, there are no reliable estimates of incidence or risk of hyponatremia from 
atypical antipsychotic drugs in older adults. To date, only one case-control study has 
examined the association between atypical antipsychotic drug use and hyponatremia.17 
This study looked at a series of voluntary reports of adverse drug reactions made to the 
World Health Organization, and found that use of olanzapine and risperidone (as well as 
other atypical antipsychotics) was associated with more reporting of hyponatremia 
compared to other adverse drug reactions. However, data from spontaneous reporting 
systems is subject to biases.18 This may be one reason why the risk of hyponatremia from 
atypical antipsychotics is reported inconsistently across popular drug prescribing 
references, such as UpToDate® and the Canadian Compendium of Pharmaceuticals and 
Specialties.  
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We conducted this population-based cohort study in older adults to understand the 
association between new use of atypical antipsychotics and the 30-day risk of 
hospitalization with hyponatremia relative to non-users of atypical antipsychotics.  
5.2 Methods 
5.2.1 Study Design and Setting 
We used multiple linked health administrative databases to conduct a retrospective, 
population-based, cohort study of older adults from 1 June 2003 through 1 March 2012 in 
Ontario, Canada. There are over two million residents 65 years and older in Ontario who 
have universal access to hospital care, physician services, and prescription drug 
coverage.19 These datasets were linked using unique encoded identifiers and were 
analyzed at the Institute for Clinical Evaluative Sciences (ICES). We conducted this 
study according to a pre-specified protocol that was approved by the institutional review 
board at Sunnybrook Health Sciences Centre, Toronto, Canada. The reporting of this 
study followed the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines (Appendix C Table C-1).20 
5.2.2 Data Sources 
We identified information related to patients, drugs, covariates, and outcomes from nine 
linked databases. For all residents with a valid provincial health card, we obtained 
demographic information and vital statistics using the Ontario Registered Persons 
Database. We used the Ontario Drug Benefits program database to identify exposure to 
atypical antipsychotics and other medications. This database accurately records 
prescription claims for outpatients over the age of 65 (error rate of 0.7%).21 We defined 
covariates using the Ontario Health Insurance Plan database, which contains information 
on health claims for inpatient and outpatient physicians’ services. We identified 
diagnostic and procedural information on all hospitalizations and emergency department 
visits using the Canadian Institute for Health Information’s Discharge Abstract Database 
and National Ambulatory Care Reporting System database, respectively. Similarly, we 
used the Ontario Mental Health Reporting System database to obtain mental health 
information. We obtained atypical antipsychotic prescriber information from the ICES 
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Physician Database. We identified serum sodium measurements using datasets from 
Gamma-Dynacare Medical Laboratories (a laboratory service provider in Ontario) and 
Cerner (an electronic medical record system that is used by 12 hospitals in southwestern 
Ontario). We have used these databases to research adverse drug events and health 
outcomes in several other studies (including outcomes of hyponatremia and health 
services).22–26  
The databases were complete for almost all variables considered in this study, with 
the exception of income quintile, rural residence, and prescriber information (missing in 
less than 0.5%, 0.1%, and 11% of older adults, respectively). We used codes from the 
International Classification of Diseases, 9th revision (ICD-9) and 10th revision (ICD-10) 
to ascertain baseline comorbidities in the five years prior to cohort entry. Outcomes were 
identified using only ICD-10 codes as these events would have occurred following 
implementation of this coding system in 2002. The diagnostic codes used in our study are 
detailed in Appendix C Table C-2. 
5.2.3 Cohort 
For our exposed group, we considered all older adults in Ontario who had evidence of a 
hospital diagnosis or physician claim for a psychiatric condition (dementia, 
schizophrenia, bipolar disorder, unipolar depression/anxiety, or Parkinson’s disease) 
within the previous five years and who commenced treatment with risperidone, 
olanzapine or quetiapine (users). These are the atypical antipsychotics used most 
frequently in our region. We defined new use as no prescriptions for any type of 
antipsychotic drug in the prior six months. Patients could only be prescribed one atypical 
antipsychotic so that we could compare mutually exclusive groups in subgroup analyses. 
The date of the prescription served as the index date (cohort entry date). We then 
identified a referent group of older adults from the Ontario population who were not 
prescribed any kind of antipsychotic drug (non-users). We randomly assigned an index 
date to non-users based on the distribution of index dates for the users.  
We excluded the following individuals from analyses: (1) patients discharged from 
hospital in the two days prior to their index date to ensure new outpatient antipsychotic 
use (in the case of the users; or the possibility of a new outpatient atypical antipsychotic 
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prescription in the case of non-users), and (2) patients with end-stage renal disease prior 
to their index date since serum sodium levels are controlled through dialysis. We 
excluded all patients with no outpatient medications of any kind dispensed in the 90 days 
prior to their index date to ensure all were active users of the Ontario Drug Benefits 
program. 
Using a logistic regression model, we derived a propensity score for the predicted 
probability of commencing treatment with an atypical antipsychotic drug. The propensity 
score included 104 variables that were potentially associated with atypical antipsychotic 
drug use and/or hospitalization with hyponatremia (Appendix C Table C-3).27 Then using 
greedy matching, we matched 1:1 each atypical antipsychotic drug user to a non-user 
based on the following characteristics: age (within two years); sex; index date (within 1 
year); residential status (community-dwelling or long-term care); dementia, 
schizophrenia, bipolar disorder, unipolar depression/anxiety, Parkinson’s disease, chronic 
kidney disease, and congestive heart failure; diuretic use; constituency in the catchment 
area where linked serum sodium data were available; and the logit of the propensity score 
(within a caliper of ±0.2 standard deviations). A patient could only enter the study once.  
5.2.4 Outcomes 
We evaluated all outcomes within 30 days of the antipsychotic prescription as we 
expected fewer crossovers to occur between the user and non-user groups. 
5.2.4.1 Primary Outcome 
We evaluated the 30-day risk of hospitalization with hyponatremia by including 
hospitalization records with evidence of ICD-10 code E87.1 (hypo-osmolality or 
hyponatremia) in any one of 25 diagnostic fields in the CIHI Discharge Abstract 
Database. Based on a validation study conducted in our region, the presence of code 
E87.1 in a given hospitalization identifies older patients with a median serum sodium 
value of 125 mmol/L at hospital admission (interquartile range [IQR] 120 to 130 
mmol/L), whereas its absence identifies a median value of 137 mmol/L (IQR 135 to 139 
mmol/L). The specificity of the code is over 99%, while sensitivity is 11% for 
hyponatremia defined as a serum sodium concentration ≤132 mmol/L. The sensitivity of 
the code increases when hyponatremia is defined by lower serum sodium 
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concentrations.28 The full study is included in Appendix E. 
5.2.5 Statistical Analyses 
We used standardized differences to compare baseline characteristics between user and 
non-user groups. This metric describes differences between the group means relative to 
the pooled standard deviation with a value less than 10% indicating adequate balance.29 
We used conditional logistic regression to estimate odds ratios and 95% confidence 
intervals (CIs). We evaluated the association between atypical antipsychotic drug use and 
a hospitalization with hyponatremia in the following pre-specified subgroups: 1) atypical 
antipsychotic type (risperidone, quetiapine, or olanzapine), 2) atypical antipsychotic dose 
(higher dose vs. normal dose; higher dose defined by a higher than median starting daily 
dose for the study cohort) (precise definitions in Appendix C Table C-2), 3) chronic 
kidney disease, 4) congestive heart failure, and 5) diuretic use. We identified chronic 
kidney disease and congestive heart failure using separate validated algorithms of 
hospital diagnostic codes.30,31 In the case of antipsychotic drug type and dose, we defined 
the subgroup by the characteristic in users with non-users following their matched user. 
We determined subgroup p-values using interaction terms in the logistic regression 
models.  
All odds ratios were approximated as relative risks (appropriate given the 
incidences observed). We expressed risk in both relative and absolute terms. We 
performed all analyses using SAS version 9.4 (SAS Institute, Cary, North Carolina). Any 
results where the number of events were less than six were not allowed to be reported in 
order to minimize any risk of patient re-identification in our data sources (which we 
described as too few events). Detailed methods are provided in Chapter 3. 
5.2.5.1 Additional Analyses 
We tested the specificity of our findings by evaluating the 30-day risk of hospitalization 
with bowel obstruction in the two groups. We expected antipsychotic use would not alter 
the risk of bowel obstruction, and reasoned that a null association with this outcome 
would enhance causal inference in our hyponatremia analyses.  
We re-evaluated the outcome of hospitalization with hyponatremia in our existing 
cohort at a time that preceded the index date by 90 days (a time when no patient would 
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have been prescribed an atypical antipsychotic drug). After re-applying exclusion criteria 
at this time, we followed retained matched pairs to re-assess the 30-day risk. In this 
analysis, a null association would enhance the assertion that the two groups were similar 
in their baseline risk for hyponatremia in the absence of atypical antipsychotic drug use.  
We also examined the risk factors associated with hospitalization with 
hyponatremia separately in users and non-users using multiple logistic regression. The 
risk factors that we considered were age (per year); sex; chronic kidney disease, 
congestive heart failure, diabetes, liver disease, cancer, hypothyroidism, previous 
hyponatremia; and receipt of a diuretic, antiepileptic, antidepressant, and antineoplastic 
drugs.  
5.3 Results 
5.3.1 Baseline Characteristics 
Prior to matching, we identified 92 090 antipsychotic users and 175 836 non-users who 
were eligible for our study. Cohort selection and baseline characteristics are presented in 
Figure 5-1 and Table 5-1, respectively. In the unmatched cohort antipsychotic users 
compared to non-users were more likely to be older and reside in a long-term care 
facility, and prior to cohort entry were more likely to receive a greater number of 
medications and health care services compared to non-users. We successfully matched 58 
008 users to 58 008 non-users, and baseline characteristics were well balanced between 
the two groups (104 characteristics measured; full baseline table presented in Appendix C 
Table C-4). The mean age was 81 years and 67% were women. Nearly 48% of the users 
were prescribed risperidone and family physicians wrote 70% of the prescriptions.  
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409 945 Without at least one 
outpatient medication dispensed in 
the 90 days prior to the index date 
  
16 325 Discharged from a hospital or 
emergency room in the two days prior 
to the index date 
 
6041 Evidence of end-stage renal 
disease prior to the index date 
 
119 790 Ontario residents >65 years of age with 
evidence of a baseline psychiatric disorder who 
were dispensed a new oral outpatient 
prescription for one of the following atypical 
antipsychotic drugs prior to the index date: 
quetiapine, olanzapine or risperidone (from 
June 2003 to March 2012). 
608 147 Ontario residents >65 years of age with 
evidence of a baseline psychiatric disorder who 
were not dispensed an oral outpatient 
prescription for any antipsychotic drug in the six 
months prior to the randomly assigned index 
date (from June 2003 to March 2012). 
26 619 Discharged from a hospital 
or emergency room in the two days 
prior to the index date  
 
1081 Evidence of end-stage renal 
disease prior to the index date 
 
58 008 antipsychotic 
users 
58 008 antipsychotic 
non-users 
Matched 
(1:1) 
 
Remaining 
 
Excluded 
 
175 836 
 
92 090 
 
Figure 5-1. Cohort selection 
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Table 5-1. Baseline characteristics of atypical antipsychotic users and non-users* 
Characteristic Unmatched Matched 
 Antipsychotic  
users 
(n=92 090) 
Antipsychotic 
 non-users 
 (n=175 836) 
Standardized 
Differencea 
Antipsychotic  
users 
(n=58 008) 
Antipsychotic 
 non-users 
 (n=58 008) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 81 (7.8) 79 (7.9) 29.2% 81 (7.7) 81 (7.7) 0.3% 
Women 58 647 (63.7%) 111 968 (63.7%) 0 38 736 (66.8%) 38 736 (66.8%) 0 
Income quintileb       
1 (low) 20 160 (21.9%) 37 436 (21.3%) 1.5% 12 331 (21.3%) 13 081 (22.6%) 3.1% 
2 18 854 (20.5%) 36 395 (20.7%) 0.6% 11 888 (20.5%) 12 057 (20.8%) 0.7% 
3 (medium) 17 999 (19.6%) 33 861 (19.3%) 0.7%  11 630 (20.1%) 11 408 (19.7%) 1.0% 
4 17 607 (19.1%) 33 206 (18.9%) 0.6% 11 213 (19.3%) 10 847 (18.7%) 1.6% 
5 (high) 17 058 (18.5%) 34 373 (19.6%) 2.6% 10 946 (18.9%) 10 615 (18.3%) 1.5% 
Rural residence 11 759 (12.8%) 23 484 (13.4%)  1.7% 7671 (13.2%) 7557 (13.0%) 0.6% 
Long-term care 32 644 (35.5%) 26 705 (15.2%) 47.9% 16 409 (28.3%) 16 409 (28.3%) 0 
Comorbid conditionsc       
Charlson comorbidity index, mean (SD) 1.68 (1.8) 1.56 (1.8) 6.7% 0.87 (1.5) 0.94 (1.5) 4.7% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.90 (4.2) 13.69 (4.0) 5.2% 13.37 (4.2) 13.69 (4.1) 7.8% 
Dementia 71 933 (78.1%) 92 049 (52.4%) 56.2% 44 715 (77.1%) 44 715 (77.1%) 0 
Schizophrenia 14 838 (16.1%) 14 072 (8.0%) 25.1% 4756 (8.2%) 4756 (8.2%) 0 
Bipolar disorder 10 174 (11.1%) 11 377 (6.5%) 16.3% 3295 (5.7%) 3295 (5.7%) 0 
Unipolar depression/anxiety 28 419 (30.9%) 74 574 (42.4%) 24.2% 15 038 (25.9%) 15 038 (25.9%) 0 
Parkinson’s disease 8652 (9.4%) 19 015 (10.8%) 4.7% 3780 (6.5%) 3780 (6.5%) 0 
Congestive heart failure 19 029 (20.7%) 33 627 (19.1%) 3.9% 10 038 (17.3%) 10 038 (17.3%) 0 
Chronic kidney disease 8127 (8.8%) 15 323 (8.7%) 0.4% 3140 (5.4%) 3140 (5.4%) 0 
Hypertension 65 205 (70.8%) 131 562 (74.8%) 9.0% 40 929 (70.6%) 40 419 (69.7%) 1.9% 
Chronic liver disease 2980 (3.2%) 6388 (3.6%) 2.2% 1664 (2.9%) 1807 (3.1%) 1.5% 
Hypothyroidism 10 213 (11.1%) 20 354 (11.6%) 1.5% 6222 (10.7%) 6198 (10.7%) 0.1% 
Cancerd 12 145 (13.2%) 25 758 (14.7%) 4.2% 7321 (12.6%) 7864 (13.6%) 2.8% 
Diabetes mellitus 14 245 (15.5%) 30 491 (17.3%) 5.1% 17 590 (30.3%) 18 457 (31.8%) 3.2% 
Pneumonia 8006 (8.7%) 12 843 (7.3%) 5.1% 4237 (7.3%) 4755 (8.2%) 3.3% 
Coronary artery diseasee 31 417 (34.1%) 61 334 (34.9%) 1.6% 18 641 (32.1%) 19 184 (33.1%) 2.0% 
Angina 20 496 (22.3%) 42 264 (24.0%) 4.2% 12 166 (21.0%) 12 462 (21.5%) 1.3% 
Previous hyponatremia 3403 (3.7%) 5416 (3.1%) 3.4% 1766 (3.0%) 2111 (3.6%) 3.3% 
Lung disease 26 237 (28.5%) 53 842 (30.6%) 4.7% 15 489 (26.7%) 16 891 (29.1%) 5.4% 
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Seizure 1782 (1.9%) 2780 (1.6%) 2.7% 879 (1.5%) 1087 (1.9%) 2.8% 
Acute kidney injury 3453 (3.8%) 5616 (3.2%) 3.0% 1482 (2.6%) 1501 (2.6%) 0.2% 
Acute urinary retention 3337 (3.6%) 5179 (3.0%) 3.8% 1650 (2.8%) 1774 (3.1%) 1.3% 
Delirium 7112 (7.7%) 6013 (3.4%) 18.8% 3424 (5.9%) 2546 (4.4%) 6.9% 
Peripheral vascular disease 1939 (2.1%) 4061 (2.3%) 1.4% 1043 (1.8%) 1238 (2.1%) 2.4% 
Concurrent medication usef       
Number of unique drug products, mean 
(SD) 
9.71 (6.4) 8.94 (5.5) 13.0% 8.91 (5.9) 9.41 (5.6) 8.7% 
Antiepileptics 10 970 (11.9%) 16 409 (9.3%) 8.4% 5552 (9.6%) 6688 (11.5%) 6.4% 
Antidepressants 46 600 (50.6%) 65 227 (37.1%) 27.5% 25 197 (43.4%) 26 871 (46.3%) 5.8% 
Antidiabetics 14 245 (15.5%) 21 969 (12.5%) 8.6% 8526 (14.7%) 9307 (16.0%) 3.7% 
Antineoplastics 3240 (3.5%) 6 863 (3.9%) 2.0% 1958 (3.4%) 2151 (3.7%) 1.8% 
Thyroxine 16 580 (18.0%) 33 499 (19.1%) 2.7% 10 406 (17.9%) 10 846 (18.7%) 2.0% 
Potassium sparing diuretics 5390 (5.9%) 11 025 (6.3%) 1.8% 3267 (5.6%) 3236 (5.6%) 0.2% 
Non-potassium sparing diuretics  31 051 (33.7%) 61 131 (34.8%) 2.2% 18 611 (32.1%) 18 665 (32.2%) 0.2% 
ACE inhibitors and/or ARBs 39 596 (43.0%) 88 563 (50.4%) 14.8% 24 853 (42.8%) 25 660 (44.2%) 2.8% 
NSAIDs (excl. ASA) 13 638 (14.8%) 30 146 (17.1%) 6.4% 8667 (14.9%) 9047 (15.6%) 1.8% 
Calcium channel blockers 22 902 (24.9%) 49 786 (28.3%) 7.8% 14 642 (25.2%) 15 011 (25.9%) 1.5% 
Beta-adrenergic agonists 26 099 (28.3%) 55 259 (31.4%) 6.7% 16 169 (27.9%) 16 254 (28.0%) 0.3% 
Statins 29 558 (32.1%) 72 878 (41.5%) 19.5% 19 171 (33.1%) 19 514 (33.6%) 1.3% 
Benzodiazepines 33 031 (35.9%) 45 988 (26.2%) 21.1% 17 616 (30.4%) 18 692 (32.2%) 4.0% 
Healthcare contacts, mean (SD)g       
Hospitalizations 0.51 (0.9) 0.32 (0.8) 22.6% 0.40 (0.8) 0.39 (0.8) 1.3% 
Emergency department visits 1.29 (2.1) 0.84 (1.6) 24.7% 1.04 (1.6) 1.00 (1.7) 2.5% 
Family physician visits 18.57 (18.0) 13.61 (13.1) 31.9% 15.84 (15.5) 16.30 (15.3) 3.0% 
Geriatrician visits 0.82 (3.6) 0.34 (2.1) 16.9% 0.58 (2.5) 0.49 (2.4) 3.7% 
Psychiatrist visits 1.69 (7.5) 0.36 (2.5) 26.6% 0.64 (2.4) 0.40 (2.2) 10.0% 
Healthcare useh       
Previous sodium tests 63 335 (68.8%) 79 930 (45.5%) 48.5% 38 190 (64.8%) 38 145 (65.8%) 0.2% 
Carotid ultrasound 4568 (5.0%) 9137 (5.2%) 1.1% 2721 (4.7%) 2883 (5.0%) 1.3% 
Cardiac catheterization 742 (0.8%) 2334 (1.3%) 5.1% 414 (0.7%) 477 (0.8%) 1.2% 
Echocardiography 12 411 (13.5%) 27 264 (15.5%) 5.8% 7247 (12.5%) 7355 (12.7%) 0.6% 
Holter monitoring 4818 (5.2%) 10 904 (6.2%) 4.2% 2962 (5.1%) 3032 (5.2%) 0.6% 
Colorectal cancer screening 10 653 (11.6%) 29 013 (16.5%) 14.2% 6767 (11.7%) 6823 (11.8%) 0.3% 
Cervical cancer screening 2047 (2.2%) 8290 (4.7%) 13.7% 1447 (2.5%) 1427 (2.5%) 0.2% 
Thyroid stimulating hormone 57 414 (62.4%) 100 900 (57.4%) 10.1% 34 911 (60.2%) 34 766 (59.9%) 0.5% 
Bone mineral density test 5792 (6.3%) 18 558 (10.6%) 15.4% 4040 (7.0%) 4110 (7.1%) 0.5% 
Hearing test 3705 (4.0%) 9327 (5.3%) 6.1% 2375 (4.1%) 2537 (4.4%) 1.4% 
Computed tomography of the head 26 927 (29.2%) 25 724 (14.6%) 35.9% 13 261 (22.9%) 12 896 (22.2%) 1.5% 
115 
 
 
 
Chest x-ray 43 501 (47.2%) 69 077 (39.3%) 16.1% 24 600 (42.4%) 25 086 (43.3%) 1.7% 
Pulmonary function test 4882 (5.3%) 13 764 (7.8%) 10.2% 2901 (5.0%) 3404 (5.9%) 3.8% 
Laboratory measurementsi       
Evidence of baseline serum sodium 
measurement, N (%) 
14 346 (15.6%) 21 948 (23.8%) 20.9% 7242 (12.5%) 7242 (12.5%) 0 
Most recent serum sodium, mean (SD) 140.3 (3.5) 140.4 (3.2) 2.7% 140.4 (3.4) 140.3 (3.4) 4.4% 
 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
e Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
f Concurrent medication use in the six months preceding the index date were considered. 
g Healthcare contacts in the year preceding the index date were considered. 
h Healthcare use in the year preceding the index date was considered. 
i Serum sodium measurements were obtained at a mean (SD) of 139 (101) days in users and 142 (100) days in non-users, prior to the index date.  
116 
 
 
 
5.3.2 Primary Outcome 
Results for the primary outcome are presented in Table 5-2. Atypical antipsychotic use 
was associated with a greater 30-day risk of hospitalization with hyponatremia compared 
to non-use (86/58 008 [0.15%] vs. 53/58 008 [0.09%]; relative risk 1.62 [95% CI 1.15 to 
2.29]).  
Results from subgroup analyses are presented in Figure 5-2. The relative 
association between atypical antipsychotic drug use and hospitalization with 
hyponatremia was not influenced by atypical antipsychotic type, atypical antipsychotic 
dose, chronic kidney disease, congestive heart failure or diuretic use (all p-values for 
interaction >0.05). Subgroup results for chronic kidney disease could not be presented as 
there were too few events. 
 
Table 5-2. 30-day risk of hospitalization with hyponatremia (defined by a hospital 
diagnosis code) in atypical antipsychotic drug users and non-users 
 Events, No. (%)a 
Relative Risk 
(95% CI) 
Absolute Risk 
Increase (95% CI), % 
Antipsychotic 
 users 
(n=58 008) 
Antipsychotic 
non-usersc 
(n=58 008) 
Hospitalization with 
hyponatremiab 
86 (0.15) 53 (0.09) 1.62 (1.15 to 2.29) 0.06 (0.02 to 0.10) 
 
CI=confidence interval 
a The event rates and absolute risk differences are underestimated as the hospital-based diagnosis codes 
used to define the outcomes have high speciﬁcity but low sensitivity.  
b The sensitivity and specificity of the code for hyponatremia is 11% and 99%, respectively30  
c An antipsychotic non-user group was the referent. 
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Events/At Risk, n/N (%)a 
  
 Antipsychotic user  
(n=58 008) 
Antipsychotic 
non-user  
(n=58 008) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relative Risk 
(95% CI) 
P-value for 
Interaction 
     
Antipsychotic Drug Type 
Risperidone 42/27 581 (0.15) 23/27 581 (0.08) 1.83 (1.10 to 3.04) 
0.53 Olanzapine 13/10 150 (0.13) 12/10 150 (0.12) 1.08 (0.49 to 2.37) 
Quetiapine 31/20 277 (0.15) 18/20 277 (0.09) 1.72 (0.96 to 3.08) 
    
 
Antipsychotic Drug Doseb 
   Higher Dose 27/19 791 (0.14) 17/19 791 (0.09) 1.64 (1.08 to 2.48) 
0.93 
   Normal Dose 59/38 217 (0.15) 36/38 217 (0.09) 1.59 (0.87 to 2.91) 
    
 
 
 Congestive Heart Failurec 
   Yes 27/10 038 (0.27) 15/10 038 (0.15) 1.80 (0.96 to 3.38) 
0.70 
   No 59/47 970 (0.12) 38/47 970 (0.08) 1.55 (1.03 to 2.33) 
    
 
 
 Diuretic Used 
   Yes 45/19 618 (0.23) 29/19 618 (0.15) 1.55 (0.97 to 2.48) 
0.78 
   No 41/38 390 (0.11) 24/38 390 (0.06) 1.71 (1.03 to 2.83) 
    
 
Figure 5-2. The association between antipsychotic use and hospitalization with hyponatremia assessed in four subgroups* 
CI=confidence interval. 
*Antipsychotic type, Antipsychotic dose, chronic kidney disease, congestive heart failure and use of a diuretic. Sets of drug users and non-users were matched on 
presence of chronic kidney disease, congestive heart failure, and baseline diuretic use. For antipsychotic type and dose, matched sets were categorized according 
to this characteristic in users. Data marker size is proportional to the inverse of the source variance. 
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is 
underestimated for some outcomes because the code for hyponatremia has high speciﬁcity but low sensitivity.  
Risk higher 
with medication 
use 
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b Higher dose was defined as a higher than median daily dose. See Appendix C Table C-2 for definitions.  
c Congestive heart failure has a sensitivity, specificity and positive predictive value of 84.3, 85.4, and 35.8%, respectively.31  
d Diuretic use includes potassium sparing and non-potassium sparing medications.  
Chronic kidney disease was included in the test for interactions but was removed from presentation as there were too few events for meaningful analysis. This 
was also done to comply with privacy regulations, to prevent the risk of re-identification when the size of the numerator is small (less than or equal to 5). Chronic 
kidney disease was identiﬁed by using an algorithm of hospital diagnosis codes validated for older adults in the study region. The algorithm identiﬁed patients 
with a median estimated glomerular ﬁltration rate of 38 mL/min/1.73m2 (interquartile range, 27–52 mL/min/1.73m2), whereas its absence identiﬁed patients with 
a median estimated glomerular ﬁltration rate of 69 mL/min/1.73m2 (interquartile range, 56–82 mL/min/1.73m2).30 
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5.3.3 Additional Analyses 
The risk of hospitalization with bowel obstruction was not significantly different between 
atypical antipsychotic users and non-users (55/58 008 [0.09%] vs. 44/58 008 [0.08%]; 
relative risk 1.25 [95% CI 0.84 to 1.86]; absolute risk increase 0.02% [95% CI -0.01% to 
0.05%]).  
Baseline characteristics were very similar in the cohort that was assessed in the 90 
days prior to the index date (Appendix C Table C-5; 42 698 retained matched pairs of 
users and non-users). When we re-examined the 30-day risk of hospitalization with 
hyponatremia at that time, we did not observe a significant difference between users and 
non-users (relative risk 1.19 [95% CI 0.74 to 1.92]).  
In our cohort, older age, cancer, and prior hyponatremia were significant risk 
factors for future hyponatremia in atypical antipsychotic users (Table 5-3).  
Table 5-3. Risk factors for hospitalization with hyponatremia in antipsychotic medication 
users and non-users when each group was analyzed separately* 
CI=confidence interval 
* Separate multivariable logistic regression models created for atypical antipsychotic users and non-users. 
 
 
 
 Antipsychotic users 
(n=58 008) 
Antipsychotic non-users 
(n=58 008) 
Hospitalization with hyponatremia Relative risk (95% CI) Relative risk (95% CI) 
Older age (per year) 1.04 (1.01 to 1.07) 1.02 (0.98 to 1.06) 
Women (vs. men) 1.36 (0.80 to 2.79) 2.36 (1.09 to 5.12) 
Chronic kidney disease (yes vs. no) 1.44 (0.70 to 2.96) 1.04 (0.37 to 2.97) 
Congestive heart failure (yes vs. no) 1.22 (0.73 to 2.04) 1.13 (0.58 to 2.18) 
Diabetes (yes vs. no) 0.74 (0.45 to 1.21) 1.09 (0.61 to 1.94) 
Liver disease (yes vs. no) 1.51 (0.54 to 4.20) 1.18 (0.28 to 4.92) 
Cancer (yes vs. no) 1.84 (1.05 to 3.23) 0.78 (0.32 to 1.94) 
Hypothyroidism (yes vs. no) 1.19 (0.65 to 2.16) 0.71 (0.28 to 1.78) 
Previous hyponatremia (yes vs. no) 8.21 (4.93 to 13.66) 7.99 (4.26 to14.95) 
Diuretic use (yes vs. no) 1.56 (0.98 to 2.50) 1.85 (1.03 to 3.32) 
Antiepileptic use (yes vs. no) 1.25 (0.64 to 2.46) 1.17 (0.52 to 2.63) 
Antidepressant use (yes vs. no)  1.24 (0.81 to 1.91) 0.97 (0.56 to 1.68) 
Antineoplastic use (yes vs. no) 0.78 (0.24 to 2.58) 1.83 (0.53 to 6.28) 
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5.4 Discussion 
Among older adults newly prescribed an atypical antipsychotic drug, we observed a 
modest increase in the relative and absolute risks of hospitalization with hyponatremia in 
users compared to non-users.  
The results of this population-based study inform us about the nature of the 
association between atypical antipsychotic drugs and hyponatremia. Our estimate is 
similar to that obtained in a previous case-control study that used individual case safety 
reports of hyponatremia to estimate a “reporting odds ratio” of 1.55 (95% CI 1.41 to 
1.69).17 This is a measure of disproportionality that estimates the extent to which 
hyponatremia is reported in association with an atypical antipsychotic drug relative to 
reports of hyponatremia with other drugs. The low absolute risk observed in our study is 
likely influenced by the low sensitivity of the hospital diagnosis code for hyponatremia 
(~11%), which underestimates the true incidence by up to eight-fold.28 Currently, 
UpToDate® a popular reference widely used by physicians, warns of the possibility of 
hyponatremia and recommends monitoring the concentration of serum sodium in older 
adults upon initiation of an atypical antipsychotic drug.32–34 Another important physician 
reference in our region, the Canadian Compendium of Pharmaceuticals and Specialties, 
does not provide information or recommendations related to hyponatremia with atypical 
antipsychotic medications.35–37 Updates to these product monographs are warranted to 
make physicians aware of this risk.  
Unlike with other psychotropic medications, such as selective serotonin or 
norepinephrine reuptake inhibitors (second-generation antidepressants), there is only a 
modest risk of hospitalization with hyponatremia from atypical antipsychotic drugs. In 
the current study, we could not corroborate our primary findings using laboratory data as 
there were too few events in this subpopulation. Additionally, we could not confirm if 
patients who did not present to hospital also had hyponatremia, as again there were a 
limited number of events to evaluate the outcome of outpatient hyponatremia (using data 
from outpatient laboratories). It also would have been useful to know if the hyponatremia 
observed in our study was symptomatic (i.e. if patients presented to hospital with both 
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hyponatremia and delirium). However, this too was not possible given the limited number 
of events. The risk factors for hospitalization with hyponatremia among atypical 
antipsychotic drug users were older age, cancer, and a history of hyponatremia.  
There are important strengths of our study. The use of Ontario’s healthcare 
databases including data on universal prescription drug coverage allowed us to estimate a 
rare adverse event with good precision in a large representative sample size. We used a 
propensity score-matched design to reduce confounding that is often found in 
observational studies. In addition, the results of our two additional analyses support our 
primary study finding. The null association seen with atypical antipsychotic drug use and 
bowel obstruction provides some reassurance that residual confounding is unlikely to 
have influenced the primary results.  
There are some limitations of our study. First, as the sensitivity of the hospital 
diagnosis code for hyponatremia was low, we would have preferred to supplement our 
primary findings using serum sodium laboratory values. With codes however, we were 
able to capture those patients whose hyponatremia would be considered clinically 
significant (median serum sodium level of 125 mmol/L [IQR 120-130 mmol/l] as found 
in our validation study).28 Second, although our user and non-user groups were well-
balanced after matching, unmeasured confounding variables may have influenced our 
estimates of risk. For example, it is possible that the patients who used atypical 
antipsychotics in our study were more likely than non-users to experience psychogenic 
polydipsia, a condition characterized by excessive fluid consumption.38 Third, we could 
not be confident of the indication for which the atypical antipsychotic drug was 
prescribed. Both users and non-users had evidence of a psychiatric condition in the 
previous five years. This restriction was applied to ensure that we had a large 
representative sample of similar types of patients in our study. Fourth, we were unable to 
look at the long-term risk of hyponatremia, because the median length of time in follow-
up for antipsychotic use was only 57 days. When an antipsychotic is prescribed, only 
short duration use is encouraged, particularly in those with dementia (6-12 weeks), which 
is an unapproved indication.39,40 Alternatively, poor adherence to the medication could 
also explain the short duration observed.41,42 Finally, we could only study older adults 
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within our data sources. Younger patients are often healthier and may be less susceptible 
to drug-induced hyponatremia. 
To our knowledge, this is the first population-based study to examine the 
association between atypical antipsychotic drug use and hyponatremia among older 
adults. We recommend that additional studies be conducted in this area. Future studies 
should consider using serum sodium laboratory values to better estimate the risk of 
hyponatremia from atypical antipsychotics. In patients who are chronic users of 
antipsychotics, future studies could examine whether there is a long-term risk of 
hyponatremia from these drugs. Even mild, chronic forms of hyponatremia can have 
important consequences, negatively impacting quality of life.43 Better knowledge of these 
risks can help to guide drug prescribing, monitoring and interventions to prevent or 
mitigate adverse drug events. For now, we recommend judicious prescribing of atypical 
antipsychotic drugs to minimize adverse events. When a patient presents with severe 
hyponatremia, atypical antipsychotic drugs can be considered as a potential reason for the 
finding.  
5.5 Conclusion 
We found a modest increase in the 30-day risk of hospitalization with hyponatremia 
among older adults prescribed an atypical antipsychotic drug compared to those who 
were not. The association was less pronounced than seen with other psychotropic drugs. 
Additional studies, preferably using laboratory data, are needed to ensure reproducibility 
of the findings. 
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6.1 Introduction
The incidence of epilepsy is highest in old age, with an estimated 60 to 135 new cases per 
100,000 older adults each year.1,2 Carbamazepine, valproic acid, phenytoin and 
topiramate are commonly used antiepileptic drugs for the control of focal and generalized 
seizures, and can be initiated as monotherapy.3–6 These drugs are also often used in 
treatment of non-epileptic conditions such as pain and psychiatric disorders. 
Hyponatremia is an adverse effect of several psychotropic drugs, including 
carbamazepine and valproic acid, which is suspected to occur mainly through the 
syndrome of inappropriate antidiuretic hormone secretion.7 A decrease in the serum 
sodium concentration can sometimes result in symptomatic hyponatremia, leading to 
hospitalization or death.8,9 These risks are of particular concern in older adults who often 
have altered physiology, have multiple comorbidities, and use multiple drugs.  
The reported incidence of carbamazepine-induced hyponatremia ranges widely 
from less than 1% to 40%.10 Several small clinical studies have noted decreases in the 
concentration of serum sodium following carbamazepine use, but most were uncontrolled 
and none quantified the magnitude of risk.11–18 Hyponatremia with valproic acid was 
identified in a single case-control study but it is not known if phenytoin or topiramate 
associate with hyponatremia.19 Based on a few small studies, phenytoin was found to 
reverse hyponatremia by inhibiting antidiuretic hormone release, but results were 
inconsistent.20,21 A product monograph for topiramate lists hyponatremia as a rare 
adverse event when used with other antiepileptic drugs, although no studies have 
evaluated this association.22  
We examined the 30-day risk of hospitalization with hyponatremia associated with 
initiating carbamazepine, valproic acid, phenytoin or topiramate in the non-hospitalized 
setting relative to no antiepileptic use.  
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6.2 Methods 
6.2.1 Study Design and Setting 
We conducted two population-based, retrospective cohort studies in Ontario, Canada, 
among adults over 65 years between 1 June 2003 and 1 March 2015. Over two million 
older adults in Ontario have universal access to hospital care, physician services, and 
prescription drug coverage.23 These datasets were linked using unique encoded identifiers 
and analyzed at the Institute for Clinical Evaluative Sciences (ICES). The reporting of 
this study followed the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines (Appendix D Table D-1).24 This study was approved by the 
institutional review board at Sunnybrook Health Sciences Centre, Toronto, Canada. 
6.2.2 Data Sources 
We used nine linked databases to identify patient information, medication use, outcomes 
and other important variables. We identified demographic information and vital statistics 
using the Ontario Registered Persons Database. We used the Ontario Drug Benefits 
program database to identify prescriptions for antiepileptic drugs and other medications. 
For outpatients over the age of 65, this database records prescription claims with an error 
rate of 0.7%.25 We defined several variables using the Ontario Health Insurance Plan 
database, which contains information on health claims for inpatient and outpatient 
physicians’ services. We obtained diagnostic and procedural information on all 
hospitalizations and emergency department visits using the Canadian Institute for Health 
Information’s Discharge Abstract Database and National Ambulatory Care Reporting 
System database, respectively. We used the Ontario Mental Health Reporting System 
database to obtain information on mental health admissions. We used the ICES Physician 
Database to ascertain study antiepileptic drug prescriber information. In a subpopulation, 
we obtained serum sodium laboratory measurements using datasets from Gamma-
Dynacare Medical Laboratories (an outpatient laboratory service provider in Ontario) and 
Cerner (an electronic medical record system used by 12 hospitals in southwestern Ontario 
available from June 2003 to March 2012). We have used these databases to research 
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adverse drug events and health outcomes in other studies (including outcomes of 
hyponatremia and health services).26–28 
We used the International Classification of Diseases, 9th revision (ICD-9) and 10th 
revision (ICD-10) to ascertain baseline comorbidities, and only ICD-10 to identify 
outcomes as these events occurred after the implementation of this coding system in 2002 
(codes detailed in Appendix D Table D-2). The databases were complete for all variables 
considered in this study, except for prescriber information, income quintile, and 
rural/urban residence, which were missing in less than 12%, 0.5%, and 0.05%, 
respectively. 
6.2.3 Cohorts 
Users: We established two cohorts of older adults who were newly dispensed an 
outpatient antiepileptic drug of interest. The first cohort consisted of those dispensed 
carbamazepine (referred to as carbamazepine users), an antiepileptic drug where a risk of 
hyponatremia is well appreciated. The second cohort consisted of those dispensed any 
one of valproic acid, phenytoin, or topiramate (referred to as V-P-T users), three 
antiepileptic drugs where the potential risk of hyponatremia is less understood. We 
considered any one of V-P-T as a single group of users in our primary analysis to 
maximize the sample size and statistical power. We defined the index date (cohort entry 
date) as the date of the prescription for the antiepileptic drug. We considered only new 
users of these drugs by excluding patients who received a prescription for any type of 
antiepileptic drug in the six months preceding the index date. Patients could only be 
dispensed one of the four aforementioned antiepileptic drugs so that in additional 
analyses we could compare mutually exclusive groups. Each patient could enter either of 
the two cohorts only once. 
Non-users: For each cohort study, we identified a group of older adults from the Ontario 
population who did not have a prescription for any type of antiepileptic drug in the six 
months prior to a randomly assigned index date that was assigned based on the 
distribution of index dates of the antiepileptic drug users. A non-user was eligible to be a 
match in both cohorts. 
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From both the user and non-user groups, we excluded the following patients: i) 
those with no outpatient medications of any kind dispensed in the 90 days prior to their 
index date to ensure active use of the provincial universal drug benefit program, ii) those 
discharged from a hospital or emergency department in the two days prior to their index 
date to ensure these were new outpatient antiepileptic prescriptions (in the case of users; 
or the possibility of a new outpatient antiepileptic prescription for non-users), and iii) 
those with end-stage renal disease prior to their index date since serum sodium 
concentrations are controlled through dialysis.  
Using a logistic regression model, we derived propensity scores for the predicted 
probability of receiving antiepileptic treatment given a set of characteristics that were 
potentially related to antiepileptic treatment and/or hospitalization with hyponatremia 
(Appendix D Table D-3).29 Using greedy matching, we matched each carbamazepine user 
1:3 to non-users and each V-P-T user 1:2 to non-users, based on the following 
characteristics: age (within two years); sex; index date (within 1 year); residential status 
(community-dwelling or long-term care); evidence of epilepsy/seizure, chronic kidney 
disease, congestive heart failure, and diuretic use; constituency in the catchment area 
where linked serum sodium data were available; and the logit of the propensity score 
(within a caliper of ±0.2 standard deviations).  
Given that treatment allocation was decided based on routine care, propensity score 
matching was used to ensure user and non-user groups were balanced on a wide range of 
characteristics. The matching ratios were selected in order to maximize precision while 
minimizing the loss of antiepileptic drug users in the respective cohorts.  
6.2.4 Outcomes 
We evaluated all outcomes within 30 days of the index date. This timeframe was selected 
to avoid crossover in drug therapy that could occur with longer periods of follow up. 
6.2.4.1 Primary Outcome 
The primary outcome was hospitalization with hyponatremia in the 30 days following the 
index date, defined by evidence of ICD-10 code E87.1 (hypo-osmolality or 
hyponatremia) in any one of 25 diagnostic fields during a given hospitalization. In our 
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previous validation study, we found that the code had a sensitivity, specificity, and 
positive predictive value of 11%, 99% and 82%, respectively. The presence of the code 
for hyponatremia identified older patients with a median serum sodium value of 125 
mmol/L at hospital admission (interquartile range [IQR] 120 to 130 mmol/L); when the 
code was absent, the median value was 137 (IQR 135 to 139) mmol/L.30 The full study is 
included in Appendix E. 
6.2.5 Statistical Analyses 
We used standardized differences to compare baseline characteristics between each user 
and non-user group (a more appropriate method for the size of the studies). This metric 
describes differences between the group means relative to the pooled standard deviation 
with a value greater than 10% indicating imbalance.31 We used conditional logistic 
regression to estimate odds ratios and 95% confidence intervals (CIs) for both cohorts. 
All odds ratios were approximated as relative risks (appropriate given the incidences 
observed). We expressed risk in both relative and absolute terms. We compared the two 
estimates obtained from each cohort by calculating the relative risk ratio (assuming 
independent samples).32 
We also conducted five pre-specified subgroup analyses. We evaluated the 30-day 
risk of hospitalization with hyponatremia for V-P-T use vs. non-use by antiepileptic drug 
type (valproic acid, phenytoin, topiramate). In both carbamazepine and V-P-T cohorts, 
we evaluated the association in the following subgroups: i) antiepileptic dose (high vs. 
normal), ii) chronic kidney disease, iii) congestive heart failure, and iv) diuretic use. We 
identified chronic kidney disease and congestive heart failure using validated algorithms 
of hospital diagnosis codes from our region.33,34 In the case of antiepileptic type and dose, 
we defined the subgroup by the characteristic in users, with non-users following their 
matched user. We determined subgroup p-values using interaction terms in the 
conditional logistic regression models.  
We performed all analyses using SAS version 9.4 (SAS Institute, Cary, North 
Carolina). Any results where the number of events were less than six were not allowed to 
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be reported in order to minimize any risk of patient re-identification in our data sources 
(which we described as too few events). Detailed methods are provided in Chapter 3.    
6.2.5.1 Additional Analyses 
First, among a subpopulation residing in a catchment area where linked laboratory data 
were available, we evaluated the association between antiepileptic use and hospitalization 
with hyponatremia within 30 days using serum sodium values (defined by a concentration 
≤132 mmol/L) (when possible).35  
Second, in another subpopulation for which information on outpatient laboratory 
data were available, we examined the association between antiepileptic use and outpatient 
hyponatremia within 30 days using serum sodium values (defined by a concentration 
≤132 mmol/L).  
Third, we evaluated the association between antiepileptic use and hospitalization 
with bowel obstruction within 30 days. Since bowel obstruction was not expected to be 
influenced by antiepileptic use, we reasoned that a null association with this outcome 
would enhance causal inference in our hyponatremia analyses.36 
Fourth, we explored which characteristics were associated with hospitalization with 
hyponatremia both in carbamazepine and V-P-T users. The characteristics evaluated 
included age (per year); sex; evidence of chronic kidney disease, congestive heart failure, 
diabetes, liver disease, cancer, hypothyroidism, previous hyponatremia; and receipt of 
diuretic, antidepressant, antipsychotic, and antineoplastic drugs. 
6.3 Results 
6.3.1 Baseline Characteristics 
Prior to matching, we identified 24 905 carbamazepine users, 26 365 V-P-T users, and 1 
289 530 non-users (cohort selection presented in Figure 6-1). In the unmatched cohorts, 
compared to non-users, both carbamazepine and V-P-T users had higher comorbidity 
scores, were dispensed a greater number of medications, were more likely to have a 
recorded diagnosis of epilepsy/seizure, migraines, mood and anxiety disorders, and were 
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more likely to have underwent magnetic resonance imaging and/or computed tomography 
of the head. Carbamazepine users were more likely to be diagnosed with trigeminal 
neuralgia and neuropathic pain, while V-P-T users were more likely to be diagnosed with 
bipolar disorder. 21 191 carbamazepine users were matched 1:3 to 63 573 non-users and 
20 155 V-P-T users were matched 1:2 to 40 310 non-users. Less than 5% of non-users 
were the same adults in both cohorts. In both matched cohorts, the standardized 
difference was at most 10% across the 120 characteristics measured (Tables 6-1 and 6-2; 
full tables presented in Appendix D Tables D-4 and D-5). Among carbamazepine users 
and non-users, the mean age was 76 years, 63% were women, and 5% resided in a long-
term care facility. Among V-P-T users and non-users, the mean age was 76 years, 58% 
were women, and 22% resided in a long-term care facility. In both cohorts, family 
physicians were the most frequent antiepileptic prescribers (carbamazepine, 72%; V-P-T, 
64%), and the mean (standard deviation) baseline sodium value in both users and non-
users when available in our data sources was 140 (3) mmol/L. 
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51 270  1 289 530  
431 518 Without at least one 
outpatient medication dispensed in 
the 90 days prior to the index date 
  
17 524 Discharged from a hospital in 
the two days prior to the index date 
 
6312 Evidence of end-stage renal 
disease prior to the index date 
 
 
69 449 Ontario residents >65 years of age who 
were dispensed a new oral outpatient 
prescription for one of the following antiepileptic 
drugs prior to the index date: carbamazepine, 
valproic acid, phenytoin or topiramate (from 
June 2003 to March 2015). 
1 744 884 Ontario residents >65 years of age 
who were not dispensed an oral outpatient 
prescription for any antiepileptic drug in the six 
months prior to the randomly assigned index 
date (from June 2003 to March 2015). 
17 640 Discharged from a hospital 
or emergency department in the two 
days prior to the index date  
 
539 Evidence of end-stage renal 
disease prior to the index date 
 
Remaining 
 
Excluded 
 
Matched 
(1:3) 
 
21 191 
carbamazepine users  
20 155  
V-P-T users  
Matched 
(1:2) 
 
63 573 
carbamazepine users  
40 310 
V-P-T users  
Figure 6-1. Cohort selection 
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Table 6-1. Baseline characteristics of carbamazepine users and non-users (1:3 matching ratio)* 
Characteristic Unmatched  Matched  
 Carbamazepine  
users 
(n= 24 905) 
Antiepileptic 
 non-users 
 (n= 1 289 530) 
Standardized 
Differencea 
Carbamazepine 
users 
(n=21 191) 
Antiepileptic 
non-users 
 (n=63 573) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 76 (7.1) 76 (7.2) 0.8% 76 (6.9) 76 (6.8) 0.3% 
Women 15 436 (62.0%) 742 126 (57.6%) 9.0% 13 284 (62.7%) 39 852 (62.7%) 0 
Income quintileb       
1  (low) 5388 (21.6%) 251 859 (19.5%) 5.2% 4508 (21.3%) 13 924 (21.9%) 1.5% 
2 5171 (20.8%) 269 597 (20.9%) 0.4% 4415 (20.8%) 13 123 (20.6%) 0.5% 
3 (medium) 4960 (19.9%) 252 663 (19.6%) 0.8% 4314 (20.3%) 12 960 (20.4%) 0.1% 
4 4798 (19.3%) 253 301 (19.6%) 1.0% 4099 (19.3%) 12 261 (19.3%) 0.1% 
5 (high) 4495 (18.1%) 258 046 (20.0%) 5.0% 3855 (18.2%) 11 305 (17.8%) 1.1% 
Rural residencec 4108 (16.5%)  182 927 (14.2%) 6.4% 3461 (16.3%) 10 623 (16.7%) 1.0% 
Long-term care 1691 (6.8%)  57 445 (4.5%) 10.2% 984 (4.6%) 2 952 (4.6%) 0 
Comorbid conditionsd       
Charlson comorbidity index, mean (SD) 0.8 (1.5) 0.6 (1.3) 15.9% 0.7 (1.4) 0.7 (1.4) 0 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.2 (4.3) 11.5 (4.2) 41.0% 12.9 (4.2) 13.0 (4.1) 2.2% 
Epilepsy/seizuree 12 046 (48.4%)  396 047 (30.7%) 36.7% 9802 (46.3%) 29 406 (46.3%) 0 
Migraine 1780 (7.2%) 39 661 (3.1%) 18.6% 1358 (6.4%) 4095 (6.4%) 0.1% 
Trigeminal neuralgia 3235 (13.0%) 11 567 (0.9%) 49.0% 1377 (6.5%) 3817 (6.0%) 2.0% 
Neuropathic pain 734 (3.0%)  18 587 (1.4%) 10.3% 535 (2.5%) 1530 (2.4%) 0.8% 
Bipolar disorder  143 (0.6%)  2154 (0.2%) 6.7% 561 (2.7%) 1667 (2.6%) 0.2% 
Mood disorder 683 (2.7%)  15 713 (1.2%) 11.0% 2442 (11.5%) 7286 (11.5%) 0.2% 
Anxiety disorder 11 293 (45.3%)  463 445 (35.9%) 19.2% 9335 (44.1%) 28 233 (44.4%) 0.7% 
Benign brain tumour 446 (1.8%)  7600 (0.6%) 11.1% 312 (1.5%  952 (1.5%) 0.2% 
Brain cancer 234 (0.9%) 3001 (0.2%) 9.3% 141 (0.7%) 437 (0.7%) 0.3% 
Brain injury 127 (0.5%)  3896 (0.3%) 3.3% 97 (0.5%)  266 (0.4%) 0.6% 
Parkinson’s disease 671 (2.7%) 24 413 (1.9%) 5.4% 508 (2.4%) 1537 (2.4%) 0.1% 
Congestive heart failure 3516 (14.1%) 144 842 (11.2%) 8.7% 2417 (11.4%) 7251 (11.4%) 0 
Chronic kidney disease 1640 (6.6%)  77 172 (6.0%) 2.5% 920 (4.3%) 2760 (4.3%) 0 
Hypertension 18 180 (73.0%) 953 061 (73.9%) 2.1% 15 300 (72.2%) 45 888 (72.2%) 0 
Chronic liver disease 842 (3.4%) 39 103 (3.0%) 2.0% 686 (3.2%) 2026 (3.2%) 0.3% 
Hypothyroidism 2571 (10.3%) 121 865 (9.5%) 2.9% 2186 (10.3%) 6474 (10.2%) 0.4% 
Cancerf 3553 (14.3%) 168 419 (13.1%) 3.5% 2969 (14.0%) 8803 (13.9%) 0.5% 
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Diabetes mellitus 7116 (28.6%)  358 136 (27.8%) 1.8% 5943 (28.0%) 17 346 (27.3%) 1.7% 
Diabetic neuropathy 172 (0.7%)  3216 (0.3%) 6.5% 112 (0.5%) 275 (0.4%) 1.4% 
Diabetic retinopathy 155 (0.6%) 5031 (0.4%) 3.3% 109 (0.5%) 334 (0.5%) 0.2% 
Pneumonia 1187 (4.8%) 43 322 (3.4%) 7.1% 868 (4.1%) 2442 (3.8%) 1.3% 
Coronary artery diseaseg 7785 (31.3%) 356 915 (27.7%) 7.9% 6276 (29.6%) 18 916 (29.8%) 0.3% 
Angina 5885 (23.6%) 245 038 (19.0%) 11.3% 4763 (22.5%) 14 575 (22.9%) 1.1% 
Previous hyponatremia 536 (2.2%)  16 299 (1.3%) 6.9% 378 (1.8%) 1158 (1.8%) 0.3% 
Previous delirium 444 (1.8%)  14 306 (1.1%) 5.6% 276 (1.3%) 919 (1.5%) 1.2% 
Peripheral vascular disease 585 (2.4%) 18 175 (1.4%) 6.9% 417 (2.0%) 1290 (2.0%) 0.4% 
Lung disease  7392 (29.7%)  310 878 (24.1%) 12.6% 6067 (28.6%) 18 487 (29.1%) 1.0% 
Concurrent medication useh       
Number of unique drug products, mean 
(SD) 
8.9 (6.0) 7.1 (4.7) 33.5% 8.4 (5.6) 8.4 (5.4) 0.2% 
Antipsychotics 1473 (5.9%) 48 323 (3.7%) 10.1% 1070 (5.1%) 3276 (5.2%) 0.5% 
Antidepressants 7781 (31.2%) 215 229 (16.7%) 34.6% 6056 (28.6%) 18 644 (29.3%) 1.7% 
Antidiabetics 4496 (18.1%) 225 528 (17.5%) 1.5% 3766 (17.8%) 10 934 (17.2%) 1.5% 
Antineoplastics 960 (3.9%)  44 902 (3.5%) 2.0% 799 (3.8%) 2416 (3.8%) 0.2% 
Thyroxine 4136 (16.6%) 204 370 (15.8%) 2.1% 3513 (16.6%) 10 393 (16.4%) 0.6% 
Potassium sparing diuretics 1578 (6.3%) 69 702 (5.4%) 4.0% 1278 (6.0%) 3600 (5.7%) 1.6% 
Non-potassium sparing diuretics  7563 (30.4%) 383 139 (29.7%) 1.4% 6053 (28.6%) 18 324 (28.8%) 0.6% 
ACE inhibitors and/or ARBs 11 605 (46.6%) 627 455 (48.7%) 4.1% 9815 (46.3%) 29 171 (45.9%) 0.9% 
NSAIDs (excl. ASA) 6267 (25.2%)  224 624 (17.4%) 19.0% 5286 (24.9%) 16 556 (26.0%) 2.5% 
Calcium channel blockers 6940 (27.9%) 361 121 (28.0%) 0.3% 5789 (27.3%) 17 310 (27.2%) 0.2% 
Beta-adrenergic antagonists 7165 (28.8%) 385 357 (29.9%) 2.4% 6011 (28.4%) 17 643 (27.8%) 1.4% 
Statins 9439 (37.9%) 542 836 (42.1%) 8.6% 8082 (38.1%) 23 835 (37.5%) 1.3% 
Benzodiazepines 6597 (26.5%) 216 925 (16.8%) 23.6% 5289 (25.0%) 16 528 (26.0%) 2.4% 
Antibiotics 9553 (38.4%) 388 511 (30.1%) 17.4% 7870 (37.1%) 23 707 (37.3%) 0.3% 
Healthcare contacts, mean (SD)i       
Hospitalizations 0.6 (1.1)  0.4 (0.9) 19.4% 0.6 (1.1) 0.6 (1.1) 0.9% 
Emergency department visits 1.0 (1.8) 0.5 (1.2) 29.5% 0.8 (1.6) 0.8 (1.7) 1.3% 
Family physician visits 12.8 (13.0) 9.0 (9.2) 34.4% 11.5 (10.9) 11.5 (11.2) 0.4% 
Geriatrician visits 0.2 (1.9) 0.1 (1.1) 6.7% 0.1 (1.5) 0.1 (1.3) 0 
Psychiatrist visits 0.4 (3.7) 0.1 (1.8) 9.1% 0.3 (3.2) 0.3 (3.2) 0.3% 
Neurologist visits 0.4 (2.0) 0.1 (0.7) 23.9% 0.31 (1.0) 0.2 (1.1) 6.6% 
Healthcare usej       
Previous sodium tests 14 835 (59.6%)  745 101 (57.8%) 3.6% 12 217 (57.7%) 36 567 (57.5%) 0.3% 
Carotid ultrasound 1750 (7.0%) 53 990 (4.2%) 12.4% 1382 (6.5%) 4024 (6.3%) 0.8% 
Cardiac catheterization 380 (1.5%) 18 080 (1.4%) 1.0% 2572 (12.1%) 7795 (12.3%) 0.4% 
Echocardiography 4106 (16.5%) 190 435 (14.8%) 4.7% 1308 (6.2%) 3971 (6.3%) 0.3% 
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Holter monitoring 1761 (7.1%) 70 045 (5.4%) 6.8% 315 (1.5%) 890 (1.4%) 0.7% 
Thyroid stimulating hormone 13 181 (52.9%) 665 897 (51.6%) 2.6% 11 073 (52.3%) 32 855 (51.7%) 1.2% 
Magnetic resonance imaging of the head 1581 (6.3%) 20 572 (1.6%) 24.5% 997 (4.7%) 2942 (4.6%) 0.4% 
Computed tomography of the head 4443 (17.8%)  90 235 (7.0%) 33.3% 3130 (14.8%) 9373 (14.7%) 0.1% 
Chest x-ray 9594 (38.5%) 388 460 (30.1%) 17.8% 7697 (36.3%) 23 389 (36.8%) 1.0% 
Pulmonary function test 2127 (8.5%) 95 359 (7.4%) 4.2% 1766 (8.3%) 5248 (8.3%) 0.3% 
Electroencephalography  860 (3.5%) 4318 (0.3%) 23.0% 454 (2.1%) 1125 (1.8%) 2.7% 
Laboratory measurementsk       
Most recent serum sodium, N (%) 3631 (14.6%) 183 468 (14.2%) 1.0% 2592 (12.2%) 7776 (12.2%) 0 
Most recent serum sodium, mean (SD) 140.3 (3.4) 140.6 (3.0) 9.8% 140.4 (3.3) 140.5 (3.0) 4.1% 
 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.32% missing values in matched users and non-users. 
These patients were included in income quintile 3 (“average” income). 
c There were less than 0.04% missing values in both matched users and non-users. These patients were included in the urban category. 
d Comorbid conditions in the five years preceding the index date were considered. 
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the 
condition. 
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
h Concurrent medication use in the six months preceding the index date were considered. 
i Healthcare contacts in the year preceding the index date were considered. 
j Healthcare use in the year preceding the index date was considered. 
k Serum sodium measurements were obtained at a median (IQR) of 132 (58 to 229) days prior to the index date in users, and 134 (64 to 230) days in non-users.  
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Table 6-2. Baseline characteristics of valproic acid (V), phenytoin (P), and topiramate (T) users and non-users (1:2 matching ratio)* 
Characteristic Unmatched Matched 
 V-P-T 
users 
(n= 26 365) 
Antiepileptic 
 non-users 
 (n= 1 289 530) 
Standardized 
Differencea 
V-P-T 
users 
(n= 20 155) 
Antiepileptic 
 non-users 
 (n= 40 310) 
Standardized 
Differencea 
Demographic       
Age, years, mean (SD) 76 (7.7)  76 (7.2) 5.6% 76 (7.7) 76 (7.6) 0% 
Women 14 780 (56.1%)  742 126 (57.6%) 3.0% 11 708 (58.1%) 23 416 (58.1%) 0% 
Income quintileb       
1  (low) 5693 (21.6%) 251 859 (19.5%) 5.1% 4321 (21.4%) 8818 (21.9%) 1.1% 
2 5424 (20.6%) 269 597 (20.9%) 0.8% 4182 (20.8%) 8280 (20.5%) 0.5% 
3 (medium) 5020 (19.0%) 252 663 (19.6%) 1.4% 3897 (19.3%) 7799 (19.4%) 0% 
4 5078 (19.3%) 253 301 (19.6%) 1.0% 3908 (19.4%) 7687 (19.1%) 0.8% 
5 (high) 5044 (19.1%)  258 046 (20.0%) 2.2% 3847 (19.1%) 7726 (19.2%) 0.2% 
Rural residencec 3601 (13.7%) 182 927 (14.2%) 1.5% 2835 (14.1%) 5887 (14.6%) 1.5% 
Long-term care 7071 (26.8%) 57 445 (4.5%) 64.7% 4482 (22.2%) 8964 (22.2%) 0% 
Comorbid conditionsd       
Charlson comorbidity index, mean (SD) 1.2 (1.7)   0.6 (1.3) 37.5% 0.9 (1.5) 0.9 (1.6) 0.7% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.5 (4.5) 
  
11.5 (4.2) 45.4% 13.0 (4.5) 13.0 (4.3) 1.4% 
Epilepsy/seizuree 16 029 (60.8%) 396 047 (30.7%) 63.3% 11 602 (57.6%) 23 204 (57.6%) 0.0% 
Migraine 2461 (9.3%)  39 661 (3.1%) 26.2% 1831 (9.1%) 3878 (9.6%) 1.8% 
Trigeminal neuralgia 470 (1.8%) 11 567 (0.9%) 7.7% 364 (1.8%) 784 (1.9%) 1.0% 
Neuropathic pain 476 (1.8%)  18 587 (1.4% 2.9% 350 (1.7%) 730 (1.8%) 0.6% 
Bipolar disorder  1176 (4.5%)  2154 (0.2%) 28.9% 1962 (9.7%) 3773 (9.4%) 1.3% 
Mood disorder 2461 (9.3%) 15 713 (1.2%) 36.9% 4556 (22.6%) 9210 (22.8%) 0.6% 
Anxiety disorder 15 118 (57.3%)  463 445 (35.9%) 43.9% 10 918 (54.2%) 22 697 (56.3%) 4.3% 
Benign brain tumour 898 (3.4%) 7600 (0.6%) 20.2% 466 (2.3%) 928 (2.3%) 0.1% 
Brain cancer 864 (3.3%) 3001 (0.2%) 23.3% 353 (1.8%) 702 (1.7%) 0.1% 
Brain injury 716 (2.7%) 3896 (0.3%) 19.9% 360 (1.8%) 595 (1.5%) 2.4% 
Parkinson’s disease 1522 (5.8%) 24 413 (1.9%) 20.3% 1024 (5.1%) 2001 (5.0%) 0.5% 
Congestive heart failure 3933 (14.9%) 144 842 (11.2%) 10.9% 2294 (11.4%) 4588 (11.4%) 0.0% 
Chronic kidney disease 1990 (7.5%) 77 172 (6.0%) 6.2% 787 (3.9%) 1574 (3.9%) 0.0% 
Hypertension 17 695 (67.1%) 953 061 (73.9%) 14.9% 13 253 (65.8%) 25 604 (63.5%) 4.7% 
Chronic liver disease 978 (3.7%) 39 103 (3.0%) 3.8% 697 (3.5%) 1390 (3.4%) 0.1% 
Hypothyroidism 2733 (10.4%) 121 865 (9.5%) 3.1% 2014 (10.0%) 3924 (9.7%) 0.9% 
Cancerf 3910 (14.8%) 168 419 (13.1%) 5.1% 2856 (14.2%) 5929 (14.7%) 1.5% 
Diabetes mellitus 7416 (28.1%)  358 136 (27.8%) 0.8% 5337 (26.5%) 9930 (24.6%) 4.2% 
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Diabetic neuropathy 147 (0.6%) 3216 (0.2%) 4.9% 87 (0.4%) 159 (0.4%) 0.6% 
Diabetic retinopathy 128 (0.5%) 5031 (0.4%) 1.4% 65 (0.3%) 144 (0.4%) 0.6% 
Pneumonia 1910 (7.2%) 43 322 (3.4%) 17.4% 1174 (5.8%) 2281 (5.7%) 0.7% 
Coronary artery diseaseg 7848 (29.8%) 356 915 (27.7%) 4.6% 5593 (27.7%) 11 096 (27.5%) 0.5% 
Angina 5275 (20.0%) 245 038 (19.0%) 2.5% 3802 (18.9%) 7598 (18.8%) 0.0% 
Previous hyponatremia 874 (3.3%) 16 299 (1.3%) 13.7% 529 (2.6%) 1037 (2.6%) 0.3% 
Previous delirium 1454 (5.5%) 14 306 (1.1%) 24.8% 766 (3.8%) 1436 (3.6%) 1.3% 
Peripheral vascular disease 573 (2.2%) 18 175 (1.4%) 5.8% 397 (2.0%) 795 (2.0%) 0.0% 
Lung disease  7547 (28.6%)  310 878 (24.1%) 10.3% 5515 (27.4%) 11 110 (27.6%) 0.4% 
Concurrent medication useh       
Number of unique drug products, mean 
(SD) 
9.1 (6.7)  7.1 (4.7) 35.3% 8.5 (6.3) 8.4 (5.6) 1.9% 
Antipsychotics 6978 (26.5%) 48 323 (3.7%) 66.9% 4369 (21.7%) 8520 (21.1%) 1.3% 
Antidepressants 10 751 (40.8%) 215 229 (16.7%) 55.2% 7617 (37.8%) 15 852 (39.3%) 3.2% 
Antidiabetics 4096 (15.5%)  225 528 (17.5%) 5.3% 2991 (14.8%) 5735 (14.2%) 1.7% 
Antineoplastics 919 (3.5%) 44 902 (3.5%) 0% 671 (3.3%) 1394 (3.5%) 0.7% 
Thyroxine 4417 (16.8%) 204 370 (15.8%) 2.4% 3321 (16.5%) 6754 (16.8%) 0.7% 
Potassium sparing diuretics 1193 (4.5%) 69 702 (5.4%) 4.1% 863 (4.3%) 1701 (4.2%) 0.3% 
Non-potassium sparing diuretics  6980 (26.5%)  383 139 (29.7%) 7.2% 4951 (24.6%) 9791 (24.3%) 0.6% 
ACE inhibitors and/or ARBs 10 045 (38.1%) 627 455 (48.7%) 21.4% 7706 (38.2%) 14 777 (36.7%) 3.3% 
NSAIDs (excl. ASA) 4027 (15.3%) 224 624 (17.4%) 5.8% 3266 (16.2%) 6583 (16.3%) 0.3% 
Calcium channel blockers 5673 (21.5%) 361 121 (28.0%) 15.1% 4343 (21.5%) 8205 (20.4%) 2.9% 
Beta-adrenergic agonists 6746 (25.6%) 385 357 (29.9%) 9.6% 5085 (25.2%) 9607 (23.8%) 3.2% 
Statins 8540 (32.4%) 542 836 (42.1%) 20.2% 6516 (32.3%) 12 125 (30.1%) 4.9% 
Benzodiazepines 7956 (30.2%) 216 925 (16.8%) 31.9% 5633 (27.9%) 11 896 (29.5%) 3.5% 
Antibiotics 9449 (35.8%) 388 511 (30.1%) 12.2% 7114 (35.3%) 14 184 (35.2%) 0.2% 
Healthcare contacts, mean (SD)i       
Hospitalizations 0.8 (1.3)  0.4 (0.9) 33.0% 0.7 (1.2) 0.6 (1.1) 3.5% 
Emergency department visits 1.3 (1.9) 0.5 (1.2) 46.3% 1.0 (1.6) 1.0 (1.8) 2.9% 
Family physician visits 17.2 (19.1)  9.0 (9.2) 58.4% 14.5 (15.5) 14.2 (14.7) 2.1% 
Geriatrician visits 0.6 (3.6) 0.1 (1.1) 19.7% 0.4 (2.5) 0.3 (2.1) 3.1% 
Psychiatrist visits 2.7 (11.5)  0.1 (1.8) 38.2% 1.2 (4.8) 0.8 (4.1) 10.1% 
Neurologist visits 0.8 (2.9)  0.1 (0.7) 39.5% 0.5 (1.6) 0.4 (1.5) 8.5% 
Healthcare usej       
Previous sodium tests 17 093 (64.8%) 745 101 (57.8%) 14.5% 12 566 (62.3%) 24 958 (61.9%) 0.9% 
Carotid ultrasound 2639 (10.0%) 53 990 (4.2%) 22.8% 1554 (7.7%) 3378 (8.4%) 2.5% 
Cardiac catheterization 389 (1.5%) 18 080 (1.4%) 0.6% 257 (1.3%) 555 (1.4%) 0.9% 
Echocardiography 4921 (18.7%) 190 435 (14.8%) 10.5% 3187 (15.8%) 6374 (15.8%) 0.0% 
Holter monitoring 2397 (9.1%) 70 045 (5.4%) 14.1% 1528 (7.6%) 3023 (7.5%) 0.3% 
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Thyroid stimulating hormone 15 359 (58.3%) 665 897 (51.6%) 13.3% 11 412 (56.6%) 22 543 (55.9%) 1.4% 
Magnetic resonance imaging of the head 3094 (11.7%) 20 572 (1.6%) 41.5% 1492 (7.4%) 2982 (7.4%) 0.0% 
Computed tomography of the head 9758 (37.0%)  90 235 (7.0%) 77.7% 5500 (27.3%) 11 201 (27.8%) 1.1% 
Chest x-ray 12 588 (47.7%) 388 460 (30.1%) 36.7% 8411 (41.7%) 17 024 (42.2%) 1.0% 
Pulmonary function test 1996 (7.6%) 95 359 (7.4%) 0.7% 1497 (7.4%) 3066 (7.6%) 0.7% 
Electroencephalography  2672 (10.1%) 4318 (0.3%) 45.1% 826 (4.1%) 1240 (3.1%) 5.5% 
Laboratory measurementsk       
Most recent serum sodium, N (%) 3681 (14.0%) 183 468 (14.2%) 0.8% 2253 (11.2%) 4506 (11.2%) 0% 
Most recent serum sodium, mean (SD) 140.3 (3.4) 140.6 (3.0) 7.9% 140.4 (3.3) 140.5 (3.1) 3.1% 
 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.35% and 0.32% missing values in matched users and non-
users, respectively. These patients were included in income quintile 3 (“average” income). 
c There were less than 0.07% missing values in matched users and non-users. These patients were included in the urban category. 
d Comorbid conditions in the five years preceding the index date were considered. 
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the 
condition. 
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
h Concurrent medication use in the six months preceding the index date were considered. 
i Healthcare contacts in the year preceding the index date were considered. 
j Healthcare use in the year preceding the index date was considered. 
k Serum sodium measurements were obtained at a median (IQR) of 128 (56 to 234) days prior to the index date in users, and 139 (63 to 237) days in non-users. 
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6.3.2 Primary Outcome 
Carbamazepine use was associated with a higher 30-day risk of hospitalization with 
hyponatremia vs. non-use (relative risk 8.20 [95% CI 5.40 to 12.46]) (Table 6-3). The 
relative association between carbamazepine use and hospitalization with hyponatremia 
was modified by concomitant use of a diuretic (diuretic use: relative risk 14.00 [95% CI 
6.82 to 28.76] vs. diuretic non-use: relative risk 5.71 [95% CI 3.37 to 9.69]; interaction p-
value = 0.049). The association was not modified by carbamazepine dose, congestive 
heart failure, or chronic kidney disease (p-values for interaction > 0.05) (Figure 6-2). 
Subgroup results for chronic kidney disease could not be presented (too few events).  
V-P-T use was also associated with a higher 30-day risk of hospitalization with 
hyponatremia vs. non-use (relative risk 2.62 [95% CI 1.57 to 4.36]) (Table 6-3). The 
association between V-P-T use and hospitalization with hyponatremia was not modified 
by drug type, dose, congestive heart failure, chronic kidney disease, or concomitant use 
of diuretics (p-values for interaction > 0.05) (Figure 6-3). Subgroup results for drug type, 
congestive heart failure and chronic kidney disease could not be presented (too few 
events).  
The relative risk of hospitalization with hyponatremia observed with 
carbamazepine use compared to non-use was 3.13 fold higher (95% CI 1.62 to 6.10) than 
the relative risk observed with V-P-T use compared to non-use.  
Table 6-3. 30-day risk of hospitalization with hyponatremia (hospital diagnosis code) in 
antiepileptic users and non-users 
Antiepileptic Drug Typea Events, No. (%)b 
Relative Risk 
(95% CI) 
Antiepileptic non-usersc 30 / 63 573 (0.05) 1.00 (reference) 
Carbamazepine users 82 / 21 191 (0.39) 8.20 (5.40 to 12.46) 
   
Antiepileptic non-usersc 26 / 40 310 (0.06) 1.00 (reference) 
V-P-T users 34 / 20 155 (0.17) 2.62 (1.57 to 4.36) 
V-P-T=valproic acid, phenytoin, topiramate, CI=confidence interval 
a An antiepileptic non-user group was selected as the referent. 
b The event rates and absolute risk differences are underestimated by eight-fold, as the hospital-based 
diagnosis codes used to define hyponatremia in our region have high speciﬁcity (99%) but low sensitivity 
(11%).30 
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 Events/At Risk, n/N (%)a    
 Carbamazepine 
user (n=20 600) 
Carbamazepine 
non-user (n=61 800) 
 
 
 
Relative Risk 
(95% CI) 
P-value for 
Interaction 
     
Congestive Heart Failureb     
   Yes 16 / 2547 (0.63) 8 / 7641 (0.10) 6.00 (2.57 to 14.02) 
0.22 
   No 61 / 18 053 (0.34) 17 / 54 159 (0.03) 11.32 (6.53 to 19.64) 
     
Diuretic Usec     
   Yes 46 / 6759 (0.68) 15 / 20 277 (0.07) 9.73 (5.35 to 17.70) 
0.92 
   No 31 / 13 841 (0.22) 10 / 41 523 (0.02) 9.30 (4.56 to 18.97) 
     
Carbamazepine Dosed     
   Higher Dose 41 / 10 260 (0.40) 11 / 30 780 (0.04) 7.71 (4.16 to 14.30) 
0.34 
Normal Dose 36 / 10 340 (0.35) 14 / 31 020 (0.05) 12.12 (6.07 to 24.20) 
   
 
 
 
 
 
 
 
 
  
Figure 6-2. The association between carbamazepine use and hospitalization with hyponatremia assessed in three subgroups* 
CI=confidence interval.  
*Congestive heart failure, baseline use of a diuretic, and carbamazepine dose. Sets of medication users and non-users were matched on presence of congestive 
heart failure and baseline diuretic use. For carbamazepine dose, matched sets were categorized according to this characteristic in users. Data marker size is 
proportional to the inverse of the source variance. 
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is 
underestimated by eight-fold because the code for hyponatremia has high speciﬁcity but low sensitivity.30  
b Congestive heart failure has a sensitivity, specificity and positive predictive value of 84.3, 85.4, and 35.8%, respectively.34  
c Diuretic use includes potassium sparing and non-potassium sparing medications.  
d Higher dose was defined as a higher than median daily dose. See Appendix D Table D-2 for definitions.  
 
 
 
Risk higher 
with carbamazepine use 
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Figure 6-3. The association between valproic acid (V), phenytoin (P), topiramate (T) use and hospitalization with hyponatremia 
assessed in two subgroups* 
 
CI=confidence interval.  
*Baseline use of a diuretic and V-P-T dose. Sets of medication users and non-users were matched on presence of congestive heart failure and baseline diuretic 
use. For V-P-T dose, matched sets were categorized according to this characteristic in users. Data marker size is proportional to the inverse of the source variance 
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is 
underestimated by eight-fold because the code for hyponatremia has high speciﬁcity but low sensitivity.30  
b Diuretic use includes potassium sparing and non-potassium sparing medications.  
c Higher dose was defined as a higher than median daily dose. See Appendix D Table D-2 for definitions. 
 Events/At Risk, n/N (%)a    
 V-P-T 
 user (n=20 155) 
Antiepileptic 
 non-user (n=40 310) 
 
 
 
 
 
 
 
Relative Risk 
(95% CI) 
P-value for 
Interaction 
   
  
Diuretic Useb 
   Yes 9 / 5244 (0.17) 10 / 10 488 (0.10) 1.80 (0.73 to 4.43) 
0.32 
   No 25 / 14 911 (0.17) 16 / 29 822 (0.05) 3.13 (1.67 to 5.85) 
    
 
V-P-T Dosec 
   Higher Dose 13 / 6789 (0.19) 10 / 13 578 (0.07) 2.60 (1.14 to 5.93) 
0.99 
Normal Dose 21 / 13 366 (0.16) 16 / 26 732 (0.06) 2.63 (1.37 to 5.03) 
    
 
 
 
Risk higher 
with V-P-T use 
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6.3.3 Additional Analyses 
Among the subpopulation for which linked laboratory data were available, baseline 
characteristics were very similar in carbamazepine users and non-users (Appendix D 
Table D-6, 678 carbamazepine users matched to 2034 non-users). Carbamazepine use vs. 
non-use was associated with a higher 30-day risk of hospitalization with hyponatremia 
(9/678 [1.33%] vs. 6/2034 [0.29%]; relative risk 4.50 [95% CI 1.60 to 12.64]; absolute 
risk increase 1.04% [95% CI 0.14% to 1.90%]). There were too few events to report 
similar results with V-P-T use.  
Carbamazepine use vs. non-use was associated with a higher 30-day risk of 
hyponatremia in an outpatient laboratory (26/2592 [1.00%] versus 14/7776 [0.18%], 
relative risk 5.57 [95% CI 2.91 to 10.67], absolute risk increase 0.82% [95% CI 0.43% to 
1.22%]), as was V-P-T use vs. non-use (19/2253 [0.84%] vs. 17/4506 [0.38%], relative 
risk 2.24 [95% CI 1.16 to 4.30], absolute risk increase 0.47% [95% CI 0.05% to 0.88%]).  
There was no association between antiepileptic use vs. non-use and the risk of 
hospitalization with bowel obstruction in either cohort (carbamazepine, 15/21 191 
[0.07%] vs. 33/63 573 [0.05%], relative risk 1.37 [95% CI 0.74 to 2.54]); V-P-T, 13/20 
155 [0.06%] vs. 19/40 310 [0.05%], relative risk 1.37 [95% CI 0.68 to 2.77]).  
In carbamazepine users, older age, cancer, diuretic use, and a history of 
hyponatremia were significant risk factors for hyponatremia; while in V-P-T users, 
cancer, hypothyroidism, and a history of hyponatremia were significant risk factors 
(Table 6-4). 
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Table 6-4. Risk factors for hospitalization with hyponatremia in carbamazepine users and 
valproic acid (V), phenytoin (P), and topiramate (T) users* 
CI=confidence interval 
* Separate multivariable logistic regression models created for carbamazepine users and V-P-T non-users 
6.4 Discussion 
We observed that carbamazepine use compared to no antiepileptic use was associated 
with an approximate 8.2-fold higher relative risk of hospitalization with hyponatremia 
within 30 days of drug initiation. The association between carbamazepine use and 
hospitalization with hyponatremia was evident across multiple types of older patients 
including those who took normal or higher doses of carbamazepine, those with and 
without congestive heart failure, and those with or without concurrent diuretic use. 
However, the risk appeared higher in the setting of concurrent diuretic use. Although 
subgroup analyses should be interpreted cautiously, a synergistic effect between 
carbamazepine and diuretics in the development of hyponatremia is biologically 
plausible. Interactions between carbamazepine and diuretics have also been observed in 
other reports.37,38  
The risk of hyponatremia with three other antiepileptic drugs, valproic acid, 
phenytoin and topiramate, is less well understood. Use of any of these three drugs 
compared to no antiepileptic use was associated with a 2.6-fold higher relative risk of 
 Carbamazepine users 
(n=21 191) 
V-P-T users 
(n=20 155) 
Hospitalization with hyponatremia Relative risk (95% CI) Relative risk (95% CI) 
Older age (per year) 1.07 (1.03 to 1.10) 1.01 (0.96 to 1.06) 
Women (vs. men) 1.43 (0.86 to 2.36) 1.23 (0.59 to 2.59) 
Chronic kidney disease (yes vs. no) 1.57 (0.73 to 3.38) 1.19 (0.27 to 5.23) 
Congestive heart failure (yes vs. no) 0.87 (0.47 to 1.59) 0.65 (0.21 to 2.04) 
Diabetes (yes vs. no) 1.55 (0.93 to 2.61) 2.10 (0.93 to 4.78) 
Liver disease (yes vs. no) 0.98 (0.30 to 3.16) 2.91 (0.99 to 8.56) 
Cancer (yes vs. no) 2.02 (1.16 to 3.50) 2.83 (1.32 to 6.04) 
Hypothyroidism (yes vs. no) 1.20 (0.63 to 2.30) 5.32 (2.59 to 10.94) 
Previous hyponatremia (yes vs. no) 6.67 (3.43 to 12.99) 7.64 (3.21 to 18.18) 
Diuretic use (yes vs. no) 1.73 (1.09 to 2.76) 0.87 (0.38 to 1.97) 
Antipsychotic use (yes vs. no) 0.88 (0.35 to 2.23) 0.89 (0.35 to 2.28) 
Antidepressant use (yes vs. no)  1.02 (0.63 to 1.65) 0.64 (0.30 to 1.40) 
Antineoplastic use (yes vs. no) 1.24 (0.50 to 3.05) 1.54 (0.43 to 5.48) 
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hospitalization with hyponatremia within 30 days of drug initiation. Although this risk 
between antiepileptic drug use and hospitalization with hyponatremia was no different 
across each antiepileptic drug type, phenytoin use compared to no antiepileptic use was 
associated with an approximate four-fold higher relative risk of hospitalization with 
hyponatremia (not presented to prevent risk of re-identification). Compared to those who 
initiated valproic acid, phenytoin use was associated with an approximate 2.6-fold higher 
adjusted relative risk in 30-day hospitalization with hyponatremia. These findings run 
contrary to prior studies, which suggest phenytoin rather than predisposing to 
hyponatremia minimizes it, through the inhibition of antidiuretic hormone release.20,21  
The likelihood a patient will experience an outcome, referred to as the absolute risk 
or absolute risk increase, is more useful for patient care than a relative association. 
Several results in our study used a diagnosis code to assess the presence of hyponatremia, 
which can underestimate the true incidence of hyponatremia by up to a factor of eight. 
When we defined the outcome using a sodium value ≤132 mmol/L, carbamazepine use 
compared to non-use was associated with a one percent increase in the 30-day absolute 
risk of hospitalization with hyponatremia. Despite the small increase in absolute risk, 
carbamazepine-induced hyponatremia may account for hundreds of potentially 
preventable hospitalizations each year. Mild (chronic) hyponatremia can result in 
impaired gait, attention deficits, and falls, while severe hyponatremia can cause 
confusion, seizures, coma, or even death.39,40   
In the Compendium for Pharmaceuticals and Specialties (CPS; the Canadian 
standard for product monographs) and in UpToDate® (a point-of-care medical resource), 
hyponatremia is listed as an adverse event of carbamazepine and valproic acid, but not 
phenytoin.41,42 If other studies corroborate our findings, changes to these prescribing 
references should be considered to include a description of hyponatremia with phenytoin. 
If a patient presents to hospital with symptomatic hyponatremia, phenytoin can be 
considered as one potential reversible cause. The CPS and UpToDate® recommend 
monitoring of serum sodium in older adults upon initiation of carbamazepine. No 
recommendations are provided for valproic acid in either reference. The utility and 
intensity of monitoring sodium levels before and after antiepileptic drug initiation in 
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older adults could be a subject of future investigation, and a strategy of monitoring could 
prove prudent particularly in the case of carbamazepine and phenytoin.  
Our study has many strengths. We used Ontario’s healthcare databases that 
included data on universal prescription drug coverage in older adults. This provided us 
with a large representative sample of patients who received the study antiepileptic drugs 
in routine care, enabling us to study a rare but important adverse drug event. We also 
took a number of approaches to minimize the effects of confounding and bias that are 
inherent to observational studies. First, we used a propensity score-matched design to 
make our user and non-user groups as comparable as possible on a large set of baseline 
indicators of health. We also considered a negative control outcome of bowel obstruction 
and observed no association, which provides some reassurance that the primary findings 
were less likely to be influenced by residual confounding. Second, to overcome the 
limitations of the code, we corroborated our primary results with sodium laboratory 
measurements (when possible). Finally, we conducted several additional analyses to 
confirm the association was robust. 
Our study also has some limitations. First, despite our efforts to eliminate sources 
of confounding, we may have failed to account for important unmeasured confounders. 
For example, some lesions in the brain are associated both with seizures and 
hyponatremia through a syndrome of inappropriate antidiuretic hormone. Nevertheless, 
the statistical technique we used resulted in comparison groups that were similar on 
multiple indicators of baseline health. Second, the code for hyponatremia had limited 
sensitivity, indicating that several patients included in our study could have had 
hyponatremia but did not get diagnosed as such. Also, we could have missed those 
patients with hyponatremia that did not present to hospital. We would have preferred to 
use sodium measurements in the V-P-T cohort, but this was not feasible due to the 
limited availability of lab data. Third, there were an inadequate number of patients 
prescribed topiramate, precluding us from drawing meaningful conclusions for this drug. 
Fourth, we did not know the degree to which the hyponatremia was symptomatic, but we 
do know that the code for hyponatremia detects a median sodium value of 125 mmol/L at 
hospital admission indicating that the hyponatremia was likely clinically important.30 
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Fifth, we could not be confident of the medical indication for the antiepileptic drug use, 
nor could we be sure the patient adhered to their prescribed drug regimen, as this 
information was not provided in our data sources. Those patients who were prescribed an 
antiepileptic drug to treat a psychiatric disorder could have been predisposed to 
hyponatremia from primary polydipsia, a condition characterized by compulsive fluid 
intake.43 However, we did not expect this to represent a large percent of our population. 
Sixth, since the relationship between carbamazepine use and hyponatremia is well-
known, it is possible that a physician was more likely to order a blood test to check the 
sodium level in patients taking carbamazepine. Finally, we could only study older adults 
within our data sources. Younger patients are often healthier and may be less susceptible 
to drug-induced hyponatremia. 
6.5 Conclusion 
In summary, among older adults prescribed an antiepileptic drug in routine care, we 
found a higher risk of hospitalization with hyponatremia with carbamazepine and V-P-T. 
The results of our study inform physicians and pharmacists about this potential risk, and 
may guide future investigations in developing strategies to monitor sodium levels before 
and after initiation of an antiepileptic drug. 
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7.1 Introduction 
The main objective of this thesis was to better understand the risk of hyponatremia 
among older adults taking psychotropic drugs. Specifically, there was an interest to study 
select second-generation antidepressants, atypical antipsychotics, and antiepileptic drugs, 
all of which are commonly used by this segment of the population. Additionally, this 
thesis explored whether the observed risks were modified by the following factors: i) 
congestive heart failure, ii) chronic kidney disease, iii) concomitant diuretic use, iv) 
psychotropic drug dose, and v) psychotropic drug type. In the second-generation 
antidepressants study, a concomitant outcome of hyponatremia and delirium was 
evaluated to determine whether the observed hyponatremia was symptomatic. As well, 
the risk factors for hyponatremia in patients taking these drugs were examined in each 
study. The data sources used in this thesis allowed for a comprehensive examination of 
the research questions in a Canadian setting, addressing many limitations of previous 
research. 
7.2 Integrated Discussion 
7.2.1 Summary of Findings 
Overall, hyponatremia was significantly associated with three major groups of 
psychotropic drugs used in routine care. Although there was a risk of hyponatremia from 
atypical antipsychotic drugs (OR=1.62), it was small and may not be as concerning as the 
risks of hyponatremia from second-generation antidepressants (OR=5.5), and 
antiepileptic drugs (carbamazepine, OR=8.2; valproic acid [V]-phenytoin [P]-topiramate 
[T], OR=2.6). Several sensitivity and additional analyses confirmed the robustness of the 
results, which provides reassurance that the associations observed are true. As well, the 
risk estimates were consistent with those of Movig et al., Kirby et al., (antidepressants) 
Mannesse et al., (antipsychotics) and Beers et al. (valproic acid) but extends the 
observations made to older adults in non-hospitalized settings in Ontario, with better 
precision and control for confounders.1–5 The current studies also extend the results to 
other drugs that have not been extensively examined (i.e. mirtazapine, duloxetine, 
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escitalopram [second-generation antidepressants], risperidone, olanzapine, quetiapine 
[atypical antipsychotics], valproic acid, phenytoin, topiramate [antiepileptics]). However, 
the risk of hyponatremia with V-P-T is novel and needs to be confirmed in additional 
studies. In addition, even though the absolute risk increases were small, in the context of 
a rapidly aging population and increasing use of these drugs, this translates into 
thousands of hospitalizations each year.  
Symptomatic hyponatremia is often associated with mental status changes, and can 
have important medical implications for a patient.6–8 For example, altered mental status 
further increases the risk for falls and aspiration pneumonia.8 In the second-generation 
antidepressants study, there was some indication of symptomatic hyponatremia, which 
emphasizes the severity of this condition. There were too few events in the other studies 
to accurately assess this outcome. 
A borderline interaction was identified only with carbamazepine and diuretic use. 
This observed quantitative interaction is biologically plausible and is clinically relevant, 
indicating that the risk of hyponatremia is greater when carbamazepine and diuretics are 
taken simultaneously. For each study, the risk of hyponatremia did not vary by drug type, 
dose, the presence of chronic kidney disease, and the presence of congestive heart failure. 
The failure to detect interactions with other subgroups could truly be indicative of no 
difference in risk across the groups or could be due to study related factors (discussed 
further in the limitations section). 
In second-generation antidepressant users, older age, female sex, liver disease, 
previous hyponatremia, and concomitant diuretic use were associated with hospitalization 
with hyponatremia. This is consistent with findings from previous studies, and are widely 
accepted causes of hyponatremia.1,2,9,10 In atypical antipsychotic users, older age, cancer, 
and previous hyponatremia were associated with hospitalization with hyponatremia. This 
is the first study to examine the risk factors for this relationship. In carbamazepine users, 
older age, cancer, diuretic use, and a history of hyponatremia were significant risk factors 
and in V-P-T users, cancer, hypothyroidism, and a history of hyponatremia were 
significant risk factors. These were the first studies to examine the potential associations 
between these risk factors with carbamazepine/V-P-T use and hyponatremia.   
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7.2.2 Clinical Importance and Implications 
The findings from this thesis are of clinical value as they add to the evidence-base related 
to psychotropic drug-induced hyponatremia. These results should be used to increase 
awareness among physicians, nurse practitioners, and pharmacists of the risks of 
hyponatremia associated with certain second-generation antidepressants, atypical 
antipsychotics, and antiepileptic drugs. In these studies, patients were hospitalized with 
hyponatremia, which is a clinically meaningful event. As found in the validation study, 
those patients who had a code for hyponatremia present on their record had a median 
serum sodium value of 125 mmol/L (IQR 120 to 130 mmol/L) while those patients with 
no such code had a median serum sodium value of 137 mmol/L (IQR of 135 to 139 
mmol/L).11 A median value of 125 mmol/L indicates that more severe forms of 
hyponatremia tend to be recorded as a diagnosis in a patients chart at hospital admission. 
Although we cannot be certain if hyponatremia was the responsible cause of the 
hospitalization, it certainly may have contributed to it. As well, the symptomatic 
hyponatremia observed in the antidepressants study highlights that some of the 
hyponatremia was clinically important. Also, the results of this thesis did not show a 
difference in the risk across the various second-generation antidepressants, atypical 
antipsychotics, and V-P-T. If an elderly patient presents to hospital with symptomatic 
hyponatremia, the specific drugs that were studied should all be considered as culprits. 
Particular attention should be given to older adults taking carbamazepine and diuretics 
simultaneously, as they have a higher risk of developing hyponatremia.  
The results of this thesis also have the potential to influence clinical prescribing 
practices, particularly in older adults. But first, benefit-risk should be assessed for a 
patient when considering prescribing one of these psychotropic drugs. Indeed, the 
absolute increases in the risks of hospitalization with hyponatremia were small, so the 
amount of benefit from these drugs likely outweighs the amount of risk. Clinicians should 
continue to prescribe these drugs as required but should be mindful of the potential risk 
of hyponatremia. Careful consideration should be given to those groups who have an 
increased likelihood of developing hyponatremia. For example, in this thesis older adults 
who had a prior episode of hyponatremia were at particular risk of developing 
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hyponatremia after starting a second-generation antidepressant, atypical antipsychotic or 
carbamazepine. Serum sodium levels should be assessed in patients prior to starting a 
particular drug regimen, to ensure that they are not initially hyponatremic. Development 
of a clinical prediction rule in predicting the probability of hyponatremia from any of 
these psychotropic drugs can also be considered to inform prescribing.12 Physicians and 
nurse practitioners would also benefit from updated prescribing guidelines in the 
Compendium of Pharmaceuticals and Specialties (CPS) and UptoDate® for some of the 
drug classes.  
7.2.2.1 Current Warnings and Recommendations in Prescribing 
Guidelines 
For second-generation antidepressants, both the CPS and UptoDate® warn of the potential 
for hyponatremia with these drugs. However, the CPS provides no recommendations to 
monitor serum sodium, and for some drugs, suggests drug discontinuation in the presence 
of symptomatic hyponatremia.13–21 UptoDate® suggests monitoring serum sodium levels 
in older adults when initiating or adjusting doses.22–30 Updates to the guidelines 
concerning groups that are at particular risk for hyponatremia should be provided. 
For atypical antipsychotics, hyponatremia is not even listed as an adverse event of 
olanzapine and quetiapine in the CPS but for all three drugs, UptoDate® suggests 
monitoring serum sodium levels in older adults when initiating or adjusting doses.31–36 
Given the findings from the atypical antipsychotics study, the CPS should consider 
should warn of the potential risk of hyponatremia with olanzapine and quetiapine. As 
well, the risk factors for hyponatremia in these patients should be outlines. 
For carbamazepine, the CPS and UptoDate® both list hyponatremia as an adverse 
event. The CPS indicates monitoring of serum sodium levels only in patients with renal 
disorders or in those taking diuretics.37 On the other hand, UptoDate® suggests 
monitoring serum sodium levels in older adults when initiating or adjusting doses.38 For 
valproic acid, phenytoin, and topiramate, a risk of hyponatremia is not listed in either 
prescribing reference.39–44 The findings with these drugs are novel, which explains the 
lack of information provided in these sources. More studies are needed to confirm the 
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study findings but clinicians should be cognizant of the potential risk and exercise 
caution when prescribing these drugs. 
7.2.2.2 Strategies for the Prevention of Drug-Induced 
Hyponatremia 
Strategies to mitigate hyponatremia need to be explored. The inconsistent messages 
across the two prescribing references warrant additional studies to determine the optimal 
strategy of managing hyponatremia when using certain second-generation 
antidepressants, atypical antipsychotics, or antiepileptic drugs. In many cases, the 
guidelines suggest to monitor serum sodium at specific points around the time of 
antidepressant/antipsychotic/carbamazepine prescription, or in particular groups of 
patients. Based on studies conducted in the area of antidepressants, a few authors have 
suggested that a routine serum sodium work-up be conducted within the first 2 weeks of 
initiating treatment, particularly in patients with additional risk factors for 
hyponatremia.1,45–47 Other strategies are also possible. For example, fluid restriction (less 
than 1 to 1.5 L per day) may be a viable option when initiating the drug in a person at 
higher risk for hyponatremia.48 If low serum sodium levels persist, physicians may 
choose to discontinue the drug or prescribe an alternate drug in patients when feasible. 
Alternatively, concomitant use of a “vaptan” (antidiuretic hormone receptor blocker) may 
be a possibility.49,50 However, vaptans are new drugs that are very costly so may not be a 
desired method of treatment.49 Overall, a cost-benefit analysis should be conducted to 
evaluate any one of these strategies. 
7.3 Strengths and Limitations 
7.3.1 Strengths 
Strengths of this thesis have been highlighted in the discussion sections of each chapter; 
however, several key strengths deserve mention.  
First, use of Ontario’s large healthcare administrative databases provided a 
comprehensive examination of psychotropic drug-induced hyponatremia. This thesis used 
multiple linked databases from Ontario, which offered a number of advantages (datasets 
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summarized in Chapter 3). Ontario is Canada’s most populous province with over two 
million older adults enrolled in the provincial health insurance plan. These databases 
have been extensively studied in several settings, and have proven validity.51–57 The 
Ontario Drug Benefits database was comprehensive (over 4,400 drug products available) 
and extremely reliable, with an error rate of only 0.7% (95% CI 0.5% to 0.9%).58,59 The 
Canadian Institute of Health Information database included information on all 
hospitalizations made in Ontario, allowing for ascertainment of the outcome for all 
patients across a broad region. These large databases provided population-based data, 
which allowed for a large representative sample, and adequate statistical power to enable 
the study of a rare adverse drug event. Rare adverse events are usually not detected in 
randomized controlled trials owing to their small sample sizes.60 In addition, answering 
the primary question of these studies with a randomized controlled trial would be very 
expensive, may not be ethical, and would not reflect real-world practice. A trial would 
entail frequent sodium testing, which would introduce “artificial” surveillance, whereas 
the cohort study captured the surveillance, as it would occur in routine care. Furthermore, 
older individuals and those with significant comorbidities are often excluded from these 
studies, which impairs their generalizability.61,62 
Second, robust methodology was used in this thesis to minimize the effects of bias 
and confounding. In pharmacoepidemiologic studies, exposure to a specific treatment is 
influenced by a number of patient, physician, and health care system factors.63 
Consequently, the baseline characteristics between exposed and unexposed patients may 
differ systematically, and may ultimately influence the estimated treatment effect. In this 
thesis, propensity score methods were used to reduce the impact of this treatment 
selection bias. A number of variables were included in the propensity score model to 
ensure both exposed and unexposed groups were similar on a large range of 
characteristics. In addition, a number of sensitivity analyses were conducted to ensure the 
role of bias and confounding were minimal. Indeed, the results of these analyses 
confirmed that the influence of bias and confounding was negligible. As well, a new-user 
design was used to ensure that the observed hyponatremia was attributed to the 
psychotropic drug and not due to another reason. The outcome was assessed using a 30-
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day risk window to minimize cross-over between drug therapies, and because 
hyponatremia was often identified during this time-frame in prior studies.  
Third, the set of studies comprising this thesis are the first to be conducted in a 
Canadian setting. To date, prior research on this topic was conducted in other regions of 
the world. It was important to conduct Canadian studies as differences in healthcare 
systems across countries may result in differential estimates of hyponatremia. Unlike 
many other countries, prescription drug use and healthcare coverage is universal for older 
adults in Canada. In addition, this thesis overcame several limitations of prior research. 
For example, the focus was on outpatients who are usually healthier than inpatients and 
are also more representative of the general older adult population.  
7.3.2 Limitations 
Limitations of this thesis are recognized and described in the discussion section of each 
chapter. Overall, this research had some limitations.  
In each of these studies, the primary outcome of hyponatremia was assessed using a 
hospital diagnosis code, which is known to underestimate the true event rate. In the 
validation study by Gandhi et al., while the specificity of the hospital diagnosis code 
(ICD-10 code) for hyponatremia was greater than 99%, sensitivity was only 11% when 
defined using a serum sodium threshold of ≤132 mmol/L (see appendix E for article).11 
As hyponatremia often occurs in the presence of other diseases, it tends to be an under-
diagnosed condition. As well, symptoms of hyponatremia resemble common side effects 
of medications or symptoms of other underlying conditions, which may complicate the 
differential diagnosis. Furthermore, trained coders are not permitted to interpret 
laboratory values but can record a diagnosis for a laboratory-based condition if the 
diagnosis was explicitly indicated in the patient’s chart. This means that even if the 
patient had a low sodium level documented in their chart, it would not get coded as 
hyponatremia unless the physician specifically noted the diagnosis. Combined, these 
factors contribute to the low sensitivity of the code. For this reason, use of laboratory data 
to assess the outcome of hyponatremia was of particular value. However, these data were 
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only available for a subpopulation (<5% of the population of Ontario), which resulted in 
smaller sample sizes and lower event rates.  
It is possible that study related factors contributed to the lack of interactions 
identified. There is a possibility that some of the subgroup definitions were imprecise. 
For example, the sensitivity and positive predictive value of the codes to define chronic 
kidney disease were moderate (38% and 59%, respectively).64 As such, the codes may 
have failed to capture the whole spectrum of chronic kidney disease, precluding 
identification of a potential interaction. Another likely explanation is that the subgroups 
were too underpowered to detect potential interactions.   
Despite these studies being population-based with thousands of patients, some 
models could not be fit or some analyses were not meaningful due to too few events in 
the strata. This was a problem in some subgroup analyses (particularly with chronic 
kidney disease), and in the assessment of symptomatic hyponatremia. The association 
with hyponatremia and delirium could only be estimated in the antidepressant study, as 
this outcome is highly insensitive (but very specific). As previously discussed, 
hyponatremia is often asymptomatic and may not require clinical attention. Thus, 
presence of symptomatic hyponatremia in the antipsychotics and antiepileptics studies 
would have been more informative for clinicians, as this would indicate a certain degree 
of severity. 
Within the datasets used, only drug dispensing information was available. Just 
because a patient filled a prescription does not indicate that they adhered to the 
prescribing regimen. However, the median duration of prescription drug use in these 
studies was between 50 and 90 days depending on the drug class. Therefore, this is less of 
a concern for this study where the outcomes were ascertained with a short follow-up 
time.  
Many patients take psychotropic drugs for off-label conditions. To avoid selection 
bias, in the antidepressants and antipsychotics studies, only patients with a diagnosed 
medical condition for a labeled indication of the drug were included. Therefore, the 
results may not be generalizable to the segment of the population who take these 
163 
 
 
 
 
medications for other reasons. Nonetheless, the mechanism of hyponatremia would be the 
same in these patients, so similar results would be expected. 
7.4 Future Direction 
This thesis addressed numerous limitations of previous studies done in the field; 
however, there are still many unanswered questions regarding hyponatremia. 
First, future population-based research should use laboratory data to evaluate the 
risk of hyponatremia, ideally collected within a defined follow-up schedule, particularly 
for antipsychotic and antiepileptic drugs (besides carbamazepine). Serum sodium data are 
the gold standard for determining the presence of hyponatremia. This is especially useful 
for detecting milder forms of hyponatremia. This would provide a more accurate 
incidence of the disorder and would allow for a better assessment of severity. 
Second, this thesis focused on short-term outcomes but it would be worthwhile for 
other studies to determine the long-term impact of hyponatremia in patients taking 
psychotropic drugs. As mild chronic hyponatremia is receiving increasing attention as a 
potential concern, clinicians may benefit from this knowledge to guide on-going care in 
older adults taking these drugs.  
Third, drug-induced hyponatremia is a potentially preventable problem if 
appropriate management strategies are put into place. Large-scale prospective studies 
should be conducted to determine an optimal strategy for the prevention and early 
monitoring of hyponatremia in the outpatient setting (described above). This strategy 
should especially be considered in older adults who are already at risk for developing 
hyponatremia. If these studies find that a particular management strategy results in fewer 
hyponatremia events, this would have a significant impact on the healthcare system. 
7.5 Conclusion  
With a rapidly growing population in Canada and around the world, the use of 
psychotropic drugs is becoming more prevalent. Awareness of adverse drug events is an 
important part of safe prescribing practices. The knowledge gained from this thesis can 
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inform patient care, improve prescribing guidelines, mitigate poor outcomes including 
hospitalizations, and guide future studies. Prompt recognition of both symptomatic and 
asymptomatic hyponatremia is important for preventing hyponatremia-related 
consequences. 
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Appendix A 
Table A-1. Modified Downs and Black checklist for non-randomized studies1 
(Prospective and Retrospective Studies) 
Item Criteria Possible 
Answers 
Reporting 
1 Is the hypothesis/aim/objective of the study clearly described? Yes = 1 
No = 0 
2 Are the main outcomes to be measured clearly described in the Introduction or 
Methods section? If the main outcomes are first mentioned in the Results 
section, the question should be answered no. 
 
Yes = 1 
No = 0 
3 Are the characteristics of the patients included in the study clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. 
In case-control studies, a case-definition and the source for controls should be 
given. 
 
Yes = 1 
No = 0 
 
4 Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? A list of principal confounders is provided.  
 
Yes = 2 
Partially = 1 
No = 0 
5 Are the main findings of the study clearly described? Simple outcome data 
(including denominators and numerators) should be reported for all major 
findings so that the reader can check the major analyses and conclusions. 
(This question does not cover statistical tests which are considered below). 
 
Yes = 1 
No = 0 
 
6 Does the study provide estimates of the random variability in the data for the 
main outcomes? In non-normally distributed data the interquartile range of 
results should be reported. In normally distributed data the standard error, 
standard deviation or confidence intervals should be reported. If the distribution 
of the data is not described, it must be assumed that the estimates used were 
appropriate and the question should be answered yes.  
 
Yes = 1 
No = 0 
7 Have the characteristics of patients lost to follow-up been described? This 
should be answered yes where there were no losses to follow-up or where 
losses to follow-up were so small that findings would be unaffected by their 
inclusion. This should be answered no where a study does not report the 
number of patients lost to follow-up.  
 
Yes = 1 
No = 0 
8 Have actual probability values been reported (e.g. 0.035 rather than <0.05) for 
the main outcomes except where the probability value is less than 0.001? 
 
Yes = 1 
No = 0 
External validity  
9 Were the subjects asked to participate in the study representative of the entire 
population from which they were recruited? The study must identify the source 
population for patients and describe how the patients were selected. Patients 
would be representative if they comprised the entire source population, an 
unselected sample of consecutive patients, or a random sample. Random 
sampling is only feasible where a list of all members of the relevant population 
exists. Where a study does not report the proportion of the source population 
from which the patients are derived, the question should be answered as 
unable to determine.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
10 Were those subjects who were prepared to participate representative of the 
entire population from which they were recruited? The proportion of those 
asked who agreed should be stated. Validation that the sample was 
representative would include demonstrating that the distribution of the main 
Yes = 1 
No = 0 
Unable to 
determine = 0 
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confounding factors was the same in the study sample and the source 
population. 
 
 
11 Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? For the 
question to be answered yes the study should demonstrate that the 
intervention was representative of that in use in the source population. The 
question should be answered no if, for example, the intervention was 
undertaken in a specialist centre unrepresentative of the hospitals most of the 
source population would attend.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
Internal validity – bias  
12 If any of the results of the study were based on “data dredging”, was this made 
clear? Any analyses that had not been planned at the outset of the study 
should be clearly indicated. If no retrospective unplanned subgroup analyses 
were reported, then answer yes.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
13 In trials and cohort studies, do the analyses adjust for different lengths of 
follow-up of patients, or in case-control studies, is the time period between the 
intervention and outcome the same for cases and controls? Where follow-up 
was the same for all study patients the answer should be yes. If different 
lengths of follow-up were adjusted for by, for example, survival analysis the 
answer should be yes. Studies where differences in follow-up are ignored 
should be answered no.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
14 Were the statistical tests used to assess the main outcomes appropriate? The 
statistical techniques used must be appropriate to the data. For example 
nonparametric methods should be used for small sample sizes. Where little 
statistical analysis has been undertaken but where there is no evidence of bias, 
the question should be answered yes. If the distribution of the data (normal or 
not) is not described it must be assumed that the estimates used were 
appropriate and the question should be answered yes.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
15 Was compliance with the intervention/s reliable? Where there was 
noncompliance with the allocated treatment or where there was contamination 
of one group, the question should be answered no. For studies where the effect 
of any misclassification was likely to bias any association to the null, the 
question should be answered yes.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
16 Were the main outcome measures used accurate (valid and reliable)? For 
studies where the outcome measures are clearly described, the question 
should be answered yes. For studies which refer to other work or that 
demonstrates the outcome measures are accurate, the question should be 
answered as yes. 
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
Internal validity – confounding (selection bias)  
17 Were the patients in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited from the same 
population? For example, patients for all comparison groups should be selected 
from the same hospital. The question should be answered unable to determine 
for cohort and case-control studies where there is no information concerning 
the source of patients included in the study. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
18 Were study subjects in different intervention groups (trials and cohort studies) 
or were the cases and controls (case-control studies) recruited over the same 
period of time? For a study which does not specify the time period over which 
patients were recruited, the question should be answered as unable to 
determine. 
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
19 Was there adequate adjustment for confounding in the analyses from which the Yes = 1 
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main findings were drawn? This question should be answered no for trials if: 
the main conclusions of the study were based on analyses of treatment rather 
than intention to treat; the distribution of known confounders in the different 
treatment groups was not described; or the distribution of known confounders 
differed between the treatment groups but was not taken into account in the 
analyses. In non-randomized studies if the effect of the main confounders was 
not investigated or confounding was demonstrated but no adjustment was 
made in the final analyses the question should be answered as no.  
 
No = 0 
Unable to 
determine = 0 
 
20 Were losses of patients to follow-up taken into account? If the numbers of 
patients lost to follow-up are not reported, the question should be answered as 
unable to determine. If the proportion lost to follow-up was too small to affect 
the main findings, the question should be answered yes.  
 
Yes = 1 
No = 0 
Unable to 
determine = 0 
 
Power  
21* Did the study have sufficient power to detect a clinically important effect where 
the probability value for a difference being due to chance is less than 5%? 
Sample sizes have been calculated to detect a difference of x% and y%.  
Yes = 1 
No = 0 
Unable to 
determine = 0 
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Table A-2. Case reports describing hyponatremia from psychotropic drugs 
Study/ 
Country 
Case details Relevant 
drugs 
studied 
Outcomes and notes 
Second-generation Antidepressant Drugs 
Patil et al. (2014)2 
 
United Kingdom 
84-year old female 
recently diagnosed with 
depression and admitted 
with confusion, gait 
disturbance, vomiting and 
lethargy 
Citalopram -1 week after starting citalopram, pt 
was hospitalized with a serum sodium 
of 110 mmol/L 
-After withdrawal of treatment for 6 
days, serum sodium rose to 131 
mmol/L 
Shubrata et al. 
(2012)3 
 
India 
64-year old male admitted 
with memory deficits, 
apathy, and impairment in 
daily activities. He was 
diagnosed with 
depressive pseudo 
dementia 
Sertraline -Baseline serum sodium was 138 
mmol/L 
-Seizure occurred after 4 days of 
starting treatment 
-Serum sodium dropped to 115 mmol/L 
-Sertaline was withdrawn and serum 
sodium rose to 134 mmol/L in 4 days 
Cerimele and 
Robinson (2011)4 
 
United States of 
America 
87-year old female with 
dementia and major 
depressive disorder was 
admitted with aggression, 
depressed mood, anxiety, 
insomnia, and suicidal 
ideation 
Sertraline -Baseline serum sodium at admission 
was 140 mmol/L 
-After 4 days of starting sertraline, 
serum sodium dropped to 126 mmol/L 
-Treatment was withdrawn and serum 
sodium rose to 135 mmol/L in 6 days 
Famularo et al. 
(2009)5 
 
Italy 
76-year old female with 
depression was admitted 
with lethargy and 
confusion 
Mirtazapine -Long term therapy with 
hydrochlorothiazide (diuretic) 
-After 2 months of starting mirtazapine 
therapy, serum sodium dropped to 114 
mmol/L 
-2 days of mirtazapine and 
hydrochlorothiazide withdrawal, serum 
sodium returned to 146 mmol/L 
-Diuretic drug use is also known to 
cause HN 
Gabriel et al. 
(2009)6 
 
Canada 
49-year old male admitted 
with severely depressed 
mood 
 
Fluvoxamine -Started fluvoxamine treatment at 
admission 
-After 10 days, pt developed 
headaches, a grand mal seizure, and 
became lethargic 
-Serum sodium was 114 mmol/L 
-Serum sodium returned to 139-141 
mmol/L after 4 days of fluvoxamine 
withdrawal 
Mussig et al. 
(2009)7 
 
Germany 
85-year old female with 
major depression was 
hospitalized with unstable 
gait and a decrease in 
vigilance 
Duloxetine -After 6 days use, serum sodium 
was107 mmol/l 
-Duloxetine discontinued and serum 
sodium normalized within 10 days 
Atalay et al. (2007)8 
 
Turkey 
76-year old male with 
depression and agitation 
was admitted after 
placement of a partial hip 
prosthesis following 
fracture 
Escitalopram 
(anti-
depressant) 
and 
Quetiapine 
(anti-
psychotic) 
-Admission baseline serum sodium 
level was 134 mmol/ 
-After 3 days of dual drugs treatment, 
serum sodium was 124-128 mmol/L 
-Escitalopram discontinued and serum 
sodium rose to 130 mmol/L 
-Quetiapine therapy was maintained 
for a few days but serum sodium was 
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still below normal values 
-Quetiapine discontinued, serum 
sodium normalized to 138 mmol/L   
-Quetiapine can also cause HN 
Covyeou and 
Jackson (2007)9 
 
United States of 
America 
75-year old female with 
depression was admitted 
with confusion 
Escitalopram -Long term therapy with amlodipine, 
hydro-chlorothiazide, alprazolam and 
esomeprazole 
-After 5 days of starting escitalopram 
treatment, serum sodium fell from 136 
mmol/L to 116 mmol/L 
-Escitalopram was discontinued and 
serum sodium rose to 139 mmol/L in 5 
days 
-Pt received medications known to 
cause HN 
Kruger (2007)10 
 
Germany 
All pts had recurrent 
major depressive 
episodes and were in 
treatment of a severe 
acute episode: 
 
i) 35-year old female, 
baseline serum sodium of 
146 mmol/L 
ii) 70-year old female, 
baseline serum sodium of 
140 mmol/L 
iii) 45-year old female, 
baseline serum sodium of 
150 mmol/L 
iv) 67-year old male, 
baseline serum sodium of 
148 mmol/L 
v) 56-year old male, 
baseline serum sodium of 
142 mmol/L 
Duloxetine -After 4-6 weeks of initiating 
duloxetine, pts complained of physical 
symptoms, including fatigue, lethargy, 
and headache 
-Serum sodium at admission: 
 
i) 122 mmol/L 
ii) 120 mmol/L 
iii) 118 mmol/L 
iv) 121 mmol/L 
v) 118mmol/L 
 
-All symptoms of HN and abnormal 
serum sodium resolved within 2 weeks 
of duloxetine withdrawal 
 
Bavbek et al. 
(2006)11  
 
Turkey 
67-year old female with 
depression was admitted 
with abdominal pain, 
nausea, vomiting, 
decreased food intake, 
and agitation 
Citalopram 
Mirtazapine 
-Pt started citalopram treatment 2 
months prior admission 
-Serum sodium was 110 mmol/L at 
admission 
-Citalopram was stopped and HN 
resolved 
-Pt then started mirtazapine therapy 
and was discharged 
-Serum sodium was normal after 3 
weeks of new treatment 
-Pt was admitted again after 5 months 
with nausea and vomiting 
-Serum sodium was 115 mmol/L 
-Mirtazapine was withdrawn and HN 
resolved 
Serum sodium normalized at 2 and 4 
weeks after discharge 
Cury et al. (2006)12 
 
Brazil 
77-year old male with 
depression was admitted 
to hospital with lack of 
appetite, somnolence and 
fever 
Sertraline -Sertraline therapy was started 6 
months before 
-Baseline serum sodium at admission 
was 146 mmol/L 
-20 days after increased sertraline 
dosage, serum sodium dropped to 125 
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mmol/L 
-After 21 days of sertraline withdrawal, 
serum sodium normalized to 138 
mmol/L 
Wakita et al. 
(2005)13 
 
Japan 
79-year old female with 
depression was admitted 
with confusion and fatigue 
Paroxetine -Long-term use of paroxetine 
-Stopped for 3 months 
-Resumed paroxetine again 3 days 
prior to admission 
-Serum sodium at admission was 112 
mmol/L 
-Serum sodium normalized after 5 
days of paroxetine withdrawal 
Flores et al. 
(2004)14 
 
Mexico 
61-year old male with 
malaise, confusion and 
seizure 
Citalopram -Admitted with serum sodium of 124 
mmol/L after 2 weeks of starting 
citalopram 
-5 days after citalopram withdrawal, 
serum sodium rose to 134 mmol/L 
Nahshoni et al. 
(2004)15 
 
Israel 
62-year old female with 
major depressive 
episodes was admitted 
after a syncope and fall 
with minor head injury 
Escitalopram  
 
-3 weeks prior admission, pt started 
escitalopram therapy 
-Serum sodium was 110 mmol/L 
-After 1 week of withdrawal, serum 
sodium normalized to 135 mmol/L 
Roxanas (2003)16 
 
Australia 
86-year old female with 
depression had a 
previous episode of HN 
while taking venlafaxine 
Mirtazapine -Baseline serum sodium was 135 
mmol/L 
-After 4 days of staring mirtazapine, 
serum sodium dropped to 130 mmol/L 
-After 10 days of mirtazapine 
withdrawal, serum sodium rose to 134 
mmol/L 
-Previous history of HN while taking 
another anti-depressant 
-Pt was taking hydrochlorothiazide 
(diuretic) as well, which could have 
contributed to HN 
Schouten and 
Sepers (2001)17 
 
The Netherlands 
78-year old female with 
depression was admitted 
due to a collapse from 
severe aortic stenosis, 
complicated by a head 
injury 
Paroxetine -Baseline serum sodium at admission 
was 134 mmol/L 
-18 days after paroxetine initiation, 
serum sodium dropped to 109 mmol/L 
-Serum sodium normalized after 12 
days of paroxetine withdrawal  
Odeh et al. (1999)18 
 
Israel 
97-year old male with 
depression was admitted 
with a 5-day history of 
progressive weakness, 
confusion, lethargy, and 
stupor 
Paroxetine -4 days prior to symptoms, pt started 
paroxetine 
-At admission, serum sodium was 104 
mmol/L 
-Serum sodium normalized after 5 
days of paroxetine withdrawal 
Burke and Fanker 
(1996)19 
 
Australia 
 
74-year old male with 
recurrent major 
depression was admitted 
with social withdrawal, 
amotivation, anhedonia, 
depressed mood, 
neglected self-care and 
suicidal ideation 
Fluoxetine -Fluoxetine was started at admission 
(normal serum sodium) 
-21 days later, pt fell with minor head 
injury 
-Serum sodium was 126 mmol/L  
-20 days of fluoxetine withdrawal, 
serum sodium rose to 138 mmol/L  
Druckenbrod and 
Mulsant (1994)20 
 
United States of 
America 
83-year old female with 
major depression was 
admitted with a history of 
recurrent depression 
Fluoxetine -Long term use of fluoxetine (on/off) 
-1 month of increased dose of 
fluoxetine prior to admission 
-Serum sodium was 109 mmol/L at 
admission 
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-Serum sodium normalized 5 weeks 
after fluoxetine withdrawal 
Blacksten and Birt 
(1993)21 
 
United States of 
America 
92-year old female with 
depression was admitted 
with weakness 
Fluoxetine -13 days after starting fluoxetine, pt 
developed HN 
-8 days after discontinuing fluoxetine, 
HN resolved 
 
Atypical Antipsychotic Drugs 
Koufakis (2016)22 
 
Greece 
65-year old female with 
schizophrenia was 
admitted with seizure 
Quetiapine -Pt started quetiapine 3 months prior to 
admission 
-Admitted with serum sodium of 108 
mmol/L 
-After 6 days of quetiapine withdrawal, 
serum sodium normalized to 135 
mmol/L  
Trevizol et al. 
(2016)23 
 
Brazil 
20-year old male with 
polydipsia and 
schizophrenia was 
admitted with nausea, 
vomiting, confusion and 
disorientation 
Quetiapine -Pt started 1 week treatment of 
quetiapine 
-Hospitalized with serum sodium of 
105 mmol/L 
-Normalization of serum sodium after 3 
days of quetiapine withdrawal 
-Polydipsia can also cause HN 
Bakhla et al. 
(2014)24 
 
India 
63-year old male 
diagnosed with recurrent 
depressive disorder and 
current episode of severe 
depression with psychotic 
symptoms 
 
Olanzapine -Long term use of escitalopram 
(antidepressant) which can also cause 
HN 
-Pt started olanzapine treatment 1 
month prior to admission 
-Hospitalized with disorientation and 
serum sodium of 118 mmol/L  
-After 2 days of olanzapine withdrawal, 
serum sodium rose to 138 mmol/L 
Ranga et al. 
(2014)25 
 
India 
22-year female with 
paranoid schizophrenia 
was admitted with seizure 
Risperidone -After 5 days of starting risperidone 
therapy, pt was admitted to hospital 
with serum sodium of 118 mmol/L 
-Treatment was discontinued at 
admission and 3 days later, serum 
sodium rose to 134 mmol/L 
Dudeja et. al 
(2010)26 
 
United Kingdom 
48-year old female with 
mixed bipolar affective 
disorder, schizoid 
personality disorder, and 
hypocholesterolemia was 
admitted in a postictal 
confusional state 
following a seizure 
Olanzapine -Olanzapine therapy for the past 2 
years  
-Admitted to hospital with serum 
sodium of 114 mmol/L 
-Discontinuation of olanzapine 
normalized serum sodium 
Chogtu et al. 
(2009)27 
 
India 
34-year old male 
diagnosed of chronic 
schizophrenia 
was admitted with 
confusion and agitation 
Risperidone -Long term therapy of chlorpromazine 
(antipsychotic)  
-After 10 days of starting risperidone, 
pt had a seizure and a serum sodium 
of 111 mmol/L 
-Discontinuation of risperidone for 3 
days and serum sodium returned to 
135 mmol/L 
Kahn et al. (2009)28 
 
United States of 
America 
56-year old male with 
mood disorder and 
delirium was hospitalized 
with a hip fracture 
Risperidone -Pt started chemotherapy with 
cyclophosphamide, which can cause 
HN 
-After 6 days, pt was diagnosed with 
acute post-renal failure 
-Serum sodium dropped to 129 mmol/L 
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-Medications were tapered off and 
risperidone therapy began 
-Baseline serum sodium was 135 
mmol/L 
-After 2 days of risperidone therapy, 
serum sodium dropped to 128 mmol/L 
-Discontinued risperidone, serum 
sodium normalized after several days 
Patel et al. (2009)29 
 
United States of 
America 
64-year old female was 
discharged 3 days prior to 
re-admission after 
suffering from a fall with a 
facial bone fracture and 
scalp hematoma. She 
was re-admitted with 
seizure followed by 
altered mental status 
Quetiapine -History of paroxetine and clonazepam 
use, which was discontinued when pt 
was initially discharged (serum sodium 
at 135 mmol/L) 
-At discharge, quetiapine was 
prescribed 
-After single dose of quetiapine, pt was 
hospitalized with a serum sodium of 
112 mmol/L  
-Withdrawal of quetiapine for 2 days, 
serum sodium rose to 131 mmol/L 
-Previous antidepressant and 
antiepileptic drug use could also cause 
HN 
Atalay et al. (2007)8 
 
Turkey 
76-year old male with 
depression and agitation 
was admitted after 
placement of a partial hip 
prosthesis following 
fracture 
Quetiapine 
(anti-
psychotic) 
and 
Escitalopram 
(anti-
depressant) 
-Admission baseline serum sodium 
level was 134 mmol/ 
-After 3 days of treatment, serum 
sodium was 124-128 mmol/L 
-Escitalopram discontinued and serum 
sodium rose to 130 mmol/L 
-Quetiapine therapy was maintained 
for a few days but serum sodium was 
still below normal values 
-Quetiapine discontinued, serum 
sodium normalized to 138 mmol/L 
-Escitalopram can also cause HN 
Vucicevic et al. 
(2007)30 
 
Croatia 
44-year old male on 
several psychotropic 
drugs was admitted 
unconscious 
Olanzapine 
 
-Long term therapy of paroxetine, 
fluphenazine, haloperidol and 
olanzapine 
-Presented to hospital with serum 
sodium of 104 mmol/L 
-2 hours post admission, pt expired 
from cerebral edema 
-Long term use of several drugs known 
to cause HN 
Collins and 
Anderson (2000)31 
 
United Kingdom 
76-year old female who 
had been untreated for 
schizophrenia for 23 
years was admitted after 
head injury (occipital 
fracture) 
Risperidone -Baseline serum sodium of 134 mmol/L 
at admission 
-After 2 weeks of starting risperidone 
thepary, serum sodium dropped to 116 
mmol/L 
-Serum sodium returned back to 
baseline after 21 days of risperidone 
withdrawal 
Antiepileptic Drugs 
Gupta et al. 
(2015)32 
 
United States of 
America 
54-year old female with 
bipolar disorder had 
intentionally overdosed 
on valproic acid and 
presented to hospital with 
drowsiness, disorientation 
and nausea 
Valproic acid -Serum sodium was 99 mmol/L at 
admission 
-Long term therapy of paroxetine, 
clonazepam and valproic acid 
-After 6 days of valproic acid 
withdrawal, serum sodium rose to 135 
mmol/L 
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- Long term use of drugs known to 
cause HN 
Patel et al. (2010)33 
 
United States of 
America 
54-year old male with 
schizophrenia was 
admitted for agitation, 
threatening behavior, and 
medication refusal 
Valproic acid -At admission, baseline serum sodium 
was 139 mmol/L and pt started 
risperidone therapy 
-During the course of treatment, 
valproic acid was introduced at high 
dose for 2 weeks 
-Serum sodium dropped to 126 mmol/L 
-After 7 days later of tapering dose of 
valproic acid, serum sodium rose to 
132 mmol/L 
-After a few weeks of stopping valproic 
acid, serum sodium normalized to 137 
mmol/L 
-Risperidone is known to cause HN as 
well, but its dose was not changed 
throughout hospitalization 
-Pt had another incident shortly after 
where valproic acid was taken and 
serum sodium dropped to 127 mmol 
-Upon stopping valproic acid, serum 
sodium returned to 140 mmol 
Van der Lubbe et 
al. (2009)34 
 
The Netherlands 
53-year old female with 
trigeminal neuralgia was 
referred to clinic due to 
recurrent nausea and low 
serum sodium values 
Carbamaze-
pine 
-Long term carbamazepine use 
-Serum sodium range 124-135 mmol/L 
-Hospitalized with nausea and serum 
sodium of 128 mmol/L 
Krysiak and 
Okopien35 (2007) 
 
Poland 
59-year old male with 
hypertension was 
admitted with cerebral 
edema and seizures 
Carbamaze-
pine 
-After 6 days from initiating 
hydrochlorotiazide (diuretic)and 
carbamazepine therapy, pt 
experienced weakness, mild anorexia 
and vomiting 
-Serum sodium was 126 mmol/L 
-Hydrochlorotiazide was discontinued, 
but carbamazepine therapy continued 
for a few days 
-Serum sodium fell to 112 mmol/L 
-Serum sodium normalized after 
withdrawal of carbamazepine 
-Diuretic use could have contributed to 
HN 
Salawu and 
Danburam36 (2007) 
 
Nigeria 
29-year old female 
presented with seizures 
Carbamaze-
pine 
-Baseline serum sodium at 135 mmol/L 
-After starting carbamazepine for 7 
days, serum sodium fell to 121 mmol/L 
-Serum sodium normalized after 2 
weeks of carbamazepine withdrawal 
Kuz and 
Manssourrian 
(2005)37 
 
United States of 
America 
44-year old female with 
bipolar disorder, post-
traumatic stress disorder 
and schizo- affective 
disorder was admitted 
after experiencing 2 new 
seizures 
Carbamaze-
pine 
-Long term use of carbamazepine, 
paroxetine, risperidone and buspirone 
-Pt overdosed on carbamazepine and 
was admitted with a serum sodium of 
122 mmol/L 
-Carbamazepine was withdrawn and 
serum sodium rose to 136 mmol/L 
-Long term use of drugs known to 
cause HN 
Velissaris et al. 
(2003)38 
 
67-year old male with 
trigeminal neuralgia was 
admitted electively for 
Carbamaze-
pine 
-Long-term carbamazepine use 
-Mild HN at admission, serum sodium 
at 132 mmol/L 
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Abbreviations: ADH=antidiuretic hormone; SIADH=syndrome of inappropriate antidiuretic hormone 
secretion; pts=patients; HN=hyponatremia 
 
 
 
 
 
 
 
 
 
 
 
United Kingdom coronary artery bypass 
grafting  
-2 days after cardio-pulmonary bypass, 
serum sodium was 128 mmol/L 
-Diuretics were discontinued, but 
carbamazepine therapy continued 
-6 days post-surgery, serum sodium 
fell to drop to 125 mmol/L 
-Carbamazepine was gradually 
decreased and stopped, serum sodium 
returned to 132 mmol/L 
-Previous HN and use of diuretics 
could have contributed to HN 
Matsumura et al. 
(2001)39 
 
Japan 
40-year old male with 
cerebral palsy, mental 
retardation and absence 
epilepsy was admitted 
with grand mal seizures  
Carbamaze-
pine 
-Pt was treated with carbamazepine, 
haloperidol, biperiden, phenytoin, 
clonazepam and levome-promazine 
-Prior to admission, pt drank excessive 
water  
-Presented with serum sodium of 98 
mmol/L 
-2 months earlier, serum sodium was 
135 mmol/L 
-Use of several drugs known to cause 
HN 
-Previous HN and excessive water 
intake could also have contributed to 
HN 
Miyaoka et al. 
(2001)40 
 
Japan 
62-year old male with 
epilepsy was admitted 
with amnesia and 
disorientation after 
seizure 
Valproic acid -Long-term valproic acid use 
-History of previous HN and seizures 
(serum sodium range 117-120 mmol/L) 
-Serum sodium at 127 mmol/L upon 
hospital admission 
-Valproic acid was replaced with 
another anti-epileptic, zonisamide, and 
HN was resolved  
-Previous HN could have contributed to 
HN 
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Table A-3. Hyponatremia warnings and recommendations from drug prescribing 
references 
Drug Compendium of Pharmaceuticals and 
Specialties® 
UptoDate® 
Second-generation Antidepressant Drugs 
Citalopram Hyponatremia and SIADH have been 
reported as a rare adverse event with use 
of citalopram. The majority of these 
occurrences have been in elderly 
individuals, some in patients taking 
diuretics or who were otherwise volume-
depleted. Elderly female patients in 
particular seem to be a group at risk. 
Geriatrics (≥65 years of age) - A longer 
half-life and decreased clearance have 
been demonstrated in the elderly, 
therefore lower doses and a lower 
maximum dose should be considered. As 
with other SSRIs, caution should be 
exercised in treating elderly female 
patients who may be more susceptible to 
adverse events such as hyponatremia and 
SIADH. 
Geriatric Patients: High-Risk Medication - 
SSRIs are identified in the Beers Criteria 
as potentially inappropriate medications 
to be used with caution in patients 65 
years and older because of the potential 
to cause or exacerbate SIADH or 
hyponatremia; monitor sodium 
concentration closely when initiating or 
adjusting the dose in older adults (Beers 
Criteria). 
Adverse Reaction Significant: <1% 
(Limited to important or life threatening) – 
Hyponatremia  
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L), predominately in the elderly; 
reversible with discontinuation of 
treatment. Volume depletion and/or 
concurrent use of diuretics likely 
increases risk. 
Escitalopram As with other antidepressants, cases of 
hyponatremia and SIADH have been 
reported with escitalopram as a rare 
adverse event. The majority of these 
occurrences have been in elderly 
individuals, some in patients taking 
diuretics or who were otherwise volume-
depleted. Elderly female patients in 
particular seem to be a group at risk. 
Caution should be exercised in patients at 
risk, such as the elderly, or patients with 
cirrhosis, or if used in combination with 
other medications which may cause 
hyponatremia. 
Metabolism and Nutrition Disorder - Rare: 
hyponatremia. 
Elderly: Use caution in elderly patients; 
may be potentially inappropriate in 
patients with a history of falls or fractures, 
and may cause or exacerbate SIADH or 
hyponatremia; monitor sodium closely 
with initiation or dosage adjustments in 
older adults (Beers Criteria). 
Bioavailability and half-life are increased 
by 50% in the elderly. 
Paroxetine Several cases of hyponatremia have been 
reported. The hyponatremia appeared to 
be reversible when paroxetine was 
discontinued. The majority of these 
occurrences have been in elderly 
individuals, some in patients taking 
diuretics or who were otherwise volume 
Adverse Reaction Significant: <1% 
(Limited to important or life threatening) – 
Hyponatremia 
Precautions - Elderly: Use caution in 
elderly patients; may be potentially 
inappropriate in patients with a history of 
falls or fractures, and may cause or 
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depleted. 
Metabolic and Nutritional Disorder - 
Infrequent: hyponatremia (predominantly in 
the elderly), which is sometimes due to 
SIADH. 
exacerbate SIADH or hyponatremia; 
monitor sodium closely with initiation or 
dosage adjustments in older adults. 
Medication associated with potent 
anticholinergic properties which may be 
inappropriate in older adults depending 
on comorbidities (e.g., dementia, delirium) 
(Beers Criteria). 
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L), predominately in the elderly. 
Volume depletion and/or concurrent use 
of diuretics likely increases risk. 
Fluoxetine Several cases of hyponatremia (some with 
serum sodium lower than 110 mmol/L) 
have been reported. The hyponatremia 
appeared to be reversible when fluoxetine 
was discontinued. Although these cases 
were complex with varying possible 
etiologies, some were possibly due to the 
SIADH. The majority of these occurrences 
have been in older patients and in patients 
taking diuretics or who were otherwise 
volume depleted. 
In two 6-week controlled studies, in-
patients ≥60 years of age, 10 of 323 
fluoxetine patients and 6 of 327 placebo 
recipients had a lowering of serum sodium 
below the reference range; this difference 
was not statistically significant. The lowest 
observed concentration of sodium in a 
fluoxetine treated patient was 129 mmol/L. 
The observed decreases were not 
clinically significant. 
Adverse Reaction Significant: <1% 
(Limited to important or life threatening) – 
Hyponatremia 
Precautions - Elderly: Use caution in 
elderly patients; may be potentially 
inappropriate in patients with a history of 
falls or fractures, and may cause or 
exacerbate syndrome of inappropriate 
antidiuretic hormone secretion or 
hyponatremia (SIADH); monitor sodium 
closely with initiation or dosage 
adjustments in older adults (Beers 
Criteria). 
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L), predominately in the elderly. 
Volume depletion and/or concurrent use 
of diuretics likely increases risk. Consider 
discontinuation if symptomatic 
hyponatremia occurs. 
Fluvoxamine As with other SSRIs, hyponatremia has 
been rarely reported and appeared to be 
reversible when fluvoxamine was 
discontinued. Some cases were possibly 
due to the SIADH. The majority of reports 
were associated with older patients. 
Elderly patients, patient taking diuretics, 
and patients who are otherwise volume 
depleted may be at greater risk for this 
event. Discontinuation of fluvoxamine 
should be considered in patients with 
symptomatic hyponatremia and 
appropriate medical intervention should be 
instituted. Symptoms may include 
Adverse Reaction Significant: <1% 
(Limited to important or life threatening) – 
Hyponatremia 
Precautions - Elderly: Use caution in 
elderly patients; may be potentially 
inappropriate in patients with a history of 
falls or fractures, and may cause or 
exacerbate SIADH or hyponatremia; 
monitor sodium closely with initiation or 
dosage adjustments in older adults 
(Beers Criteria). Bioavailability and half-
life are increased by 50% in the elderly.  
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headache, difficulty concentrating, memory 
impairment, confusion, weakness, and 
unsteadiness, which may lead to falls. 
Post-Market Adverse Drug Reactions - 
Rarely, hyponatremia and SIADH have 
been reported 
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L), predominately in the elderly. 
Hyponatremia is reversible with 
discontinuation of treatment. Volume 
depletion and/or concurrent use of 
diuretics likely increases risk. 
Duloxetine Hyponatremia may occur as a result of 
treatment with SSRIs and SNRIs, including 
duloxetine. In many cases, this 
hyponatremia appears to be the result of 
the SIADH. Cases with serum sodium 
lower than 110 mmol/L have been reported 
and appeared to be reversible when 
duloxetine was discontinued. Elderly 
patients may be at greater risk of 
developing hyponatremia with SSRIs and 
SNRIs. Also, patients taking diuretics or 
who are otherwise volume depleted may 
be at greater risk. Discontinuation of 
duloxetine should be considered in 
patients with symptomatic hyponatremia 
and appropriate medical intervention 
should be instituted. Signs and symptoms 
of hyponatremia include headache, 
difficulty concentrating, memory 
impairment, confusion, weakness, and 
unsteadiness, which may lead to falls. 
More severe and/or acute cases have 
been associated with hallucination, 
syncope, seizure, coma, respiratory arrest, 
and death. 
Geriatric Patients: High-Risk Medication - 
SNRIs are identified in the Beers Criteria 
as potentially inappropriate medications 
to be used with caution in patients 65 
years and older due to its potential to 
cause or exacerbate SIADH or 
hyponatremia; monitor sodium 
concentration closely when initiating or 
adjusting the dose in older adults (Beers 
Criteria). 
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L), predominately in the elderly. 
Volume depletion and/or concurrent use 
of diuretics likely increases risk. 
Sertraline Hyponatremia may occur as a result of 
treatment with SSRIs or SNRIs including 
sertraline. In many cases, hyponatremia 
appears to be the result of a SIADH. 
Cases of serum sodium levels lower than 
110 mmol/L have been reported. Elderly 
patients may be at greater risk of 
developing hyponatremia with SSRIs and 
SNRIs. Also patients taking diuretics or 
who are otherwise volume-depleted may 
be at greater risk. Several cases of 
hyponatremia have been reported and 
appeared to be reversible when sertraline 
was discontinued. Discontinuation of 
sertraline should be considered in patients 
with symptomatic hyponatremia and 
appropriate medical intervention should be 
instituted. 
Signs and symptoms of hyponatremia 
include headache, difficulty concentrating, 
memory impairment, confusion, weakness 
and unsteadiness which may lead to falls. 
Adverse Reaction Significant: <1% 
(Limited to important or life threatening) – 
Hyponatremia 
Precautions - Elderly: Use caution in 
elderly patients; may be potentially 
inappropriate in patients with a history of 
falls or fractures, and may cause or 
exacerbate syndrome of inappropriate 
antidiuretic hormone secretion or 
hyponatremia; monitor sodium closely 
with initiation or dosage adjustments in 
older adults (Beers Criteria). 
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L), predominately in the elderly. 
Volume depletion and/or concurrent use 
of diuretics likely increases risk. 
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Signs and symptoms associated with more 
severe and/or acute cases have included 
hallucination, syncope, seizure, coma, 
respiratory arrest, and death. 
Venlafaxine Cases of hyponatremia may occur with 
venlafaxine, usually in volume-depleted or 
dehydrated patients. Elderly patients, 
patients taking diuretics, and patients who 
are otherwise volume depleted, may be at 
greater risk for this event. 
The hyponatremia appeared to be 
reversible when venlafaxine was 
discontinued. 
Metabolic and Nutritional Disorder - 
Infrequent: hyponatremia. 
Adverse Reaction Significant: <1% 
(Limited to important or life threatening) – 
Hyponatremia 
Precautions - Elderly: Use caution in 
elderly patients; may cause or exacerbate 
SIADH or hyponatremia; monitor sodium 
closely with initiation or dosage 
adjustments in older adults (Beers 
Criteria). 
Concerns relating to adverse reactions - 
SIADH and hyponatremia: SSRIs and 
SNRIs have been associated with the 
development of SIADH; hyponatremia 
has been reported rarely (including 
severe cases with serum sodium <110 
mmol/L). Age (the elderly), volume 
depletion, and/or concurrent use of 
diuretics likely increases risk. Discontinue 
treatment in patients with symptomatic 
hyponatremia. 
Monitoring Parameters: Blood pressure 
should be regularly monitored, especially 
in patients with a high baseline blood 
pressure; may cause mean increase in 
hyponatremia. 
Mirtazapine Hyponatremia has been reported very 
rarely with the use of mirtazapine. Caution 
should be exercised in patients at risk, 
such as elderly patients or patients 
concomitantly treated with medications 
known to cause hyponatremia. 
Metabolism and Nutrition Disorders - 
hyponatremia. 
Precautions - Elderly: Use caution in 
elderly patients; may cause or exacerbate 
SIADH; monitor sodium closely with 
initiation or dosage adjustments in older 
adults (Beers Criteria). 
Concerns relating to adverse reactions - 
May cause hyponatremia. Use caution in 
patients at risk, such as elderly or patients 
concomitantly treated with medications 
known to cause hyponatremia. 
Atypical Antipsychotic Drugs 
Risperidone Hyponatremia is a less common clinical 
trial adverse drug reaction (≤1%) and is 
considered an infrequent metabolic and 
nutritional disorder with risperidone use. In 
cases of overdose, hyponatremia was 
reported. 
<1% (Limited to important or life-
threatening): Hyponatremia. 
 
Elderly: use may cause or exacerbate 
SIADH secretion or hyponatremia; 
monitor sodium closely with initiation or 
dosage adjustments in older adults 
(Beers Criteria). 
Olanzapine Not listed Elderly: use may cause or exacerbate 
SIADH secretion or hyponatremia; 
monitor sodium closely with initiation or 
dosage adjustments in older adults. May 
also be inappropriate in older adults 
depending on comorbidities (e.g., 
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dementia, delirium) due to its potent 
anticholinergic effects (Beers Criteria). 
Quetiapine 
 
Not listed Elderly: use may cause or exacerbate 
SIADH secretion or hyponatremia; 
monitor sodium closely with initiation or 
dosage adjustments in older adults 
(Beers Criteria). Dose escalation should 
be performed with caution in elderly 
patients; consider slower rates of dose 
titration and lower target doses. 
Antiepileptic Drugs 
Carbamazepine In patients with pre-existing renal 
conditions associated with low sodium or 
in patients treated concomitantly with 
sodium-lowering medicinal products (e.g. 
diuretics, medicinal products associated 
with inappropriate ADH secretion), serum 
sodium levels should be measured prior to 
initiating carbamazepine therapy. 
Thereafter, serum sodium levels should be 
measured after approximately two weeks 
and then at monthly intervals for the first 
three months during therapy, or according 
to clinical need. These risk factors may 
apply especially to the elderly and renally-
compromised patients 
Carbamazepine is identified as a 
potentially inappropriate medication to be 
used with caution in patients 65 years and 
older due to the potential to cause or 
exacerbate SIADH secretion or 
hyponatremia; monitor sodium 
concentration closely when initiating or 
adjusting the dose in older adults (Beers 
Criteria). 
 
 
Valproic Acid Not listed Not listed 
Phenytoin Not listed Not listed 
Topiramate Not listed Not listed 
Abbreviations: SIADH=syndrome of inappropriate antidiuretic hormone secretion; SSRI=Selective 
Serotonin Reuptake Inhibitor; SNRI=Serotonin–norepinephrine reuptake inhibitors 
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Appendix B 
Table B-1. STROBE Checklist 
 Item 
No 
Recommendation Reported 
Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
Title, Abstract 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found 
Abstract 
Introduction 
  Background/rationale 2 Explain the scientific background and 
rationale for the investigation being reported 
Introduction 
  Objectives 3 State specific objectives, including any pre-
specified hypotheses 
Introduction 
Methods 
  Study design 4 Present key elements of study design early in 
the paper 
Methods 
  Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Methods 
  Participants 6 (a) Give the eligibility criteria, and the sources 
and methods of selection of participants. 
Describe methods of follow-up 
Methods, 
Appendix 
Figure 1 
(b) For matched studies, give matching 
criteria and number of exposed and 
unexposed 
Methods, 
Table 1, 
Appendix 
Table 3 
  Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if 
applicable 
Methods, 
Appendix 
Table 2 
  Data sources/measurement 8 For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than 
one group 
Methods, 
Appendix 
Tables 2 
  Bias 9 Describe any efforts to address potential 
sources of bias 
Discussion 
  Study size 10 Explain how the study size was arrived at Methods; 
based on 
availability of 
the data 
  Quantitative variables 11 Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen and 
why 
Methods 
  Statistical methods 12 (a) Describe all statistical methods, including 
those used to control for confounding 
Methods 
(b) Describe any methods used to examine 
subgroups and interactions 
Methods 
(c) Explain how missing data were addressed Methods 
(d) If applicable, explain how loss to follow-up 
was addressed 
Not 
applicable 
(e) Describe any sensitivity analyses Methods 
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Results 
  Participants 13 (a) Report numbers of individuals at each 
stage of study—e.g. numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analyzed 
Methods, 
Results, 
Appendix 
Figure 1 
(b) Give reasons for non-participation at each 
stage 
Methods, 
Appendix 
Figure 1 
  (c) Consider use of a flow diagram Appendix 
Figure 1 
  Descriptive data 14 (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders 
Table 1, 
Appendix 
Tables 4, 5, 
6, 
(b) Indicate number of participants with 
missing data for each variable of interest 
Methods 
(c) Summarize follow-up time (e.g. average 
and total amount) 
Results, 
Table 2, 3 
  Outcome data 15 Report numbers of outcome events or 
summary measures over time 
Results, 
Table 2, 3, 
Figure 1 
  Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% confidence 
interval). Make clear which confounders were 
adjusted for and why they were included 
Results, 
Table 2, 3 
Figure 1 
(b) Report category boundaries when 
continuous variables were categorized 
Methods 
(c) If relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
Results, 
Table 2, 3 
  Other analyses 17 Report other analyses done—e.g. analyses of 
subgroups and interactions, and sensitivity 
analyses 
Results, 
Figure 1, 
Appendix 
Figure 2, 
Appendix 
Tables 7, 8 
Discussion 
  Key results 18 Summarize key results with reference to 
study objectives 
Discussion 
  Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion 
  Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar 
studies, and other relevant evidence 
Discussion 
  Generalizability 21 Discuss the generalizability (external validity) 
of the study results 
Discussion 
Other information 
  Funding 22 Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which the 
present article is based 
Acknowledge-
ments 
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Table B-2. Coding definitions for exposure, outcomes, and comorbid conditions 
Variable Database Code/Definition 
Comorbidities 
Mood Disorders CIHI-DAD ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968, 3004, 311, 
2962, 2963, 2969 
ICD-10 F30, F31, F340, F32, F33, F341, F381, F348, F349, 
F380, F388, F39 
OMHRS DSM-IV 29600, 29601, 29602, 29603, 29604, 29605, 29606, 
29640, 29641, 29642, 29643, 29644, 29645, 29646, 29650, 
29651, 29652, 29653, 29654, 29655, 29656, 29660, 29661, 
29662, 29663, 29664, 29665, 29666, 29670, 29680, 29689, 
30113, 29383, 29690, 29620, 29621, 29622, 29623, 29624, 
29625, 29626, 29630, 29631, 29632, 29633, 29634, 29635, 
29636, 30040, 31100 
OHIP 296, 311, Q020 
Anxiety disorder CIHI-DAD ICD-9 3000, 3002, 3003, 3098, 3083 
ICD-10 F40, F41, F42, F430, F431, F438, F439 
OMHRS DSM-IV 30001, 30021, 30022, 30029, 30023, 30030, 30981, 
30830, 30002, 29384, 30000 
OHIP 300 
Congestive heart failure CIHI-DAD ICD-9 425, 5184, 514, 428 
ICD-10 I500, I501, I509, I255, J81 
CCP 4961, 4962, 4963, 4964 
CCI 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR 
OHIP 428, R701, R702, Z429 
Chronic kidney disease CIHI-DAD ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 582, 583, 580, 
581, 584, 585, 586, 587, 5880, 5888, 5889, 5937 
ICD-10 E102, E112, E132, E142, I12, I13, N08, N18, N19 
OHIP 403, 585 
Hypertension CIHI-DAD ICD-9 401, 402, 403, 404, 405 
ICD10 I10, I11, I12, I13, I15 
OHIP 401, 402, 403, 
Chronic liver disease CIHI-DAD ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 7824, 
V026, 2750, 2751, 7891, 7895, 571 
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162, 
B942, Z225, E831, E830, K70, K713, K714, K715, K717, 
K721, K729, K73, K74, K753, K754, K758, K759, K76, K77 
OHIP 571, 573, 070, Z551, Z554 
Hypothyroidism  CIHI-DAD ICD-9 243, 2440, 2441, 2442, 2443, 2448, 2449 
ICD-10 E030, E031, E032, E033, E034, E035, E038, E039, 
E890 
OHIP 243, 244 
Cancer CIHI-DAD ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 205, 
206, 207, 208 
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 
991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56, 
C61, C82, C83, C85, C91, C92, C93, C94, C95, C00, D05 
OHIP 203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 174, 
175, 183, 185 
Diabetes Mellitus CIHI-DAD ICD-9 250 
ICD-10 E10, E11, E13, E14 
OHIP 250, K029, K030, Q040 
Pneumonia  CIHI-DAD ICD-9 480, 481, 482, 483, 484, 485, 486, 7700 
ICD-10 J12, J13, J14, J15, J16, J17, J18, P23 
Coronary artery disease CIHI-DAD ICD-9 410 412, 414, 4292, 4295, 4296, 4297 
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ICD-10 I21, I22, I23, I24, I25, Z955, Z958, Z959, R931, T822 
CCP 4801, 4802, 4803, 4804, 4805, 481, 482, 483 
CCI 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76 
OHIP 410, 412, R741, R742, R743, G298, E646, E651, E652, 
E654, E655, G262, Z434, Z448 
Angina CIHI-DAD ICD-9 413 
ICD-10 I20 
OHIP 413 
Atrial fibrillation/flutter CIHI-DAD ICD-9 4273 
ICD-10 I48 
Previous hyponatremia CIHI-DAD ICD-9 2761 
ICD-10 E871 
Myocardial Infarction  ICD-9 410 
ICD-10 I21, I22 
Haemorrhagic stroke CIHI-DAD ICD-9 430, 431 
ICD-10 I600, I601, I602, I603, I604, I605, I606, I607, I609, I61 
Ischemic stroke CIHI-DAD ICD-9 436, 4340, 4341, 4349, 3623 
ICD-10 I630, I631, I632, I633, I634, I635, I638, I639, I64, 
H341 
Transient ischemic attack CIHI-DAD ICD-9 435 
ICD-10 G450, G451, G452, G453, G458, G459, H340 
Chronic lung disease CIHI-DAD ICD-9 491, 492, 493, 494, 495, 496, 500, 501, 502, 503, 504, 
505, 5064, 5069, 5081, 515, 516, 517, 5185, 5188, 5198, 
5199, 4168, 4169 
ICD-10 I272, I278, I279, J40, J41, J42, J43, J44, J45, J47, 
J60, J61, J62, J63, J64, J65, J66, J67, J68, J701, J703, J704, 
J708, J709, J82, J84, J92, J941, J949, J953, J961, J969, 
J984, J988, J989, J99 
OHIP 491, 492, 493, 494, 496, 501, 502, 515, 518, 519 
J689, J889 
Epilepsy/Seizure CIHI-DAD ICD-9 345, 7803 
ICD-10 G40, G41, R560, R568 
Acute kidney injury CIHI-DAD ICD-9 584 
ICD-10 N17 
Hypotension CIHI-DAD ICD-9 458 
ICD-10 I95 
Acute urinary retention CIHI-DAD ICD-9 7882 
ICD-10 R33 
Delirium CIHI-DAD ICD-9 293 
ICD-10 F05 
Peripheral vascular 
disease 
CIHI-DAD ICD-9 4402, 4408, 4409, 5571, 4439, 444 
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551 
CCP 5125, 5129, 5014, 5016, 5018, 5028, 5038 
CCI 1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 1KG57, 
1KG76MI, 1KG87 
OHIP R787, R780, R797, R804, R809, R875, R815, R936, R783, 
R784,R785, E626, R814, R786, R937, R860, R861, R855, 
R856, R933, R934, R791, E672, R794, R813, R867, E649 
Outcomes 
Hyponatremia* CIHI-DAD ICD-10 E871 
Delirium CIHI-DAD ICD-10 F05 
OMHRS DSM IV 29300, 78009 
Bowel obstruction CIHI-DAD ICD-10 K56 
Median Medication Doses 
Citalopram ODB Higher dose: >20 mg/day; Normal dose ≤20 mg/day 
Escitalopram Higher dose: >10 mg/day; Normal dose ≤10 mg/day 
Duloxetine Higher dose: >30 mg/day; Normal dose ≤30 mg/day 
Fluvoxamine Higher dose: >50 mg/day; Normal dose ≤50 mg/day 
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Fluoxetine Not included in the assessment of higher vs. normal dose.  
Mirtazapine Higher dose: >15 mg/day; Normal dose ≤15 mg/day 
Paroxetine Higher dose: >20 mg/day; Normal dose ≤20 mg/day 
Sertraline Higher dose: >50 mg/day; Normal dose ≤50 mg/day 
Venlafaxine Higher dose: >56.25 mg/day; Normal dose ≤56.25 mg/day 
CCI=Canadian Classification of Health Interventions. CCP=Canadian Classification of Diagnostic, 
Therapeutic and Surgical Procedures. CIHI-DAD=Canadian Institute for Health Information Discharge 
Abstract Database. ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International 
Classification of Diseases, Tenth Revision. Ontario Drug Benefit database=ODB. OHIP=Ontario Health 
Insurance Plan database. OMHRS=Ontario Mental Health Reporting System database. RPDB=Ontario’s 
Registered Persons Database. 
*Validation of the code for hyponatremia was performed on approximately 64 499 hospitalizations with 
linked laboratory measurements for serum sodium. See Methods section for a description of the validation. 
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Table B-3. Variables included in propensity score model 
Variable Category Variable 
Demographics Age, sex, rural neighborhood 
Income  
Index date  
Comorbid conditions Charlson comorbidity index, Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mood disorder, anxiety disorder, congestive heart failure, 
chronic kidney disease, hypertension, chronic liver disease, hypothyroidism, 
cancer, diabetes mellitus, pneumonia, coronary artery disease, angina, atrial 
fibrillation/flutter, myocardial infarction, hemorrhagic stroke, ischemic stroke, 
transient ischemic attack, chronic lung disease, epilepsy/seizure, acute kidney 
injury, hypotension, acute urinary retention, peripheral vascular disease 
Concurrent medication 
use 
Number of unique drug products, anticonvulsant, antipsychotic, antidiabetics, 
antineoplastic, thyroxin, potassium sparing diuretic, non-potassium sparing 
diuretic, ACE inhibitor and/or ARB, NSAID (excluding aspirin), calcium 
channel blocker, beta-adrenergic antagonist, statin, benzodiazepine, digoxin, 
overactive bladder medication, antibiotic, warfarin, anticoagulant, antiplatelet, 
acetylcholine inhaler, corticosteroid inhaler, beta-agonist inhaler, 
cholinesterase inhibitor, lithium, glucose tests strips. 
Number of healthcare 
contacts 
Hospitalization, emergency department visit, family physician visit, 
psychiatrist visit, geriatrician visit, neurologist visit, nephrologist visit, 
cardiologist visit, urologist visit, obstetrician/gynecologist visit  
Number of healthcare 
uses 
Previous sodium tests, carotid ultrasound, cardiac catheterization, 
echocardiography, holter monitoring, cardiac stress test, coronary 
endarterectomy, colorectal cancer screening, cervical cancer screening, 
prostate-specific antigen test, mammography, flu shot, bone mineral density 
test, hearing test, cystoscopy, cataract surgery, computed tomography of the 
head, computed tomography of the neck, computed tomography of the 
thorax, computed tomography of the abdomen, computed tomography of the 
pelvis, computed tomography of the spine, computed tomography of the 
extremities, chest x-ray, pulmonary function test, electroencephalography, 
urine culture, heart valve replacement, at-home physician service, cholesterol 
test 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin 
II receptor blocker. NSAID=non-steroidal anti-inflammatory drug. 
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Table B-4. Full baseline characteristics of second-generation antidepressant users and non-users* 
Characteristic Unmatched Matched 
 Antidepressant  
users 
(n=172 552) 
Antidepressant  
non-users 
 (n=297 501) 
Standardized 
Differencea 
Antidepressant  
users 
(n=138 246) 
Antidepressant  
non-users 
 (n=138 246) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 76 (7.5) 75 (7.2) 5.9% 76 (7.3) 76 (7.2) 0.3% 
Women 116 830 (67.7%) 177 662 (59.2%) 16.7% 93 303 (67.5%) 93 303 (67.5%) 0% 
Income quintileb       
1 (low) 35 747 (20.7%) 59 184 (19.9%) 2.0% 28 057 (20.3%) 28 574 (20.7%) 0.9% 
2 35 935 (20.8%) 61 849 (20.8%) 0.1% 28 853 (20.9%) 28 954 (20.9%) 0.2% 
3 (medium) 33 863 (19.6%) 58 284 (19.6%) 0.1% 27 166 (19.7%) 27 279 (19.7%) 0.2% 
4 33 049 (19.2%) 58 377 (19.6%) 1.2% 26 684 (19.3%) 26 504 (19.2%) 0.3% 
5 (high) 33 958 (19.7%) 59 807 (20.1%) 1.1% 27 486 (19.9%) 26 935 (19.5%) 1.0% 
Year of cohort entry       
2003-2004 42 604 (24.7%) 49 712 (16.7%) 19.8% 31 266 (22.6%) 31 020 (22.4%) 0.4% 
2005-2006 38 283 (22.2%) 60 244 (20.3%) 4.7% 30 224 (21.9%) 30 251 (21.9%) 0% 
2007-2008 33 371 (19.3%) 68 544 (23.0%) 9.1% 27 577 (19.9%) 27 931 (20.2%) 0.6% 
2009-2010 37 114 (21.5%) 70 972 (23.9%) 5.6% 31 101 (22.5%) 30 804 (22.3%) 0.5% 
2011-2012 21 180 (12.3%) 48 029 (16.1%) 11.1% 18 078 (13.1%) 18 240 (13.2%) 0.3% 
Rural residence 21 796 (12.6%) 34 381 (11.6%) 3.3% 17 660 (12.8%)  17 015 (12.3%) 1.4% 
Long-term care 14 989 (8.7%) 10 812 (3.6%) 21.1% 6859 (5.0%) 6859 (5.0%) 0% 
Comorbid conditionsc       
Charlson comorbidity index, mean (SD) 0.8 (1.5) 0.6 (1.3) 14.0% 0.6 (1.3) 0.6 (1.4) 3.0% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.5 (3.8) 12.5 (3.7) 25.0% 13.0 (3.8) 13.1 (3.7) 0.8% 
Mood disorder 44 363 (25.7%) 34 484 (11.6%) 0.4% 24 207 (17.5%) 24 207 (17.5%) 0 
Anxiety disorderd 159 901 (92.7%) 282 632 (95.0%) 10.0% 129 861 (93.9%) 129 861 (93.9%) 0 
Congestive heart failure 25 766 (14.9%) 35 778 (12.0%) 8.5% 16 735 (12.1%) 16 735 (12.1%) 0 
Chronic kidney disease 10 798 (6.3%)   17 931 (6.0%) 1.0% 6094 (4.4%) 6094 (4.4%) 0 
Hypertension 129 149 (74.8%) 226 854 (76.3%) 3.3% 102 983 (74.5%) 101 948 (73.7%) 1.7% 
Chronic liver disease 6608 (3.8%) 10 759 (3.6%) 1.1% 5152 (3.7%) 4966 (3.6%) 0.7% 
Hypothyroidism 20 098 (11.7%) 32 199 (10.8%) 2.6% 15 723 (11.4%) 15 472 (11.2%) 0.6% 
Cancere 26 002 (15.1%) 43 459 (14.6%) 1.3% 19 741 (14.3%) 20 943 (15.1%)  2.5% 
Diabetes mellitus 14 371 (8.3%) 26 405 (8.9%) 2.0% 11 298 (8.2%) 11 234 (8.1%) 0.2% 
Pneumonia 9350 (5.4%) 10 796 (3.6%) 8.6% 5681 (4.1%) 5775 (4.2%) 0.3% 
Coronary artery diseasef 54 319 (31.5%) 89 377 (30.0%) 3.1% 40 738 (29.5%) 41 051 (29.7%) 0.5% 
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Angina 40 486 (23.5%) 62 974 (21.2%) 5.5% 30 250 (21.9%) 30 287 (21.9%) 0.1% 
Atrial fibrillation/flutter  12 991 (7.5%) 17 860 (6.0%) 6.1% 8527 (6.2%) 8781 (6.4%) 0.8% 
Previous hyponatremia 3889 (2.3%) 3941 (1.3%) 7.0% 2353 (1.7%) 2257 (1.6%) 0.5% 
Myocardial infarction 7488 (4.3%) 11 084 (3.7%) 3.1% 5007 (3.6%) 5107 (3.7%) 0.4% 
Hemorrhagic stroke 857 (0.5%) 712 (0.2%) 4.3% 479 (0.3%) 472 (0.3%) 0.1% 
Ischemic stroke 6685 (3.9%) 5802 (2.0%) 11.5% 3653 (2.6%) 3771 (2.7%) 0.5% 
Transient ischemic attack 2445 (1.4%) 2754 (0.9%) 4.6% 1582 (1.1%) 1571 (1.1%) 0.1% 
Lung disease 53 458 (31.0%) 78 087 (26.3%) 10.5% 40 129 (29.0%) 40 321 (29.2%) 0.3% 
Epilepsy/seizure 1763 (1.0%) 2056 (0.7%) 3.6% 1053 (0.8%) 1092 (0.8%) 0.3% 
Acute kidney injury 3745 (2.2%) 4689 (1.6%) 4.4% 1964 (1.4%) 2009 (1.5%) 0.3% 
Hypotension 3462 (2.0%) 3837 (1.3%) 5.6% 2071 (1.5%) 2024 (1.5%) 0.3% 
Acute urinary retention 3099 (1.8%) 4100 (1.4%) 3.3% 1913 (1.4%) 1981 (1.4%) 0.4% 
Previous delirium 4015 (2.3%) 3640 (1.2%) 8.4% 2104 (1.5%) 2103 (1.5%) 0 
Peripheral vascular disease 2974 (1.7%) 3973 (1.3%) 3.2% 1923 (1.4%) 1999 (1.4%) 0.5% 
Concurrent medication useg       
Number of unique drug products, mean 
(SD) 
11.5 (7.4) 9.4 (6.1) 31.0% 10.5 (6.6) 10.4 (6.5) 0.9% 
Antiepileptics 16 212 (9.4%) 15 602 (5.2%) 16.0% 10 901 (7.9%) 10 499 (7.6%) 1.1% 
Antipsychotics 13 052 (7.6%) 11 759 (4.0%) 15.5% 7609 (5.5%) 7659 (5.5%) 0.2% 
Antidiabetics 27 160 (15.7%) 50 240 (16.9%) 3.1% 20 847 (15.1%) 21 461 (15.5%) 1.2% 
Antineoplastics 6848 (4.0%) 11 287 (3.8%) 0.9% 5199 (3.8%) 5636 (4.1%) 2.0% 
Thyroxine 29 654 (17.2%) 48 974 (16.5%) 1.9% 23 403 (16.9%) 23 457 (17.0%) 0.1% 
Potassium sparing diuretics 6498 (3.8%) 10 213 (3.4%) 1.8% 4827 (3.5%) 5020 (3.6%) 0.8% 
Non-potassium sparing diuretics  51 687 (30.0%) 86 612 (29.1%) 1.8% 38 879 (28.1%) 38 550 (27.9%) 0.5% 
ACE inhibitors and/or ARBs 79 341 (46.0%) 149 937 (50.4%) 8.9% 63 863 (46.2%) 63 390 (45.9%) 0.7% 
NSAIDs (excl. ASA) 34 309 (19.9%) 53 241 (17.9%) 5.1% 26 986 (19.5%) 27 803 (20.1%) 1.5% 
Calcium channel blockers 44 345 (25.7%) 80 594 (27.1%) 3.2% 35 214 (25.5%) 35 342 (25.6%) 0.2% 
Beta-adrenergic agonists 48 093 (27.9%) 88 616 (29.8%) 4.2% 37 652 (27.2%) 37 995 (27.5%) 0.6% 
Statins 64 831 (37.6%) 128 405 (43.2%) 11.4% 53 052 (38.4%) 52 777 (38.2%) 0.4% 
Benzodiazepines 67 701 (39.2%) 61 887 (20.8%) 41.1% 48 049 (34.8%) 46 320 (33.5%) 2.6% 
Digoxin 3 498 (2.0%) 4 641 (1.6%) 3.5% 2420 (1.8%) 2437 (1.8%) 0.1% 
Overactive bladder 3 833 (2.2%) 4 558 (1.5%) 5.1% 2765 (2.0%) 2747 (2.0%) 0.1% 
Antibiotics 45 116 (26.1%) 75 710 (25.4%) 1.6% 37 379 (27.0%) 37 911 (27.4%) 0.9% 
Warfarin 2418 (1.4%) 3380 (1.1%) 2.4% 1731 (1.3%) 1725 (1.2%) 0 
Anticoagulents 760 (0.4%) 887 (0.3%) 2.3% 479 (0.3%) 483 (0.3%) 0 
Antiplatlets 7591 (4.4%) 11 651 (3.9%) 2.4% 5507 (4.0%) 5687 (4.1%) 0.7% 
Acetylcholine inhalers 8329 (4.8%) 10 790 (3.6%) 6.0% 5965 (4.3%) 5910 (4.3%) 0.2% 
Corticosteroid inhalers 7889 (4.6%) 11 531 (3.9%) 3.5% 5929 (4.3%) 6103 (4.4%) 0.6% 
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Beta-agonist inhalers 17 997 (10.4%) 24 697 (8.3%) 7.3% 13 258 (9.6%) 13 343 (9.7%) 0.2% 
Cholinesterase inhibitors 8201 (4.8%) 6621 (2.2%) 13.8% 4800 (3.5%) 4853 (3.5%) 0.2% 
Lithium 413 (0.2%) 604 (0.2%) 0.8% 258 (0.2%) 285 (0.2%) 0.4% 
Glucose test strips 16 961 (9.8%) 31 425 (10.6%) 2.4% 13 228 (9.6%) 13 545 (9.8%) 0.8% 
Healthcare contacts, mean (SD)h       
Hospitalizations 0.4 (0.8) 0.2 (0.5) 25.4% 0.3 (0.6) 0.3 (0.7) 1.7% 
Emergency department visits 1.0 (1.8) 0.6 (1.3) 27.1% 0.8 (1.5) 0.7 (1.5) 3.4% 
Family physician visits 19.3 (19.9)  14.8 (14.0) 26.8% 16.9 (16.4) 16.5 (15.3) 2.1% 
Geriatrician visits 0.4 (2.9) 0.2 (1.5) 13.3% 0.3 (1.6) 0.2 (1.6) 3.2% 
Psychiatrist visits 0.6 (3.9) 0.2 (2.0) 13.4% 0.3 (2.3) 0.2 (2.3) 4.0% 
Neurologist visits 0 (0.2) 0 (0.1) 6.3% 0 (0.2) 0 (0.2) 0 
Nephrologist visits 0 (0.1) 0 (0.1) 0 0 (0.1) 0 (0.1) 0 
Cardiologist visits 0.1 (0.2) 0.1 (0.2) 4.3% 0.1 (0.2) 0.1 (0.2) 0 
Urologist visits 0 (0.2) 0 (0.2) 0 0 (0.2) 0 (0.2) 0 
Obstetrician/Gynecologist visits 0 (0.1) 0 (0.1) 0 0 (0.1) 0 (0.1) 0 
Healthcare usei       
Previous sodium tests 108 033 (62.6%) 172 302 (57.9%) 9.6% 83 879 (60.7%) 80 886 (58.5%) 4.4% 
Carotid ultrasound 10 937 (6.3%) 14 166 (4.8%) 6.9% 7816 (5.7%) 7996 (5.8%) 0.6% 
Cardiac catheterization 3293 (1.9%) 4401 (1.5%) 3.3% 2327 (1.7%) 2311 (1.7%) 0.1% 
Echocardiography 31 184 (18.1%) 47 863 (16.1%) 5.3% 23 425 (16.9%) 23 657 (17.1%) 0.4% 
Holter monitoring 13 196 (7.6%) 18 248 (6.1%) 6.0% 9913 (7.2%) 9844 (7.1%) 0.2% 
Cardiac stress test 21 156 (12.3%) 32 566 (10.9%) 4.1% 16 265 (11.8%) 16 400 (11.9%) 0.3% 
Coronary endarterectomy 154 (0.1%) 204 (0.1%) 0.7% 112 (0.1%) 121 (0.1%) 0.2% 
Colorectal cancer screening 35 246 (20.4%) 63 516 (21.3%) 2.3% 28 856 (20.9%) 27 638 (20.0%) 2.2% 
Cervical cancer screening 12 870 (7.5%) 22 600 (7.6%) 0.5% 11 054 (8.0%) 11 111 (8.0%) 0.2% 
Prostate specific antigen test 5637 (3.3%) 12 656 (4.3%) 5.2% 5052 (3.7%) 4860 (3.5%) 0.7% 
Mammography 16 702 (9.7%) 28 363 (9.5%) 0.5% 14 038 (10.2%) 14 086 (10.2%) 0.1% 
Flu shot 96 940 (56.2%) 172 764 (58.1%) 3.8% 79 259 (57.3%) 78 450 (56.7%) 1.2% 
Thyroid stimulating hormone 103 460 (60.0%) 162 166 (54.5%) 11.0% 81 060 (58.6%) 80 776 (58.4%) 0.4% 
Bone mineral density test 23 220 (13.5%) 40 668 (13.7%) 0.6% 19 452 (14.1%) 19 433 (14.1%) 0 
Hearing test 10 395 (6.0%) 15 668 (5.3%) 3.3% 8086 (5.8%) 7967 (5.8%) 0.4% 
Cytoscopy 8203 (4.8%) 12 430 (4.2%) 2.8% 6054 (4.4%) 6130 (4.4%) 0.3% 
Cataract surgery 8594 (5.0%) 15 050 (5.1%) 0.4% 6960 (5.0%) 6867 (5.0%) 0.3% 
Computed tomography of the head 28 544 (16.5%) 22 761 (7.7%) 27.5% 17 175 (12.4%) 16 389 (11.9%) 1.7% 
Computed tomography of the neck 1854 (1.1%) 1999 (0.7%) 4.3% 1220 (0.9%) 1306 (0.9%) 0.7% 
Computed tomography of the thorax 12 431 (7.2%) 14 432 (4.9%) 9.9% 8335 (6.0%) 8813 (6.4%) 1.4% 
Computed tomography of the abdomen 17 791 (10.3%) 20 987 (7.1%) 11.6% 12 036 (8.7%) 12 509 (9.0%) 1.2% 
Computed tomography of the pelvis 15 897 (9.2%) 18 778 (6.3%) 10.9% 10 743 (7.8%) 11 185 (8.1%) 1.2% 
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Computed tomography of the spine 4534 (2.6%) 4642 (1.6%) 7.5% 2957 (2.1%) 3009 (2.2%) 0.3% 
Computed tomography of the extremities 1276 (0.7%) 1288 (0.4%) 4.0% 798 (0.6%) 734 (0.5%) 0.6% 
Chest x-ray 74 792 (43.3%) 97 878 (32.9%) 21.6% 54 158 (39.2%) 54 782 (39.6%) 0.9% 
Pulmonary function test 17 023 (9.9%) 25 317 (8.5%) 4.7% 12 975 (9.4%) 13 134 (9.5%) 0.4% 
Electroencephalography  1867 (1.1%) 1516 (0.5%) 6.4% 1132 (0.8%) 1039 (0.8%) 0.8% 
Urine culture 49 199 (28.5%) 67 274 (22.6%) 13.6% 35 905 (26.0%) 35 819 (25.9%) 0.1% 
Heart valve replacement 331 (0.2%) 350 (0.1%) 1.9% 201 (0.1%) 182 (0.1%) 0.4% 
At-home physician services 10 642 (6.2%) 9556 (3.2%) 14.0% 6417 (4.6%) 6163 (4.5%) 0.9% 
Cholesterol tests 90 701 (52.6%) 172 646 (58.0%) 11.0% 75 382 (54.5%) 74 923 (54.2%) 0.7% 
Laboratory measurementsj       
Evidence of baseline serum sodium 
measurement, N (%) 
31 228 (18.1%) 51 076 (17.2%) 2.4% 22 280 (16.1%) 22 280 (16.1%) 0 
Most recent serum sodium, mean (SD) 140.2 (3.4) 140.6 (3.1) 12.3% 140.4 (3.3) 140.5 (3.2) 3.1% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 0.10 was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive depression” was included into the anxiety disorder category 
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
g Concurrent medication use in the six months preceding the index date were considered. 
h Healthcare contacts in the year preceding the index date were considered. 
i Healthcare use in the year preceding the index date was considered. 
j Serum sodium measurements were obtained at a mean (SD) of 140 (102) days in users and 149 (101) days in non-users (matched groups), prior to the index 
date.  
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Table B-5. Baseline characteristics of second-generation antidepressant users and non-users for a subpopulation residing in a hospital 
catchment area with available serum sodium data* 
Characteristic Unmatched Matched 
 Antidepressant  
users 
(n=7423) 
Antidepressant  
non-users  
(n=9754) 
Standardized 
Differencea 
Antidepressant  
users 
(n=4186) 
Antidepressant  
non-users  
(n=4186) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 76 (7.5) 76 (7.3) 3.1% 75 (6.9) 75 (6.8) 0 
Women 5072 (68.3%) 5917 (60.6%) 16.1% 2889 (69.0%) 2889 (69.0%) 0 
Income quintileb       
1 (low) 1725 (23.2%) 2195 (22.5%) 1.8% 915 (21.9%) 928 (22.2%) 0.7% 
2 1317 (17.7%) 1890 (19.4%) 4.2% 749 (17.9%) 872 (20.8%) 7.4% 
3 (medium) 1502 (20.2%) 1969 (20.2%) 0.1% 878 (21.0%) 824 (19.7%) 3.2% 
4 1231 (16.6%) 1637 (16.8%) 0.5% 727 (17.4%) 711 (17.0%) 1.0% 
5 (high) 1648 (22.2%) 2063 (21.2%) 2.6% 917 (21.9%) 851 (20.3%) 3.9% 
Rural residence 674 (9.1%) 998 (10.2%) 3.9% 367 (8.8%) 421 (10.1%) 4.4% 
Long-term care 570 (7.7%) 396 (4.1%) 15.4% 57 (1.4%) 57 (1.4%) 0 
Comorbid conditionsc       
Charlson comorbidity index, mean (SD) 0.7 (1.5) 0.6 (1.3) 13.9% 0.5 (1.2) 0.5 (1.2%) 0 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.3 (3.7) 12.2 (3.7) 30.3% 12.5 (3.6) 12.3 (3.6%) 3.3% 
Mood disorder 2038 (27.5%) 1163 (11.9%) 40.0% 424 (10.1%) 424 (10.1%) 0 
Anxiety disorderd 6679 (90.0%) 9212 (94.4) 17.0% 4023 (96.1%) 4023 (96.1%) 0 
Congestive heart failure 1051 (14.2%) 1233 (12.6) 4.5% 251 (6.0%) 251 (6.0%) 0 
Chronic kidney disease 330 (4.4%) 417 (4.3) 0.8% 42 (1.0%) 42 (1.0%) 0 
Hypertension 5691 (76.7%) 7798 (79.9) 8.0% 3177 (75.9%) 3249 (77.6%) 4.0% 
Chronic liver disease 246 (3.3%) 286 (2.9) 2.2% 123 (2.9%) 117 (2.8%) 0.9% 
Hypothyroidism 911 (12.3%) 1140 (11.7) 1.8% 515 (12.3%) 535 (12.8%) 1.4% 
Cancere 1203 (16.2%) 1441 (14.8) 4.0% 619 (14.8%) 622 (14.9%) 0.2% 
Diabetes mellitus 577 (7.8%) 857 (8.8) 3.7% 326 (7.8%) 326 (7.8%) 0 
Pneumonia 356 (4.8%) 316 (3.2) 7.9% 104 (2.5%) 112 (2.7%) 1.2% 
Coronary artery diseasef 2034 (27.4%) 2848 (29.2) 4.0% 919 (22.0%) 1047 (25.0%) 7.2% 
Angina 1422 (19.2%) 1730 (17.7) 3.7% 633 (15.1%) 654 (15.6%) 1.4% 
Atrial fibrillation/flutter  524 (7.1%) 597 (6.1) 3.8% 181 (4.3%) 198 (4.7%) 2.0% 
Previous hyponatremia 143 (1.9%) 109 (1.1) 6.6% 45 (1.1%) 32 (0.8%) 3.3% 
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Myocardial infarction 337 (4.5%) 416 (4.3) 1.3% 123 (2.9%) 138 (3.3%) 2.1% 
Hemorrhagic stroke 33 (0.4%) 22 (0.2) 3.8% 8 (0.2%) 7 (0.2%) 0.6% 
Ischemic stroke 241 (3.2%) 180 (1.8%) 8.9% 68 (1.6%) 70 (1.7%) 0.4% 
Transient ischemic attack 97 (1.3%) 67 (0.7%) 6.2% 28 (0.7%) 33 (0.80%) 1.4% 
Lung disease 2078 (28.0%) 2230 (22.9%) 11.8% 1020 (24.4%) 988 (23.6%) 1.8% 
Epilepsy/seizure 87 (1.2%) 61 (0.6%) 5.8% 27 (0.6%) 19 (0.5%) 2.6% 
Acute kidney injury 153 (2.1%) 167 (1.7%) 2.6% 32 (0.8%) 37 (0.9%) 1.3% 
Hypotension 131 (1.8%) 108 (1.1%) 5.5% 41 (1.0%) 33 (0.8%) 2.0% 
Acute urinary retention 141 (1.9%) 124 (1.3%) 5.0% 53 (1.3%) 34 (0.8%) 4.5% 
Previous delirium 141 (1.9%) 103 (1.1%) 7.0% 44 (1.1%) 26 (0.6%) 4.7% 
Peripheral vascular disease 119 (1.6%) 116 (1.2%) 3.5% 43 (1.0%) 41 (1.0%) 0.5% 
Concurrent medication useg       
Number of unique drug products, mean 
(SD) 
10.9 (6.8) 9.4 (5.6) 23.4% 9.2 (5.6) 9.3 (5.4) 1.6% 
Antiepileptics 648 (8.7%) 609 (6.2%) 9.5% 276 (6.6%) 292 (7.0%) 1.5% 
Antipsychotics 490 (6.6%) 458 (4.7%) 8.3% 147 (3.5%) 160 (3.8%) 1.7% 
Antidiabetics 1181 (15.9%)  1776 (18.2%) 6.1% 625 (14.9%) 629 (15.0%) 0.3% 
Antineoplastics 352 (4.7%) 425 (4.4%) 1.8% 189 (4.5%) 197 (4.7%) 0.9% 
Thyroxine 1381 (18.6%) 1888 (19.4%) 1.9% 781 (18.7%) 838 (20.0%) 3.4% 
Potassium sparing diuretics 360 (4.9%) 426 (4.4%) 2.3% 186 (4.4%) 150 (3.6%) 4.4% 
Non-potassium sparing diuretics 2361 (31.8%) 3364 (34.5%) 5.7% 1109 (26.5%) 1127 (26.9%) 1.0% 
ACE inhibitors and/or ARBs 3291 (44.3%) 5285 (54.2%) 19.8% 1867 (44.6%) 2028 (48.4%) 7.7% 
NSAIDs (excl. ASA) 1807 (24.3%) 1393 (14.3%) 25.7% 769 (18.4%) 881 (21.0%) 6.7% 
Calcium channel blockers 1933 (26.0%) 2772 (28.4%) 5.3% 1039 (24.8%) 1086 (25.9%) 2.6% 
Beta-adrenergic agonists 2138 (28.8%) 3282 (33.6%) 10.5% 1113 (26.6%) 1234 (29.5%) 6.4% 
Statins 2663 (35.9%) 4508 (46.2%) 21.1% 1558 (37.2%) 1711 (40.9%) 7.5% 
Benzodiazepines 2931 (39.5%) 2422 (24.8%) 31.8% 1352 (32.3%) 1407 (33.6%) 2.8% 
Digoxin 160 (2.2%) 179 (1.8%) 2.3% 59 (1.4%) 60 (1.4%) 0.2% 
Overactive bladder 183 (2.5%) 177 (1.8%) 4.5% 83 (2.0%) 79 (1.9%) 0.7% 
Antibiotics 2187 (29.5%) 2669 (27.4%) 4.7% 1121 (26.8%) 1189 (28.4%) 3.6% 
Warfarin 96 (1.3%) 129 (1.3%) 0.3% 47 (1.1%) 47 (1.1%) 0 
Anticoagulents 31 (0.4%) 28 (0.3%) 2.2% 12 (0.3%) 11 (0.3%) 0.5% 
Antiplatlets 286 (3.9%) 382 (3.9%) 0.3% 136 (3.2%)  143 (3.4%) 0.9% 
Acetylcholine inhalers 354 (4.8%) 417 (4.3%) 2.4% 159 (3.8%) 181 (4.3%) 2.7% 
Corticosteroid inhalers 257 (3.5%) 323 (3.3%) 0.8% 131 (3.1%) 165 (3.9%) 4.4% 
Beta-agonist inhalers 725 (9.8%) 840 (8.6%) 4.0% 354 (8.5%) 386 (9.2%) 2.7% 
Cholinesterase inhibitors 309 (4.2%) 221 (2.3%) 10.8% 92 (2.2%) 93 (2.2%) 0.2% 
Lithium 15 (0.2%) 29 (0.3%) 1.9% ≤ 5 (≤0.1%) 8 (0.2%) ≤1.8% 
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Glucose test strips 706 (9.5%) 1122 (11.5%) 6.5% 396 (9.5%) 404 (9.7%) 0.7% 
Healthcare contacts, mean (SD)h       
Hospitalizations 0.4 (0.8) 0.2 (0.6) 25.2% 0.2 (0.5) 0.2 (0.6) 1.9% 
Emergency department visits 1.0 (1.7) 0.6 (1.3) 24.2% 0.7 (1.2) 0.7 (1.3) 0.8% 
Family physician visits 18.1 (17.0) 14.2 (11.7) 27.0% 14.6 (12.4) 14.3 (11.7) 2.9% 
Geriatrician visits 0.7 (4.7) 0.1 (1.6) 18.5% 0.3 (1.5) 0 (1.4) 9.2% 
Psychiatrist visits 0.4 (3.0) 0.1 (1.8) 9.6% 0.1 (0.8) 0 (1.6) 0 
Neurologist visits 0 (0.2) 0 (0.1) 6.7% 0 (0.2) 0 (0.2) 0 
Nephrologist visits 0 (0.1) 0 (0.1) 0% 0 (0.1) 0 (0.1) 0 
Cardiologist visits 0 (0.2) 0 (0.2) 6.1% 0 (0.2) 0 (0.2) 0 
Urologist visits 0 (0.2) 0 (0.2) 0 0 (0.2) 0 (0.2) 6.1% 
Obstetrician/Gynecologist visits 0 (0.1) 0 (0.1) 8.3% 0 (0.1) 0 (0.1) 8.3% 
Healthcare usei       
Previous sodium tests 4544 (61.2%) 5780 (59.3%) 4.0% 2432 (58.1%) 2404 (57.4%) 1.4% 
Carotid ultrasound 494 (6.7%) 574 (5.9%) 3.2% 228 (5.4%) 258 (6.2%) 3.1% 
Cardiac catheterization 131 (1.8%) 133 (1.4%) 3.2% 44 (1.1%) 59 (1.4%) 3.3% 
Echocardiography 956 (12.9%) 1117 (11.5%) 4.4% 437 (10.4%) 477 (11.4%) 3.1% 
Holter monitoring 483 (6.5%) 575 (5.9%) 2.5% 247 (5.9%) 263 (6.3%) 1.6% 
Cardiac stress test 884 (11.9%) 1006 (10.3%) 5.1% 440 (10.5%) 443 (10.6%) 0.2% 
Coronary endarterectomy 6 (0.1%) ≤ 5 (≤ 0.1%) ≤ 1.2% ≤ 5 (≤ 0.1%) ≤ 5 (≤ 0.1%) 0 
Colorectal cancer screening 1637 (22.1%) 2123 (21.8%) 0.7% 954 (22.8%) 951 (22.7%) 0.2% 
Cervical cancer screening 472 (6.4%) 563 (5.8%) 2.5% 317 (7.6%) 298 (7.1%) 1.7% 
Prostate specific antigen test 328 (4.4%) 558 (5.7%) 5.9% 224 (5.4%) 214 (5.1%) 1.1% 
Mammography 583 (7.9%) 711 (7.3%) 2.1% 367 (8.8%) 359 (8.6%) 0.7% 
Flu shot 4377 (59.0%) 5882 (60.3%) 2.7% 2601 (62.1%) 2525 (60.3%) 3.7% 
Thyroid stimulating hormone 4258 (57.4%) 5132 (52.6%) 9.6% 2353 (56.2%) 2385 (57.0%) 1.5% 
Bone mineral density test 803 (10.8%) 967 (9.9%) 3.0% 497 (11.9%) 475 (11.3%) 1.6% 
Hearing test 526 (7.1%) 575 (5.9%) 4.8% 266 (6.4%) 261 (6.2%) 0.5% 
Cytoscopy 289 (3.9%) 316 (3.2%) 3.5% 148 (3.5%) 134 (3.2%) 1.9% 
Cataract surgery 390 (5.3%) 528 (5.4%) 0.7% 213 (5.1%) 222 (5.3%) 1.0% 
Computed tomography of the head 1188 (16.0%) 713 (7.3%) 27.3% 410 (9.8%) 374 (8.9%) 3.0% 
Computed tomography of the neck 70 (0.9%) 48 (0.5%) 5.3% 26 (0.6%) 27 (0.6%) 0.3% 
Computed tomography of the thorax 476 (6.4%) 377 (3.9%) 11.6% 186 (4.4%) 201 (4.8%) 1.7% 
Computed tomography of the abdomen 820 (11.0%) 684 (7.0%) 14.1% 344 (8.2%) 347 (8.3%) 0.3% 
Computed tomography of the pelvis 710 (9.6%) 593 (6.1%) 13.0% 293 (7.0%) 306 (7.3%) 1.2% 
Computed tomography of the spine 198 (2.7%) 180 (1.8%) 5.5% 84 (2.0%) 110 (2.6%) 4.1% 
Computed tomography of the extremities 69 (0.9%) 50 (0.5%) 4.9% 26 (0.6%) 26 (0.6%) 0 
Chest x-ray 3164 (42.6%) 3022 (31.0%) 24.3% 1433 (34.2%) 1448 (34.6%) 0.8% 
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Pulmonary function test 690 (9.3%) 748 (7.7%) 5.8% 319 (7.6%) 388 (9.3%) 5.9% 
Electroencephalography  83 (1.1%) 56 (0.6%) 5.9% 33 (0.8%) 32 (0.8%) 0.3% 
Urine culture 1988 (26.8%) 1965 (20.1%) 15.7% 921 (22.0%) 901 (21.5%) 1.2% 
Heart valve replacement 9 (0.1%) 17 (0.2%) 1.4% ≤ 5 (≤ 0.1%) 6 (0.1%) ≤ 0.7% 
At-home physician services 419 (5.6%) 291 (3.0%) 13.1% 115 (2.7%) 129 (3.1%) 2.0% 
Cholesterol tests 3693 (49.8%) 5590 (57.3%) 15.2% 2263 (54.1%) 2379 (56.8%) 5.6% 
Laboratory measurementsj       
Evidence of baseline serum sodium 
measurement, N (%) 
4243 (57.2%) 4709 (48.3%) 17.8% 2153 (51.4%) 2153 (51.4%) 0 
Most recent serum sodium, mean (SD) 139.0 (3.6) 139.6 (3.5) 16.9 139.3 (3.6) 139.6 (3.5) 8.5% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive depression” was included into the anxiety disorder category 
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
g Concurrent medication use in the six months preceding the index date were considered. 
h Healthcare contacts in the year preceding the index date were considered. 
i Healthcare use in the year preceding the index date was considered. 
j Serum sodium measurements were obtained at a mean (SD) of 123 (100) days in users and 142 (100) days in non-users (matched groups), prior to the index 
date. 
 
205 
 
 
 
 
Table B-6. Baseline characteristics of matched second-generation antidepressant users 
and non-users at 90 days prior to the index date* 
Characteristic Matched 
 Antidepressant 
users 
(n=90 195) 
Antidepressant  
non-users  
(n=90 195) 
Standardized 
Differencea 
Demographic    
Age, mean (SD), years 76 (7.2) 76 (7.2) 0 
Women 61 315 (68.0%) 61 311 (68.0%) 0 
Income quintileb    
1  (low) 18 475 (20.5%) 18 573 (20.6%) 0.3% 
2 19 044 (21.1%) 18 974 (21.0%) 0.2% 
3 (medium) 17 788 (19.7%) 17 769 (19.7%) 0.1% 
4 17 179 (19.0%) 17 235 (19.1%) 0.2% 
5 (high) 17 709 (19.6%) 17 644 (19.6%) 0.2% 
Rural residence 11 041 (12.2%) 11 013 (12.2%) 0.1% 
Long-term care 3693 (4.1%) 5371 (6.0%) 8.5% 
Comorbid conditionsc    
Charlson comorbidity index, mean (SD) 0.5 (1.2) 0.6 (1.2) 4.1% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.2 (3.7) 13.2 (3.7) 0.5% 
Mood disorder 12 884 (14.3%) 13 997 (15.5%) 3.0% 
Anxiety disorderd 86 097 (95.5%) 86 216 (95.6%) 1.0% 
Congestive heart failure 10 523 (11.7%) 10 733 (11.9%) 0.7% 
Chronic kidney disease 3898 (4.3%) 4006 (4.4%) 0.6% 
Hypertension 67 790 (75.2%) 66 871 (74.1%) 2.3% 
Chronic liver disease 3243 (3.6%) 3339 (3.7%) 0.6% 
Hypothyroidism 10 450 (11.6%) 10 291 (11.4%) 0.6% 
Cancere 12 695 (14.1%) 13 314 (14.8%) 2.0% 
Diabetes mellitus 28 286 (31.4%) 28 378 (31.5%) 0.2% 
Pneumonia 3154 (3.5%) 3374 (3.7%) 1.3% 
Coronary artery diseasef 26 872 (29.8%) 27 196 (30.2%) 0.8% 
Angina 19 826 (22.0%) 19 850 (22.0%) 0.1% 
Atrial fibrillation/flutter  5340 (5.9%) 5823 (6.5%) 2.2% 
Previous hyponatremia 1358 (1.5%) 1429 (1.6%) 0.6% 
Myocardial infarction 2960 (3.3%) 3151 (3.5%) 1.2% 
Hemorrhagic stroke 248 (0.3%) 307 (0.3%) 1.2% 
Ischemic stroke 1913 (2.1%) 2271 (2.5%) 2.6% 
Transient ischemic attack 884 (1.0%) 873 (1.0%) 0.1% 
Lung disease 25 727 (28.5%) 26 087 (28.9%) 0.9% 
Epilepsy/seizure 623 (0.7%) 660 (0.6%) 0.5% 
Acute kidney injury 1088 (1.2%) 1156 (1.3%) 0.7% 
Hypotension 1206 (1.3%) 1257 (1.4%) 0.5% 
Acute urinary retention 1564 (1.7%) 1701 (1.9%) 1.1% 
Previous delirium 1244 (1.4%) 1300 (1.4%) 0.5% 
Peripheral vascular disease 1279 (1.4%) 1374 (1.5%) 0.5% 
Concurrent medication useg    
Number of unique drug products, mean 
(SD) 
7.18 (4.8) 7.38 (4.8) 4.1% 
Antiepileptics 6724 (7.5%) 6628 (7.3%) 0.4% 
Antipsychotics 4496 (5.0%) 4925 (5.5%) 2.1% 
Antidiabetics 12 265 (13.6%) 12 397 (13.7%) 0.4% 
Antineoplastics 3241 (3.6%) 3582 (4.0%) 2.0% 
Thyroxine 15 411 (17.1%)  15 349 (17.1%) 0.2% 
Potassium sparing diuretics 4860 (5.4%) 5465 (6.1%) 2.9% 
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Non-potassium sparing diuretics 25 190 (27.9%) 25 297 (28.0%) 0.3% 
ACE inhibitors and/or ARBs 42 038 (46.6%) 41 329 (45.8%) 1.6% 
NSAIDs (excl. ASA) 18 197 (20.2%) 17 848 (19.8%) 1.0% 
Calcium channel blockers 23 071 (25.6%) 23 068 (25.6%) 0 
Beta-adrenergic agonists 24 582 (27.3%) 24 775 (27.5%) 0.5% 
Statins 34 500 (38.3%) 34 050 (37.8%) 1.0% 
Benzodiazepines 30 317 (33.6%) 29 265 (32.4%) 2.5% 
Overactive bladder 3311 (3.7%) 3189 (3.5%) 0.7% 
Antibiotics 30 204 (33.5%) 32 123 (35.6%) 4.5% 
Warfarin 6599 (7.3%) 8338 (9.2%) 7.0% 
Anticoagulents 397 (0.4%) 561 (0.6%) 2.5% 
Antiplatlets 4273 (4.7%) 4666 (5.2%) 2.0% 
Acetylcholine inhalers 4680 (5.2%) 4956 (5.5%) 1.4% 
Corticosteroid inhalers 5086 (5.6%) 5655 (6.3%) 2.7% 
Beta-agonist inhalers 10 697 (11.9%) 11 521 (12.8%) 2.8% 
Cholinesterase inhibitors 5352 (5.9%) 4659 (5.2%) 3.4% 
Lithium 252 (0.3%) 408 (0.5%) 2.9% 
Glucose test strips 9702 (10.8%) 9963 (11.0%) 0.9% 
Healthcare contacts, mean (SD)h    
Hospitalizations 0.2 (0.6) 0.2 (0.6) 3.3% 
Emergency department visits 0.7 (1.3) 0.7 (1.4) 2.2% 
Family physician visits 11.6 (10.7) 11.9 (10.8) 2.8% 
Geriatrician visits 0.1 (1.11) 0.1 (1.3) 0 
Psychiatrist visits 0.3 (1.9) 0.2 (2.2) 1.4% 
Neurologist visits 0.2 (1.1) 0.2 (1.0) 2.9% 
Nephrologist visits 0.1 (0.7) 0.1 (0.8) 1.4% 
Cardiologist visits 1.0 (2.5) 1.1 (2.6) 3.1% 
Urologist visits 0.3 (1.3) 0.3 (1.3) 0 
Obstetrician/Gynecologist visits 0.1 (0.8) 0.1 (0.8) 1.2% 
Healthcare usei    
Previous sodium tests 53 136 (58.9%) 51 989 (57.6%) 2.6% 
Carotid ultrasound 4669 (5.2%) 5137 (5.7%) 2.3% 
Cardiac catheterization 1278 (1.4%) 1407 (1.6%) 1.2% 
Echocardiography 14 180 (15.7%) 14 664 (16.3%) 1.5% 
Holter monitoring 6003 (6.7%) 6145 (6.8%) 0.6% 
Cardiac stress test 10 054 (11.1%) 10 131 (11.2%) 0.3% 
Coronary endarterectomy 53 (0.1%) 72 (0.1%) 0.8% 
Colorectal cancer screening 18 334 (20.3%) 17 613 (19.5%) 2.0% 
Cervical cancer screening 7157 (7.9%) 7084 (7.9%) 0.3% 
Prostate specific antigen test 3058 (3.4%) 2971 (3.3%) 0.5% 
Mammography 9356 (10.4%) 9260 (10.3%) 0.3% 
Flu shot 52 749 (58.5%) 51 683 (57.3%) 2.4% 
Thyroid stimulating hormone 51 277 (56.9%) 51 532 (57.1%) 0.6% 
Bone mineral density test 12 965 (14.4%) 12 979 (14.4%) 0 
Hearing test 5406 (6.0%) 5025 (5.6%) 1.8% 
Cytoscopy 3822 (4.2%) 3893 (4.3%) 0.4% 
Cataract surgery 4495 (5.0%) 4435 (4.9%) 0.3% 
Computed tomography of the head 9239 (10.2%) 9792 (10.9%) 2.0% 
Computed tomography of the neck 669 (0.7%) 770 (0.9%) 1.3% 
Computed tomography of the thorax 4586 (5.1%) 5214 (5.8%) 3.1% 
Computed tomography of the abdomen 6905 (7.7%) 7451 (8.3%) 2.2% 
Computed tomography of the pelvis 6131 (6.8%) 6598 (7.3%) 2.0% 
Computed tomography of the spine 1819 (2.0%) 1800 (2.0%) 0.2% 
Computed tomography of the extremities 434 (0.5%) 453 (0.5%) 0.3% 
Chest x-ray 32 787 (36.4%) 34 123 (37.8%) 3.1% 
Pulmonary function test 8041 (8.9%) 8059 (8.9%) 0.1% 
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Electroencephalography  646 (0.7%) 652 (0.7%) 0.1% 
Urine culture 22 785 (25.3%) 22 922 (25.4%) 0.3% 
Heart valve replacement 99 (0.1%) 111 (0.1%) 0.4% 
At-home physician services 3771 (4.2%) 3756 (4.2%) 0.1% 
Cholesterol tests 48 526 (53.8%) 48 209 (53.4%) 0.7% 
Laboratory measurementsj    
Evidence of baseline serum sodium 
measurement, N (%) 
13 697 (15.2%) 13 911 (15.4%) 0.7% 
Most recent serum sodium, mean (SD) 140.6 (3.1) 140.60 (3.1) 0 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin 
II receptor blocker. IQR=interquartile range. NSAID=Non-steroidal anti-inflammatory drug. SD=standard 
deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a 
measure of the difference between groups with respect to the pooled standard deviation; a standardized 
difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive 
depression” was included into the anxiety disorder category 
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin 
lymphoma, liver, ovarian, esophageal 
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous 
coronary intervention. 
g Concurrent medication use in the six months preceding the index date were considered. 
h Healthcare contacts in the year preceding the index date were considered. 
i Healthcare use in the year preceding the index date was considered. 
j Laboratory measurements in the seven days to one year preceding the index date were considered. 
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Figure B-1. Sensitivity analysis of hidden bias 
A sensitivity analysis for the maximum p-value for a significance level of α (0.05) when γ > 1 and Δ > 1. 
The solid curve represents values of γ and Δ where the maximum p-value equals to α. The shaded area 
represents values of γ and Δ where the maximum p-value is less than α. The white area represents values of 
γ and Δ where the maximum p-value is greater than α. 
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Appendix C 
Table C-1. STROBE Checklist 
 Item 
No 
Recommendation Reported 
Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
Title, Abstract 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found 
Abstract 
Introduction 
  Background/rationale 2 Explain the scientific background and 
rationale for the investigation being reported 
Introduction 
  Objectives 3 State specific objectives, including any pre-
specified hypotheses 
Introduction 
Methods 
  Study design 4 Present key elements of study design early 
in the paper 
Methods 
  Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Methods 
  Participants 6 (a) Give the eligibility criteria, and the 
sources and methods of selection of 
participants. Describe methods of follow-up 
Methods, Figure 
1 
(b) For matched studies, give matching 
criteria and number of exposed and 
unexposed 
Methods, Table 
1, Appendix 
Table 3, 4, 5 
  Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if 
applicable 
Methods, 
Appendix Table 
2 
  Data sources/measurement 8 For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than 
one group 
Methods, 
Appendix 
Tables 2 
  Bias 9 Describe any efforts to address potential 
sources of bias 
Methods, 
Discussion 
  Study size 10 Explain how the study size was arrived at Methods; based 
on availability of 
the data 
  Quantitative variables 11 Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen and 
why 
Methods 
  Statistical methods 12 (a) Describe all statistical methods, including 
those used to control for confounding 
Methods 
(b) Describe any methods used to examine 
subgroups and interactions 
Methods 
(c) Explain how missing data were 
addressed 
Methods 
(d) If applicable, explain how loss to follow-
up was addressed 
Not applicable 
(e) Describe any sensitivity analyses Methods 
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Results 
  Participants 13 (a) Report numbers of individuals at each 
stage of study—e.g. numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analyzed 
Methods, Figure 
1, Results 
(b) Give reasons for non-participation at 
each stage 
Methods, Figure 
1 
  (c) Consider use of a flow diagram Figure 1 
  Descriptive data 14 (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders 
Table 1, 
Appendix 
Tables 4, 5 
(b) Indicate number of participants with 
missing data for each variable of interest 
Not applicable 
(c) Summarize follow-up time (e.g. average 
and total amount) 
Results, Table 2 
  Outcome data 15 Report numbers of outcome events or 
summary measures over time 
Results, Table 
2, Figure 1 
  Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% confidence 
interval). Make clear which confounders 
were adjusted for and why they were 
included 
Results, Table 
2, Figure 1 
(b) Report category boundaries when 
continuous variables were categorized 
Methods 
(c) If relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
Results, Table 2 
  Other analyses 17 Report other analyses done—e.g. analyses 
of subgroups and interactions, and sensitivity 
analyses 
Results, 
Appendix Table 
6 
Discussion 
  Key results 18 Summarize key results with reference to 
study objectives 
Discussion 
  Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion 
  Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar 
studies, and other relevant evidence 
Discussion 
  Generalizability 21 Discuss the generalizability (external validity) 
of the study results 
Discussion 
Other information 
  Funding 22 Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which the 
present article is based 
Funding/support 
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Table C-2. Coding definitions for comorbid conditions, outcomes and exposures 
Variable Database Code/Definition 
Comorbidities 
Dementia CIHI-DAD ICD-9 2900, 2901, 2903, 2904, 2908, 2909, 2948, 2949, 
3310, 3311, 3312, 2941, 797 
ICD-10 F065, F066, F068, F069, F09, F00, F01, F02, F03, 
F051, G30, G31, R54 
OMHRS DSM-IV 29040, 29041, 29042, 29043, 29120, 29282, 
29410, 29411, 29480, 78090 
OHIP 290, 331, 797 
Schizophrenia or other 
psychotic disorder 
CIHI-DAD ICD-9 2950, 2951, 2952, 2953, 2954, 2955, 2956, 2957, 
2958, 2959, 2970, 2971, 2972, 2973, 2978, 2979, 2980, 
2981, 2983, 2984, 2988, 2989 
ICD-10 F060, F062, F105, F107, F115, F117, F125, F127, 
F135, F137, F145, F147, F155, F157, F165, F167, F175, 
F177, F185, F187, F195, F197, F200, F201, F202, F203, 
F204, F205, F206, F208, F209, F220, F228, F229, F230, 
F231, F232, F233, F238, F239, F24, F250, F251, F252, 
F258, F259, F28, F29 
OMHRS DSM-IV 29130, 29150, 29211, 29212, 29381, 29382, 
29510, 29520, 29530, 29540, 29560, 29570, 29590, 
29710, 29730, 29880, 29890 
OHIP 291, 292, 295, 297, 298, Q021 
Bipolar disorder CIHI-DAD ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968 
ICD-10 F300, F301, F302, F308, F309, F310, F311, F312, 
F313, F314, F315, F316, F317, F318, F319 
OMHRS DSM-IV 29600, 29601, 29602, 29603, 29604, 29605, 
29606, 29640, 29641, 29642, 29643, 29644, 29645, 
29646, 29650, 29651, 29652, 29653, 29654, 29655, 
29656, 29660, 29661, 29662, 29663, 29664, 29665, 
29666, 29670, 29680, 29689 
OHIP 296, Q020 
Major depression and/or 
anxiety disorder 
CIHI-DAD ICD-9 2962, 2963, 3000, 3002, 3003, 3004, 3091, 311 
ICD-10 F063, F064, F320, F321, F322, F323, F328, F329, 
F330, F331, F332, F333, F334, F338, F339, F341, F400, 
F401, F402, F408, F409, F410, F411, F412, F413, F418, 
F419, F420, F421, F422, F428, F429, F430, F431 
OMHRS DSM-IV 29189, 29284, 29289, 29383, 29384, 29620, 
29621, 29622, 29623, 29624, 29625, 29626, 29630, 
29631, 29632, 29633, 29634, 29635, 29636, 30000, 
30001, 30002, 30021, 30022, 30023, 30029, 30030, 
30040, 30113 
OHIP 311 
Parkinson’s disease CIHI-DAD ICD-9 332 
ICD-10 G20, F023 
OMHRS 332 
Congestive heart failure CIHI-DAD ICD-9 425, 5184, 514, 428 
ICD-10 I500, I501, I509, I255, J81 
CCP 4961, 4962, 4963, 4964 
CCI 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 
1HZ53SYFR 
OHIP 428, R701, R702, Z429 
Chronic kidney disease CIHI-DAD ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 582, 583, 
580, 581, 584, 585, 586, 587, 5880, 5888, 5889, 5937 
ICD-10 E102, E112, E132, E142, I12, I13, N08, N18, N19 
OHIP 403, 585 
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Hypertension CIHI-DAD ICD-9 401, 402, 403, 404, 405 
ICD10 I10, I11, I12, I13, I15 
OHIP 401, 402, 403, 
Chronic liver disease CIHI-DAD ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 
7824, V026, 2750, 2751, 7891, 7895, 571 
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162, 
B942, Z225, E831, E830, K70, K713, K714, K715, K717, 
K721, K729, K73, K74, K753, K754, K758, K759, K76, 
K77 
OHIP 571, 573, 070, Z551, Z554 
Hypothyroidism  CIHI-DAD ICD-9 243, 2440, 2441, 2442, 2443, 2448, 2449 
ICD-10 E030, E031, E032, E033, E034, E035, E038, 
E039, E890 
OHIP 243, 244 
Cancer CIHI-DAD ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 
205, 206, 207, 208 
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 
991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56, 
C61, C82, C83, C85, C91, C92, C93, C94, C95, C00, D05 
OHIP 203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 
174, 175, 183, 185 
Diabetes Mellitus CIHI-DAD ICD-9 250 
ICD-10 E10, E11, E13, E14 
OHIP 250, K029, K030, Q040 
Pneumonia  CIHI-DAD ICD-9 480, 481, 482, 483, 484, 485, 486, 7700 
ICD-10 J12, J13, J14, J15, J16, J17, J18, P23 
Coronary artery disease CIHI-DAD ICD-9 410 412, 414, 4292, 4295, 4296, 4297 
ICD-10 I21, I22, I23, I24, I25, Z955, Z958, Z959, R931, 
T822 
CCP 4801, 4802, 4803, 4804, 4805, 481, 482, 483 
CCI 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76 
OHIP 410, 412, R741, R742, R743, G298, E646, E651, E652, 
E654, E655, G262, Z434, Z448 
Angina CIHI-DAD ICD-9 413 
ICD-10 I20 
OHIP 413 
Atrial fibrillation/flutter CIHI-DAD ICD-9 4273 
ICD-10 I48 
Previous hyponatremia CIHI-DAD ICD-9 2761 
ICD-10 E871 
Myocardial Infarction  ICD-9 410 
ICD-10 I21, I22 
Haemorrhagic stroke CIHI-DAD ICD-9 430, 431 
ICD-10 I600, I601, I602, I603, I604, I605, I606, I607, I609, 
I61 
Ischemic stroke CIHI-DAD ICD-9 436, 4340, 4341, 4349, 3623 
ICD-10 I630, I631, I632, I633, I634, I635, I638, I639, I64, 
H341 
Transient ischemic 
attack 
CIHI-DAD ICD-9 435 
ICD-10 G450, G451, G452, G453, G458, G459, H340 
Chronic lung disease CIHI-DAD ICD-9 491, 492, 493, 494, 495, 496, 500, 501, 502, 503, 
504, 505, 5064, 5069, 5081, 515, 516, 517, 5185, 5188, 
5198, 5199, 4168, 4169 
ICD-10 I272, I278, I279, J40, J41, J42, J43, J44, J45, J47, 
J60, J61, J62, J63, J64, J65, J66, J67, J68, J701, J703, 
J704, J708, J709, J82, J84, J92, J941, J949, J953, J961, 
J969, J984, J988, J989, J99 
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OHIP 491, 492, 493, 494, 496, 501, 502, 515, 518, 519 
J689, J889 
Seizure CIHI-DAD ICD-9 345, 7803 
ICD-10 G40, G41, R560, R568 
Acute kidney injury CIHI-DAD ICD-9 584 
ICD-10 N17 
Hypotension CIHI-DAD ICD-9 458 
ICD-10 I95 
Acute urinary retention CIHI-DAD ICD-9 7882 
ICD-10 R33 
Delirium CIHI-DAD ICD-9 293 
ICD-10 F05 
Peripheral vascular 
disease 
CIHI-DAD ICD-9 4402, 4408, 4409, 5571, 4439, 444 
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551 
CCP 5125, 5129, 5014, 5016, 5018, 5028, 5038 
CCI 1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 1KG57, 
1KG76MI, 1KG87 
OHIP R787, R780, R797, R804, R809, R875, R815, R936, 
R783, R784,R785, E626, R814, R786, R937, R860, R861, 
R855, R856, R933, R934, R791, E672, R794, R813, 
R867, E649 
Outcomes 
Hyponatremia* CIHI-DAD ICD-10 E871 
Bowel obstruction CIHI-DAD ICD-10 K56 
Exposures 
Risperidone ODB Higher dose: >0.5 mg/day; Normal dose ≤0.5 mg/day 
Olanzapine Higher dose: >2.5 mg/day; Normal dose ≤2.5 mg/day 
Quetiapine Higher dose: >25 mg/day; Normal dose ≤25 mg/day 
CCI=Canadian Classification of Health Interventions. CCP=Canadian Classification of Diagnostic, 
Therapeutic and Surgical Procedures. CIHI-DAD=Canadian Institute for Health Information Discharge 
Abstract Database. ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International 
Classification of Diseases, Tenth Revision. Ontario Drug Benefit database=ODB. OHIP=Ontario Health 
Insurance Plan database. OMHRS=Ontario Mental Health Reporting System database. RPDB=Ontario’s 
Registered Persons Database. 
*Validation of the code for hyponatremia was performed on approximately 64 499 hospitalizations with 
linked laboratory measurements for serum sodium. See Methods section for a description of the validation. 
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Table C-3. Variables included in propensity score model 
Demographics Age, sex, rural neighborhood 
Income  
Index date  
Residential status 
(community-dwelling or 
long-term care) 
 
Comorbid conditions Charlson comorbidity index, Johns Hopkins ACG System Aggregated 
Diagnosis Groups, dementia, schizophrenia, bipolar disorder, unipolar 
depression/anxiety, Parkinson’s disease, congestive heart failure, chronic 
kidney disease, hypertension, chronic liver disease, hypothyroidism, cancer, 
diabetes mellitus, pneumonia, coronary artery disease, angina, atrial 
fibrillation/flutter, myocardial infarction, hemorrhagic stroke, ischemic stroke, 
transient ischemic attack, chronic lung disease, seizure, acute kidney injury, 
hypotension, acute urinary retention, peripheral vascular disease 
Concurrent medication 
use 
Number of unique drug products, anticonvulsant, antidepressant, 
antidiabetics, antineoplastic, thyroxin, potassium sparing diuretic, non-
potassium sparing diuretic, ACE inhibitor and/or ARB, NSAID (excluding 
aspirin), calcium channel blocker, beta-adrenergic antagonist, statin, 
benzodiazepine, digoxin, overactive bladder medication, antibiotic, warfarin, 
anticoagulant, antiplatelet, acetylcholine inhaler, corticosteroid inhaler, beta-
agonist inhaler, cholinesterase inhibitor, lithium, glucose tests strips. 
Number of healthcare 
contacts 
Hospitalization, emergency department visit, family physician visit, 
psychiatrist visit, geriatrician visit, neurologist visit, nephrologist visit, 
cardiologist visit, urologist visit, obstetrician/gynecologist visit 
Number of healthcare 
uses 
Previous sodium tests, carotid ultrasound, cardiac catheterization, 
echocardiography, holter monitoring, cardiac stress test, coronary 
endarterectomy, colorectal cancer screening, cervical cancer screening, 
prostate-specific antigen test, mammography, flu shot, bone mineral density 
test, hearing test, cystoscopy, cataract surgery, computed tomography of the 
head, computed tomography of the neck, computed tomography of the 
thorax, computed tomography of the abdomen, computed tomography of the 
pelvis, computed tomography of the spine, computed tomography of the 
extremities, chest x-ray, pulmonary function test, electroencephalography, 
urine culture, heart valve replacement, at-home physician service, 
cholesterol test 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin 
II receptor blocker. NSAID=non-steroidal anti-inflammatory drug. 
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Table C-4. Full baseline characteristics of atypical antipsychotic medication users and non-users* 
Characteristic Unmatched Matched 
 Antipsychotic  
users 
(n=92 090) 
Antipsychotic 
 non-users 
 (n=175 836) 
Standardized 
Differencea 
Antipsychotic  
users 
(n=58 008) 
Antipsychotic 
 non-users 
 (n=58 008) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 81 (7.8) 79 (7.9) 29.2% 81 (7.7) 81 (7.7) 0.3% 
Women 58 647 (63.7%) 111 968 (63.7%) 0 38 736 (66.8%) 38 736 (66.8%) 0 
Income quintileb       
1 (low) 20 160 (21.9%) 37 436 (21.3%) 1.5% 12 331 (21.3%) 13 081 (22.6%) 3.1% 
2 18 854 (20.5%) 36 395 (20.7%) 0.6% 11 888 (20.5%) 12 057 (20.8%) 0.7% 
3 (medium) 17 999 (19.6%) 33 861 (19.3%) 0.7% 11 630 (20.1%) 11 408 (19.7%) 1.0% 
4 17 607 (19.1%) 33 206 (18.9%) 0.6% 11 213 (19.3%) 10 847 (18.7%) 1.6% 
5 (high) 17 058 (18.5%) 34 373 (19.6%) 2.6% 10 946 (18.9%) 10 615 (18.3%) 1.5% 
Year of cohort entry       
2003-2004 19 653 (21.3%) 31 335 (17.8%) 8.9% 11 417 (19.7%) 11 312 (19.5%) 0.5% 
2005-2006 21 756 (23.6%) 38 010 (21.6%) 4.8% 13 395 (23.1%) 13 430 (23.2%) 0.1% 
2007-2008 18 970 (20.6%) 35 337 (20.1%) 1.3% 11 962 (20.6%) 11 762 (20.3%) 0.9% 
2009-2010 19 814 (21.5%) 42 371 (24.1%) 6.2% 13 317 (23.0%) 13 341 (23.0%) 0.1% 
2011-2012 11 897 (12.9%) 28 783 (16.4%) 9.8% 7917 (13.7%) 8163 (14.1%) 1.2% 
Rural residence 11 759 (12.8%) 23 484 (13.4%)  1.7% 7671 (13.2%) 7557 (13.0%) 0.6% 
Long-term care 32 644 (35.5%) 26 705 (15.2%) 47.9% 16 409 (28.3%) 16 409 (28.3%) 0 
Prescribing Physician        
Family Physician  64 900 (70.5%)   40 829 (70.4%)   
Psychiatrist 7420 (8.1%) 3989 (6.9%) 
Geriatrician 4387 (4.8%) 3356 (5.8%) 
Neurologist 1943 (2.1%) 1367 (2.4%) 
Other  3383 (3.7%) 2139 (3.7%) 
Missing 10 057 (10.9%) 6328 (10.9%) 
Comorbid conditionsc       
Charlson comorbidity index, mean (SD) 1.68 (1.8) 1.56 (1.8) 6.7% 0.87 (1.5) 0.94 (1.5) 4.7% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.90 (4.2) 13.69 (4.0) 5.2% 13.37 (4.2) 13.69 (4.1) 7.8% 
Dementia 71 933 (78.1%) 92 049 (52.4%) 56.2% 44 715 (77.1%) 44 715 (77.1%) 0 
Schizophrenia 14 838 (16.1%) 14 072 (8.0%) 25.1% 4756 (8.2%) 4756 (8.2%) 0 
Bipolar disorder 10 174 (11.1%) 11 377 (6.5%) 16.3% 3295 (5.7%) 3295 (5.7%) 0 
Unipolar depression/anxiety 28 419 (30.9%) 74 574 (42.4%) 24.2% 15 038 (25.9%) 15 038 (25.9%) 0 
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Parkinson’s disease 8652 (9.4%) 19 015 (10.8%) 4.7% 3780 (6.5%) 3780 (6.5%) 0 
Congestive heart failure 19 029 (20.7%) 33 627 (19.1%) 3.9% 10 038 (17.3%) 10 038 (17.3%) 0 
Chronic kidney disease 8127 (8.8%) 15 323 (8.7%) 0.4% 3140 (5.4%) 3140 (5.4%) 0 
Hypertension 65 205 (70.8%) 131 562 (74.8%) 9.0% 40 929 (70.6%) 40 419 (69.7%) 1.9% 
Chronic liver disease 2980 (3.2%) 6388 (3.6%) 2.2% 1664 (2.9%) 1807 (3.1%) 1.5% 
Hypothyroidism 10 213 (11.1%) 20 354 (11.6%) 1.5% 6222 (10.7%) 6198 (10.7%) 0.1% 
Cancerd 12 145 (13.2%) 25 758 (14.7%) 4.2% 7321 (12.6%) 7864 (13.6%) 2.8% 
Diabetes mellitus 14 245 (15.5%) 30 491 (17.3%) 5.1% 17 590 (30.3%) 18 457 (31.8%) 3.2% 
Pneumonia 8006 (8.7%) 12 843 (7.3%) 5.1% 4237 (7.3%) 4755 (8.2%) 3.3% 
Coronary artery diseasee 31 417 (34.1%) 61 334 (34.9%) 1.6% 18 641 (32.1%) 19 184 (33.1%) 2.0% 
Angina 20 496 (22.3%) 42 264 (24.0%) 4.2% 12 166 (21.0%) 12 462 (21.5%) 1.3% 
Atrial fibrillation/flutter  9841 (10.7%) 17 100 (9.7%) 3.2% 5428 (9.4%) 5613 (9.7%) 1.1% 
Previous hyponatremia 3403 (3.7%) 5416 (3.1%) 3.4% 1766 (3.0%) 2111 (3.6%) 3.3% 
Myocardial infarction 4741 (5.2%) 9010 (5.1%) 0.1% 2585 (4.5%) 2696 (4.7%) 0.9% 
Hemorrhagic stroke 698 (0.8%) 935 (0.5%) 2.8% 331 (0.6%) 404 (0.7%) 1.6% 
Ischemic stroke 5328 (5.8%) 7628 (4.3%) 6.6% 2725 (4.7%) 3340 (5.8%) 4.8% 
Transient ischemic attack 1818 (2.0%) 3074 (1.8%) 1.7% 1023 (1.8%) 1176 (2.0%) 1.9% 
Lung disease 26 237 (28.5%) 53 842 (30.6%) 4.7% 15 489 (26.7%) 16 891 (29.1%) 5.4% 
Seizure 1782 (1.9%) 2780 (1.6%) 2.7% 879 (1.5%) 1087 (1.9%) 2.8% 
Acute kidney injury 3453 (3.8%) 5616 (3.2%) 3.0% 1482 (2.6%) 1501 (2.6%) 0.2% 
Hypotension 2704 (2.9%) 4572 (2.6%) 2.1% 1320 (2.3%) 1398 (2.4%) 0.9% 
Acute urinary retention 3337 (3.6%) 5179 (3.0%) 3.8% 1650 (2.8%) 1774 (3.1%) 1.3% 
Delirium 7112 (7.7%) 6013 (3.4%) 18.8% 3424 (5.9%) 2546 (4.4%) 6.9% 
Peripheral vascular disease 1939 (2.1%) 4061 (2.3%) 1.4% 1043 (1.8%) 1238 (2.1%) 2.4% 
Concurrent medication usef       
Number of unique drug products, mean 
(SD) 
9.71 (6.4) 8.94 (5.5) 13.0% 8.91 (5.9%) 9.41 (5.6) 8.7% 
Antiepileptics 10 970 (11.9%) 16 409 (9.3%) 8.4% 5552 (9.6%) 6688 (11.5%) 6.4% 
Antidepressants 46 600 (50.6%) 65 227 (37.1%) 27.5% 25 197 (43.4%) 26 871 (46.3%) 5.8% 
Antidiabetics 14 245 (15.5%) 21 969 (12.5%) 8.6% 8526 (14.7%) 9307 (16.0%) 3.7% 
Antineoplastics 3240 (3.5%) 6863 (3.9%) 2.0% 1958 (3.4%) 2151 (3.7%) 1.8% 
Thyroxine 16 580 (18.0%) 33 499 (19.1%) 2.7% 10 406 (17.9%) 10 846 (18.7%) 2.0% 
Potassium sparing diuretics 5390 (5.9%) 11 025 (6.3%) 1.8% 3267 (5.6%) 3236 (5.6%) 0.2% 
Non-potassium sparing diuretics  31 051 (33.7%) 61 131 (34.8%) 2.2% 18 611 (32.1%) 18 665 (32.2%) 0.2% 
ACE inhibitors and/or ARBs 39 596 (43.0%) 88 563 (50.4%) 14.8% 24 853 (42.8%) 25 660 (44.2%) 2.8% 
NSAIDs (excl. ASA) 13 638 (14.8%) 30 146 (17.1%) 6.4% 8667 (14.9%) 9047 (15.6%) 1.8% 
Calcium channel blockers 22 902 (24.9%) 49 786 (28.3%) 7.8% 14 642 (25.2%) 15 011 (25.9%) 1.5% 
Beta-adrenergic agonists 26 099 (28.3%) 55 259 (31.4%) 6.7% 16 169 (27.9%) 16 254 (28.0%) 0.3% 
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Statins 29 558 (32.1%) 72 878 (41.5%) 19.48% 19 171 (33.1%) 19 514 (33.6%) 1.3% 
Benzodiazepines 33 031 (35.9%) 45 988 (26.2%) 21.12% 17 616 (30.4%) 18 692 (32.2%) 4.0% 
Digoxin 5923 (6.4%) 10 434 (5.9%) 2.07% 3 523 (6.1%) 3848 (6.6%) 2.3% 
Overactive bladder 5188 (5.6%) 8652 (4.9%) 3.19% 3 094 (5.3%) 3311 (5.7%) 1.6% 
Antibiotics 35 094 (38.1%) 63 965 (36.4%) 3.58% 20 856 (36.0%) 21 900 (37.8%) 3.7% 
Warfarin 9610 (10.4%) 19 752 (11.2%) 2.57% 5 761 (9.9%) 6189 (10.7%) 2.4% 
Anticoagulents 895 (1.0%) 1287 (0.7%) 2.61% 476 (0.8%) 463 (0.8%) 0.3% 
Antiplatlets 6665 (7.2%) 13 455 (7.7%) 1.58% 4009 (6.9%) 4511 (7.8%) 3.3% 
Acetylcholine inhalers 6454 (7.0%) 13 153 (7.5%) 1.82% 3731 (6.4%) 4319 (7.5%) 4.0% 
Corticosteroid inhalers 5309 (34.2%) 11 301 (13.8%) 49.09% 3183 (5.5%) 3647 (6.3%) 3.4% 
Beta-agonist inhalers 11 801 (12.8%) 25 019 (14.2%) 4.14% 6974 (12.0%) 8061 (13.9%) 5.6% 
Cholinesterase inhibitors 31 505 (34.2%) 24 342 (13.8%) 49.09% 18 139 (31.3%) 16 804 (29.0%) 5.0% 
Lithium 1176 (1.3%) 1042 (0.6%) 7.12% 367 (0.6%) 412 (0.7%) 1.0% 
Glucose test strips 10 411 (11.3%) 23 666 (13.5%) 6.54% 6162 (10.6%) 6784 (11.7%) 3.4% 
Healthcare contacts, mean (SD)g       
Hospitalizations 0.51 (0.9) 0.32 (0.8) 22.6% 0.40 (0.8) 0.39 (0.8) 1.3% 
Emergency department visits 1.29 (2.1) 0.84 (1.6) 24.7% 1.04 (1.6) 1.00 (1.7) 2.5% 
Family physician visits 18.57 (18.0) 13.61 (13.1) 31.9% 15.84 (15.5) 16.30 (15.3) 3.0% 
Geriatrician visits 0.82 (3.6) 0.34 (2.1) 16.9% 0.58 (2.5) 0.49 (2.4) 3.7% 
Psychiatrist visits 1.69 (7.5) 0.36 (2.5) 26.6% 0.64 (2.4) 0.40 (2.2) 10.0% 
Neurologist visits 0.43 (2.2) 0.29 (1.2) 8.2% 0.30 (1.2) 0.31 (1.3) 0.8% 
Nephrologist visits 0.16 (1.1) 0.15 (1.0) 0.9% 0.11 (0.9) 0.12 (0.9) 1.1% 
Cardiologist visits 1.23 (3.2) 1.16 (2.9) 2.3% 1.03 (2.7) 1.03 (2.7) 0 
Urologist visits 0.32 (1.5) 0.33 (1.3) 0.7% 0.28 (1.3) 0.29 (1.3) 0.8% 
Obstetrician/Gynecologist visits 0.07 (0.6) 0.09 (0.6) 3.3% 0.07 (0.5) 0.07 (0.5) 0 
Healthcare useh       
Previous sodium tests 63 335 (68.8%) 79 930 (45.5%) 48.5% 38 190 (64.8%) 38 145 (65.8%) 0.2% 
Carotid ultrasound 4568 (5.0%) 9137 (5.2%) 1.1% 2721 (4.7%) 2883 (5.0%) 1.3% 
Cardiac catheterization 742 (0.8%) 2334 (1.3%) 5.1% 414 (0.7%) 477 (0.8%) 1.2% 
Echocardiography 12 411 (13.5%) 27 264 (15.5%) 5.8% 7247 (12.5%) 7355 (12.7%) 0.6% 
Holter monitoring 4818 (5.2%) 10 904 (6.2%) 4.2% 2962 (5.1%) 3032 (5.2%) 0.6% 
Cardiac stress test 5757 (6.3%) 15 993 (9.1%) 10.7% 3542 (6.1%) 3700 (6.4%) 1.1% 
Coronary endarterectomy 45 (0.1%) 112 (0.1%) 0.6% 32 (0.1%) 31 (0.1%) 0.1% 
Colorectal cancer screening 10 653 (11.6%) 29 013 (16.5%) 14.2% 6767 (11.7%) 6823 (11.8%) 0.3% 
Cervical cancer screening 2047 (2.2%) 8290 (4.7%) 13.7% 1447 (2.5%) 1427 (2.5%) 0.2% 
Prostate specific antigen test 1147 (1.3%) 4580 (2.6%) 9.9% 770 (1.3%) 792 (1.4%) 0.3% 
Mammography 3507 (3.8%) 12 320 (7.0%) 14.2% 2425 (4.2%) 2370 (4.1%) 0.5% 
Flu shot 42 439 (46.1%) 95 645 (54.4%) 16.7% 27 859 (48.0%) 27 553 (47.5%) 1.1% 
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Thyroid stimulating hormone 57 414 (62.4%) 100 900 (57.4%) 10.1% 34 911 (60.2%) 34 766 (59.9%) 0.5% 
Bone mineral density test 5792 (6.3%) 18 558 (10.6%) 15.4% 4040 (7.0%) 4110 (7.1%) 0.5% 
Hearing test 3705 (4.0%) 9327 (5.3%) 6.1% 2375 (4.1%) 2537 (4.4%) 1.4% 
Cytoscopy 3959 (4.3%) 7739 (4.4%) 0.5% 2253 (3.9%) 2325 (4.0%) 0.6% 
Cataract surgery 3233 (3.5%) 8372 (4.8%) 6.3% 2137 (3.7%) 2122 (3.7%) 0.1% 
Computed tomography of the head 26 927 (29.2%) 25 724 (14.6%) 35.9% 13 261 (22.9%) 12 896 (22.2%) 1.5% 
Computed tomography of the neck 741 (0.8%) 1309 (0.7%) 0.7% 417 (0.7%) 469 (0.8%) 1.0% 
Computed tomography of the thorax 5054 (5.5%) 9369 (5.3%) 0.7% 2638 (4.6%) 3175 (5.5%) 4.2% 
Computed tomography of the abdomen 7773 (8.4%) 13 668 (7.8%) 2.5% 4109 (7.1%) 4574 (7.9%) 3.1% 
Computed tomography of the pelvis 7177 (7.8%) 12 371 (7.0%) 2.9% 3799 (6.6%) 4165 (7.2%) 2.5% 
Computed tomography of the spine 2003 (2.2%) 3474 (2.0%) 1.4% 1030 (1.8%) 1106 (1.9%) 1.0% 
Computed tomography of the extremities 675 (0.7%) 1085 (0.6%) 1.4% 368 (0.6%) 392 (0.7%) 0.5% 
Chest x-ray 43 501 (47.2%) 69 077 (39.3%) 16.1% 24 600 (42.4%) 25 086 (43.3%) 1.7% 
Pulmonary function test 4882 (5.3%) 13 764 (7.8%) 10.2% 2901 (5.0%) 3404 (5.9%) 3.8% 
Electroencephalography  1664 (1.8%) 1836 (1.0%) 6.4% 791 (1.4%) 826 (1.4%) 0.5% 
Urine culture 35 750 (38.8%) 49 370 (28.1%) 22.9% 20 385 (35.1%) 19 477 (33.6%) 3.3% 
Heart valve replacement 72 (0.1%) 208 (0.1%) 1.3% 43 (0.1%) 32 (0.1%) 0.8% 
At-home physician services 11 389 (12.4%) 11 474 (6.5%) 20.1% 5832 (10.1%) 5684 (9.8%) 0.9% 
Cholesterol tests 33 009 (35.8%) 83 296 (47.4%) 23.6% 21 686 (37.4%) 20 975 (36.2%) 2.5% 
Laboratory measurementsi       
Most recent serum sodium, N (%) 14 346 (15.6%) 21 948 (23.8%) 20.9% 7242 (12.5%) 7242 (12.5%) 0 
Most recent serum sodium, mean (SD) 140.3 (3.5) 140.4 (3.22) 2.7% 140.43 (3.4) 140.28 (3.4) 4.4% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal 
e Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
f Concurrent medication use in the six months preceding the index date were considered. 
g Healthcare contacts in the year preceding the index date were considered. 
h Healthcare use in the year preceding the index date was considered. 
i Serum sodium measurements were obtained at a mean (SD) of 140 (102) days in users and 149 (101) days in non-users, prior to the index date.  
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Table C-5. Baseline characteristics of matched atypical antipsychotic users and non-
users at 90 days prior to the index date* 
Characteristic Matched 
 Antipsychotic  
users 
(n=42 698) 
Antipsychotic 
 non-users  
(n=42 698) 
Standardized 
Differencea 
Demographic    
Age, mean (SD), years 81 (7.6) 81 (7.6) 0.3% 
Women 28 842 (67.6%) 28 842 (67.6%) 0% 
Income quintileb    
1  (low) 9552 (22.4%) 8927 (20.9%) 3.6% 
2 8899 (20.8%) 8726 (20.4%) 1.0% 
3 (medium) 8389 (19.7%) 8615 (20.2%) 1.3% 
4 8003 (18.7%) 8362 (19.6%) 2.1% 
5 (high) 7855 (18.4%) 8068 (18.9%) 1.3% 
Rural residence 5698 (13.3%) 5586 (13.1%) 0.8% 
Long-term care 9303 (21.8%) 12 168 (28.5%) 15.5% 
Comorbid conditionsc    
Charlson comorbidity index, mean (SD) 1.39 (1.6) 1.49 (1.7) 6.2% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.28 (4.1) 13.61 (4.1) 8.1% 
Congestive heart failure 6911 (16.2%) 7118 (16.7%) 1.3% 
Chronic kidney disease 2001 (4.7%) 2097 (4.9%) 1.1% 
Hypertension 30 047 (70.4%) 29 571 (69.3%) 2.4% 
Chronic liver disease 1159 (2.7%) 1234 (2.9%) 1.1% 
Hypothyroidism 4666 (10.9%) 4616 (10.8%) 0.4% 
Cancerd 5154 (12.1%) 5612 (13.1%) 3.2% 
Diabetes mellitus 12 666 (29.7%) 13 389 (31.4%) 3.7% 
Pneumonia 2771 (6.5%) 3270 (7.7%) 4.6% 
Coronary artery diseasee 13 535 (31.7%) 13 873 (32.5%) 1.7% 
Angina 8930 (20.9%) 9049 (21.2%) 0.7% 
Atrial fibrillation/flutter  3600 (8.4%) 3925 (9.2%) 2.7% 
Previous hyponatremia 1129 (2.6%) 1493 (3.5%) 4.9% 
Myocardial infarction 1703 (4.0%) 1835 (4.3%) 1.6% 
Hemorrhagic stroke 222 (0.5%) 290 (0.7%) 2.1% 
Ischemic stroke 1771 (4.2%) 2411 (5.7%) 7.0% 
Transient ischemic attack 745 (1.7%) 827 (1.9%) 1.4% 
Lung disease 11 061 (25.9%) 12 066 (28.3%) 5.3% 
Seizure 616 (1.4%) 757 (1.8%) 2.6% 
Acute kidney injury 904 (2.1%) 963 (2.3%) 0.9% 
Hypotension 889 (2.1%) 979 (2.3%) 1.4% 
Acute urinary retention 1055 (2.5%) 1268 (3.0%) 3.1% 
Delirium 1815 (4.3%) 1993 (4.7%) 2.0% 
Peripheral vascular disease 682 (1.6%) 840 (2.0%) 2.8% 
Concurrent medication usef    
Number of unique drug products, mean 
(SD) 
8.49 (5.6) 9.15 (5.5) 11.9%  
Antiepileptics 3739 (8.8%) 4745 (11.1%) 7.9% 
Antidepressants 17 715 (41.5%) 19 285 (45.2%) 7.4% 
Antidiabetics 1389 (3.3%) 1734 (4.1%) 4.3% 
Antineoplastics 1364 (3.2%) 1518 (3.6%) 2.0% 
Thyroxine 7811 (18.3%) 7933 (18.6%) 0.7% 
Potassium sparing diuretics 2298 (5.4%) 2279 (5.3%) 0.2% 
Non-potassium sparing diuretics 13 157 (30.8%) 13 513 (31.7%) 1.8% 
ACE inhibitors and/or ARBs 18 563 (43.5%) 18 720 (43.8%) 0.7% 
220 
 
 
 
 
NSAIDs (excl. ASA) 6379 (14.9%) 6737 (15.8%) 2.3% 
Calcium channel blockers 10 735 (25.1%) 10 881 (25.5%) 0.8% 
Beta-adrenergic agonists 11 686 (27.4%) 11 732 (27.5%) 0.2% 
Statins 14 073 (33.0%) 13 956 (32.7%) 0.6% 
Benzodiazepines 11 309 (26.5%) 13 273 (31.1%) 10.2% 
Overactive bladder 2308 (5.4%) 2406 (5.6%) 1.0% 
Antibiotics 14 310 (33.5%) 15 890 (37.2%) 7.8% 
Warfarin 4407 (10.3%) 4050 (9.5%) 2.8% 
Anticoagulents 241 (0.6%) 327 (0.8%) 2.5% 
Antiplatlets 2874 (6.7%) 3132 (7.3%) 2.4% 
Acetylcholine inhalers 2515 (5.9%) 2944 (6.9%) 4.1% 
Corticosteroid inhalers 2257 (5.3%) 2687 (6.3%) 4.3% 
Beta-agonist inhalers 5694 (13.3%) 4801 (11.2%) 6.4% 
Cholinesterase inhibitors 12 415 (29.1%) 14 273 (33.4%) 9.4% 
Lithium 262 (0.6%) 273 (0.6%) 0.3% 
Glucose test strips 4239 (9.9%) 4866 (11.4%) 4.8% 
Healthcare contacts, mean (SD)g    
Hospitalizations 0.29 (0.7) 0.36 (0.8) 9.7% 
Emergency department visits 0.84 (1.4) 0.93 (1.6) 5.9% 
Family physician visits 14.22 (14.1) 16.05 (15.2) 12.5% 
Geriatrician visits 0.44 (2.0) 0.48 (2.5) 1.8% 
Psychiatrist visits 0.39 (1.8) 0.38 (2.2) 0.5% 
Neurologist visits 0.28 (1.0) 0.31 (1.3) 2.6% 
Nephrologist visits 0.08 (0.7) 0.10 (0.8) 2.7% 
Cardiologist visits 0.86 (2.3) 0.96 (2.6) 4.1% 
Urologist visits 0.25 (1.1) 0.28 (1.2) 2.6% 
Obstetrician/Gynecologist visits 0.07 (0.5) 0.07 (0.5) 0 
Healthcare useh    
Previous sodium tests 27 877 (65.3%) 27 206 (63.7%) 3.3% 
Carotid ultrasound 1798 (4.2%) 2085 (4.9%) 3.2% 
Cardiac catheterization 278 (0.7%) 304 (0.7%) 0.7% 
Echocardiography 4654 (10.9%) 5124 (12.0%) 3.5% 
Holter monitoring 2055 (4.8%) 2189 (5.1%) 1.4% 
Cardiac stress test 2399 (5.6%) 2668 (6.3%) 2.7% 
Coronary endarterectomy 17 (0) 15 (0) 0.2% 
Colorectal cancer screening 4910 (11.5%) 5094 (11.9%) 1.3% 
Cervical cancer screening 1083 (2.5%) 1055 (2.5%) 0.4% 
Prostate specific antigen test 550 (1.3%) 560 (1.3%) 0.2% 
Mammography 1839 (4.3%) 1823 (4.3%) 0.2% 
Flu shot 21 271 (49.8%) 20 476 (48.0%) 3.7% 
Thyroid stimulating hormone 24 803 (58.1%) 25 398 (59.5%) 2.8% 
Bone mineral density test 3055 (7.2%) 3142 (7.4%) 0.8% 
Hearing test 1769 (4.1%) 1885 (4.4%) 1.3% 
Cytoscopy 1550 (3.6%) 1700 (4.0%) 1.8% 
Cataract surgery 1669 (3.9%) 1623 (3.8%) 0.6% 
Computed tomography of the head 7717 (18.1%) 8868 (20.8%) 6.8% 
Computed tomography of the neck 222 (0.5%) 296 (0.7%) 2.2% 
Computed tomography of the thorax 2017 (4.7%) 1528 (3.6%) 5.7% 
Computed tomography of the abdomen 2461 (5.8%) 3082 (7.2%) 5.9% 
Computed tomography of the pelvis 2256 (5.3%) 2802 (6.6%) 5.4% 
Computed tomography of the spine 632 (1.5%) 767 (1.8%) 2.5% 
Computed tomography of the extremities 204 (0.5%) 246 (0.6%) 1.4% 
Chest x-ray 15 965 (37.4%) 17 569 (41.2%) 7.7% 
Pulmonary function test 2014 (4.7%) 2385 (5.6%) 3.9% 
Electroencephalography  505 (1.2%) 575 (1.4%) 1.5% 
Urine culture 13 942 (32.7%) 14 178 (33.2%) 1.2% 
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Heart valve replacement 14 (0) 19 (0) 0.6% 
At-home physician services 3706 (8.7%) 4035 (9.5%) 2.7% 
Cholesterol tests 15 636 (36.6%) 15 309 (35.9%) 1.6% 
Laboratory measurementsi    
Most recent serum sodium, N (%) 5452 (12.8%) 5452 (12.8%) 0 
Most recent serum sodium, mean (SD) 140.6 (3.3) 140.4 (3.4) 6.9% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin 
II receptor blocker. IQR=interquartile range. NSAID=Non-steroidal anti-inflammatory drug. SD=standard 
deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a 
measure of the difference between groups with respect to the pooled standard deviation; a standardized 
difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin 
lymphoma, liver, ovarian, esophageal 
e Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous 
coronary intervention. 
f Concurrent medication use in the six months preceding the index date were considered. 
g Healthcare contacts in the year preceding the index date were considered. 
h Healthcare use in the year preceding the index date was considered. 
i Serum sodium measurements were obtained at a mean (SD) of 151 (104) days in users and 151 (105) days 
in non-users, prior to the index date. 
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Appendix D 
Table D-1. STROBE Checklist 
 Item 
No 
Recommendation Reported 
Title and abstract 1 (a) Indicate the study’s design with a commonly 
used term in the title or the abstract 
Title, 
Abstract 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what 
was found 
Abstract 
Introduction 
  Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported 
Introduction 
  Objectives 3 State specific objectives, including any pre-
specified hypotheses 
Introduction 
Methods 
  Study design 4 Present key elements of study design early in 
the paper 
Methods 
  Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Methods 
  Participants 6 (a) Give the eligibility criteria, and the sources 
and methods of selection of participants. 
Describe methods of follow-up 
Methods, 
Appendix 
Figure 1 
(b) For matched studies, give matching criteria 
and number of exposed and unexposed 
Methods, 
Table 1, 2, 
Appendix 
Table 3, 4, 5 
  Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Methods, 
Appendix 
Table 2 
 Data sources/ 
 measurement 
8 For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one 
group 
Methods, 
Appendix 
Tables 2 
  Bias 9 Describe any efforts to address potential 
sources of bias 
Discussion 
  Study size 10 Explain how the study size was arrived at Methods; 
based on 
availability of 
the data 
  Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses. If applicable, describe which 
groupings were chosen and why 
Methods 
  Statistical methods 12 (a) Describe all statistical methods, including 
those used to control for confounding 
Methods 
(b) Describe any methods used to examine 
subgroups and interactions 
Methods 
(c) Explain how missing data were addressed Methods 
(d) If applicable, explain how loss to follow-up 
was addressed 
Not 
applicable 
(e) Describe any sensitivity analyses Methods 
Results 
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  Participants 13 (a) Report numbers of individuals at each stage 
of study—e.g. numbers potentially eligible, 
examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and 
analyzed 
Methods, 
Results, 
Appendix 
Figure 1 
(b) Give reasons for non-participation at each 
stage 
Methods, 
Appendix 
Figure 1 
  (c) Consider use of a flow diagram Appendix 
Figure 1 
  Descriptive data 14 (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders 
Table 1, 2 
Appendix 
Tables 4, 5 
(b) Indicate number of participants with missing 
data for each variable of interest 
Table 1, 2 
Appendix 
Tables 4, 5 
(c) Summarize follow-up time (e.g. average and 
total amount) 
Results, 
Table 3, 
Figure 1, 
Appendix 
Table 6, 7 
  Outcome data 15 Report numbers of outcome events or summary 
measures over time 
Results, 
Table 3, 
Figure 1, 
Appendix 
Table 6, 7, 8, 
9 
  Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their 
precision (e.g. 95% confidence interval). Make 
clear which confounders were adjusted for and 
why they were included 
Results, 
Table 3, 
Figure 1, 
Appendix 
Table 6, 7, 8, 
9 
(b) Report category boundaries when 
continuous variables were categorized 
Not 
applicable 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful 
time period 
Results, 
Table 3,  
Appendix 
Table 6, 7 
  Other analyses 17 Report other analyses done—e.g. analyses of 
subgroups and interactions, and sensitivity 
analyses 
Results, 
Appendix 
Table 6, 7, 8, 
9 
Discussion 
  Key results 18 Summarize key results with reference to study 
objectives 
Discussion 
  Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any 
potential bias 
Discussion 
  Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
Discussion 
  Generalizability 21 Discuss the generalizability (external validity) of 
the study results 
Discussion 
Other information 
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  Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, 
for the original study on which the present article 
is based 
Role of 
funding 
source 
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Table D-2. Coding definitions for comorbid conditions, outcomes and exposures 
Variable Database Code/Definition 
Comorbidities 
Benign brain tumour CIHI-DAD ICD-9 2250 
ICD-10 D330, D331, D332, D339 
OHIP 225 
Brain aneurysm CIHI-DAD ICD-9 4373 
ICD-10 I671 
Brain injury CIHI-DAD ICD-9 850, 851, 852, 853, 854 
ICD-10 S06 
Brain cancer CIHI-DAD ICD-9 191 
ICD-10 C71 
OHIP 191 
Meningitis CIHI-DAD ICD-9 320, 321, 322  
ICD-10 G00, G01, G02, G03 
OHIP 320, 321 
Encephalitis CIHI-DAD ICD-9 323 
ICD-10 G04, G05 
OHIP 323 
Congenital 
malformations 
CIHI-DAD ICD-9 74781, 74789, 7479 
ICD-10 Q28 
Epilepsy/seizure CIHI-DAD ICD-9 34500, 34501, 34510, 34511, 3452, 3453, 34540, 
34541, 34550, 34551, 34560, 34561, 34570, 34571, 
34580, 34581, 34590, 34591, 7803 
ICD-10 G40, G41, R5680, R5688 
OHIP 345, 780 
Migraine CIHI-DAD ICD-9 3460, 3461, 3462, 3468, 3469 
ICD-10 G430, G431, G432, G433, G438, G439 
OHIP 346 
Congestive heart failure CIHI-DAD ICD-9 425, 5184, 514, 428 
ICD-10 I500, I501, I509, I255, J81 
OHIP 428, R701, R702, Z429 
Chronic kidney disease CIHI-DAD ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 584, 586, 
5888, 5889, 5937, 2504 
ICD-10 E102, E112, E132, E142, I12, I13, N08, N18, N19 
OHIP 403, 585 
Hypertension CIHI-DAD ICD-9 401, 402, 403, 404, 405 
ICD10 I10, I11, I12, I13, I15 
OHIP 401, 402, 403 
Chronic liver disease CIHI-DAD ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 
7824, V026, 2750, 2751, 7891, 7895, 571 
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162, 
B942, Z225, E831, E830, K70, K713, K714, K715, K717, 
K721, K729, K73, K74, K753, K754, K758, K759, K76, 
K77 
OHIP 571, 573, 070, Z551, Z554 
Hypothyroidism  CIHI-DAD ICD-9 243, 2440, 2441, 2442, 2443, 2448, 2449 
ICD-10 E030, E031, E032, E033, E034, E035, E038, 
E039, E890 
OHIP 243, 244 
Cancer CIHI-DAD ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 
205, 206, 207, 208 
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 
991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56, 
C61, C82, C83, C85, C91, C92, C93, C94, C95, C00, D05 
OHIP 203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 
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174, 175, 183, 185 
Diabetes mellitus CIHI-DAD ICD-9 250 
ICD-10 E10, E11, E13, E14 
OHIP 250, K029, K030, Q040 
Diabetic neuropathy CIHI-DAD ICD-9 3572, 25060 
ICD-10 E1040, E1041, E1042, E1048, E1049, E1140, 
E1141, E1142, E1148, E1149, E1340, E1341, E1342, 
E1348, E1349, E1440, E1441, E1442, E1448, E1449, 
G590, G632 
Diabetic retinopathy CIHI-DAD ICD-9 36201, 36202, 36210, 36212, 36229 
ICD-10 E1030, E1031, E1032, E1033, E1034, E1130, 
E1131, E1131, E1132, E1133, E1134, H360 
Pneumonia  CIHI-DAD ICD-9 480, 481, 482, 483, 484, 485, 486, 7700 
ICD-10 J12, J13, J14, J15, J16, J17, J18, P23 
Coronary artery disease CIHI-DAD ICD-9 410, 412, 414, 4292, 4295, 4296, 4297 
ICD-10 I21, I22, I24, I25, Z955, Z958, Z959, R931, T822 
OHIP 410, 412, R741, R742, R743, G298, E646, E651, E652, 
E654, E655, G262, Z434, Z448 
Angina CIHI-DAD ICD-9 413 
ICD-10 I20, I23 
OHIP 413 
Atrial fibrillation/flutter CIHI-DAD ICD-9 4273 
ICD-10 I48 
Previous hyponatremia CIHI-DAD ICD-9 2761 
ICD-10 E871 
Myocardial Infarction  ICD-9 410 
ICD-10 I21, I22 
Haemorrhagic stroke CIHI-DAD ICD-9 430, 431 
ICD-10 I600, I601, I602, I603, I604, I605, I606, I607, I609, 
I61 
Ischemic stroke CIHI-DAD ICD-9 436, 4340, 4341, 4349, 3623 
ICD-10 I630, I631, I632, I633, I634, I635, I638, I639, I64, 
H341 
Transient ischemic 
attack 
CIHI-DAD ICD-9 435 
ICD-10 G450, G451, G452, G453, G458, G459, H340 
Chronic lung disease CIHI-DAD ICD-9 491, 492, 493, 494, 495, 496, 500, 501, 502, 503, 
504, 505, 5064, 5069, 5081, 515, 516, 517, 5185, 5188, 
5198, 5199, 4168, 4169 
ICD-10 I272, I278, I279, J40, J41, J42, J43, J44, J45, J47, 
J60, J61, J62, J63, J64, J65, J66, J67, J68, J701, J703, 
J704, J708, J709, J82, J84, J92, J941, J949, J953, J961, 
J969, J984, J988, J989, J99 
OHIP 491, 492, 493, 494, 496, 501, 502, 515, 518, 519, J689, 
J889 
Acute kidney injury CIHI-DAD ICD-9 584 
ICD-10 N17 
Adrenal Insufficiency CIHI-DAD ICD-9 2554 
ICD-10 E271, E272, E273, E274 
Hypotension CIHI-DAD ICD-9 458 
ICD-10 I95 
Acute urinary retention CIHI-DAD ICD-9 7882 
ICD-10 R33 
Delirium CIHI-DAD ICD-9 29011, 2903, 2910, 29281, 2930, 2931 
ICD-10 F05 
DSM-IV 78009, 29300 
Bipolar Disorder CIHI-DAD ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968 
ICD-10 F300, F301, F302, F308, F309, F310, F311, F312, 
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F313, F314, F315, F316, F317, F318, F319 
OHIP 296, Q020 
DSM-IV 29600, 29601, 29602, 29603, 29604, 29605, 29606, 
29640, 29641, 29642, 29643, 29644, 29645, 29646, 
29650, 29651, 29652, 29653, 29654, 29655, 29656, 
29660, 29661, 29662, 29663, 29664, 29665, 29666, 
29670, 29680, 29689 
Neuropathic Pain CIHI-DAD ICD-9 7292, 3510, 3511, 3518, 3519, 3520, 3521, 3522, 
3523, 3524, 3525, 3526, 3529, 3530, 3531, 3532, 3533, 
3534, 3535, 3536, 3538, 3539, 3540, 3541, 3542, 3543, 
3544, 3545, 3548, 3549, 3550, 3551, 3552, 3553, 3554, 
3555, 3556, 3557, 3558, 3559 
ICD-10 M7920, M7921, M7922, M7923, M7924, M7925, 
M7926, M7927, M7928, M7929, G628, G629, G630, 
G631, G530, G531, G532, G533, G538, G540, G541, 
G542, G543, G544, G545, G546, G547, G548, G549, 
G550, G551, G552, G553, G558, G560, G561, G562, 
G563, G564, G568, G569, G570, G571, G572, G573, 
G574, G575, G576, G577, G578, G579, G580, G587, 
G588, G589, G590, G598, G600, G601, G602, G603, 
G608, G609, G610, G611, G618, G619, G620, G621, 
G622, G628, G629, G630, G631, G633, G634, G635, 
G636, G638 
Mood Disorders CIHI-DAD ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968, 3004, 
311, 2962, 2963, 2969 
ICD-10 F30, F31, F340, F32, F33, F341, F381, F348, 
F349, F380, F388, F39 
DSM-IV 29600, 29601, 29602, 29603, 29604, 29605, 29606, 
29640, 29641, 29642, 29643, 29644, 29645, "9646, 
29650, 29651, 29652, 29653, 29654, 29655, 29656, 
29660, 29661, 29662, 29663, 29664, 29665, 29666, 
29670, 29680, 29689, 30113, 29383, 29690, 29620, 
29621, 29622, 29623, 29624, 29625, 29626, 29630, 
29631, 29632, 29633, 29634, 29635, 29636, 30040, 
31100 
OHIP 296, 311, Q020 
Anxiety Disorders CIHI-DAD ICD-9 3000, 3002, 3003, 3098, 3083 
ICD-10 F40, F41, F42, F430, F431, F438, F439 
DSM-IV 30001, 30021, 30022, 30029, 30023, 30030, 30981, 
30830, 30002, 29384, 30000 
OHIP 300 
Parkinson Disease CIHI-DAD ICD-9 332 
ICD-10 G20, F023 
OHIP 332 
Trigeminal Neuralgia CIHI-DAD ICD-9 3501, 3502, 3508, 3509 
ICD-10 G500, G501, G508, G509 
OHIP 350 
Peripheral vascular 
disease 
CIHI-DAD ICD-9 4402, 4408, 4409, 5571, 4439, 444 
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551 
OHIP R787, R780, R797, R804, R809, R875, R815, R936, 
R783, R784, R785, E626, R814, R786, R937, R860, 
R861, R855, R856, R933, R934, R791, E672, R794, 
R813, R867, E649 
Outcomes 
Hyponatremia* CIHI-DAD ICD-10 E871 
Bowel obstruction CIHI-DAD ICD-10 K56 
Exposures 
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Carbamazepine ODB Higher dose: >300 mg/day; Normal dose ≤300 mg/day 
Valproic acid Higher dose: >500 mg/day; Normal dose ≤500 mg/day 
Phenytoin Higher dose: >300 mg/day; Normal dose ≤300 mg/day 
Topiramate Higher dose: >50 mg/day; Normal dose ≤50 mg/day 
CCI=Canadian Classification of Health Interventions. CCP=Canadian Classification of Diagnostic, 
Therapeutic and Surgical Procedures. CIHI-DAD=Canadian Institute for Health Information Discharge 
Abstract Database. ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International 
Classification of Diseases, Tenth Revision. Ontario Drug Benefit database=ODB. OHIP=Ontario Health 
Insurance Plan database. RPDB=Ontario’s Registered Persons Database. 
*Validation of the code for hyponatremia was performed on approximately 64 499 hospitalizations with 
linked laboratory measurements for serum sodium. See Methods section for a description of the validation. 
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Table D-3. Variables included in propensity score model 
Demographics Age, sex, rural neighborhood 
Income  
Index date  
Residential status 
(community-dwelling or long-
term care) 
 
Comorbid conditions Charlson comorbidity index, Johns Hopkins ACG System Aggregated 
Diagnosis Groups, benign brain tumour, brain aneurysm, brain cancer, 
brain injury, encephalitis, meningitis, epilepsy/seizure, migraine, 
congenital malformations, congestive heart failure, chronic kidney 
disease, hypertension, chronic liver disease, hypothyroidism, cancer, 
diabetes mellitus, pneumonia, coronary artery disease, angina, atrial 
fibrillation/flutter, myocardial infarction, adrenal insufficiency, 
hemorrhagic stroke, ischemic stroke, transient ischemic attack, lung 
disease, acute kidney injury, hypotension, acute urinary retention, 
peripheral vascular disease, bipolar disorder, neuropathic pain, mood 
disorders, anxiety disorders, Parkinson’s disease, trigeminal neuralgia, 
diabetic neuropathy, diabetic retinopathy 
Concurrent medication use Number of unique drug products, antipsychotic, antidepressant, 
antidiabetics, antineoplastic, thyroxin, potassium sparing diuretic, non-
potassium sparing diuretic, ACE inhibitor and/or ARB, NSAID (excluding 
aspirin), calcium channel blocker, beta-adrenergic antagonist, statins, 
benzodiazepine, digoxin, overactive bladder, antibiotics, warfarin, 
anticoagulant, antiplatelet, acetylcholine inhaler, corticosteroid inhaler, 
beta-agonist inhaler, cholinesterase inhibitor, lithium, glucose tests 
strips, baclofen. 
Number of healthcare 
contacts 
Hospitalization, emergency department visit, family physician visit, 
psychiatrist visit, geriatrician visit, neurologist visit, nephrologist visit, 
cardiologist visit, urologist visit, obstetrician/gynecologist visit 
Number of healthcare uses Previous sodium tests, carotid ultrasound, cardiac catheterization, 
echocardiography, holter monitoring, cardiac stress test, coronary 
endarterectomy, colorectal cancer screening, cervical cancer screening, 
prostate-specific antigen test, mammography, flu shot, bone mineral 
density test, hearing test, cystoscopy, cataract surgery, magnetic 
resonance imaging of the head, computed tomography of the head, 
computed tomography of the neck, computed tomography of the thorax, 
computed tomography of the abdomen, computed tomography of the 
pelvis, computed tomography of the spine, computed tomography of the 
extremities, chest x-ray, pulmonary function test, 
electroencephalography, urine culture, heart valve replacement, at-
home physician service, cholesterol test 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin 
II receptor blocker. NSAID=non-steroidal anti-inflammatory drug. 
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Table D-4. Full baseline characteristics of carbamazepine users and non-users (1:3 matching ratio)* 
Characteristic Unmatched  Matched  
 Carbamazepine  
users 
(n= 24 905) 
Antiepileptic 
non-users 
 (n= 1 289 530) 
Standardized 
Differencea 
Carbamazepine 
users 
(n=21 191) 
Antiepileptic 
non-users 
 (n=63 573) 
Standardized 
Differencea 
Demographic       
Age, mean (SD), years 76 (7.1) 76 (7.2) 0.8% 76 (6.9) 76 (6.8) 0.3% 
Women 15 436 (62.0%) 742 126 (57.6%) 9.0% 13 284 (62.7%) 39 852 (62.7%) 0 
Income quintileb       
1  (low) 5388 (21.6%) 251 859 (19.5%) 5.2% 4508 (21.3%) 13 924 (21.9%) 1.5% 
2 5171 (20.8%) 269 597 (20.9%) 0.4% 4415 (20.8%) 13 123 (20.6%) 0.5% 
3 (medium) 4960 (19.9%) 252 663 (19.6%) 0.8% 4314 (20.3%) 12 960 (20.4%) 0.1% 
4 4798 (19.3%) 253 301 (19.6%) 1.0% 4099 (19.3%) 12 261 (19.3%) 0.1% 
5 (high) 4495 (18.1%) 258 046 (20.0%) 5.0% 3855 (18.2%) 11 305 (17.8%) 1.1% 
Year of cohort entry       
2003-2004 5825 (23.4%) 232 137 (18.0%) 13.3% 4894 (23.1%) 14 761 (23.2%) 0.3% 
2005-2006 5757 (23.1%) 254 656 (19.8%) 8.2% 4974 (23.5%) 14 854 (23.4%) 0.3% 
2007-2008 4433 (17.8%) 213 249 (16.5%) 3.4% 3822 (18.0%) 11 474 (18.1%) 0 
2009-2010 3740 (15.0%) 204 621 (15.9%) 2.4% 3161 (14.9%) 9509 (15.0%) 0.1% 
2011-2012 2840 (11.4%) 196 140 (15.2%) 11.2% 2376 (11.2%) 7096 (11.2%) 0.2% 
2013-2015 2310 (9.3%) 188 727 (14.6%) 16.6% 1964 (9.3%) 5879 (9.3%) 0.1% 
Rural residencec 4108 (16.5%) 182 927 (14.2%) 6.4% 3461 (16.3%) 10 623 (16.7%) 1.0% 
Long-term care 1691 (6.8%) 57 445 (4.5%) 10.2% 984 (4.6%) 2 952 (4.6%) 0 
Prescribing physician       
Family Physician 117 850 (71.7%)   15 323 (72.3%)   
Psychiatrist 239 (1.0%) 211 (1.0%) 
Geriatrician 148 (0.6%) 128 (0.6%) 
Neurologist 2075 (8.3%) 1629 (7.7%) 
Other 1533 (6.2%) 1308 (6.2%) 
Missing 3060 (12.3%) 2592 (12.2%) 
Comorbid conditionsd       
Charlson comorbidity index, mean (SD) 0.8 (1.5) 0.6 (1.3) 15.9% 0.7 (1.4) 0.7 (1.4) 0 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.2 (4.3) 11.5 (4.2) 41.0% 12.9 (4.2) 13.0 (4.1) 2.2% 
Epilepsy/seizuree 12 046 (48.4%) 396 047 (30.7%) 36.7% 9802 (46.3%) 29 406 (46.3%) 0 
Migraine 1780 (7.2%) 39 661 (3.1%) 18.6% 1358 (6.4%) 4095 (6.4%) 0.1% 
Trigeminal neuralgia 3235 (13.0%) 11 567 (0.9%) 49.0% 1377 (6.5%) 3817 (6.0%) 2.0% 
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Neuropathic pain 734 (3.0%) 18 587 (1.4%) 10.3% 535 (2.5%) 1530 (2.4%) 0.8% 
Bipolar disorder  143 (0.6%) 2154 (0.2%) 6.7% 561 (2.7%) 1667 (2.6%) 0.2% 
Mood disorder 683 (2.7%) 15 713 (1.2%) 11.0% 2442 (11.5%) 7286 (11.5%) 0.2% 
Anxiety disorder 11 293 (45.3%) 463 445 (35.9%) 19.2% 9335 (44.1%) 28 233 (44.4%) 0.7% 
Benign brain tumour 446 (1.8%) 7600 (0.6%) 11.1% 312 (1.5%) 952 (1.5%) 0.2% 
Brain aneurysm 30 (0.1%) 423 (0%) 3.2% 25 (0.1%) 64 (0.1%) 0.5% 
Brain cancer 234 (0.9%) 3001 (0.2%) 9.3% 141 (0.7%) 437 (0.7%) 0.3% 
Brain injury 127 (0.5%) 3896 (0.3%) 3.3% 97 (0.5%) 266 (0.4%) 0.6% 
Encephalitis 40 (0.2%) 676 (0.1%) 3.3% 25 (0.1%) 69 (0.1%) 0.3% 
Meningitis 42 (0.2%) 840 (0.1%) 3.0% 30 (0.1%) 88 (0.1%) 0.1% 
Parkinson’s disease 671 (2.7%) 24 413 (1.9%) 5.4% 508 (2.4%) 1537 (2.4%) 0.1% 
Congestive heart failure 3516 (14.1%) 144 842 (11.2%) 8.7% 2417 (11.4%) 7251 (11.4%) 0 
Chronic kidney disease 1640 (6.6%) 77 172 (6.0%) 2.5% 920 (4.3%) 2760 (4.3%) 0 
Hypertension 18 180 (73.0%) 953 061 (73.9%) 2.1% 15 300 (72.2%) 45 888 (72.2%) 0 
Chronic liver disease 842 (3.4%) 39 103 (3.0%) 2.0% 686 (3.2%) 2026 (3.2%) 0.3% 
Hypothyroidism 2571 (10.3%) 121 865 (9.5%) 2.9% 2186 (10.3%) 6474 (10.2%) 0.4% 
Cancerf 3553 (14.3%) 168 419 (13.1%) 3.5% 2969 (14.0%) 8803 (13.9%) 0.5% 
Diabetes mellitus 7116 (28.6%) 358 136 (27.8%) 1.8% 5943 (28.0%) 17 346 (27.3%) 1.7% 
Diabetic neuropathy 172 (0.7%) 3216 (0.3%) 6.5% 112 (0.5%) 275 (0.4%) 1.4% 
Diabetic retinopathy 155 (0.6%) 5031 (0.4%) 3.3% 109 (0.5%) 334 (0.5%) 0.2% 
Pneumonia 1187 (4.8%) 43 322 (3.4%) 7.1% 868 (4.1%) 2442 (3.8%) 1.3% 
Coronary artery diseaseg 7785 (31.3%) 356 915 (27.7%) 7.9% 6276 (29.6%) 18 916 (29.8%) 0.3% 
Angina 5885 (23.6%) 245 038 (19.0%) 11.3% 4763 (22.5%) 14 575 (22.9%) 1.1% 
Atrial fibrillation/flutter  1621 (6.5%) 73 573 (5.7%) 3.4% 1235 (5.8%) 3587 (5.6%) 0.8% 
Previous hyponatremia 536 (2.2%) 16 299 (1.3%) 6.9% 378 (1.8%) 1158 (1.8%) 0.3% 
Previous delirium 444 (1.8%) 14 306 (1.1%) 5.6% 276 (1.3%) 919 (1.5%) 1.2% 
Myocardial infarction 988 (4.0%) 43 693 (3.4%) 3.1% 745 (3.5%) 2225 (3.5%) 0.1% 
Adrenal insufficiency 9 (0%)  471 (0%) 0% 7 (0%) 16 (0%) 0.5% 
Hemorrhagic stroke 123 (0.5%) 2561 (0.2%) 5.0% 77 (0.4%) 246 (0.4%) 0.4% 
Ischemic stroke 807 (3.2%) 22 836 (1.8%) 9.4% 568 (2.7%) 1655 (2.6%) 0.5% 
Transient ischemic attack 336 (1.4%) 9789 (0.8%) 5.8% 231 (1.1%) 694 (1.1%) 0 
Acute kidney injury 460 (1.9%) 20 448 (1.6%) 2.0% 272 (1.3%) 787 (1.2%) 0.4% 
Hypotension 428 (1.7%) 16 113 (1.3%) 3.9% 289 (1.4%) 853 (1.3%) 0.2% 
Acute urinary retention 558 (2.2%) 21 821 (1.7%) 4.0% 422 (2.0%) 1205 (1.9%) 0.7% 
Peripheral vascular disease 585 (2.4%) 18 175 (1.4%) 6.9% 417 (2.0%) 1290 (2.0%) 0.4% 
Lung disease  7392 (29.7%) 310 878 (24.1%) 12.6% 6067 (28.6%) 18 487 (29.1%) 1.0% 
Concurrent medication useh       
Number of unique drug products, mean 8.9 (6.0) 7.1 (4.7) 33.5% 8.4 (5.6) 8.4 (5.4) 0.2% 
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(SD) 
Antipsychotics 1473 (5.9%) 48 323 (3.7%) 10.1% 1070 (5.1%) 3276 (5.2%) 0.5% 
Antidepressants 7781 (31.2%) 215 229 (16.7%) 34.6% 6056 (28.6%) 18 644 (29.3%) 1.7% 
Antidiabetics 4496 (18.1%) 225 528 (17.5%) 1.5% 3766 (17.8%) 10 934 (17.2%) 1.5% 
Antineoplastics 960 (3.9%) 44 902 (3.5%) 2.0% 799 (3.8%) 2416 (3.8%) 0.2% 
Thyroxine 4136 (16.6%) 204 370 (15.8%) 2.1% 3513 (16.6%) 10 393 (16.4%) 0.6% 
Potassium sparing diuretics 1578 (6.3%) 69 702 (5.4%) 4.0% 1278 (6.0%) 3600 (5.7%) 1.6% 
Non-potassium sparing diuretics  7563 (30.4%) 383 139 (29.7%) 1.4% 6053 (28.6%) 18 324 (28.8%) 0.6% 
ACE inhibitors and/or ARBs 11 605 (46.6%) 627 455 (48.7%) 4.1% 9815 (46.3%) 29 171 (45.9%) 0.9% 
NSAIDs (excl. ASA) 6267 (25.2%) 224 624 (17.4%) 19.0% 5286 (24.9%) 16 556 (26.0%) 2.5% 
Calcium channel blockers 6940 (27.9%) 361 121 (28.0%) 0.3% 5789 (27.3%) 17 310 (27.2%) 0.2% 
Beta-adrenergic antagonists 7165 (28.8%) 385 357 (29.9%) 2.4% 6011 (28.4%) 17 643 (27.8%) 1.4% 
Statins 9439 (37.9%) 542 836 (42.1%) 8.6% 8082 (38.1%) 23 835 (37.5%) 1.3% 
Benzodiazepines 6597 (26.5%) 216 925 (16.8%) 23.6% 5289 (25.0%) 16 528 (26.0%) 2.4% 
Digoxin 1044 (4.2%) 46 646 (3.6%) 3.0% 812 (3.8%) 2459 (3.9%) 0.2% 
Overactive bladder 986 (4.0%) 35 023 (2.7%) 6.9% 811 (3.8%) 2433 (3.8%) 0 
Antibiotics 9553 (38.4%) 388 511 (30.1%) 17.4% 7870 (37.1%) 23 707 (37.3%) 0.3% 
Warfarin 1947 (7.8%) 100 225 (7.8%) 0.2% 1549 (7.3%) 4635 (7.3%) 0.1% 
Anticoagulents 213 (0.9%) 13 884 (1.1%) 2.3% 170 (0.8%) 469 (0.7%) 0.7% 
Antiplatelets 1555 (6.2%) 63 795 (4.9%) 5.6% 1224 (5.8%) 3550 (5.6%) 0.8% 
Acetylcholine inhalers 1528 (6.1%) 69 110 (5.4%) 3.3% 1204 (5.7%) 3769 (5.9%) 1.1% 
Corticosteroid inhalers 1623 (3.9%) 74 369 (3.6%) 1.7% 1375 (3.6%) 4085 (3.6%) 0.5% 
Beta-agonist inhalers 3278 (13.2%) 150 199 (11.6%) 4.6% 2681 (12.7%) 8069 (12.7%) 0.1% 
Cholinesterase inhibitors 970 (3.9%) 45 953 (3.6%) 1.7% 752 (3.6%) 2315 (3.6%) 0.5% 
Lithium 101 (0.4%) 2397 (0.2%) 4.0% 76 (0.4%) 249 (0.4%) 0.5% 
Glucose test strips 3562 (14.3%) 165 484 (12.8%) 4.3% 2958 (13.0%) 8543 (13.4%) 1.5% 
Baclofen 449 (1.8%) 6414 (0.5%) 12.3% 294 (1.4%) 924 (1.5%) 0.6% 
Healthcare contacts, mean (SD)i       
Hospitalizations 0.6 (1.1)  0.4 (0.9) 19.4% 0.6 (1.1) 0.6 (1.1) 0.9% 
Emergency department visits 1.0 (1.8) 0.5 (1.2) 29.5% 0.8 (1.6) 0.8 (1.7) 1.3% 
Family physician visits 12.8 (13.0) 9.0 (9.2) 34.4% 11.5 (10.9) 11.5 (11.2) 0.4% 
Geriatrician visits 0.2 (1.9) 0.1 (1.1) 6.7% 0.1 (1.5) 0.1 (1.3) 0 
Psychiatrist visits 0.4 (3.7) 0.1 (1.8) 9.1% 0.3 (3.2) 0.3 (3.2) 0.3% 
Neurologist visits 0.4 (2.0) 0.1 (0.7) 23.9% 0.31 (1.0) 0.2 (1.1) 6.6% 
Nephrologist visits 0.1 (0.9) 0.1 (0.7) 2.4% 0.1 (0.8) 0.1 (0.7) 1.3% 
Cardiologist visits 1.1 (2.6) 0.9 (2.3) 7.7% 1.0 (2.4) 1.0 (2.3) 0.9% 
Urologist visits 0.3 (1.4) 0.3 (1.2) 3.1% 0.3 (1.4) 0.3 (1.3) 0 
Obstetrician/Gynecologist visits 0.1 (0.6) 0.1 (0.7) 1.6% 0.1 (0.6) 0.1 (0.7) 1.6% 
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Healthcare usej       
Previous sodium tests 14 835 (59.6%) 745 101 (57.8%) 3.6% 12 217 (57.7%) 36 567 (57.5%) 0.3% 
Carotid ultrasound 1750 (7.0%) 53 990 (4.2%) 12.4% 1382 (6.5%) 4024 (6.3%) 0.8% 
Cardiac catheterization 380 (1.5%) 18 080 (1.4%) 1.0% 2572 (12.1%) 7795 (12.3%) 0.4% 
Echocardiography 4106 (16.5%) 190 435 (14.8%) 4.7% 1308 (6.2%) 3971 (6.3%) 0.3% 
Holter monitoring 1761 (7.1%) 70 045 (5.4%) 6.8% 315 (1.5%) 890 (1.4%) 0.7% 
Cardiac stress test 3095 (12.4%) 127 001 (9.8%) 8.2% 3309 (15.6%) 9737 (15.3%) 0.8% 
Coronary endarterectomy 22 (0.1%) 788 (0.1%) 1.0% 20 (0.1%) 50 (0.1%) 0.5% 
Colorectal cancer screening 4510 (18.1%) 243 069 (18.8%) 1.9% 3846 (18.2%) 11 413 (18.0%) 0.5% 
Cervical cancer screening 1364 (5.5%) 77 134 (6.0%) 2.2% 1234 (5.8%) 3687 (5.8%) 0.1% 
Prostate specific antigen test 783 (3.1%) 48 576 (3.8%) 3.4% 683 (3.2%) 2127 (3.4%) 0.7% 
Mammography 2250 (9.0%) 120 405 (9.3%) 1.0% 1994 (9.4%) 6117 (9.6%) 0.7% 
Flu shot 13 809 (55.4%) 703 334 (54.5%) 1.8% 11 829 (55.8%) 35 703 (56.2%) 0.7% 
Thyroid stimulating hormone 13 181 (52.9%) 665 897 (51.6%) 2.6% 11 073 (52.3%) 32 855 (51.7%) 1.2% 
Bone mineral density test 2871 (11.5%) 151 488 (11.7%) 0.7% 2542 (12.0%) 7582 (11.9%) 0.2% 
Hearing test 1403 (5.6%) 58 607 (4.5%) 5.0% 1164 (5.5%) 3478 (5.5%) 0.1% 
Cytoscopy 1160 (4.7%) 48 227 (3.7%) 4.6% 951 (4.5%) 2909 (4.6%) 0.4% 
Cataract surgery 1221 (4.9%) 61 776 (4.8%) 0.5% 1046 (4.9%) 3193 (5.0%) 0.4% 
Magnetic resonance imaging of the head 1581 (6.3%) 20 572 (1.6%) 24.5% 997 (4.7%) 2942 (4.6%) 0.4% 
Computed tomography of the head 4443 (17.8%)
  
90 235 (7.0%) 33.3% 3130 (14.8%) 9373 (14.7%) 0.1% 
Computed tomography of the neck 348 (1.4%) 7581 (0.6%) 8.2% 250 (1.2%) 762 (1.2%) 0.2% 
Computed tomography of the thorax 1563 (6.3%) 56 709 (4.4%) 8.4% 1256 (5.9%) 3680 (5.8%) 0.6% 
Computed tomography of the abdomen 2237 (9.0%) 81 533 (6.3%) 10.0% 1759 (8.3%) 5361 (8.4%) 0.5% 
Computed tomography of the pelvis 1999 (8.0%) 72 632 (5.6%) 9.5% 1560 (7.4%) 4750 (7.5%) 0.4% 
Computed tomography of the spine 939 (3.8%) 18 193 (1.4%) 14.9% 706 (3.3%) 2021 (3.2%) 0.9% 
Computed tomography of the extremities 197 (0.8%) 5709 (0.4%) 4.4% 152 (0.7%) 445 (0.7%) 0.2% 
Chest x-ray 9594 (38.5%) 388 460 (30.1%) 17.8% 7697 (36.3%) 23 389 (36.8%) 1.0% 
Pulmonary function test 2127 (8.5%) 95 359 (7.4%) 4.2% 1766 (8.3%) 5248 (8.3%) 0.3% 
Electroencephalography  860 (3.5%) 4318 (0.3%) 23.0% 454 (2.1%) 1125 (1.8%) 2.7% 
Urine culture 6081 (24.4%) 260 583 (20.2%) 10.1% 4865 (23.0%) 14 487 (22.8%) 0.4% 
Heart valve replacement 31 (0.1%) 1444 (0.1%) 0.4% 26 (0.1%) 61 (0.1%) 0.8% 
At-home physician services 1163 (4.7%) 36 321 (2.8%) 9.8% 864 (4.1%) 2539 (4.0%) 0.4% 
Cholesterol tests 12 830 (51.5%) 732 331 (56.8%) 10.6% 11 054 (52.2%) 32 633 (51.3%) 1.7% 
Laboratory measurementsk       
Most recent serum sodium, N (%) 3631 (14.6%) 183 468 (14.2%) 1.0% 2592 (12.2%) 7776 (12.2%) 0 
Most recent serum sodium, mean (SD) 140.3 (3.4) 140.6 (3.0) 9.8% 140.4 (3.3) 140.5 (3.0) 4.1% 
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ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.32% missing values in matched users and non-users. 
These patients were included in income quintile 3 (“average” income). 
c There were less than 0.04% missing values in both matched users and non-users. These patients were included in the urban category. 
d Comorbid conditions in the five years preceding the index date were considered. 
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the 
condition. 
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal. 
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
h Concurrent medication use in the six months preceding the index date were considered. 
i Healthcare contacts in the year preceding the index date were considered. 
j Healthcare use in the year preceding the index date was considered. 
k Serum sodium measurements were obtained at a median (IQR) of 132 (58 to 229) days prior to the index date in users, and 134 (64 to 230) days in non-users.  
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Table D-5. Full baseline characteristics of valproic acid (V), phenytoin (P), and topiramate (T) users and non-users (1:2 matching 
ratio)* 
Characteristic Unmatched Matched 
 V-P-T 
users 
(n= 26 365) 
Antiepileptic 
 non-users 
 (n= 1 289 530) 
Standardized 
Differencea 
V-P-T 
users 
(n= 20 155) 
Antiepileptic 
 non-users 
 (n= 40 310) 
Standardized 
Differencea 
Demographic       
Age, years, mean (SD) 76 (7.7)  76 (7.2) 5.6% 76 (7.7) 76 (7.6) 0% 
Women 14 780 (56.1%) 742 126 (57.6%) 3.0% 11 708 (58.1%) 23 416 (58.1%) 0% 
Income quintileb       
1  (low) 5693 (21.6%) 251 859 (19.5%) 5.1% 4321 (21.4%) 8818 (21.9%) 1.1% 
2 5424 (20.6%) 269 597 (20.9%) 0.8% 4182 (20.8%) 8280 (20.5%) 0.5% 
3 (medium) 5020 (19.0%) 252 663 (19.6%) 1.4% 3897 (19.3%) 7799 (19.4%) 0% 
4 5078 (19.3%) 253 301 (19.6%) 1.0% 3908 (19.4%) 7687 (19.1%) 0.8% 
5 (high) 5044 (19.1%) 258 046 (20.0%) 2.2% 3847 (19.1%) 7726 (19.2%) 0.2% 
Year of cohort entry       
2003-2004 4513 (17.1%) 232 137 (18.0%) 2.3% 3738 (18.6%) 7461 (18.5%) 0.1% 
2005-2006 5072 (19.2%) 254 656 (19.7%) 1.3% 4056 (20.1%) 8154 (20.2%) 0.3% 
2007-2008 4216 (16.0%) 213 249 (16.5%) 1.5% 3172 (15.7%) 6308 (15.7%) 0.3% 
2009-2010 4033 (15.3%) 204 621 (15.9%) 1.6% 2908 (14.4%) 5844 (14.5%) 0.2% 
2011-2012 4273 (16.2%) 196 140 (15.2%) 2.7% 3132 (15.5%) 6275 (15.6%) 0.1% 
2013-2015 4258 (16.2%) 188 727 (14.6%) 4.2% 3149 (15.6%) 6268 (15.6%) 0.2% 
Rural residencec 3601 (13.7%) 182 927 (14.2%) 1.5% 2835 (14.1%) 5887 (14.6%) 1.5% 
Long-term care 7071 (26.8%) 57 445 (4.5%) 64.7% 4482 (22.2%) 8964 (22.2%) 0% 
Prescribing physician       
Family Physician 16 630 (63.1%)   12 924 (64.1%)   
Psychiatrist 2202 (8.4%) 1495 (7.4%) 
Geriatrician 255 (1.0%) 181 (0.9%) 
Neurologist 2678 (10.2%) 2060 (10.2%) 
Other 1603 (6.1%) 1242 (6.2%) 
Missing 2997 (11.4%) 2253 (11.2%) 
Comorbid conditionsd       
Charlson comorbidity index, mean (SD) 1.2 (1.7)  0.6 (1.3) 37.5% 0.9 (1.5) 0.9 (1.6) 0.7% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
13.5 (4.5)
 
11.5 (4.2) 45.4% 13.0 (4.5) 13.0 (4.3) 1.4% 
236 
 
 
 
 
  
Epilepsy/seizuree 16 029 (60.8%) 396 047 (30.7%) 63.3% 11 602 (57.6%) 23 204 (57.6%) 0.0% 
Migraine 2461 (9.3%) 39 661 (3.1%) 26.2% 1831 (9.1%) 3878 (9.6%) 1.8% 
Trigeminal neuralgia 470 (1.8%) 11 567 (0.9%) 7.7% 364 (1.8%) 784 (1.9%) 1.0% 
Neuropathic pain 476 (1.8%) 18 587 (1.4% 2.9% 350 (1.7%) 730 (1.8%) 0.6% 
Bipolar disorder  1176 (4.5%) 2154 (0.2%) 28.9% 1962 (9.7%) 3773 (9.4%) 1.3% 
Mood disorder 2461 (9.3%) 15 713 (1.2%) 36.9% 4556 (22.6%) 9210 (22.8%) 0.6% 
Anxiety disorder 15 118 (57.3%) 463 445 (35.9%) 43.9% 10 918 (54.2%) 22 697 (56.3%) 4.3% 
Benign brain tumour 898 (3.4%) 7600 (0.6%) 20.2% 466 (2.3%) 928 (2.3%) 0.1% 
Brain aneurysm 56 (0.2%) 423 (0%) 5.1% 29 (0.1%) 55 (0.1%) 0.2% 
Brain cancer 864 (3.3%) 3001 (0.2%) 23.3% 353 (1.8%) 702 (1.7%) 0.1% 
Brain injury 716 (2.7%) 3896 (0.3%) 19.9% 360 (1.8%) 595 (1.5%) 2.4% 
Encephalitis 123 (0.5%) 676 (0.1%) 8.1% 55 (0.3%) 75 (0.2%) 1.8% 
Meningitis 89 (0.3%) 840 (0.1%) 6.1% 43 (0.2%) 76 (0.2%) 0.6% 
Parkinson’s disease 1522 (5.8%) 24 413 (1.9%) 20.3% 1024 (5.1%) 2001 (5.0%) 0.5% 
Congestive heart failure 3933 (14.9%) 144 842 (11.2%) 10.9% 2294 (11.4%) 4588 (11.4%) 0.0% 
Chronic kidney disease 1990 (7.5%) 77 172 (6.0%) 6.2% 787 (3.9%) 1574 (3.9%) 0.0% 
Hypertension 17 695 (67.1%) 953 061 (73.9%) 14.9% 13 253 (65.8%) 25 604 (63.5%) 4.7% 
Chronic liver disease 978 (3.7%) 39 103 (3.0%) 3.8% 697 (3.5%) 1390 (3.4%) 0.1% 
Hypothyroidism 2733 (10.4%) 121 865 (9.5%) 3.1% 2014 (10.0%) 3924 (9.7%) 0.9% 
Cancerf 3910 (14.8%) 168 419 (13.1%) 5.1% 2856 (14.2%) 5929 (14.7%) 1.5% 
Diabetes 7416 (28.1%) 358 136 (27.8%) 0.8% 5337 (26.5%) 9930 (24.6%) 4.2% 
Diabetic neuropathy 147 (0.6%) 3216 (0.2%) 4.9% 87 (0.4%) 159 (0.4%) 0.6% 
Diabetic retinopathy 128 (0.5%) 5031 (0.4%) 1.4% 65 (0.3%) 144 (0.4%) 0.6% 
Pneumonia 1910 (7.2%) 43 322 (3.4%) 17.4% 1174 (5.8%) 2281 (5.7%) 0.7% 
Coronary artery diseaseg 7848 (29.8%) 356 915 (27.7%) 4.6% 5593 (27.7%) 11 096 (27.5%) 0.5% 
Angina 5275 (20.0%) 245 038 (19.0%) 2.5% 3802 (18.9%) 7598 (18.8%) 0.0% 
Atrial fibrillation/flutter  2404 (9.1%) 73 573 (5.7%) 13.1% 1507 (7.5%) 2930 (7.3%) 0.8% 
Previous hyponatremia 874 (3.3%) 16 299 (1.3%) 13.7% 529 (2.6%) 1037 (2.6%) 0.3% 
Previous delirium 1454 (5.5%) 14 306 (1.1%) 24.8% 766 (3.8%) 1436 (3.6%) 1.3% 
Myocardial infarction 1078 (4.1%) 43 693 (3.4%) 3.7% 707 (3.5%) 1420 (3.5%) 0.1% 
Adrenal Insufficiency 27 (0.1%) 471 (0%) 2.5% 15 (0.1%) 40 (0.1%) 0.8% 
Hemorrhagic stroke 506 (1.9%) 2561 (0.2%) 16.9% 248 (1.2%) 399 (1.0%) 2.3% 
Ischemic stroke 2101 (8.0%) 22 836 (1.8%) 29.1% 1199 (5.9%) 2350 (5.8%) 0.5% 
Transient ischemic attack 611 (2.3%) 9789 (0.8%) 12.7% 391 (1.9%) 771 (1.9%) 0.2% 
Acute kidney injury 899 (3.4%) 20 448 (1.6%) 11.7% 420 (2.1%) 716 (1.8%) 2.2% 
Hypotension 698 (2.6%) 16 113 (1.2%) 10.1% 414 (2.1%) 806 (2.0%) 0.4% 
Acute urinary retention 821 (3.1%) 21 821 (1.7%) 9.3% 503 (2.5%) 980 (2.4%) 0.4% 
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Peripheral vascular disease 573 (2.2%) 18 175 (1.4%) 5.8% 397 (2.0%) 795 (2.0%) 0.0% 
Lung disease  7547 (28.6%) 310 878 (24.1%) 10.3% 5515 (27.4%) 11 110 (27.6%) 0.4% 
Concurrent medication useh       
Number of unique drug products, mean 
(SD) 
9.1 (6.7)  7.1 (4.7) 35.3% 8.5 (6.3) 8.4 (5.6) 1.9% 
Antipsychotics 6978 (26.5%) 48 323 (3.7%) 66.9% 4369 (21.7%) 8520 (21.1%) 1.3% 
Antidepressants 10 751 (40.8%) 215 229 (16.7%) 55.2% 7617 (37.8%) 15 852 (39.3%) 3.2% 
Antidiabetics 4096 (15.5%) 225 528 (17.5%) 5.3% 2991 (14.8%) 5735 (14.2%) 1.7% 
Antineoplastics 919 (3.5%) 44 902 (3.5%) 0% 671 (3.3%) 1394 (3.5%) 0.7% 
Thyroxine 4417 (16.8%) 204 370 (15.8%) 2.4% 3321 (16.5%) 6754 (16.8%) 0.7% 
Potassium sparing diuretics 1193 (4.5%) 69 702 (5.4%) 4.1% 863 (4.3%) 1701 (4.2%) 0.3% 
Non-potassium sparing diuretics  6980 (26.5%) 383 139 (29.7%) 7.2% 4951 (24.6%) 9791 (24.3%) 0.6% 
ACE inhibitors and/or ARBs 10 045 (38.1%) 627 455 (48.7%) 21.4% 7706 (38.2%) 14 777 (36.7%) 3.3% 
NSAIDs (excl. ASA) 4027 (15.3%) 224 624 (17.4%) 5.8% 3266 (16.2%) 6583 (16.3%) 0.3% 
Calcium channel blockers 5673 (21.5%) 361 121 (28.0%) 15.1% 4343 (21.5%) 8205 (20.4%) 2.9% 
Beta-adrenergic agonists 6746 (25.6%) 385 357 (29.9%) 9.6% 5085 (25.2%) 9607 (23.8%) 3.2% 
Statins 8540 (32.4%) 542 836 (42.1%) 20.2% 6516 (32.3%) 12 125 (30.1%) 4.9% 
Benzodiazepines 7956 (30.2%) 216 925 (16.8%) 31.9% 5633 (27.9%) 11 896 (29.5%) 3.5% 
Digoxin 1026 (3.9%) 46 646 (3.6%) 1.4% 739 (3.7%) 1494 (3.7%) 0.2% 
Overactive bladder 959 (3.6%) 35 023 (2.7%) 5.3% 709 (3.5%) 1446 (3.6%) 0.4% 
Antibiotics 9449 (35.8%) 388 511 (30.1%) 12.2% 7114 (35.3%) 14 184 (35.2%) 0.2% 
Warfarin 2234 (8.5%) 100 225 (7.8%) 2.6% 1603 (8.0%) 3167 (7.9%) 0.4% 
Anticoagulents 440 (1.7%) 13 884 (1.1%) 5.1% 303 (1.5%) 536 (1.3%) 1.5% 
Antiplatlets 2191 (8.3%) 63 795 (4.9%) 13.5% 1502 (7.5%) 3044 (7.6%) 0.4% 
Acetylcholine inhalers 1676 (6.4%) 69 110 (5.4%) 4.2% 1225 (6.1%) 2427 (6.0%) 0.2% 
Corticosteroid inhalers 1532 (13.2%) 74 369 (3.6%) 35.2% 1209 (11.8%) 2373 (11.8%) 0.2% 
Beta-agonist inhalers 3318 (12.6%) 150 199 (11.6%) 2.9% 2527 (12.5%) 4958 (12.3%) 0.7% 
Cholinesterase inhibitors 3473 (13.2%) 45 953 (3.6%) 35.2% 2381 (11.8%) 4738 (11.8%) 0.2% 
Lithium 839 (3.2%) 2397 (0.2%) 23.4% 332 (1.6%) 660 (1.6%) 0.1% 
Glucose test strips 3085 (11.7%) 165 484 (12.8%) 3.5% 2251 (11.2%) 4244 (10.5%) 2.1% 
Baclofen 335 (1.3%) 6414 (0.5%) 8.3% 230 (1.1%) 485 (1.2%) 0.6% 
Healthcare contacts, mean (SD)i       
Hospitalizations 0.8 (1.3)  0.4 (0.9) 33.0% 0.7 (1.2) 0.6 (1.1) 3.5% 
Emergency department visits 1.3 (1.9) 0.5 (1.2) 46.3% 1.0 (1.6) 1.0 (1.8) 2.9% 
Family physician visits 17.2 (19.1) 9.0 (9.2) 58.4% 14.5 (15.5) 14.2 (14.7) 2.1% 
Geriatrician visits 0.6 (3.6) 0.1 (1.1) 19.7% 0.4 (2.5) 0.3 (2.1) 3.1% 
Psychiatrist visits 2.7 (11.5) 0.1 (1.8) 38.2% 1.2 (4.8) 0.8 (4.1) 10.1% 
Neurologist visits 0.8 (2.9)  0.1 (0.7) 39.5% 0.5 (1.6) 0.4 (1.5) 8.5% 
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Nephrologist visits 0.2 (1.2)  0.1 (0.7) 7.1% 0.1 (0.9) 0.1 (0.8) 1.2% 
Cardiologist visits 1.4 (3.4)  0.9 (2.3) 17.0% 1.1 (2.7) 1.1 (2.6) 1.5% 
Urologist visits 0.3 (1.5)  0.3 (1.2) 2.9% 0.3 (1.3) 0.3 (1.3) 0.8% 
Obstetrician/Gynecologist visits 0.1 (0.6) 0.1 (0.7) 3.3% 0.1 (0.6) 0.1 (0.6) 1.7% 
Healthcare usej       
Previous sodium tests 17 093 (64.8%) 745 101 (57.8%) 14.5% 12 566 (62.3%) 24 958 (61.9%) 0.9% 
Carotid ultrasound 2639 (10.0%) 53 990 (4.2%) 22.8% 1554 (7.7%) 3378 (8.4%) 2.5% 
Cardiac catheterization 389 (1.5%) 18 080 (1.4%) 0.6% 257 (1.3%) 555 (1.4%) 0.9% 
Echocardiography 4921 (18.7%) 190 435 (14.8%) 10.5% 3187 (15.8%) 6374 (15.8%) 0.0% 
Holter monitoring 2397 (9.1%) 70 045 (5.4%) 14.1% 1528 (7.6%) 3023 (7.5%) 0.3% 
Cardiac stress test 2485 (9.4%) 127 001 (9.8%) 1.4% 1833 (9.1%) 3643 (9.0%) 0.2% 
Coronary endarterectomy 45 0.2%) 788 (0.1%) 3.2% 22 (0.1%) 53 (0.1%) 0.6% 
Colorectal cancer screening 3823 (14.5%) 243 069 (18.8%) 11.7% 3010 (14.9%) 5838 (14.5%) 1.3% 
Cervical cancer screening 1014 (3.8%) 77 134 (6.0%) 9.9% 878 (4.4%) 1648 (4.1%) 1.3% 
Prostate specific antigen test 704 (2.7%) 48 576 (3.8%) 6.2% 567 (2.8%) 1182 (2.9%) 0.7% 
Mammography 1771 (6.7%) 120 405 (9.3%) 9.7% 1437 (7.1%) 2889 (7.2%) 0.1% 
Flu shot 11 305 (42.9%) 703 334 (54.5%) 23.5% 8988 (44.6%) 17 657 (43.8%) 1.6% 
Thyroid stimulating hormone 15 359 (58.3%) 665 897 (51.6%) 13.3% 11 412 (56.6%) 22 543 (55.9%) 1.4% 
Bone mineral density test 2148 (8.1%) 151 488 (11.7%) 12.1% 1766 (8.8%) 3325 (8.2%) 1.8% 
Hearing test 1124 (4.3%) 58 607 (4.5%) 1.4% 890 (4.4%) 1762 (4.4%) 0.2% 
Cytoscopy 1215 (4.6%) 48 227 (3.7%) 4.3% 841 (4.2%) 1690 (4.2%) 0.1% 
Cataract surgery 958 (3.6%) 61 776 (4.8%) 5.8% 767 (3.8%) 1493 (3.7%) 0.5% 
Magnetic resonance imaging of the head 3094 (11.7%) 20 572 (1.6%) 41.5% 1492 (7.4%) 2982 (7.4%) 0.0% 
Computed tomography of the head 9758 (37.0%) 90 235 (7.0%) 77.7% 5500 (27.3%) 11 201 (27.8%) 1.1% 
Computed tomography of the neck 540 (2.0%) 7581 (0.6%) 12.8% 293 (1.5%) 642 (1.6%) 1.1% 
Computed tomography of the thorax 2268 (8.6%) 56 709 (4.4%) 17.1% 1451 (7.2%) 3045 (7.6%) 1.4% 
Computed tomography of the abdomen 2789 (10.6%) 81 533 (6.3%) 15.3% 1860 (9.2%) 3725 (9.2%) 0.0% 
Computed tomography of the pelvis 2495 (9.5%) 72 632 (5.6%) 14.5% 1631 (8.1%) 3249 (8.1%) 0.1% 
Computed tomography of the spine 762 (2.9%) 18 193 (1.4%) 10.2% 485 (2.4%) 912 (2.3%) 1.0% 
Computed tomography of the extremities 262 (1.0%) 5709 (0.4%) 6.5% 163 (0.8%) 333 (0.8%) 0.2% 
Chest x-ray 12 588 (47.7%) 388 460 (30.1%) 36.7% 8411 (41.7%) 17 024 (42.2%) 1.0% 
Pulmonary function test 1996 (7.6%) 95 359 (7.4%) 0.7% 1497 (7.4%) 3066 (7.6%) 0.7% 
Electroencephalography  2672 (10.1%) 4318 (0.3%) 45.1% 826 (4.1%) 1240 (3.1%) 5.5% 
Urine culture 8332 (31.6%) 260 583 (20.2%) 26.2% 5965 (29.6%) 11 710 (29.0%) 1.2% 
Heart valve replacement 72 (0.3%) 1444 (0.1%) 3.7% 33 (0.2%) 81 (0.2%) 0.9% 
At-home physician services 1978 (7.5%) 36 321 (2.8%) 21.3% 1256 (6.2%) 2402 (6.0%) 1.1% 
Cholesterol tests 11 674 (44.3%) 732 331 (56.8%) 25.2% 9136 (45.3%) 17 461 (43.3%) 4.1% 
Laboratory measurementsk       
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Most recent serum sodium, N (%) 3681 (14.0%) 183 468 (14.2%) 0.8% 2253 (11.2%) 4506 (11.2%) 0% 
Most recent serum sodium, mean (SD) 140.3 (3.4) 140.6 (3.0) 7.9% 140.4 (3.3) 140.5 (3.1) 3.1% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range. 
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation. 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with 
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.35% and 0.32% missing values in matched users and non-
users, respectively. These patients were included in income quintile 3 (“average” income). 
c There were less than 0.07% missing values in matched users and non-users. These patients were included in the urban category. 
d Comorbid conditions in the five years preceding the index date were considered. 
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the 
condition. 
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal. 
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention. 
h Concurrent medication use in the six months preceding the index date were considered. 
i Healthcare contacts in the year preceding the index date were considered. 
j Healthcare use in the year preceding the index date was considered. 
k Serum sodium measurements were obtained at a median (IQR) of 128 (56 to 234) days prior to the index date in users, and 139 (63 to 237) days in non-users. 
 
 
 
 
 
 
240 
 
 
 
Table D-6. Baseline characteristics of carbamazepine users and non-users for a 
subpopulation residing in a hospital catchment area with available serum sodium data* 
Characteristic Matched 
 Carbamazepine 
users 
(n=678) 
Antiepileptic 
 non-users  
(n=2034) 
Standardized 
Differencea 
Demographic    
Age, years, mean (SD) 75 (6.6)  75 (6.5) 0.2% 
Women 435 (64.2%)  1305 (64.2%) 0% 
Income quintileb    
1  (low) 162 (23.9%) 441 (21.7%) 5.3% 
2 123 (18.1%) 390 (19.2%) 2.7% 
3 (medium) 148 (21.8%) 434 (21.3%) 1.2% 
4 128 (18.9%) 406 (20.0%) 2.7% 
5 (high) 117 (17.3%)  363 (17.8%) 1.6% 
Rural residence 98 (14.5%)  362 (17.8%) 9.1% 
Long-term care 12 (1.8%)  36 (1.8%) 0.0% 
Comorbid conditionsc    
Charlson comorbidity index, mean (SD) 0.5 (1.1) 0.5 (1.1) 3.7% 
Johns Hopkins ACG System Aggregated 
Diagnosis Groups, mean (SD) 
11.7 (3.7) 11.9 (3.9) 4.7% 
Epilepsy/seizured 239 (35.3%) 717 (35.3%) 0% 
Migraine 33 (4.9%) 80 (3.9%) 4.6% 
Trigeminal neuralgia  0 (0%)   0 (0%) 0% 
Neuropathic pain 10 (1.5%)  34 (1.7%) 1.6% 
Bipolar disorder  7 (1.0%)  17 (0.8%) 2.0% 
Mood disorder 57 (8.4%)  174 (8.6%) 0.5% 
Anxiety disorder 264 (38.9%)  776 (38.2%) 1.6% 
Benign brain tumour ≤5 (≤0.7%) 9 (0.4%) ≤2.4% 
Brain aneurysm ≤5 (≤0.7%)  ≤5 (≤0.3%) ≤3.1% 
Brain cancer 0 (0%) ≤5 (≤0.3%) ≤7.0% 
Brain injury ≤5 (≤0.7%) 6 (0.3%) 0% 
Encephalitis 0 (0%)   0 (0%) 0% 
Meningitis 0 (0%)   ≤5 (≤0.3%) ≤7.0% 
Parkinson’s disease 13 (1.9%) 35 (1.7%) 1.5% 
Congestive heart failure 41 (6.1%) 123 (6.1%) 0% 
Chronic kidney disease ≤5 (≤0.7%)  6 (0.3%) 0% 
Hypertension 494 (72.9%) 1495 (73.5%) 1.4% 
Chronic liver disease 18 (2.7%) 42 (2.2%) 3.9% 
Hypothyroidism 63 (9.3%) 206 (10.1%) 2.8% 
Cancere 92 (13.6%) 265 (13.0%) 1.6% 
Diabetes 162 (23.9%)  474 (23.3%) 1.4% 
Diabetic neuropathy ≤5 (≤0.7%)  ≤5 (≤0.3%) 3.1% 
Diabetic retinopathy ≤5 (≤0.7%)  11 (0.5%) 3.8% 
Pneumonia 19 (2.8%) 50 (2.5%) 2.2% 
Coronary artery diseasef 160 (23.6%) 487 (23.9%) 0.8% 
Angina 107 (15.8%) 326 (16.0%) 0.7% 
Atrial fibrillation/flutter  30 (4.4%) 95 (4.7%) 1.2% 
Previous hyponatremia 10 (1.5%) 26 (1.3%) 1.7% 
Previous delirium ≤5 (≤0.7%) 15 (0.7%) ≤0% 
Myocardial infarction 25 (3.7%) 58 (2.9%) 4.7% 
Adrenal Insufficiency ≤5 (≤0.7%)  ≤5 (≤0.3%) ≤3.1% 
Hemorrhagic stroke 0 (0%)   ≤5 (≤0.3%) 6.3% 
Ischemic stroke 18 (2.7%) 30 (1.5%) 8.3% 
Transient ischemic attack ≤5 (≤0.7%) 10 (0.5%) ≤1.3% 
Acute kidney injury ≤5 (≤0.7%) 11 (0.5%) ≤1.4% 
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Hypotension ≤5 (≤0.7%) 21 (1.0%) ≤4.9% 
Acute urinary retention 13 (1.9%) 33 (1.6%) 2.2% 
Peripheral vascular disease 15 (2.2%) 37 (1.8%) 2.8% 
Lung disease  164 (24.2%)  472 (23.2%) 2.3% 
Concurrent medication useg    
Number of unique drug products, mean 
(SD) 
7.3 (4.4)   6.7 (4.1) 12.6% 
Antipsychotics 20 (3.0%) 64 (3.2%) 1.1% 
Antidepressants 162 (23.9%)  520 (25.6%) 3.9% 
Antidiabetics 116 (17.1%) 290 (14.3%) 7.9% 
Antineoplastics 29 (4.3%) 76 (3.7%) 2.8% 
Thyroxine 90 (13.3%)  324 (15.9%) 7.5% 
Potassium sparing diuretics 47 (6.9%)  136 (6.7%) 1.0% 
Non-potassium sparing diuretics 196 (28.9%)  585 (28.8%) 0.3% 
ACE inhibitors and/or ARBs 302 (44.5%)  887 (43.6%) 1.9% 
NSAIDs (excl. ASA) 184 (27.1%)  515 (25.3%) 4.1% 
Calcium channel blockers 182 (26.8%) 493 (24.2%) 6.0% 
Beta-adrenergic agonists 197 (29.1%) 552 (27.1%) 4.3% 
Statins 254 (37.5%) 661 (32.5%) 10.4% 
Benzodiazepines 159 (23.5%) 534 (26.3%) 6.5% 
Digoxin 31 (4.6%) 74 (3.6%) 4.7% 
Overactive bladder 29 (4.3%) 71 (3.5%) 4.1% 
Antibiotics 258 (38.1%) 660 (32.5%) 11.8% 
Warfarin 0 (0%) 0 (0%) 0% 
Anticoagulents ≤5 (≤0.7%) ≤5 (≤0.3%) ≤6.3% 
Antiplatlets 25 (3.7%) 78 (3.8%) 0.8% 
Acetylcholine inhalers 32 (4.7%) 113 (5.6%) 3.8% 
Corticosteroid inhalers 35 (1.6%) 86 (2.5%) 6.2% 
Beta-agonist inhalers 67 (9.9%) 216 (10.6%) 2.4% 
Cholinesterase inhibitors 11 (1.6%) 51 (2.5%) 6.2% 
Lithium ≤5 (≤0.7%) 9 (0.4%) ≤5.4% 
Glucose test strips 77 (11.4%) 243 (12.0%) 1.8% 
Baclofen ≤5 (≤0.7%) 10 (0.5%) 0.7% 
Healthcare contacts, mean (SD)h    
Hospitalizations 0.5 (0.9)  0.4 (0.8) 3.5% 
Emergency department visits 0.6 (1.1) 0.6 (1.2) 0.9% 
Family physician visits 10.1 (7.5)  9.4 (7.8) 8.5% 
Geriatrician visits 0.2 (2.1)  0.1 (1.0) 4.6% 
Psychiatrist visits 0.1 (0.8)  0.1 (1.2) 4.1% 
Neurologist visits 0.2 (0.6)  0.1 (0.6) 8.3% 
Nephrologist visits 0 (0.3)  0 (0.2) 0% 
Cardiologist visits 0.5 (1.4)  0.6 (1.5) 2.7% 
Urologist visits 0.2 (1.1)  0.3 (1.1) 2.8% 
Obstetrician/Gynecologist visits 0.1 (0.4) 0.1 (0.6) 4.1% 
Healthcare usei    
Previous sodium tests 362 (53.4%) 1099 (54.0%) 1.3% 
Carotid ultrasound 38 (5.6%) 103 (5.1%) 2.4% 
Cardiac catheterization ≤5 (≤0.7%) 22 (1.1%) ≤5.4% 
Echocardiography 73 (10.8%) 176 (8.7%) 7.1% 
Holter monitoring 31 (4.6%) 89 (4.4%) 2.0% 
Cardiac stress test 67 (9.9%) 210 (10.3%) 1.5% 
Coronary endarterectomy 0 (0%) 0 (0%) 0% 
Colorectal cancer screening 135 (19.9%) 399 (19.6%) 0.7% 
Cervical cancer screening 37 (5.5%) 117 (5.8%) 1.3% 
Prostate specific antigen test 31 (4.6%) 70 (3.4%) 5.8% 
Mammography 56 (8.3%) 159 (7.8%) 1.6% 
Flu shot 431 (63.6%)  1232 (60.6%) 6.2% 
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Thyroid stimulating hormone 286 (42.2%) 900 (44.3%) 4.2% 
Bone mineral density test 73 (10.8%) 224 (11.0%) 0.8% 
Hearing test 38 (5.6%) 110 (5.4%) 0.9% 
Cytoscopy 12 (1.8%) 72 (3.5%) 11.0% 
Cataract surgery 40 (5.9%) 114 (5.6%) 1.3% 
Magnetic resonance imaging of the head 9 (1.3%) 28 (1.4%) 0.4% 
Computed tomography of the head 63 (9.3%)  152 (7.5%) 6.6% 
Computed tomography of the neck 9 (1.3%) 16 (0.8%) 5.3% 
Computed tomography of the thorax 29 (4.3%) 69 (3.4%) 4.6% 
Computed tomography of the abdomen 57 (8.4%) 134 (6.6%) 6.9% 
Computed tomography of the pelvis 49 (7.2%) 120 (5.9%) 5.4% 
Computed tomography of the spine 17 (2.5%) 55 (2.7%) 1.2% 
Computed tomography of the extremities 9 (1.3%) 12 (0.6%) 7.6% 
Chest x-ray 206 (30.4%) 589 (29.0%) 3.1% 
Pulmonary function test 32 (4.7%) 150 (7.4%) 11.2% 
Electroencephalography  ≤5 (≤0.7%) 0 (0%) ≤5.4% 
Urine culture 119 (17.6%) 374 (18.39%) 2.2% 
Heart valve replacement 0 (0%) ≤5 (≤0.3%) 3.1% 
At-home physician services 24 (3.5%) 47 (2.3%) 7.3% 
Cholesterol tests 335 (49.4%) 972 (47.8%) 3.3% 
Laboratory measurementsj    
Most recent serum sodium, N (%) 231 (34.1%) 693 (34.1%) 0% 
Most recent serum sodium, mean (SD) 139.8 (3.3)  140.0 (3.0) 8.6% 
ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin 
II receptor blocker. IQR=interquartile range. NSAID=Non-steroidal anti-inflammatory drug. SD=standard 
deviation. 
Characteristics in which there were ≤5 events were not presented for reasons of privacy 
* Data are presented as the number (percentage) of patients, unless otherwise reported. 
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a 
measure of the difference between groups with respect to the pooled standard deviation; a standardized 
difference greater than 10% was considered as a meaningful difference between the groups. 
b Income was categorized into fifths of average neighborhood income on the index date.   
c Comorbid conditions in the five years preceding the index date were considered. 
d Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present 
to hospital, which underestimates the prevalence of the condition. 
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin 
lymphoma, liver, ovarian, esophageal. 
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous 
coronary intervention. 
g Concurrent medication use in the six months preceding the index date were considered. 
h Healthcare contacts in the year preceding the index date were considered. 
i Healthcare use in the year preceding the index date was considered. 
j Serum sodium measurements were obtained at a median (IQR) of 150 (69 to 236) days in users and 130 
(58 to 226) days in non-users, prior to the index date. 
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Abstract 
Objective: To evaluate the validity of the International Classification of Diseases, Tenth 
Revision (ICD-10) diagnosis code for hyponatremia (E87.1) in two settings: at 
presentation to the emergency department and at hospital admission. 
Design: Population-based retrospective validation study. 
Setting: Twelve hospitals in Southwestern Ontario, Canada, from 2003 to 2010.  
Participants: Patients aged 66 years and older with serum sodium laboratory 
measurements at presentation to the emergency department (n=64,581) and at hospital 
admission (n=64,499). 
Main outcome measures: Sensitivity, specificity, positive predictive value and negative 
predictive value comparing various ICD-10 diagnostic coding algorithms for 
hyponatremia to serum sodium laboratory measurements (reference standard). Median 
serum sodium values comparing patients who were code positive and code negative for 
hyponatremia.  
Results: The sensitivity of hyponatremia (defined by a serum sodium ≤132 mmol/L) for 
the best performing ICD-10 coding algorithm was 7.5% at presentation to the emergency 
department (95% confidence interval (CI): 7.0% to 8.2%) and 10.6% at hospital 
admission (95% CI: 9.9% to 11.2%). Both specificities were greater than 99%. In the two 
settings, the positive predictive values were 96.4% (95% CI: 94.6% to 97.6 %) and 82.3% 
(95% CI: 80.03% to 84.4%), while the negative predictive values were 89.2% (95% CI: 
89.0% to 89.5%) and 87.1% (95% CI: 86.8% to 87.4%). In patients who were code 
positive for hyponatremia, the median (interquartile range) serum sodium measurements 
were 123 (119 to 126) mmol/L and 125 (120 to 130) mmol/L in the two settings. In code 
negative patients, the measurements were 138 (136 to 140) mmol/L and 137 (135 to 139) 
mmol/L.  
Conclusions: The ICD-10 diagnostic code for hyponatremia differentiates between two 
groups of patients with distinct serum sodium measurements at both presentation to the 
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emergency department and at hospital admission. However, these codes underestimate 
the true incidence of hyponatremia due to low sensitivity.    
 
Keywords: hyponatremia, hyponatraemia, serum sodium, validation, validity, diagnostic 
accuracy, sensitivity, specificity, International Classification of Diseases  
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Introduction 
Large health administrative databases are widely used in pharmacoepidemiologic and 
health services research.1 They offer several advantages including increased efficiency 
and large sample sizes. Despite their usefulness, an important limitation of these 
databases is that researchers frequently rely on hospital-based diagnostic codes contained 
within the databases to define conditions of interest, rather than reference standard 
diagnoses.2 The inaccuracy of codes may introduce measurement error, which has a 
number of implications including underestimation of the true incidence of a condition. 
Accordingly, understanding the validity of various diagnostic codes remains of 
paramount importance.  
Hyponatremia is an electrolyte disorder and is generally defined by a low serum 
sodium concentration.3,4 It is one of the most common types of abnormalities of its kind 
affecting 15% to 30% of hospitalized patients.5,6 Depending on its severity and rapidity of 
onset, hyponatremia has been associated with morbidities such as confusion, seizures, 
falls, fractures as well as mortality.7–9 There are a number of causes of hyponatremia such 
as dehydration from prolonged vomiting, congestive heart failure, some forms of kidney 
disease, and medication use (e.g. diuretics).  
To date, the validity of the International Classification of Diseases, Ninth Revision 
(ICD-9) code for hyponatremia has been described in two studies. Movig et al. compared 
discharge records for hospitalized patients with laboratory data and found sensitivities of 
1.7% and 13.4% for serum sodium measurements ≤135 mmol and ≤125 mmol/L, 
respectively.10 Specificities were greater than 99%. Shea et al. evaluated outpatient 
records against laboratory measurements and reported sensitivities of 3.5% and 29.6% 
using the same thresholds to define hyponatremia.11 Specificities remained high at over 
99%.  
ICD-10 was introduced in Canada in 2002 and is currently used by 117 countries 
worldwide.12 To date there has been no validation of the ICD-10 code for hyponatremia.  
Therefore, the goal of our study was to evaluate the validity of the ICD-10 diagnosis code 
for hyponatremia (E87.1) in two settings: at presentation to the emergency department 
and at hospital admission. 
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Methods 
Study Design and Setting 
We conducted a population-based retrospective validation study using the health 
administrative databases and laboratory data in Southwestern Ontario, Canada. These 
data come from 12 hospitals that serviced a catchment area of approximately 80,000 
adults aged 65 and older in 2006 (most recent available census information).13 All 
residents received universal access to hospital and physician services. Coverage for 
medical services and medications from a single provincial payer provided a 
comprehensive set of health administrative data.  
Using a diagnostic test assessment framework, we obtained metrics of sensitivity, 
specificity, positive predictive value and negative predictive value comparing various 
ICD-10 diagnostic coding algorithms for hyponatremia to serum sodium laboratory 
measurements (the latter serving as the reference standard; see online supplementary 
Appendix A for sample two-by-two table). Since serum sodium concentration is a 
continuous measure, we also compared these values in patients who were code positive 
with those who were code negative. We conducted our study according to a pre-specified 
protocol that was approved by the institutional review board at Sunnybrook Health 
Sciences Centre (Toronto, Ontario). The relevant datasets and the analyses were held and 
conducted at the Institute for Clinical Evaluative Sciences. The reporting of this study 
follows guidelines set out for studies of diagnostic accuracy (see online supplementary 
Appendix B).14 
Data Sources 
Records from seven databases were linked using encrypted unique identifiers. We 
identified laboratory measurements, including serum sodium using Cerner® (Kansas City, 
Missouri, USA), a system that keeps patient electronic medical records.13,15 This system 
contains inpatient, outpatient and emergency room laboratory measurements. We 
identified emergency department visits using the National Ambulatory Care Reporting 
System database, and inpatient hospital admissions using the Canadian Institutes of 
Health Information Discharge Abstract Database (CIHI-DAD). These databases contain 
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detailed diagnostic and procedural information coded using ICD-9 (pre-2002) and ICD-
10 (post-2002). We obtained patient demographic data from the Registered Persons 
Database, which contains demographic information on all Ontarians ever issued a health 
card. We collected additional covariate information from the CIHI-DAD, the Ontario 
Health Insurance Plan database, which contains health claims information for both 
inpatient and outpatient services and the Ontario Drug Benefits database, which contains 
highly accurate records of all outpatient prescriptions dispensed to patients ≥65 years of 
age (error rate <1%).16 For a subpopulation, we also obtained baseline laboratory 
measurements prior to hospital encounters from Gamma-Dynacare, a provider of 
outpatient laboratory services to residents in Southwestern Ontario. These databases have 
been used extensively to research health outcomes and health services.17–20 
Participants  
In order to assess the validity of the hyponatremia code, we created two separate cohorts 
restricting cohort entry to patients with at least one serum sodium measurement at 
presentation to an emergency department or at hospital admission, respectively. These 
measurements were available beginning 1 June 2003, which is when we began accrual for 
the study and continued to 30 September 2010. To ensure all participants had at least one 
full year of medication use data, we restricted entry to those aged 66 years and older at 
the time of the serum sodium measurement. The selection criteria are described below 
and outlined in online supplementary Appendix C.   
We excluded measurements when the date of an emergency department or inpatient 
serum sodium test did not align with an emergency department visit or inpatient hospital 
admission included in the administrative databases (see online supplementary Appendix 
C for alignment definitions). To ensure we had data for the full hospital admission to the 
time of discharge (particularly for patients accrued in the second half of 2010) we 
excluded admissions where the duration of the visit exceeded 90 days. As such, study 
follow-up occurred until 31 December 2010. To assess hyponatremia upon presentation 
to the emergency department, patients had to have at least one emergency department 
serum sodium measurement on the day of or one day after the emergency department 
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registration date. To assess hyponatremia at hospital admission, we restricted to patients 
who had at least one emergency department serum sodium measurement two days prior 
to the hospital admission date or one inpatient serum sodium measurement the day of or 
one day after the hospital admission date. For both settings, when multiple serum sodium 
tests were performed, we selected the lowest value to define the presence of 
hyponatremia. In cases where multiple emergency department visits or hospital 
encounters were identified per patient over the study period, we randomly selected one 
visit/encounter. We denoted the emergency department registration date or inpatient 
hospital admission date as the index date.  
Diagnostic Test (Hyponatremia ICD-10 coding algorithms) 
In Canada, trained coders record appropriate diagnostic codes and their associated 
attributes based on information from a patient’s chart. Coders follow the Canadian 
Coding Standards developed by CIHI.21 Based on these guidelines, coders are not 
permitted to interpret laboratory test results but can record a laboratory-based condition if 
the physician has documented the diagnosis in the medical chart. Within the NACRS 
database, coders are allowed to include up to 10 diagnoses per visit. The first diagnosis 
listed is the main problem for the client’s visit that required evaluation and/or treatment 
or management as determined by the physician at the end of the visit. CIHI-DAD 
provides the ability to record up to 25 diagnoses, each with a corresponding diagnosis 
type. For example, a diagnosis type of ‘M’ is used to refer to the diagnosis that was most 
responsible for the greatest portion of the length of stay or greatest use of resources, 
while a diagnosis type of ‘1’ refers to a condition that existed prior to admission.   
In this study, we developed two unique algorithms to assess hyponatremia at 
presentation to the emergency department and four unique algorithms at hospital 
admission based on possible diagnosis types. We used the ICD-10 code E87.1, which is 
defined as “hypo-osmolality and hyponatraemia”. The two emergency department 
algorithms identified records with code E87.1 recorded: i) as the main problem (referred 
to as “main diagnosis”), or ii) in any of the 10 potential diagnostic fields (referred to as 
“all diagnosis”). The four hospital admission algorithms identified records with code 
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E87.1 recorded: i) with the diagnosis type of ‘M’ (most responsible) (referred to as “most 
responsible diagnosis”), ii) with the diagnosis type of ‘1’ (pre-admit comorbidity) or ‘W’, 
‘X’ or ‘Y’ (service transfer diagnosis) (referred to as “admission diagnosis”), iii) with a 
diagnosis type of ‘M’ and a diagnosis type of ‘1’ (referred to as “admission diagnosis and 
most responsible diagnosis”), or iv) in any one of 25 potential diagnosis fields and any 
diagnosis type (referred to as “all diagnosis”).  
Reference Standard (serum sodium values) 
Serum sodium was analyzed in the laboratory using a Roche Modular Ion Selective 
Electrode® system (Basel, Switzerland). We considered four thresholds when defining our 
reference standard of hyponatremia: serum sodium <135 mmol/L, ≤132 mmol/L, ≤130 
mmol/L, and ≤125 mmol/L. Our primary definition of hyponatremia was a serum sodium 
≤132 mmol/L while the other definitions were explored to investigate the impact of 
disease severity.7,8  
Statistical Analysis 
We used descriptive statistics to summarize demographic characteristics, comorbidities, 
prescription drug claim information and prior laboratory testing for patients in both 
settings. We calculated sensitivity, specificity, positive predictive value and negative 
predictive value for each diagnostic coding algorithm (formulas presented in Appendix 
A). We calculated 95% confidence intervals (CI) for single proportions using the Wilson 
Score method.22 We repeated these calculations for each hyponatremia threshold. We 
expressed continuous variables as medians with interquartile ranges (IQR). We compared 
means using independent samples t-tests. We conducted all analysis using SAS 
(Statistical Analysis Software) version 9.2 (SAS Institute Incorporated, Cary, North 
Carolina, USA, 2008). 
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Results 
Over the seven-year study period, there were a total 64 581 patients with serum sodium 
measurements at presentation to the emergency department and 64 499 at hospital 
admission. Of these patients, 7446 (11.5%) and 9135 (14.2%) had serum sodium 
measurements ≤132 mmol/L, respectively. Baseline characteristics of the two cohorts are 
presented in Table F-1. The median age of the patients on the index date was 77 years 
and just over half the patients were women. Over 50% of each cohort had serum sodium 
measurements available prior to the index date and mean values were normal (Table F-1). 
Table E-1. Baseline characteristics for patients with serum sodium measurements 
obtained in the emergency department and upon hospital admission 
Characteristic Emergency Department  
(n = 64 581) 
Hospital Admission  
(n = 64 499) 
Demographics    
Median age (IQR), years 77 (71 to 83) 77 (71 to 83) 
Women 35 361 (55.2%) 32 965 (51.1%) 
Income Quintile   
1 (low) 14 224 (22.0%) 13 879 (21.5%) 
2 12 862 (19.9%) 12 974 (20.1%) 
3 (middle) 12 564 (19.5%) 12 795 (19.8%) 
4 11 511 (17.8%) 11 601 (18.0%) 
5 (high) 12 431 (19.3%) 12 435 (19.3%) 
Year of Cohort Entrya    
2003-2004 6535 (10.1%) 11 599 (18.0%) 
2005-2006 15 208 (23.6%) 15 639 (24.3%) 
2007-2008 20 586 (31.2%) 18 437 (28.6%) 
2009-2010 22 252 (34.5%) 18 824 (29.2%) 
Rural Location 11 417 (17.7%) 13 286 (20.6%) 
From a Long-term Care Facility 4147 (6.42%) 3674 (5.7%) 
Comorbiditiesb   
Chronic kidney disease 5339 (8.3%) 6399 (9.9%) 
Diabetes mellitusc 13 148 (20.4%) 13 640 (21.2%) 
Peripheral vascular disease 1685 (2.6%) 2940 (4.6%) 
Coronary artery diseased 26 963 (41.8%) 30 608 (47.5%) 
Congestive heart failure 13 674 (21.2%) 15 249 (23.6%) 
Systemic malignancye 27 003 (41.8%) 29 835 (46.3%) 
Stroke/Transient ischemic attack 2508 (3.9%) 2671 (4.1%) 
Chronic liver disease 1217 (1.9%) 1684 (2.6%) 
Medication use in preceding 6 months   
Angiotensin-converting enzyme inhibitor 22 706 (35.2%) 23 759 (36.8%) 
Angiotensin-receptor blocker 10 474 (16.2%) 10 005 (15.5%) 
Potassium sparing diuretic 5699 (8.8%) 6166 (9.6%) 
Non-potassium sparing diuretic 25 930 (40.2%) 27 144 (42.1%) 
Calcium channel blocker 19 092 (29.6%) 19 895 (30.9%) 
β-Adrenergic antagonist 21 957 (34.0%) 23 417 (36.3%) 
Statins 24 873 (38.5%) 25 303 (39.2%) 
NSAIDs (excluding aspirin) 11 637 (18.0%) 12 530 (19.4%) 
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Antiepileptics 3828 (5.9%) 3733 (5.8%) 
Antidepressants 15 710 (24.3%) 15 102 (23.4%) 
Antipsychotics 3944 (6.1%) 3611 (5.6%) 
Benzodiazepines  15 274 (23.7%) 15 532 (24.1%) 
Antineoplastic agents 3280 (5.1%) 3631 (5.6%) 
Hypothyroidism agents 10 444 (16.2%) 9954 (15.4%) 
Baseline Laboratory Measurementsf    
Serum sodium levels, mmol/L   
Median (IQR) 139 (137 to 141) 139 (137 to 141) 
Range 95 to 180 95 to 173 
Hyponatremia category   
<135 mmol/L 5587 (17.0%) 6561 (16.7%) 
≤132 mmol/L 2064 (6.3%) 2397 (6.1%) 
≤130 mmol/L 1030 (3.1%) 1169 (3.0%) 
≤125 mmol/L 130 (0.4%) 171 (0.4%) 
Serum potassium levels, mmol/L, median 
(IQR) 
4.2 (3.8 to 4.5) 4.1 (3.8 to 4.5) 
Serum creatinine levels, µmol/L, median (IQR) 90 (74 to 114) 90 (74 to 114) 
eGFR mL/min/1.73 m2, median (IQR)g 62.8 (46.6 to 78.6)  63.1 (46.9 to 78.9) 
eGFR category, n (%)    
≥60 mL/min/1.73m2 20 809 (54.7%) 23 726 (55.1%) 
45-59 mL/min/1.73m2 8521 (22.4%) 9600 (22.3%) 
30-44 mL/min/1.73m2 5520 (14.5%) 6036 (14.0%) 
15-29 mL/min/1.73m2 2368 (6.2%) 2687 (6.2%) 
<15 mL/min/1.73m2 842 (2.2%) 1035 (2.4%) 
Abbreviations: IQR, interquartile range; eGFR, estimated glomerular filtration rate 
a The year of cohort entry is also referred to as the index date 
b Assessed by administrative database ICD-9 and ICD-10 codes in the 5 years prior to the hospital 
encounter (unless stated otherwise) 
c Assessed by diabetic medication use (oral hypoglycemic or insulin use) in previous 6 months 
d Coronary artery disease includes receipt of coronary artery bypass graft surgery, percutaneous coronary 
intervention and diagnoses of angina 
e Includes the following types of malignancies: skin, mouth (lip, tonsil, etc), throat, stomach, small/large 
intestine, liver, gall bladder, pancreas, breast, male/female reproductive organs, heart, lung, bone, urinary 
system (kidney, bladder, etc), endocrine glands, as well as leukemias and lymphomas 
f Available for a subpopulation. Emergency Department cohort: A total of 32,916 (51.0%), 33,190 (51.4%) 
and 38,060 (58.9%) of the 64,581 patients had a most recent baseline serum sodium, potassium and 
creatinine measurement available in the 7 to 365 days prior to the index date, respectively. Among these 
patients, the baseline measurements were taken at a median (IQR) of 75 (26-175), 75 (26-175), and 76 (27-
173) days prior to the index date, respectively. Hospital Admission cohort: A total of 39,373 (61.0%), 
39,502 (61.2%) and 43,084 (66.8%) of the 64,499 patients had a most recent baseline serum sodium, 
potassium and creatinine measurement available in the 7 to 365 days prior to the index date, respectively. 
Among these patients, the baseline measurements were taken at a median (IQR) of 29 (14-97), 29 (14-97), 
and 31 (14-101) days prior to the index date, respectively 
g eGFR was calculated using the CKD-Epi equation.  
CKD-Epi equation: 141 x min([serum creatinine in umol/L /88·4 ]/κ, 1)α x max([serum creatinine in 
umol/L / 88·4]/κ, 1)-1·209 x 0·993Age x 1·018 [if female] x 1·159 [if African American] κ=0·7 for 
females and 0·9 for males, α= -0·329 for females and -0·411 for males, min=the minimum of Scr/κ or 1, 
max=the maximum of Scr/κ or 1.Racial information was not available in our data sources and all patients 
were assumed not to be of non African-Canadian race.  This was a reasonable assumption; as of 2006, 
African-Canadians represented less than 7% of the Ontario population. Source: 
http://www12.statcan.ca/census-recensement/2006/dp-pd/hlt/97-562/index.cfm?Lang=E 
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The sensitivity of hyponatremia when defined by a serum sodium ≤132 mmol/L 
was highest when considering evidence of code E87.1 among all potential diagnoses for 
both settings: at presentation to emergency department, 7.5% (95% CI: 7.0% to 8.2%) 
and at hospital admission, 10.6% (95% CI: 9.9% to 11.2%). In both settings the 
specificities were greater than 99%. The positive predictive values were 96.4% (95% CI: 
94.6% to 97.6%) and 82.3% (95% CI: 80.0% to 84.4%) and the negative predictive 
values were 89.2% (95% CI: 89.0% to 89.5%) and 87.1% (95% CI: 86.8% to 87.4%), 
respectively (Table F-2). 
In patients with and without baseline hyponatremia (7 to 365 days prior to hospital 
encounter), the sensitivity of the all diagnosis ICD-10 coding algorithm in the emergency 
department setting was 11.6% in those with baseline hyponatremia and 5.4% in those 
without. For similar patients in the hospital admission setting, the sensitivities were 
16.9% and 7.6%, respectively (online supplementary Appendix D). 
In both settings, the sensitivity of each ICD-10 coding algorithm for hyponatremia 
increased as the thresholds for serum sodium decreased (Table F-3). The positive 
predictive value of each ICD-10 coding algorithm for hyponatremia decreased with 
decreasing thresholds for serum sodium, as lower thresholds are less common (i.e. 25.0% 
of hospital admissions had a serum sodium ≤135 mmol/L vs. 2.3% with a value ≤ 125 
mmol/L). 
When considering all potential diagnoses, 582 (0.9%) patients were code positive 
for hyponatremia at presentation to the emergency department and 1171 (1.8%) at 
hospital admission. The median (IQR) serum sodium values among code positive patients 
were 123 (119 to 126) mmol/L and 125 (120 to 130) mmol/L in each setting, 
respectively. For those patients who were code negative, the median values were 138 
(136 to 140) mmol/L and 137 (135 to 139) mmol/L, respectively (Table F-4).  
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Table E-2. Performance of the ICD-10 coding algorithms for hyponatremia using a serum sodium measurement as the reference 
standard 
ICD-10 E87.1 
 Coding Algorithms 
Reference Standard Hyponatremia (≤132 mmol/L) 
 
Emergency Department Hospital Admission 
 + - 
Performance 
Measures 
95% CI + - 
Performance 
Measures 
95% CI 
 
All Diagnosis 
+ 561 21 
Sn= 7.53% 6.96% to 8.16% 
964 207 
Sn= 10.55% 9.94% to 11.20% 
Sp= 99.96% 99.94% to 99.98% Sp= 99.63% 99.57% to 99.67% 
- 6885 57 114 
PPV= 96.39% 94.55% to 97.63% 
8171 55 157 
PPV= 82.32% 80.03% to 84.40% 
NPV= 89.24% 89.00% to 9.48% NPV= 87.10% 86.83% to 87.36% 
 
Main Diagnosis 
+ 309 11 
Sn= 4.15% 3.72% to 4.63% 
 
Sp= 99.98% 99.97% to 99.99% 
- 7137 57 124 
PPV= 96.56% 93.95% to 98.07% 
NPV= 88.89% 88.65% to 89.13% 
 
Admission Diagnosis 
+ 
 
773 90 
Sn= 8.46% 7.91% to 9.05% 
Sp= 99.84% 99.80% to 99.87% 
- 8362 55 274 
PPV= 89.57% 87.35% to 91.44% 
NPV= 86.86% 86.59% to 87.12% 
 
Most Responsible 
Diagnosis 
+ 
 
251 4 
Sn= 2.75% 2.43% to 3.10% 
Sp= 99.99% 99.98% to 100.00% 
- 8884 55 360 
PPV= 98.43% 96.04% to 99.39% 
NPV= 86.17% 85.90% to 86.44% 
 
Admission Diagnosis + 
Most Responsible 
Diagnosis 
+ 
 
248 4 
Sn= 2.71% 1.36% to 1.74% 
Sp= 99.99% 99.98% to 100.00% 
- 8887 55 360 
PPV= 98.41% 95.99% to 99.38% 
NPV= 86.17% 74.99% to 75.66% 
Abbreviations: ICD-10=International Classification of Diseases, tenth revision; CI=confidence interval; Sn=sensitivity; Sp=specificity; PPV=positive predictive 
value; NPV=negative predictive value; +=hyponatremia yes; -=hyponatremia no
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Table E-3. Performance of the ICD-10 coding algorithms for hyponatremia for different 
levels of serum sodium measurements 
 Serum sodium measurements (mmol/L)a 
  Emergency Department Hospital Admission 
ICD-10 E87.1 
Coding Algorithms 
Performance 
Measures 
≤ 135 ≤ 130 ≤ 125 ≤ 135 ≤ 130 ≤ 125 
All Diagnosis Sensitivity 4.49% 12.58% 34.43% 6.42% 17.06% 41.68% 
Specificity 99.97%  99.95% 99.71% 99.72% 99.55% 99.12% 
PPV 97.42% 94.33% 68.21% 88.30% 77.20% 52.43% 
NPV 81.17% 94.04% 98.82% 76.21% 93.06% 98.64% 
 
Main Diagnosis Sensitivity 2.48% 6.94% 20.64%  
Specificity 99.99% 99.97% 99.87% 
PPV 97.81% 94.69% 74.38% 
NPV 80.86% 93.68% 98.58% 
 
Admission 
Diagnosis 
Sensitivity  4.97% 14.02% 36.66% 
Specificity 99.87% 99.80% 99.49% 
PPV 92.70% 86.10% 62.57% 
NPV 75.96% 92.84% 98.53% 
 
Most Responsible 
Diagnosis 
Sensitivity  1.56% 4.70% 15.48% 
Specificity 99.99% 99.99% 99.96% 
PPV 98.43% 97.65% 89.41% 
NPV 75.33% 92.14% 98.06% 
 
Admission 
Diagnosis + Most 
Responsible 
Diagnosis 
Sensitivity  1.54% 4.64% 15.41% 
Specificity 99.99% 99.99% 99.96% 
PPV 98.41% 97.62% 90.08% 
NPV 75.33% 92.14% 98.06% 
Abbreviations: ICD-10=International Classification of Diseases, tenth revision; PPV=positive predictive 
value; NPV=negative predictive value. 
a 95% confidence intervals were calculated using the Wilson score method but were not reported. All 
intervals were within ±4% of the point estimate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
256 
 
 
 
Table E-4. Serum sodium concentration (mmol/L) describing those patients where the 
ICD-10 coding algorithms did and did not indicate hyponatremia (code positive and code 
negative) 
  Emergency Department Hospital Admission 
ICD-10 E87.1 
Coding Algorithms 
 N Median IQR N Median IQR 
All Diagnosis + 582 123 119-126 1171 125 120-130 
- 63 999 138 136-140 63 328 137 135-139 
 
Main Diagnosis + 320 122 117-126  
- 64 261 138 136-140 
 
Admission Diagnosis +  863 124 119-128 
- 63 636 137 135-139 
 
Most Responsible Diagnosis +  255 120 116-123 
- 64 244 137 135-139 
 
Admission Diagnosis + Most 
Responsible Diagnosis 
+  252 120 116-123 
- 64 247 137 135-139 
Abbreviations: ICD-10=International Classification of Diseases, tenth revision; N=number; 
IQR=interquartile range; +=code positive; -=code negative. Code positive and code negative patients were 
significantly different (p < 0.0001) (means presented in box plot; Figure F-1) 
 
 
In both settings there were significant differences in mean serum sodium values 
between patients who were code positive and code negative for hyponatremia for all ICD-
10 coding algorithms (p < 0.0001 in each setting). The mean difference in serum sodium 
values between patients who were code positive and code negative in the two settings 
was 15.2 (95% CI: 14.6 to 15.7) mmol/L and 11.4 (95% CI: 10.9 to 11.9) mmol/L, 
respectively (Figure F-1).  
In the subgroup of patients with baseline pre-hospital encounter serum sodium 
measurements, the median (IQR) decrement in serum sodium values among patients who 
were code positive was 10.0 (6.0 to 15.0) mmol/L at presentation to the emergency 
department and 8.0 (4.0 to 13.0) mmol/L at hospital admission. Similar results in patients 
who were code negative were 1.0 (1.0 to 4.0) mmol/L and 2.0 (0.0 to 4.0) mmol/L, 
respectively. The mean difference in the decrement in serum sodium values between 
patients who were code positive and code negative in the two settings was 9.4 (95% CI 
8.6 to 10.2) mmol/L and 6.8 (95% CI 6.2 to 7.4) mmol/L, respectively (p < 0.0001 in 
each setting) (online supplementary Appendix E). 
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Figure E-1. Serum sodium measurements among patients who are code positive and 
code negative for hyponatremia when considering any evidence of hyponatremia (all 
diagnosis).  
For both presentations to emergency department and at hospital admission, patients who were code positive 
for hyponatremia had significantly lower serum sodium measurement than patients who were code 
negative. The boxes represent the interquartile range (50% of the values). The line across the box indicates 
the median. The star indicates the mean. The whiskers extend to the 95th and 5th percentile.  
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Discussion 
In this population-based validation study, we found that the best performing ICD-10 
coding algorithm for hyponatremia for presentation to the emergency department and at 
hospital admission settings was when the code was included in any diagnosis field, 
regardless of the associated diagnosis type. Overall, while the ICD-10 code for 
hyponatremia was highly specific, the sensitivity of the code was low. In both settings, 
there was a high false negative rate - a large number of patients with a serum sodium 
measurement below 133 mmol/L were not coded as having hyponatremia (≥90%). Even 
for severe hyponatremia (serum sodium ≤125 mmol/L), the sensitivity was maximally 
about 42%. The most responsible diagnosis is one that is responsible for the longest 
length of stay/greatest use of resources and may also be one that was present at 
admission. This was the poorest performing algorithm in our study possibly because the 
hospital admission is attributed to the underlying condition that caused the hyponatremia 
(e.g. congestive heart failure) rather than the hyponatremia per se.  
The sensitivities we observed are similar to those reported by Movig et al. and Shea 
et al. for ICD-9 coding although the sensitivities and positive predictive values found in 
our study are slightly higher for all thresholds of hyponatremia (depending on the specific 
ICD-10 coding algorithm). Also consistent with the previous validation studies, the 
sensitivity increased as the severity of hyponatremia increased. This may be because 
more mild forms of hyponatremia tend to be asymptomatic and do not usually require 
treatment, making the physician less inclined to record a diagnosis of hyponatremia in the 
medical chart.23–25   
Of the patients who had hyponatremia at presentation to the emergency department 
and at hospital admission (defined by a value ≤132 mmol/L), only 7.5% and 10.6% were 
correctly coded as demonstrating this. In other words, the diagnosis was not being written 
by a physician in the medical chart and may suggest the condition receives less attention 
than it deserves. Despite this, the code was successful in differentiating between two 
groups of patients with distinctly different serum sodium measurements at the hospital 
encounter. Patients who were code negative for hyponatremia had measurements in the 
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normal range (135-145 mmol/L) and code positive patients had much lower 
measurements (≤125 mmol/L). Patients who were code positive at hospital admission 
also demonstrated an average decrement of 8.7 mmol/L in serum sodium from a baseline 
value, the latter taken at a median of 29 days prior to hospital admission. This further 
exemplifies the point that new and more severe forms of hyponatremia tend to be 
recorded.  
Our study has several strengths. It is the first study to validate the ICD-10 code for 
hyponatremia. We validated the ICD-10 code in both the emergency department and at 
hospital admission examining different types of diagnoses. Previous studies have not 
looked at these settings nor did they examine all the possible diagnosis types as we did.  
The study was made possible by the province of Ontario’s universal healthcare and 
provincial drug plan benefits with collection of all healthcare encounters of all citizens. 
We had a large sample size to base our validation on using laboratory data from a number 
of hospitals across the province. This helped improve study generalizability and differs 
from the ICD-9 validation study of Movig et al. who used only a single hospital. Our 
large sample also provided good precision around the point estimates.  
The validity measures that we used in this study have also been used in several 
other studies comparing ICD codes with clinical outcomes.8,9,26–29 Many validation 
studies compare diagnostic codes to information written in medical charts, whereas we 
compared the diagnostic code for hyponatremia to a reference standard of laboratory 
values. Where appropriate, this is the most accurate way to determine the presence of 
hyponatremia.  
Our study does have some limitations. We evaluated the validity of the 
hyponatremia code in an elderly population and the results best generalize to adults over 
the age of 65. This patient population is very vulnerable to developing hyponatremia.3,30 
Additionally, since most pharmacoepidemiologic research using the Ontario databases 
are conducted on the elderly where receipt of prescription medications is a universal 
benefit, these findings would be especially applicable. Additional studies are required to 
validate these codes in younger patients, where hospitalization with hyponatremia is 
expected to be less frequent.  
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Laboratory data were available for about 5% of Ontario elderly residents. This 
should be considered when generalizing the results to the entire province, Canada, or 
other countries. Given that the results obtained from this study are similar to those found 
with the ICD-9 code for hyponatremia in the United States and the Netherlands, we 
anticipate the results are broadly applicable.  
We did not know the degree to which patients with hyponatremia were 
symptomatic from their low sodium values or the indication that prompted presentation to 
the emergency department or hospital admission. However, we do know the codes did 
identify acute decrements in serum creatinine as previously described. Patients with acute 
changes in serum sodium are those most likely to be symptomatic from the condition. 
We could not examine the validity of outpatient claims for hyponatremia in this 
study as there is no code available for this in our jurisdiction. Nevertheless, emergency 
department and hospital records do detect more severe forms of hyponatremia making 
this of particular interest to clinicians and policy decision makers. 
Finally, we recognize we did not capture those patients who may have had severe 
hyponatremia but did not present to the emergency department or hospital, or those who 
presented but failed to have serum sodium measured. However, the latter is less of a 
concern given serum sodium measurements are a ubiquitous and standard test for most 
patients who present for acute medical care.  
Conclusion  
Although administrative databases have inherent advantages, they have limitations in 
identifying certain conditions such as hyponatremia. As observed in this study, the ICD-
10 code for hyponatremia was able to differentiate between two groups of elderly patients 
with distinct serum sodium measurements during presentation to the emergency 
department and at hospital admission. However, the sensitivity of hyponatremia was very 
low, particularly at less severe forms of the condition, which will underestimate the true 
incidence of the condition. The results from this study will guide judicious use of the 
hyponatremia code in future research, which uses healthcare administrative databases. 
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